losartan profile

Losartan is an angiotensin II receptor blocker (ARB) used to treat high blood pressure and heart failure. It was first synthesized by DuPont Pharmaceuticals in the 1980s. Losartan works by blocking the action of angiotensin II, a hormone that causes blood vessels to narrow. This blockade leads to relaxation of blood vessels, lowering blood pressure and reducing the workload on the heart. Losartan is important because it is an effective treatment for hypertension, a major risk factor for heart disease, stroke, and kidney failure. It is also studied for its potential to prevent or delay the progression of diabetic nephropathy, a complication of diabetes that can lead to kidney failure. Losartan's effectiveness and safety have been well-established through extensive clinical trials.'

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	3961
CHEBI ID	6541
SCHEMBL ID	60
MeSH ID	M0029400

Synonym
BIDD:GT0286
BRD-K76205745-001-02-5
gtpl590
OPREA1_644635
(2-butyl-4-chloro-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazol-5-yl)methanol
losartan [inn:ban]
2-butyl-4-chloro-1-((2'-(1h-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1h-imidazole-5-methanol
SPECTRUM_001713
hsdb 7043
BSPBIO_002695
SPECTRUM5_001466
2-butyl-4-chloro-1-[p-(o-1h-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol
1h-imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9ci)
2-butyl-4-chloro-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1h-imidazole-5-methanol
dup 89
1h-imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1h-tetrazol-5-yl)(1,1'- biphenyl)-4-yl)methyl)-
2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1h-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole
1h-imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
losartan
C07072
114798-26-4
2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
DB00678
NCGC00095125-01
NCGC00095125-02
KBIO2_007329
KBIOGR_001611
KBIO3_001915
KBIO2_004761
KBIOSS_002193
KBIO2_002193
SPECTRUM4_001126
SPBIO_001893
SPECTRUM3_000998
SPECTRUM2_001677
SPECTRUM1504268
NCGC00095125-03
(2-butyl-4-chloro-1-{[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1h-imidazol-5-yl)methanol
CHEBI:6541 ,
HMS2093E22
dup-89
hgp1405
lozap
losartic
hgp-1405
angizaar
allisartan
nsc-758699
L000351
losartan (inn)
losartic (tn)
D08146
HMS1922J13
[2-butyl-5-chloro-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
(1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol
A803239
pharmakon1600-01504268
nsc758699
dtxsid7023227 ,
dtxcid103227
tox21_111435
cas-114798-26-4
bdbm82258
cas_114798-26-4
nsc_3961
AKOS015917390
AKOS015994740
CCG-39095
ec 601-329-8
(1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol
jms50mpo89 ,
unii-jms50mpo89
nsc 758699
BCP9000861
BCPP000183
FT-0631074
AB07507
EPITOPE ID:140137
S5067
[3h]-losartan
[3h]losartan
gtpl3941
losartan [who-dd]
losartan [vandf]
1h-imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
losartan [mi]
losartan [inn]
2-butyl-4-chloro-1-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)imidazole-5-methanol
HY-17512
2-butyl-4-chloro-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-methanol
{2-butyl-5-chloro-3-[2'-(2h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazol-4-yl}-methanol
2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1h-tetrazol-5-yl)-biphenyl-4-yl)methyl]imidazole
2-butyl-4-chloro-5-(hydroxymethyl)-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
SCHEMBL60
tox21_111435_1
NCGC00095125-05
KS-5004
F2173-0506
STL419984
(1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol
(2-butyl-4-chloro-1-{[2'-(2h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazol-5-yl)methanol
Q-201321
AB01563296_01
mfcd00865831
[2-butyl-4-chloro-1-({4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1h-imidazol-5-yl]methanol
sr-01000763170
SR-01000763170-3
SR-01000763170-4
losartan; 2-butyl-4-chloro-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-methanol; 2-butyl-4-chloro-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-methanol; 2-butyl-4-chloro-1-[[2'-(1h-tetrazol-5-yl)-1,1'-biphe
SBI-0206766.P001
HMS3715L11
2-butyl-4-chloro-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-methanol
[2-butyl-5-chloranyl-3-[[4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
(1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol
2-butyl-4-chloro-1-[2'-(2h-tetrazol-5-yl)-1,1'-biphenyl-4-ylmethyl]-1h- imidazole-5-methanol
lorastan
Q410074
dup89
BCP27731
BRD-K76205745-001-04-1
bdbm318822
us9624243, losartin
ex 89
NCGC00095125-15
NCGC00095125-08
BL164640
(2-butyl-4-chloro-1-{[2'-(1h-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1h-imidazol-5-yl)methanol
EN300-311953
L0378
Z2417557127
(2-butyl-4-chloro-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1h-imidazol-5-yl)methanol
losartanum
(2-butyl-4-chloro-1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-1h-imidazol-5-yl)methanol
2-n-butyl-4-chloro-5-hydroxymethyl-1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole
c09ca01
2-butyl-4-chloro-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1h-imidazole-5-methanol

Excerpt	Reference	Relevance
"Losartan is an angiotensin II receptor antagonist drug, and the observed upregulation of the renin pathway-related genes could be due to feedback from the hypotensive action of the drug."	( Spatial and single-cell transcriptome analysis reveals changes in gene expression in response to drug perturbation in rat kidney. Hasegawa, K; Kawabata, A; Onoda, N; Sakakura, M; Seki, M; Suzuki, A; Suzuki, Y; Urakawa, I; Zenkoh, J, 2022)	1.44
"Losartan is an oral antihypertensive agent that is rapidly metabolized to EXP3174 (angiotensin-subtype-1-receptor blocker) and EXP3179 (peroxisome proliferator-activated receptor gamma [PPARγ] agonist), which was shown in animal studies to reduce inflammation, enhance mitochondrial energetics, and improve muscle repair and physical performance. "	( Serum Concentrations of Losartan Metabolites Correlate With Improved Physical Function in a Pilot Study of Prefrail Older Adults. Abadir, PM; Anders, NM; Bichara, MD; Buta, B; Carey, RM; de Cabo, R; Ferrucci, L; Gabrawy, MM; Khadeer, M; Kwak, MJ; Le, A; Lee, JL; Ma, L; Marx, R; Moaddel, R; Nidadavolu, L; Rudek, MA; Siragy, HM; Tian, J; Walston, JD; Westbrook, R; Wu, Y; Xue, QL; Yang, H; Yenokyan, G; Zhang, C, 2022)	2.47
"Losartan, which functions as a typical angiotensin receptor blocker, controls the average arterial pressure of patients with essential hypertension and protects against hypertension-related secondary diseases, including proteinuria and cardiovascular injury."	( Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib. Chen, X; Fu, Y; Ridwan, KA; Saxu, R; Teng, Y; Xu, X; Yao, J; Yu, P; Zheng, W, 2022)	2.89
"Losartan is a typical Angiotensin II (ANG II) receptor antagonist and relaxes blood vessels."	( Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. Ma, Y; Yu, R; Zhou, X; Zou, J, 2022)	2.89
"Losartan is an anti-hypertensive angiotensin II (ANGII) type 1 receptor (AT1R) blocker (ARB) with many unexpected therapeutic properties, even in non-blood pressure (BP)-related diseases. "	( Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties. Atmuri, NDP; Bernatchez, P; Cait, J; Ciufolini, MA; Donen, G; Dong, Y; Hughes, M; McNagny, KM; Pechkovsky, D; Sauge, E; Sin, DD; Tam, A; Tehrani, AY; Walker, MJA; White, Z; Yuen, C, 2022)	3.61
"Losartan is an inhibitor of transforming growth factor-β signaling. "	( Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. Ambrósio, R; Bandeira, F; Pereira-Souza, AL; Salomão, MQ; Souza Lima, A; Wilson, SE, 2022)	2.6
"Losartan is an angiotensin receptor blocker (ARB) with inhibitory effects on transforming growth factor beta, previously implicated in tissue repair induced fibrosis, and has been studied to prevent stiffness following hip arthroscopy."	( The effect of losartan on range of motion and rates of manipulation in total knee arthroplasty: a retrospective matched cohort study. Arraut, J; Fiedler, B; Lygrisse, KA; Rozell, JC; Schwarzkopf, R; Singh, V, 2023)	1.99
"Losartan is an angiotensin II receptor blocker (ARB) that impedes transforming growth factor (TGF) beta signaling by inhibiting activation of signal transduction molecule extracellular signal-regulated kinase (ERK). "	( Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders. Wilson, SE, 2023)	2.79
"Losartan is an auspicious candidate, as it has demonstrated an antifibrotic effect in other organs."	( The effect of losartan on the development of post-traumatic joint stiffness in a rat model. Baranowski, A; Drees, P; Gercek, E; Harper, A; Mickan, T; Müller, L; Ritz, U; Rommens, PM; Slotina, E; Truffel, S; Wegner, E; Wunderlich, F, 2023)	1.99
"Losartan is a selective antagonist of AngⅠ type (AT1) receptor of Angiotensin Ⅱ (Ang Ⅱ), which is widely used as a clinical medicine for the hypertension. "	( Losartan, a selective antagonist of AT1 receptor, attenuates seawater inhalation induced lung injury via modulating JAK2/STATs and apoptosis in rat. Bo, L; Jin, F; Li, C; Li, P; Li, W; Liu, W; Lu, X; Mu, D; Pan, L; Sun, Y, 2017)	3.34
"Losartan treatment is a negative risk factor of arterial stiffness and reduces the risk of ACS in aged patients with essential hypertension."	( Administration of losartan improves aortic arterial stiffness and reduces the occurrence of acute coronary syndrome in aged patients with essential hypertension. Fei, JC; Guo, T; Li, MM; Lv, YH; Miao, Z; Ou, WS; Wang, BX; Wang, SX; Zhang, ZM, 2019)	2.29
"Losartan is a promising candidate drug for treatment of GPHYSD due to FBN1 defects."	( Skin fibroblasts of patients with geleophysic dysplasia due to FBN1 mutations have lysosomal inclusions and losartan improves their microfibril deposition defect. Bacino, CA; Brunetti-Pierri, N; Hicks, J; Mithbaokar, P; Piccolo, P; Polishchuk, E; Polishchuk, R; Sabatino, V, 2019)	2.17
"Losartan is a safe and metabolically neutral medication."	( [Postmarketing study of efficacy and safety of losartan during the treatment of patients with mild and moderate hypertension: LOTAR (corrected) study]. Burmazović, S; Dimković, N; Krstić, N; Lazarević, K; Micić, D; Milanović, S; Vasilijević, Z; Zorić, S, )	1.11
"Losartan is an effective anti-hypotension drug frequently used in clinic. "	( Influence of compound danshen tablet on the pharmacokinetics of losartan and its metabolite EXP3174 by liquid chromatography coupled with mass spectrometry. Chai, Y; Ma, W; Sun, S; Wang, B; Yuan, Y; Zhang, G; Zhang, H; Zhao, L, 2013)	2.07
"Losartan is a Food and Drug Administration approved antihypertensive medication that is recently emerging as an antifibrotic therapy. "	( Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. Corona, BT; Garg, K; Walters, TJ, 2014)	3.29
"Losartan is an angiotensin II receptor antagonist widely used for the treatment of hypertension, diabetic nephropathy and congestive heart failure."	( Losartan inhibits LPS + ATP-induced IL-1beta secretion from mouse primary macrophages by suppressing NALP3 inflammasome. Huang, L; Lu, MM; Mel, WJ; Meng, J; Mo, ZH; Peng, Y; Peng, ZZ; Tang, YT; Tao, LJ; Wang, F; Wu, L, 2014)	2.57
"Losartan (Cozaar™) is an angiotensin II receptor antagonist with antihypertensive activity. "	( Losartan: Comprehensive Profile. Abdel-Aziz, HA; Al-Majed, AR; Assiri, E; Khalil, NY, 2015)	3.3
"Losartan is an angiotensin II (Ang II) type I receptor (AT1R) antagonist proposed to have an antiplatelet activity via the inhibition of both the thromboxane A2 (TXA2) receptor (TP) and the glycoprotein VI (GPVI)."	( Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan. Jandrot-Perrus, M; Jiang, P; Jondeau, G; Loyau, S; Ropers, J; Tchitchinadze, M, 2015)	1.34
"Losartan (LST) is a common chemical drug used to treat high blood pressure and reduce the risk of stroke in certain people with heart disease. "	( Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9. Wang, R; Wang, Y; Yu, X; Yuan, Y; Zhang, H, 2016)	2.11
"Losartan is an angiotensin II receptor (AT-II-R) blocker that is widely used by human for blood pressure regulation. "	( Losartan sensitizes selectively prostate cancer cell to ionizing radiation. Ghasemi, A; Hosseinimehr, SJ; Pourfallah, TA; Rafiei, A; Yazdannejat, H, 2016)	3.32
"Losartan is a selective angiotensin II receptor type 1 blocker and a substrate of drug efflux transporter MDR1 (ABCB1). "	( Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients. Babaoglu, MO; Bozkurt, A; Cevik, L; Göktaş, MT; Gumus, E; Guven, GS; Kalkışım, S; Karaca, Ö; Pepedil, F; Yasar, U, 2016)	2.09
"Losartan potassium is an antihypertensive drug in the angiotensin II receptor antagonist (ARA) class. "	( Modulating effect of losartan potassium on the mutagenicity and recombinogenicity of doxorubicin in somatic cells of Drosophila melanogaster. Nepomuceno, JC; Orsolin, PC; Silva-Oliveira, RG, 2016)	2.2
"Losartan is a novel, orally active, non-peptide angiotensin II receptor antagonist which specifically blocks the angiotensin II (AT1) receptor. "	( The acute and chronic effects of losartan in heart failure. Crozier, I; Ikram, H, 1995)	2.02
"Losartan is a potent pharmaceutical drug for ALI/ARDS."	( Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Cai, L; Kong, T; Mo, H; Qi, J; Shen, L; Xiao, Z; Ye, J; Zheng, W, 2009)	2.52
"Losartan is an antihypertensive drug with all these capabilities and placebo-like side-effect profile."	( [The pleiotropic effects of losartan--the importance of decreasing uric acid level]. Cseh, J; Csiky, B; Markó, L; Mikolás, E; Mohás, M; Szíjártó, I; Wittmann, I, 2008)	1.36
"Losartan/HCTZ is an effective combination therapy, lowering blood pressure (BP) to a greater extent than losartan or HCTZ alone in patients with hypertension."	( Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Keating, GM, 2009)	2.52
"Losartan is a selective nonpeptite antagonist against type 1 angiotensin II receptors (AT1R), and has been applied in medical treatments of a variety of cardiovascular diseases, including essential hypertension."	( Cardiovascular effects of losartan and its relevant clinical application. Hu, Y; Mao, C; Rui, C; Xu, F; Xu, Z; Zhang, L, 2009)	1.37
"Losartan is an emerging therapy that may help slow down the rate of arterial dilatation."	( Loeys-Dietz syndrome: a Marfan-like syndrome associated with aggressive vasculopathy. Choo, JT; Lai, AH; Tan, TH; Wong, KY, 2009)	1.07
"Losartan is a nonpeptide angiotensin II receptor antagonist used as an antihypertensive agent. "	( Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Jia, JY; Li, SJ; Liu, GY; Liu, Y; Liu, YM; Lu, C; Qi, YL; Weng, LP; Yu, C; Zhang, MQ, 2010)	2.05
"Losartan is an effective antagonist of angiotensin II AT(1) receptors which has been shown to provide important clinical benefits in patients with hypertension, congestive heart failure and renal diseases. "	( Pharmacokinetic evaluation of losartan. Burnier, M; Wuerzner, G, 2011)	2.1
"Losartan acts as an immunomodulator that prevents the development of CD14+CD16+ pro-inflammatory monocytes in HD patients."	( Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients. Aljama, P; Alvarez-Lara, MA; Carracedo, J; Martin-Malo, A; Merino, A; Ramirez, R, 2012)	3.26
"Losartan is an angiotensin II receptor antagonist mainly used for the regulation of high blood pressure. "	( Losartan's affinity to fluid bilayers modulates lipid-cholesterol interactions. Hodzic, A; Mavromoustakos, T; Pabst, G; Rappolt, M; Zoumpoulakis, P, 2012)	3.26
"Losartan is a promising agent for the treatment of idiopathic pulmonary fibrosis and has a low toxicity profile."	( Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Couluris, M; Gross-King, M; Kinder, BW; Krischer, J; Panos, RJ; Xu, P, 2012)	1.36
"Losartan (Los) is a Food and Drug Administration-approved antihypertensive medication that has a well-tolerated side effect profile. "	( The timing of administration of a clinically relevant dose of losartan influences the healing process after contusion induced muscle injury. Ambrosio, F; Cummins, JH; Fu, FH; Huard, J; Kobayashi, T; Ota, S; Terada, S; Tobita, K; Uehara, K, 2013)	2.07
"Losartan is an orally active, selective, nonpeptide, angiotensin II AT(1) receptor antagonist. "	( Losartan in diabetic nephropathy. Carswell, CI; Goa, KL, 2003)	3.2
"Losartan is an effective antihypertensive drug with an excellent safety and tolerability profile. "	( An open comparative clinical trial to assess the efficacy and safety of losartan versus enalapril in mild to moderate hypertension. Adhikari, PM; Bhat, P; Chowta, KN; Chowta, MN, 2002)	1.99
"Losartan is an orally active angiotensin II receptor antagonist indicated for the treatment of hypertension. "	( Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry. Lo, MW; Polinko, M; Riffel, K; Song, H, 2003)	2.05
"Losartan is a specific angiotensin II receptor antagonist. "	( Losartan induced fetal toxicity. Aggarwal, R; Malhotra, N; Nayar, B; Singhal, A, 2003)	3.2
"Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class. "	( Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Devereux, RB; Lyle, PA, 2004)	3.21
"Losartan is a safe, effective long-term treatment for hypertension or posttransplant erythrocytosis (PTE) in renal transplant recipients. "	( Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. Cift, A; Dilek, K; Ersoy, A; Ersoy, C; Kahvecioglu, S, 2005)	2.13
"Losartan is a competitive antagonist that causes a parallel rightward shift of the concentration-contractile response curve to angiotensin-II, while E 3174 is a noncompetitive "insurmountable" antagonist of angiotensin-II."	( Clinical pharmacokinetics of losartan. Gehr, TW; Ghosh, S; Sica, DA, 2005)	1.34
"Losartan is a selective non-peptide angiotensin Type 1-receptor blocker (ARB) with unique uricosuric effect, not shared by other ARBs."	( Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. Chiurchiu, C; Parvanova, A; Remuzzi, G; Ruggenenti, P, 2005)	1.28
"Losartan potassium is an orally active, non-peptide angiotensin II receptor antagonist."	( Study of efficacy and safety of losartan (losar) in Asian Indian hypertensives. Chopra, D; Joshi, RM; Joshi, SR; Kale, S; Oomman, A, 2005)	1.33
"Losartan (Cozaar) is an angiotensin AT1 receptor antagonist. "	( Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Moen, MD; Wagstaff, AJ, 2005)	3.21
"Losartan is an optimum choice of medication for patients with mild-to-moderate hypertension complicating hyperuricemia."	( [The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia]. Chen, GL; Dang, AM; Liu, GZ; Zhang, YH, 2006)	1.78
"Losartan is a specific AT1 receptor antagonist which can effectively inhibit the effects of Ang II."	( Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan. Li, GS; Li, JJ; Li, NX; Peng, J; Wang, J; Xu, HX, 2007)	1.26
"Losartan appears to be a better alternative to ACE inhibitors for treating atherosclerosis in Japanese hypertensive patients."	( A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. Aoyagi, T; Nagai, R; Sonoda, M; Takenaka, K; Uno, K, 2008)	1.29
"Losartan appears to be an effective anti-hypertensive agent in patients with mild to moderate hypertension."	( Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. Bauer, IH; Lau-Sieckman, A; Reams, GP; Wu, Z, 1995)	1.4
"Losartan is a specific, nonpeptide angiotensin II receptor-1 antagonist with a vasodilator hemodynamic profile similar to that of converting enzyme inhibitors. "	( Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. Chang, P; Dickstein, K; Hall, C; Haunsø, S; Kjekshus, J; Remes, J; Willenheimer, R, 1995)	2.03
"Losartan (DuP 753) is a novel orally active angiotensin II antagonist that lowers blood pressure. "	( Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Carroll, J; Grossman, E; Peleg, E; Rosenthal, T; Shamiss, A, 1994)	1.97
"Losartan is a 4-chloro-5-hydroxymethylimidazole derivative that is a potent and highly selective angiotensin II receptor antagonist. "	( Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Chakravarty, PK; Chen, R; Chiu, SH; Stearns, RA, 1995)	2.05
"Losartan is a specific angiotensin II receptor antagonist with no agonist properties. "	( Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. DeKock, M; Dickstein, K; Fleck, E; Gottlieb, S; Kostis, J; LeJemtel, T; Levine, B, 1994)	1.97
"Losartan is a potent, nonpeptide, angiotensin II type 1 receptor antagonist. "	( Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. Bertolino, F; Bessac, AM; John, GW; Jover, B; Maffre, M; Valentin, JP, 1994)	1.73
"Losartan is a new specific angiotensin II receptor antagonist with no agonist properties that provides the opportunity to study the consequences of angiotensin II blockade. "	( Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. DeKock, M; Dickstein, K; Fleck, E; Gottlieb, SS; Kostis, J; LeJemtel, T; Levine, TB, 1993)	1.96
"Losartan is a novel nonpeptidergic antagonist of angiotensin (ANG) II subtype 1 (AT1) receptors, which effectively lowers blood pressure in high-renin hypertensive rat and blocks the pressor response to systemic ANG II. "	( Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat. Bains, JS; Ferguson, AV; Li, Z, 1993)	1.98
"8. Losartan appears to be a potent orally active angiotensin II antagonist with a relatively long duration of action."	( Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Nakashima, M; Ohtawa, M; Saitoh, K; Takayama, F; Yoshinaga, T, 1993)	1.02
"Losartan is an orally active, nonpeptide angiotensin II (Ang II) (site-1) receptor antagonist. "	( Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Barchowsky, A; Bjornsson, TD; Bradstreet, TE; Goldberg, MR; Lo, MW; McCrea, J; McWilliams, EJ; Tanaka, W, 1993)	2.12
"Losartan is a nonpeptide, competitive antagonist of the type I angiotensin II receptor. "	( Angiotensin II receptor antagonists: the prototype losartan. Porter, JA; Schaefer, KL, 1996)	1.99
"Losartan is an orally active angiotensin II antangonist that selectively blocks effects mediated by the stimulation of the AT1 subtype of the angiotensin II receptor. "	( Angiotensin II antagonists: a new class of antihypertensive agent. Brunner, HR; Waeber, B, )	1.57
"Losartan is a nonpeptide ANG II receptor antagonist that is devoid of such nonspecific effects."	( Effects of angiotensin II receptor blockade during exercise: comparison of losartan and saralasin. Stebbins, CL; Symons, JD, 1996)	1.25
"Losartan potassium is an orally active, nonpeptide angiotensin II (AII) receptor antagonist. "	( Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Goa, KL; Wagstaff, AJ, 1996)	3.18
"Losartan is a new angiotensin II type 1 (AT1) receptor antagonist and an antihypertensive drug. "	( Effects of chronic treatment with losartan on blood pressure, endothelin-like immunoreactivity and nitric oxide in normotensive rats. Bellini, G; Bocin, E; Cosenzi, A; Luxich, E; Molino, R; Plazzotta, N; Sacerdote, A; Seculin, P, 1995)	2.01
"Losartan is an effective and well-tolerated antihypertensive drug showing similar blood-pressure-lowering efficacy to that of enalapril at trough. "	( Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. Jensen, HA; Omvik, P; Tikkanen, I, 1995)	2
"Losartan is a specific, nonpeptide angiotensin II receptor antagonist. "	( Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. Chang, PI; Elkayam, U; Krauss, D; Lang, RM; Makris, L; McKelvie, RS; Ney, DE; Vaughan, DE; Yellen, LG, 1997)	2.05
"Losartan is a novel orally active nonpeptidal antihypertensive agent that specifically blocks the angiotensin II type 1 receptor. "	( Clinical safety and tolerability of losartan. Weber, M, )	1.85
"Losartan is a selective angiotensin II receptor-antagonist."	( [The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension]. Acitorio, M; Aquino, D; Caccavale, A; Coppolino, P; Cosimi, R; Iacono, A; Iarussi, D; Ratti, G; Rocereto, A; Tedesco, MA, 1998)	1.29
"Losartan potassium is an angiotensin II receptor blocker. "	( Determination of losartan and its degradates in COZAAR tablets by reversed-phase high-performance thin-layer chromatography. Brooks, MA; Gilbert, RE; Ip, DP; McCarthy, KE; Tsai, EW; Wang, Q, 1998)	2.08
"Losartan potassium is a recently marketed angiotensin II receptor antagonist. "	( The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group. Barnes, CC; Lacourcière, Y; Wilson, TW, 1998)	2.02
"Losartan is an angiotensin II receptor antagonist that is metabolized by CYP2C9 and CYP3A4 to a more potent antihypertensive metabolite, E3174. "	( The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. Hinderliter, AL; Meadowcroft, AM; Patterson, JH; Pieper, JA; Williamson, KM, 1999)	2
"Losartan is a potent non-peptide, selective angiotensin II (AngII) type 1 (AT1) receptor antagonist. "	( [Pharmacological properties and its significance in clinical practice]. Ikemoto, F; Nishikibe, M, 1999)	1.75
"Losartan is a prodrug type Angiotensin II (Ang II) AT1-receptor antagonist whose efficacy depends on the oxidase activity of individuals. "	( Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension. Hashimoto, Y; Minami, K; Narita, H; Ohashi, R, 1999)	1.97
"Losartan is an angiotensin II receptor blocker indicated for treatment of hypertension. "	( Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide--a randomized controlled trial. Fitzgerald, D; Kelly, L; Nallen, R; O'Brien, E; Owens, P; Ryan, D, 2000)	2
"Losartan is an orally active, nonpeptide, selective angiotensin subtype 1 (AT1) receptor antagonist. "	( Losartan: a review of its use, with special focus on elderly patients. McClellan, KJ; Simpson, KL, 2000)	3.19
"Losartan is a selective angiotensin AT1 receptor antagonist currently employed in the management of essential hypertension. "	( Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. Gehr, TW; Halstenson, CE; Keane, WF; Sica, DA, 2000)	2.01
"Losartan is a selective, competitive antagonist of the thromboxane A2 receptor in experiments performed in isolated vascular strips and in human and rat platelet-enriched plasma."	( Inhibition of platelet aggregability by losartan in essential hypertension. Brosnihan, KB; Ferrario, CM; Levy, PJ; Owen, J; Smith, R; Yunis, C, 2000)	1.3
"Losartan potassium is an efficacious antihypertensive agent in mild to moderate hypertension. "	( Evaluation of efficacy and safety of losartan potassium in the treatment of mild to moderate hypertension as compared to enalapril maleate. Babu, A; Bhaduri, J; Kamath, S; Kumar, TR; Raju, BS; Rao, M; Shobha, JC, 2000)	2.02
"Losartan is a non-peptidic inhibitor of AT1 receptors."	( Angiotensin II AT(1) receptor antagonists and platelet activation. Casado, S; Gómez, J; Jiménez, A; Lopez-Bloya, A; López-Farré, A; Montón, M; Núñez, A; Rico, L; Sánchez de Miguel, L, 2001)	1.03

Excerpt	Reference	Relevance
"Losartan has a dose-dependent antagonistic effect to the ET-1 induced contraction, which seems to ET(B)-receptor dependent."	( Crosstalk between the angiotensin and endothelin-system in the cerebrovasculature. Güresir, E; Konczalla, J; Mrosek, J; Platz, J; Schuss, P; Seifert, V; Vatter, H; Wanderer, S, 2013)	1.11
"Losartan has a protective effect on LPS-induced ALI, which may be partly dependent on suppressions of Th1 and Th17 polarization response."	( [Losartan modulates T helper type 1 cells and T helper type 17 cells-mediated responses in a mouse model of lipopolysaccharide-induced acute lung injury]. Guo, F; He, H; Huang, Y; Liu, J; Liu, L; Qiu, H; Yang, Y; Yu, T; Zhang, P, 2014)	2.76
"Losartan has a protective effect on heart function against myocardial interstitial fibrosis of DCM by inhibiting JAK/STAT signaling pathway and lowering the expression of TGF-β1."	( Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway. Li, D; Li, J; Wang, L, 2015)	3.3
"Losartan has a long duration of action and its ability to produce a sustained blockade of the renin-angiotensin system is due almost exclusively to the active metabolite E3174."	( Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects. Brunner, HR; Burnier, M; Waeber, B, 1995)	1.25
"Losartan, which has a high affinity for the urate/anion exchanger, has a transient uricosuric effect. "	( Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Furuse, M; Hamada, T; Hisatome, I; Igawa, O; Kinugasa, Y; Matsubara, K; Ohtahara, A; Shigemasa, C; Shimizu, H; Sonoyama, K; Tanaka, H; Yamamoto, T; Yamamoto, Y, 2002)	2.01
"Losartan has an antimigratory effect, reducing leukocyte migration by reducing ICAM-1 and P-selectin expression."	( Losartan attenuates the antimigratory effect of diclofenac in spontaneously hypertensive rats. Carvalho, MH; Cruz, JW; Fortes, ZB; Martinez, LL; Miguel, AS; Nigro, D; Oliveira, MA; Rastelli, VM; Tostes, RC, 2005)	2.49
"Losartan has a sustained duration of action, permitting once-daily dosing in many patients, and lacks partial agonist activity."	( The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Gavras, HP; Salerno, CM, )	1.12
"Thus losartan has an additional, although only partial, renoprotective effect when compared with verapamil."	( Renoprotective effect of angiotensin II receptor antagonists in experimental chronic renal failure. Avinoach, I; Ben-David, A; Eliahou, H; Matas, Z; Shahar, C; Shahmurov, M; Zimlichman, R, )	0.59
"Losartan alone has less prominent anti-inflammatory effects particularly after 28 days; however, it efficiently prevented late fibrosis."	( The inhibitory mechanisms of losartan and vitamin D on amiodarone-induced lung inflammation in rats: Role of mitogen-activated protein kinases/activator protein-1. Al-Hassan, S; Ali, RA; Alomar, H; Arafa, M; Attia, H, 2021)	1.63
"Losartan has no effect on high altitude diuresis or acute mountain sickness in well-acclimatizing individuals."	( Losartan Has No Effect on High Altitude Diuresis or Acute Mountain Sickness in Well-Acclimatizing Individuals. Bradwell, AR; Bradwell, SB; Clarke, A; Delamere, JP; Lewis, CT, 2021)	2.79
"Losartan has been proposed as a new therapeutic tool for this purpose."	( Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial. Campens, L; De Backer, J; De Nobele, S; De Paepe, A; Devos, D; Muiño-Mosquera, L, 2017)	1.56
"Losartan has been proposed to block clustering of GPVI but not to affect binding of collagen."	( Comparison of the GPVI inhibitors losartan and honokiol. Eble, JA; Heemskerk, JWM; Nagy, M; Onselaer, MB; Pallini, C; Perrella, G; Pike, JA; Poulter, NS; Quintanilla, LG; Watson, SP, 2020)	1.56
"Losartan has a dose-dependent antagonistic effect to the ET-1 induced contraction, which seems to ET(B)-receptor dependent."	( Crosstalk between the angiotensin and endothelin-system in the cerebrovasculature. Güresir, E; Konczalla, J; Mrosek, J; Platz, J; Schuss, P; Seifert, V; Vatter, H; Wanderer, S, 2013)	1.11
"Losartan has been reported to improve ASC transplantation in injured mouse muscles."	( Therapeutic effects of mouse adipose-derived stem cells and losartan in the skeletal muscle of injured mdx mice. Hwang, M; Jeong, KS; Kim, AY; Kim, CY; Kim, SY; Lee, EJ; Lee, EM; Lee, MM; Park, JK, 2015)	1.38
"Losartan has been widely evaluated for the management of hypertension."	( Managing blood pressure control in Asian patients: safety and efficacy of losartan. Cheung, BM; Cheung, TT, 2014)	1.35
"Losartan has a protective effect on LPS-induced ALI, which may be partly dependent on suppressions of Th1 and Th17 polarization response."	( [Losartan modulates T helper type 1 cells and T helper type 17 cells-mediated responses in a mouse model of lipopolysaccharide-induced acute lung injury]. Guo, F; He, H; Huang, Y; Liu, J; Liu, L; Qiu, H; Yang, Y; Yu, T; Zhang, P, 2014)	2.76
"Losartan has a protective effect on heart function against myocardial interstitial fibrosis of DCM by inhibiting JAK/STAT signaling pathway and lowering the expression of TGF-β1."	( Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway. Li, D; Li, J; Wang, L, 2015)	3.3
"Losartan has also proved useful in further defining the heterogeneity of angiotensin II receptors."	( The preclinical basis of the therapeutic evaluation of losartan. Chiu, AT; Smith, RD; Timmermans, PB; Wong, PC, 1995)	1.26
"Losartan has a long duration of action and its ability to produce a sustained blockade of the renin-angiotensin system is due almost exclusively to the active metabolite E3174."	( Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects. Brunner, HR; Burnier, M; Waeber, B, 1995)	1.25
"Losartan has been proposed for the prevention of thoracic aortic aneurysm."	( Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome. Chum, E; Chung, AW; Kim, JM; van Breemen, C; Yang, HH, 2009)	1.39
"Losartan has protective effects against CDDP-induced nephrotoxicity as evidenced by restoration of normal serum levels of creatinine and BUN, and LDH leakage. "	( Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Ain-Shoka, AA; El-Demerdash, E; Khalef, MM; Saleh, S, 2009)	2.04
"Losartan has been shown to prevent aneurysms in another mouse model of MFS, Fbn1(C1039G/+), through inhibition of the Erk1/2 pathway."	( MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome. Baxter, BT; Knispel, R; Meisinger, T; Worth, JM; Xiong, W, 2012)	1.1
"Losartan potassium has one main impurity and two primary degradates."	( Development and validation of a stability-indicating HPLC method for the simultaneous determination of losartan potassium, hydrochlorothiazide, and their degradation products. Fang, X; Hertzog, DL; McCafferty, JF; Reed, RA; Tyrrell, RJ, 2002)	1.25
"Losartan, which has a high affinity for the urate/anion exchanger, has a transient uricosuric effect. "	( Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Furuse, M; Hamada, T; Hisatome, I; Igawa, O; Kinugasa, Y; Matsubara, K; Ohtahara, A; Shigemasa, C; Shimizu, H; Sonoyama, K; Tanaka, H; Yamamoto, T; Yamamoto, Y, 2002)	2.01
"Losartan has also been shown to be effective in diabetics and in patients with atrial fibrillation, as well as in left ventricular hypertrophy regression."	( Implications of the LIFE trial. Lim, HS; Lip, GY; Nadar, S, 2003)	1.04
"Losartan has recently been suggested as a selective probe for CYP2C9 metabolic activity."	( CYP2C9 genetic variants and losartan oxidation in a Turkish population. Babaoglu, MO; Bozkurt, A; Dahl, ML; Eliasson, E; Kayaalp, SO; Sandberg, M; Yasar, U, 2004)	1.34
"Losartan has been extensively studied relative to end-organ protection, with studies having been conducted in diabetic nephropathy, heart failure, post-myocardial infarction and hypertensive patients with left ventricular hypertrophy."	( Clinical pharmacokinetics of losartan. Gehr, TW; Ghosh, S; Sica, DA, 2005)	1.34
"Losartan has an antimigratory effect, reducing leukocyte migration by reducing ICAM-1 and P-selectin expression."	( Losartan attenuates the antimigratory effect of diclofenac in spontaneously hypertensive rats. Carvalho, MH; Cruz, JW; Fortes, ZB; Martinez, LL; Miguel, AS; Nigro, D; Oliveira, MA; Rastelli, VM; Tostes, RC, 2005)	2.49
"Losartan has demonstrated renoprotective effects in animals and humans with diabetic and non-diabetic renal diseases similar to those of angiotensin-converting enzyme inhibitors, with a lower incidence of dry cough and angioneurotic oedema."	( Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. Chiurchiu, C; Parvanova, A; Remuzzi, G; Ruggenenti, P, 2005)	1.28
"Losartan has been shown to protect the diabetic kidney, at least partly independent of changes in blood pressure. "	( The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. Baggen, MG; Boersma, E; Bootsma, AH; Janssen, JA; Lamberts, SW; Zandbergen, AA, 2006)	2.02
"Losartan metabolism has been suggested as a marker for determination of CYP2C9 activity."	( Differential alteration of drug-metabolizing enzyme activities after cyclophosphamide/adriamycin administration in breast cancer patients. Altundag, K; Babaoglu, MO; Bozkurt, A; Dincel, AK; Elkiran, T; Guler, N; Harputluoglu, H; Ozisik, Y; Yasar, U, )	0.85
"Losartan has recently been reported to suppress atrial structural remodeling. "	( The effects of losartan on signal-averaged P wave in patients with atrial fibrillation. Kawano, T; Nakaya, Y; Nakayasu, K; Nomura, M, 2008)	2.14
"Losartan has been reported to have inhibitory effects on thromboxane (TP) receptor-mediated responses. "	( Differential effects of losartan and candesartan on vasoconstrictor responses in the rat. Baber, SR; Detrolio, JD; Kadowitz, PJ; Nazim, MM; Nossaman, BD, )	1.88
"Losartan has no adverse haemorheological effects and was associated with a small and statistically insignificant decrease in blood viscosity."	( Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. Bailey, RR; Gilchrist, NL; Nicholls, MG; Shand, BI, 1995)	1.41
"Losartan has been shown to lower blood pressure in patients with essential hypertension. "	( How well have animal studies with losartan predicted responses in humans? Nelson, EB; Sweet, CS, 1993)	2.01
"Losartan has been widely used to define the distribution and function of AT receptor subtypes."	( Discovery of losartan, the first angiotensin II receptor antagonist. Carini, DJ; Chiu, AT; Duncia, JV; Smith, RD; Timmermans, PB; Wexler, RR; Wong, PC, 1995)	1.38
"Losartan has a sustained duration of action, permitting once-daily dosing in many patients, and lacks partial agonist activity."	( The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Gavras, HP; Salerno, CM, )	1.12
"Losartan has proven antihypertensive effects and its safety profile in the initial controlled trials (approximately 2900 patients) and in general practice (more than 14,000 patients in Sweden) has been very good."	( Medical and cost-economy aspects of modern antihypertensive therapy--with special reference to 2 years of clinical experience with losartan. Hansson, L, 1997)	1.22
"Losartan has been worldwide marketed as the first orally active AT1 receptor antagonist with once-daily dosing for treatment of hypertension."	( [Pharmacological properties and its significance in clinical practice]. Ikemoto, F; Nishikibe, M, 1999)	1.02
"Thus losartan has an additional, although only partial, renoprotective effect when compared with verapamil."	( Renoprotective effect of angiotensin II receptor antagonists in experimental chronic renal failure. Avinoach, I; Ben-David, A; Eliahou, H; Matas, Z; Shahar, C; Shahmurov, M; Zimlichman, R, )	0.59
"Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels. "	( Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001)	2.06
"Losartan has salutary effects on postinfarction remodeling and gene expression, whereas cariporide is neutral."	( Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. Ellingsen, O; Falck, G; Loennechen, JP; Wisløff, U, 2002)	1.34
"But losartan potassium has been found to be more effective with fewer side effects when compared to enalapril maleate."	( A comparative evaluation of therapeutic effects of once a day dose of losartan potassium versus enalapril maleate in mild to moderate essential hypertension. Arora, P; Neki, NS, 2001)	1.03

Excerpt	Reference	Relevance
"Losartan failed to inhibit AEPAP after all sessions of ethanol injection, and partially reversed the ethanol-induced PA remodeling."	( Inhibition of angiotensin II type 1 receptor partially prevents acute elevation of pulmonary arterial pressure induced by endovascular ethanol injection. Fan, X; Han, Y; Jiao, X; Shen, Y; Su, L; Wang, D; Wang, Z; Zheng, L, 2023)	1.63
"Losartan promotes myocardial apoptosis after AMI in the rats through inhibiting the Ang II-induced JAK/STAT pathway."	( Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway. Liu, R; Xin, LH; Yang, XW, 2020)	3.44
"As losartan is known to inhibit proinflammatory cytokine release, we hypothesized that it improves these visceral changes."	( Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome. Miyagishi, S; Nozu, R; Nozu, T; Okumura, T; Takakusaki, K, 2020)	2.51
"Losartan did not blunt sPRR-induced elevation in systolic BP."	( Soluble Prorenin Receptor Increases Blood Pressure in High Fat-Fed Male Mice. Gatineau, E; Gong, MC; Yiannikouris, F, 2019)	1.24
"Losartan induced an increase in capillary and BrdU+ vascular densities in the infarct border zone."	( Effects of angiotensin II blockade on cardiomyocyte regeneration after myocardial infarction in rats. Forsten, H; Harjula, A; Immonen, K; Kankuri, E; Kosonen, R; Laine, M; Lakkisto, P; Palojoki, E; Segersvärd, H; Tikkanen, I, 2015)	1.14
"Losartan inhibited the increase of these inflammatory markers."	( Renal inflammatory markers during the onset of hypertension in spontaneously hypertensive rats. Heijnen, BF; Janssen, BJ; Schalkwijk, CG; Struijker-Boudier, HA; Van Essen, H, 2014)	1.12
"Losartan prevented the increase of PLC β1 and γ1 protein levels induced by HG (P<0.05)."	( Losartan, an angiotensin II type 1 receptor blocker, protects human islets from glucotoxicity through the phospholipase C pathway. Bosco, D; Cassel, R; Chauvin, MA; Chikh, K; Dubois, S; Ducreux, S; Madec, AM; Mesnier, A; Rieusset, J; Thivolet, C; Van Coppenolle, F; Vial, G, 2013)	2.55
"Losartan was stopped because of hyperkalemia and acidosis earlier in patients who were on tacrolimus than cyclosporine immunosuppression (tacrolimus, 3 ± 1 mo; cyclosporine, 4.7 ± 0.8 mo; P ≤ .001)."	( Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients. Baskın, E; Bayrakcı, US; Haberal, M; Moray, G; Sakallı, H, 2014)	1.4
"Losartan is able to suppress the LPS + ATP-induced production of IL-1beta protein."	( Losartan inhibits LPS + ATP-induced IL-1beta secretion from mouse primary macrophages by suppressing NALP3 inflammasome. Huang, L; Lu, MM; Mel, WJ; Meng, J; Mo, ZH; Peng, Y; Peng, ZZ; Tang, YT; Tao, LJ; Wang, F; Wu, L, 2014)	2.57
"Losartan can also enhance adiponectin (P<0.05) and decrease TNF-α (P<0.05) and IL-6 (P<0.01) secretion, while amlodipine can't."	( Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. Fu, SK; Gu, HF; Hu, C; Jin, HM; Liu, XL; Pan, LH; Pan, Y; Qiao, QY; Zhou, DC, 2015)	2.58
"Losartan generated a lower incidence than angiotensin-converting enzyme inhibitors of reported dry cough (risk ratio 0.19, 95% confidence interval 0.10-0.36)."	( Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. Fan, Y; Lang, Y; Wang, S; Wei, F, 2015)	2.58
"Losartan can increase the therapeutic effectiveness of doxorubicin, yielding more great antitumor benefit. "	( Losartan improves the distribution and efficacy of doxorubicin in CT26 tumor. Hu, SQ; Li, XY; Liu, JX; Wang, LY; Xiao, L, 2015)	3.3
"Losartan plays an important role in the inhibition of myocardial fibrosis. "	( Losartan Attenuates Myocardial Endothelial-To-Mesenchymal Transition in Spontaneous Hypertensive Rats via Inhibiting TGF-β/Smad Signaling. Lu, S; Ma, J; Peng, Z; Wu, M; Zhang, S; Zhong, J; Zu, C, 2016)	3.32
"Long losartan promotes regression remodeling processes of cardiac muscle and reduce preload and afterload."	( [REGRESSION OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ESSENTIAL HYPERTENSION AND LONG-TERM THERAPY WITH LOSARTAN]. Dotsenko, SY; Tokarenko, AA; Tokarenko, II, )	0.8
"Free losartan could inhibit collagen, but it would cause hypotension at the dosage of 10 mg/kg/d."	( Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer. Gao, H; He, Q; Liu, J; Ma, L; Shi, K; Wang, Y; Xia, T; Yu, Q; Zhang, L; Zhang, Q, 2018)	2.38
"Losartan could suppress the expression of COX2 and TGF-beta1 in the kidney of DN rats and attenuate the renal lesions caused by DN."	( Effect of losartan on cyclooxygenase-2 expression in normal human mesangial cells and kidneys of rats with diabetic nephropathy. Liu, ZC; Peng, WS; Yang, JH; Yuichiro, Y; Zhou, QL, 2008)	1.47
"Losartan can inhibit high glucose-induced CTGF expression in mouse mesangial cells, and the mechanisms maybe involve the interruption of ERK1/2 MAPK pathway."	( [Losartan inhibits high glucose-induced CTGF expression via ERK1/2 MAPK pathways in mouse mesangial cells]. Ning, WB; Peng, ZZ; Tao, LJ; Wang, L, 2009)	2.71
"Losartan prevented an increase in BP and SGLT2 expression in diabetic rats."	( Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Bautista, R; Escalante, B; Franco, M; Osorio, H; Rios, A; Santamaría, J, 2009)	1.38
"Losartan is known to inhibit transforming growth factor β signaling and may be a specific modulator of disease expression in this syndrome."	( Arterial tortuosity syndrome with multiple intracranial aneurysms: a case report. Levinson, JR; MacRae, CA; Nahed, BV; Naunheim, MR; Ogilvy, CS; Walcott, BP, 2011)	1.09
"Losartan can suppress the progression of prostate hyperplasia in spontaneous hypertension rats by inhibiting RAS, IGF-1 and angiogenesis."	( [Inhibitory effect of losartan on prostatic hyperplasia in spontaneous hypertension rats and its pathophysiological mechanism]. Dong, LN; Qu, XB; Shen, F; Zeng, XF; Zhang, XY; Zhao, XK, 2012)	2.14
"Losartan prevented the increase of the activity of promoter transcription induced by Ang II partly."	( [Regulation of alpha(1) type I collagen promoter by cytokines and losartan]. Gao, C; Lei, X; Mei, C; Zhou, C, 2002)	1.27
"Losartan prevented the increase in vascular resistance and improved renal blood flow under increased IAP."	( Role of angiotensin II under prolonged increased intraabdominal pressure (IAP) in pigs. Bostad, L; Grong, K; Gudmundsson, FF; Myking, OL; Svanes, K; Viste, A, 2003)	1.04
"Losartan can inhibit those deteriorations besides blood pressure lowering."	( [Relationship of hypertensive microalbuminuria and endothelial and glomerular impairment]. Sun, M; Wu, J; Zhou, HY, 2002)	1.04
"Losartan can suppress the occurrence of EAD during reperfusion following myocardial ischemia to reduce the incidence of reperfusion arrhythmias, suggesting its protective effect against myocardial ischemic injury."	( [Protective effects of losartan against myocardial ischemic reperfusion in intact canine]. Chen, YL; Huang, Z; Huo, ZC; Jia, MY; Peng, J; Wang, ZM; Yang, Y, 2005)	2.08
"Losartan prevented the increase of HBR in the AT group."	( The role of angiotensin receptor-1 blockade on electromechanical changes induced by left ventricular hypertrophy and its regression. Fry, CH; Gray, RP; Sheridan, DJ; Turner, MA, 2007)	1.06
"Losartan can increase the expression of AT1R mRNA in diabetic rat kidneys without altering the blood and renal Ang II levels."	( [Effects of losartan on the levels of angiotensin II and its type-1 receptor in diabetic rat kidney]. Chen, LH; Ding, HL; Fu, ZZ; Wu, W, 2006)	2.16
"Losartan at lower concentrations (3-100 nM) concentration dependently depressed the maximal responses to angiotensin II."	( A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations. Pfaffendorf, M; Van Zwieten, PA; Zhang, J; Zhang, JS, 1994)	1.25
"5. Losartan blocked the increase in SAP induced by AngII in the VLM and DM."	( Angiotensin II activates pressor and depressor sites of the pontomedulla that react to glutamate. Chai, CY; Chen, SY; Lin, AM; Tseng, CJ, 1996)	0.81
"Losartan may cause hyperkalemia when used with potassium-sparing diuretics, such as spironolactone or triamterene."	( [Drug-interactions and adverse effects of losartan potassium, an angiotensin II receptor antagonist]. Yoshinaga, K, 1999)	1.29
"Losartan seems to inhibit development of laser-induced choroidal neovascularization. "	( Inhibitory effect of losartan on laser-induced choroidal neovascularization in rats. Hikichi, T; Horikawa, Y; Mori, F; Sasaki, M; Takamiya, A; Takeda, M; Yoshida, A, 2001)	2.07
"Losartan prevented the increase in RV collagen but enhanced the increase in LV collagen."	( Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. Leenen, FH; White, R; Yuan, B, 2001)	1.03

Excerpt	Reference	Relevance
"Losartan, when treated as a single drug, resulted in a slight lowering of blood glucose levels in normal rats, diabetic rats and normal rabbits. "	( Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits. Anilkumar, KV; Nagaraju, B, )	1.83
"Losartan treatment for 4 weeks is associated with lower AT1R protein level, Nitrotyrosine, and Tau protein in the frontal cortex of aged IL-10-/- mice."	( Losartan Mitigates Oxidative Stress in the Brains of Aged and Inflamed IL-10-/- Mice. Abadir, PM; Cosarderelioglu, C; Saleh, N; Vajapey, R; Walston, J, 2022)	2.89
"Losartan treatment slowed muscle degeneration and activated the PI3K-AKT-mTOR and ERK/mitogen-activated protein kinase signalling pathways required for production of muscle growth factors when combined with exercise."	( Study of Therapeutic Effects of Losartan for Sarcopenia Based on the F344xBN Rat Aging Model. Kang, D; Kim, D; Park, K, )	1.86
"Losartan treatment effectively protects against cognitive (spatial memory, P < 0.01; passive avoidance P < 0.05 vs."	( Angiotensin 1 receptor antagonist attenuates acute kidney injury-induced cognitive impairment and synaptic plasticity via modulating hippocampal oxidative stress. Malek, M; Reisi, P; Sharifi, F, 2019)	1.24
"Losartan treatment effectively prevented increase of the hypothalamic Ang II concentration and the development of depression-like behavior, and also reduced the impairment of learning and memory in the stressed animals."	( Tactile stimulation of adult rats modulates hormonal responses, depression-like behaviors, and memory impairment induced by chronic mild stress: Role of angiotensin II. Casarini, DE; Costa, R; Cunha, TS; Marcondes, FK; Moreira, RP; Nogueira, MD; Sanches, A; Tamascia, ML, 2020)	1.28
"Losartan treatment also ameliorated the increase in aorta collagen content of the iron-overload group, without affecting circulating iron or vascular deposits."	( Blockade of angiotensin AT Ávila, RA; Botelho, T; Dos Santos, L; Fidelis, HG; Goes, SCE; Mageski, JGA; Marques, VB, 2020)	1.28
"Losartan treatment could increase the number of apoptotic myocardial cells after AMI in rats. "	( Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway. Liu, R; Xin, LH; Yang, XW, 2020)	3.44
"Losartan treatment alleviated some of the T2DM- induced metabolic complications, abolished the T2DM-induced hypo activity, and normalized the corticosterone level, carbonylated proteins in brain, nociception and memory."	( Protective effects of losartan on some type 2 diabetes mellitus-induced complications in Wistar and spontaneously hypertensive rats. Grozdanov, P; Kostadinova, N; Krumova, E; Mitreva-Staleva, J; Pechlivanova, D; Stoynev, A, 2020)	1.59
"Losartan-treated mice (10 mg/kg per day, drinking water, 7 months) received intracerebroventricular (1 month) administration of vehicle or AT2R antagonist PD123319 (1.6 nmol/day)."	( AT2R's (Angiotensin II Type 2 Receptor's) Role in Cognitive and Cerebrovascular Deficits in a Mouse Model of Alzheimer Disease. Fermigier, A; Hamel, E; Lacalle-Aurioles, M; Royea, J; Trigiani, LJ, 2020)	1.28
"Losartan treatment attenuated mechanical allodynia significantly."	( Losartan attenuates neuroinflammation and neuropathic pain in paclitaxel-induced peripheral neuropathy. Diallo, M; Kalynovska, N; Palecek, J; Sotakova-Kasparova, D, 2020)	2.72
"Losartan treatment was not associated with an improvement in interleukin-6 levels, or other blood measures of inflammation, immune activation, fibrosis activity or myocardial function."	( Losartan to reduce inflammation and fibrosis endpoints in HIV disease. Baker, JV; Collins, G; Deeks, S; Liappis, AP; Morse, C; Mystakelis, H; Neaton, J; Rhame, F; Rizza, S; Schacker, T; Sereti, I; Temesgen, Z; Tracy, RP; Wolfson, J, 2021)	2.79
"Losartan treatment is unlikely to reduce inflammation associated comorbidities to a clinically meaningful degree, beyond the benefits from lowering blood pressure."	( Losartan to reduce inflammation and fibrosis endpoints in HIV disease. Baker, JV; Collins, G; Deeks, S; Liappis, AP; Morse, C; Mystakelis, H; Neaton, J; Rhame, F; Rizza, S; Schacker, T; Sereti, I; Temesgen, Z; Tracy, RP; Wolfson, J, 2021)	2.79
"Losartan treatment one hour prior to SARS-CoV-2 infection reduced levels of SARS-CoV-2 nuclear protein, an indicator of virus replication, by 80% and treatment one-hour post-infection decreased viral replication by 70%."	( Losartan Inhibits SARS-CoV-2 Replication in Vitro. Crabttree, J; Freitas, B; Najafi, D; Nejat, R; Pegan, SD; Sadr, AS; Tripp, RA, 2021)	2.79
"Losartan treatment prevented these SAD-induced changes."	( Effects of losartan on vasomotor function and canonical transient receptor potential channels in the aortas of sinoaortic denervation rats. Liang, M; Liu, Y; Miao, F; Wu, H; Zhong, W, 2018)	1.59
"Losartan treatment for three weeks lowered systolic blood pressure in both Control and Restricted groups but this difference was not sustained after the cessation of treatment."	( Angiotensin receptor blockade in juvenile male rat offspring: Implications for long-term cardio-renal health. Gallo, LA; Mazzuca, MQ; Moritz, KM; Parkington, HC; Tare, M; Walton, SL; Wlodek, ME, 2018)	1.2
"Losartan or captopril treatment initiated at stroke prevented death for 60 days without lowering BP."	( Post-stroke losartan and captopril treatments arrest hemorrhagic expansion in SHRsp without lowering blood pressure. Negandhi, A; Smeda, JS; Stuckless, J; Watson, D, 2018)	1.58
"Losartan treatment is a negative risk factor of arterial stiffness and reduces the risk of ACS in aged patients with essential hypertension."	( Administration of losartan improves aortic arterial stiffness and reduces the occurrence of acute coronary syndrome in aged patients with essential hypertension. Fei, JC; Guo, T; Li, MM; Lv, YH; Miao, Z; Ou, WS; Wang, BX; Wang, SX; Zhang, ZM, 2019)	2.29
"Losartan treatment decreased the tissue expression of miR-21 and TGF-β and tissue fibrosis in kidney transplant patient, and it had a protective effect on allograft function and may delay chronic allograft dysfunction by reducing mediators of fibrosis."	( Downregulation of Profibrotic Gene Expression by Angiotensin Receptor Blockers. Nafar, M; Samavat, S; Shahraki, E, 2018)	1.92
"Losartan treatment, however, inhibited BP elevation in both rat strains, doing so to a greater extent in the treatment group SHRs."	( Reduction of blood pressure elevation by losartan in spontaneously hypertensive rats through suppression of LARG expression in vascular smooth muscle cells. Chiang, FT; Chiang, JY; Chiu, WC; Juang, JM; Su, MJ; Tsai, CT; Tseng, YZ; Wu, CK, 2020)	1.55
"Losartan-treated human dermal fibroblasts displayed decreased contractile activity, migration, and gene expression of transforming growth factor-β1, collagen I, and monocyte chemoattractant protein-1 relative to controls (p < 0.05). "	( Angiotensin II Type I Receptor Blockade Is Associated with Decreased Cutaneous Scar Formation in a Rat Model. Bezuhly, M; Boudreau, C; Gratzer, P; LeVatte, T; Marshall, J; Midgen, C; Murphy, A, 2019)	1.96
"Losartan treatment increased the baroreflex sensitivity of rSNA to pressor (67%) and depressor (140%) stimuli in the 2K-1C rats."	( Losartan reduces oxidative stress within the rostral ventrolateral medulla of rats with renovascular hypertension. Bergamaschi, CT; Campos, RR; Nishi, EE; Oliveira-Sales, EB; Simon, KA, 2013)	2.55
"Losartan-treated camels also exhibited a significant decline in ANP and BNP levels across 20 days of dehydration but the changes were not different from those seen with dehydration alone."	( ANP and BNP responses to dehydration in the one-humped camel and effects of blocking the renin-angiotensin system. Adem, A; Al Haj, M; Benedict, S; Frampton, CM; Kazzam, E; Lewis, LK; Nagelkerke, N; Nicholls, MG; Nyberg, F; Yandle, TG; Yasin, J, 2013)	1.11
"Losartan treatment completely prevented post-MI cardiac hypertrophy."	( Effects of angiotensin II blockade on cardiomyocyte regeneration after myocardial infarction in rats. Forsten, H; Harjula, A; Immonen, K; Kankuri, E; Kosonen, R; Laine, M; Lakkisto, P; Palojoki, E; Segersvärd, H; Tikkanen, I, 2015)	1.14
"Losartan treatment can delay the progression of advanced IgA nephropathy with impaired renal function."	( Advanced IgA nephropathy with impaired renal function benefits from losartan treatment in rats. Fu, W; Jin, Z; Peng, W; Wang, H; Wang, Y; Yao, W; Yin, P, 2013)	2.07
"Losartan treatment also decreased ANG II and TGF-β."	( Renin angiotensin system blockade ameliorates lead nephropathy. Chiou, TT; Hsu, CY; Huang, PC; Lee, CT; Lee, YT; Ng, HY; Tain, YL, 2013)	1.11
"Losartan treatment also abrogated fibro-inflammatory disease, assessed by markers at the protein and messenger level."	( Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging. Declèves, AE; Rychak, JJ; Sharma, K; Smith, DJ, 2013)	1.4
"Losartan treatment partially attenuated these responses."	( Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. He, P; Li, D; Zhang, B, 2014)	2.57
"Losartan treatment significantly improved several activity measurements during treatment period compared to placebo controlled group, including increased time on treadmill, traveling activity, standing activity, and decreased grid contacts (p-values<0.05, 0.001, 0.01; and 0.04 respectively)."	( Losartan improves measures of activity, inflammation, and oxidative stress in older mice. Abadir, P; Chuang, YF; Lin, CH; Roy, CN; Walston, JD; Xue, QL; Yang, H, 2014)	2.57
"Losartan treatment improved PVS-associated pulmonary hypertension and intimal hyperplasia and might be a beneficial prophylactic therapy for patients at high risk of developing PVS after pulmonary vein surgery."	( Losartan ameliorates "upstream" pulmonary vein vasculopathy in a piglet model of pulmonary vein stenosis. Caldarone, CA; Coles, JG; Fu, YY; Ide, H; Kato, H; Maynes, JT; Teichert, AM; Weisel, RD; Zhu, J, 2014)	3.29
"Losartan treatment caused a decrease in albuminuria in ZDF rats up to 15 wk of age."	( Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. Bombardi, C; Carletti, R; Castoldi, G; Dahlöf, B; di Gioia, CR; Maestroni, S; Steckelings, UM; Stella, A; Unger, T; Zerbini, G, 2014)	1.12
"Losartan treatment (intragastrically (i.g.), 10 mg/kg) was performed for 7 and 14 days after a single i.g."	( Losartan attenuates paraquat-induced pulmonary fibrosis in rats. Guo, F; Hu, XT; Li, J; Li, S; Liu, ZF; Su, L; Sun, YB, 2015)	2.58
"Losartan treatment started after onset of SE and continued for 4weeks."	( Antiepileptogenic and neuroprotective effects of losartan in kainate model of temporal lobe epilepsy. Atanasova, D; Ivanova, NM; Kortenska, L; Lazarov, N; Lozanov, V; Mitreva, R; Pechlivanova, DM; Stoynev, A; Tchekalarova, JD, 2014)	1.38
"Losartan treatment significantly decreased MAP, left ventricle hypertrophy (LVH), fibrosis, and increased cardiac ACE2 and Mas expression."	( Alteration of cardiac ACE2/Mas expression and cardiac remodelling in rats with aortic constriction. Li, B; Morgan, T; Wang, B; Wu, J; Zhang, J; Zhang, Y, 2014)	1.12
"Losartan treatment abolished the renal expression of gp91, p22, p47, oxidative stress and reduced NF-κB activation and IL-6 expression."	( Role of Angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension. Arcaya, JL; Chávez, M; Correia, D; Fernández, A; Finol, E; Pérez, M; Rincón, J; Romero, F; Summer, R; Talavera, E; Yaguas, K, 2015)	1.14
"Losartan treatment preserves FRAP levels, reduces DNA oxidative injury and thus the carcinogenesis risk."	( Losartan reduces oxidative damage to renal DNA and conserves plasma antioxidant capacity in diabetic rats. Bigagli, E; Di Serio, C; Lodovici, M; Raimondi, L; Tarantini, F, 2015)	2.58
"Losartan treatment was associated with significantly increased serum tumor necrosis factor alpha (TNF-α) level, p65 nuclei accumulation, and decreased muscle IκB-β protein level, indicating NFκB activation."	( Life or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A. Elbaz, M; Laban, S; Mitrani-Rosenbaum, S; Nevo, Y; Rabie, M; Yanay, N, 2015)	1.45
"Losartan treatment prevented tumor-induced loss of muscle mass and in vitro c26 cell proliferation, decreased tumor weight, and attenuated myocardial expression of interleukin-6."	( Losartan treatment attenuates tumor-induced myocardial dysfunction. Bicer, S; Clark, Y; Devine, RD; Jing, R; McCarthy, DO; Reiser, PJ; Stevens, SC; Velten, M; Wold, LE; Youtz, DJ, 2015)	2.58
"Losartan treatment decreased wall thickness, wall-to-lumen ratio, and coronary arteriole cell number in db/db mice."	( The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice. Cismowski, MJ; Galantowicz, ML; Husarek, KE; Katz, PS; Lucchesi, PA; Trask, AJ, 2016)	1.44
"Losartan treatment also provoked significant attenuation of endoplasmic reticulum stress parameters (GRP78, IRE1α, p-eIF2) which was consistent with reduced levels of both caspase 12 and caspase 3."	( Losartan activates sirtuin 1 in rat reduced-size orthotopic liver transplantation. Bejaoui, M; Folch-Puy, E; Palmeira, CM; Panisello, A; Pantazi, E; Pinto Rolo, A; Roselló-Catafau, J; Zaouali, MA, 2015)	2.58
"Losartan treatment prevented significant RGC loss (median loss = 2.5%, p = 0.13), while median loss with water, spironolactone, and enalapril treatments were 26%, 28% and 43%; p < 0.0001). "	( Losartan Treatment Protects Retinal Ganglion Cells and Alters Scleral Remodeling in Experimental Glaucoma. Berlinicke, CA; Jefferys, JJ; Kim, J; Kimball, EC; Mitchell, KL; Nguyen, C; Nguyen, TD; Oglesby, EN; Pease, ME; Pitha, IF; Quigley, HA; Steinhart, MR; Welsbie, DS, 2015)	3.3
"Losartan treatment limited mortality and attenuated the renal and hemodynamic abnormalities associated with Nx."	( An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney. Arias, SC; Fanelli, C; Fujihara, CK; Malheiros, DM; Souza, RA; Zatz, R, 2016)	1.49
"Losartan (LOS) treatment (10 mg/kg body weight/day) for 2 months (Ren-2 TGR+LOS) did not change NADPH oxidase-dependent O(2)(-) production in the kidney."	( NADPH oxidase activity and reactive oxygen species production in brain and kidney of adult male hypertensive Ren-2 transgenic rats. Rauchová, H; Řezáčová, L; Vaněčková, I; Vokurková, M; Zicha, J, 2015)	1.14
"Losartan treatment had no impact on growth or kidney development."	( Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction. Béland-Bonenfant, S; Bertagnolli, M; Cloutier, A; Dios, A; Gascon, G; Lukaszewski, MA; Nuyt, AM; Paradis, P; Schiffrin, EL; Sutherland, M, 2016)	1.16
"In losartan-treated denervated SHR rats, there were significant (all P < 0.05) reductions in the renal vasoconstrictor responses to neural stimuli and vasoactive agents as compared with that of untreated denervated SHR rats."	( Effect of acute unilateral renal denervation on renal hemodynamics in spontaneously hypertensive rats. Abdulla, MH; Abdullah, NA; Ameer, OZ; Johns, EJ; Khan, MA; Salman, IM; Sattar, MA, )	0.65
"Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP."	( Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Cai, L; Kong, T; Mo, H; Qi, J; Shen, L; Xiao, Z; Ye, J; Zheng, W, 2009)	2.52
"Losartan treatment resulted in a significant increase in HMW-adiponectin concentrations (45.9%) and a significant decrease in HOMA-R (23.9%) and FFA concentrations (26.5%); the percent changes were greater than those induced by CCB treatment (p<0.001, p<0.05 and p<0.01, respectively)."	( Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Higuchi, C; Naito, T; Nishimura, H; Otsuka, K; Sanaka, T; Tanihata, Y, 2008)	2.51
"Losartan treatment did not significantly change EC proliferation, but did significantly reduce EC apoptosis rates as compared to the non-treated SBR group."	( The role of angiotensin II type 1a receptor on intestinal epithelial cells following small bowel resection in a mouse model. Haxhija, EQ; Koga, H; Teitelbaum, DH; Yang, H, 2008)	1.07
"Losartan treatment decreases the activation of p42/44 MAPK to the uninfarcted control level and preserves normal LZ+ MYPT1 expression."	( Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression. Ararat, E; Brozovich, FV, 2009)	2.52
"Losartan 6-month treatment in the fixed combination has a positive effect on clinicohemodynamic and immunometabolic indices."	( [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009)	1.29
"Losartan treatment was associated with a significant decrease in the expression of several profibrogenic and NOX genes including procollagen alpha1(I) and alpha1(IV), urokinase-type plasminogen activator, metalloproteinase type 2, NOX activator 1 (NOXA-1) and organizer 1 (NOXO-1), and Rac-1."	( Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Arroyo, V; Bataller, R; Brenner, DA; Bruguera, M; Colmenero, J; Domínguez, M; Forns, X; Ginès, P; Moreno, M; Sancho-Bru, P, 2009)	1.46
"Losartan-treated Fbn1(C1039G/+) mice had lower total TGF-beta1 concentrations compared with age-matched Fbn1(C1039G/+) mice treated with placebo (P=0.01; n=18; 90+/-5 ng/mL), and circulating total TGF-beta1 levels were indistinguishable from those of age-matched wild-type mice (P=0.8)."	( Circulating transforming growth factor-beta in Marfan syndrome. Carlson, OD; De Backer, J; Dietz, HC; Fu, Q; Griswold, BF; Habashi, J; Holm, T; Huso, DL; Loch, D; Loeys, B; Matt, P; McDonnell, NB; Schoenhoff, F; Van Erp, C; Van Eyk, JE, 2009)	1.07
"Losartan treatment resulted in improvement of myocardial function and suppressed cardiac and renal fibrosis compared with the diabetic group."	( Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. Aizawa, Y; Arozal, W; Kodama, M; Ma, M; Suzuki, K; Tachikawa, H; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K, 2009)	1.07
"Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group. "	( Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. Andersson, J; Boman, JH; Boman, K; Dahlöf, B; Olofsson, M, 2010)	2.11
"Losartan treatment for 4-8 weeks reduced blood pressure of SHR to the normal levels seen in WKY. "	( Protection of retinal vasculature by losartan against apoptosis and vasculopathy in rats with spontaneous hypertension. Cai, J; Chen, B; Fang, F; Geng, YJ; Huang, X; Qu, J; Shi, X; Wang, S; Yang, D; Zhang, M, 2010)	2.08
"Losartan pretreatment offers protective effect against AngII-induced impairment of the GSIS of beta cells possibly by antagonizing the effects of AngII that causes increased ROS level and UCP2 expressions in beta-cells."	( [Protective effect of losartan on insulin secretion function of RIN-m cells against angiotensin II-induced injury and the mechanism]. Cai, DH; Chen, H; Lu, X; Lv, J; Zhang, H, 2010)	2.12
"In losartan-treated animals, isoflurane/remifentanil caused significant hypotension (42 ± 4 mmHg for isoflurane/remifentanil vs."	( Xenon/remifentanil anesthesia protects against adverse effects of losartan on hemodynamic challenges induced by anesthesia and acute blood loss. Boemke, W; Francis, RC; Klein, A; Philippi-Höhne, C; Pickerodt, PA; Reyle-Hahn, MS, 2010)	1.11
"Losartan treatment reduced albuminuria in the CC group by 5% (95% CI: -13-22, p = 0.47)."	( Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate. Ajdinović, B; Andelković, Z; Dragović, T; Hrvacević, R; Ilić, V; Kocev, N; Magić, Z, 2010)	1.3
"Losartan treatment showed a reduction in ischemic area compared with nontreated KK-Ay mice."	( Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. Horiuchi, M; Iwai, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K, 2010)	1.08
"Losartan treatment suppressed the excessive NO and lipid peroxidation production systemically without restoring them to that of healthy subjects and reduced VEGF levels while leaving sICAM-1 levels unchanged."	( The antioxidant effect of angiotensin II receptor blocker, losartan, in streptozotocin-induced diabetic rats. Chatzigeorgiou, A; Kamper, EF; Kamper, M; Lymberi, M; Tsimpoukidi, O, 2010)	1.33
"Losartan treatment reduced the mortality of TG: Mean life span was raised from 116 to 193 days (n = 18 end, p < 0.05)."	( Losartan reduces mortality in a genetic model of heart failure. Baba, HA; Gergs, U; Grossmann, C; Günther, S; Hauptmann, S; Holzhausen, HJ; Jones, LR; Kusche, T; Neumann, J; Punkt, K, 2010)	2.52
"Losartan treatment did not reverse pathologic remodeling of established HCM but did reduce non-myocyte proliferation."	( Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. Alcalai, R; Eminaga, S; Gorham, JM; Hoffman, SR; Kim, JB; Konno, T; Markwald, RR; Molkentin, JD; Nayor, M; Norris, RA; Schmitt, JP; Seidman, CE; Seidman, JG; Tager, AM; Teekakirikul, P; Toka, O; Wakimoto, H; Wang, L; Wolf, CM, 2010)	1.08
"Losartan treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild MFS, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated vascular disease."	( Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S, 2010)	1.35
"Losartan treatment (100 mg/day) reduced urinary KIM-1 by 43% over a 12-month period."	( Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Andersen, S; Hess, G; Nielsen, SE; Parving, HH; Rossing, P; Zdunek, D, 2011)	1.09
"Losartan treatment increased sinusoidal diameter, sinusoidal blood flow and portal vein flow after partial hepatectomy (P<0.05), but not after sham operation. "	( Role of angiotensin-1 receptor blockade in cirrhotic liver resection. Bahde, R; Hölzen, JP; Kebschull, L; Minin, E; Palmes, D; Schmidt, HH; Siaj, R; Spiegel, HU; Stöppeler, S; Zibert, A, 2011)	1.81
"Losartan treatment largely prevented changes in both EPCs and remnant kidney."	( ARB treatment prevents the decrease in endothelial progenitor cells and the loss of renal microvasculature in remnant kidney. Wang, Y; Yu, Y; Zheng, F; Zhou, LN, 2011)	1.09
"Losartan treatment largely prevented the loss of EPCs and preserved renal endothelial cells, which may be part of the mechanism of how it contributes to renal protection."	( ARB treatment prevents the decrease in endothelial progenitor cells and the loss of renal microvasculature in remnant kidney. Wang, Y; Yu, Y; Zheng, F; Zhou, LN, 2011)	1.09
"Losartan treatment normalized these altered levels."	( Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats. Kamata, K; Kobayashi, T; Matsumoto, T; Nemoto, S; Taguchi, K, 2011)	2.53
"Losartan treatment reduced the fibrosis in the CC UUO kidneys."	( Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. Brazin, JA; Chen, J; Estephan, R; Felsen, D; Kameue, T; Maack, T; Mora, R; O'Connor, N; Poppas, DP; Reid, AC; Seshan, SV; Silver, RB; Veerappan, A, 2012)	1.1
"Losartan treatment could be an effective tool to restore normal vascular reactivity in the renal circulation of the fructose-fed rat."	( The effect of losartan and carvedilol on renal haemodynamics and altered metabolism in fructose-fed Sprague-Dawley rats. Abdulla, MH; Abdullah, NA; Johns, EJ; Sattar, MA, 2012)	1.46
"Losartan treatment (10 mg/kg, i.v.) in both acute and chronic L-NAME treated rats, decreased MAP but the difference was not significant."	( Effect of losartan, an angiotensin II type 1 receptor antagonist on cardiac autonomic functions of rats during acute and chronic inhibition of nitric oxide synthesis. Chaswal, M; Das, S; Fahim, M; Katyal, A; Mishra, AK; Prasad, J, 2012)	1.5
"Losartan treatment increased urine and tissue ACE activity and tissue levels of angiotensins, mainly angiotensin (1-7), and improved renal and histopathologic parameters."	( Overexpression of urinary N-domain ACE in chronic kidney dysfunction in Wistar rats. Aragão, DS; Arita, DY; Arita, LS; Casarini, DE; Colucci, JA; Cunha, TS; Nogueira, MD; Perez, JD; Ronchi, FA; Teixeira, Vde P, 2012)	1.1
"Losartan treatment was associated with significant impressive improvement in muscle strength and amelioration of fibrosis. "	( Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse. Aga-Mizrachi, S; Barak, V; Brunschwig, Z; Elbaz, M; Ettinger, K; Kassis, I; Nevo, Y; Yanay, N, 2012)	3.26
"Losartan treatment normalized blood pressure and prevented the changes in plasma testosterone and prolactin, sexual behavior and spermatogenesis in the 2K1C+Los group."	( The role of AT1 receptor-mediated reproductive function in renovascular hypertension in male rats. Franci, CR; Lucion, AB; Sanvitto, GL; Weissheimer, KV, 2012)	1.1
"Losartan treatment improved albuminuria and renal pathologic lesion of KKAy mice. "	( Effect of losartan on the glomerular protein expression profile of type 2 diabetic KKAy mice. Fan, QL; Feng, JM; Jiang, Y; Liu, XD; Ma, JF; Wang, LN; Yang, G, )	1.98
"Losartan pretreatment significantly suppressed an increase in inducible nitric oxide synthase (iNOS) and sustained normal levels of eNOS expression 24h after MCAO-R injury."	( Losartan, an angiotensin II type 1 receptor blocker, ameliorates cerebral ischemia-reperfusion injury via PI3K/Akt-mediated eNOS phosphorylation. Chen, L; Liu, H; Liu, X; Wei, X; Xiang, Y; Yi, F; Zhang, X, 2012)	2.54
"Losartan treatment also caused a significant recovery in flexural strength and modulus parameters regarding respective control values, which mean losartan treated ovariectomized rats' femur had more force tolerance until break than ovariectomized rats' femur."	( Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Demir, N; Donmez, BO; Karayalcin, B; Koc, P; Oguz, N; Ozdemir, S; Sarikanat, M; Yaras, N, 2012)	1.1
"Losartan treatment was able to reduce all increases in messenger RNA expression and protein levels caused by exercise, although it could not completely reverse the heart hypertrophy."	( Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model. Benito, B; Brugada, J; Gay-Jordi, G; Guash, E; Mont, L; Nattel, S; Serrano-Mollar, A, 2013)	2.55
"Losartan treatment prevents the heart fibrosis induced by endurance exercise in training animals."	( Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model. Benito, B; Brugada, J; Gay-Jordi, G; Guash, E; Mont, L; Nattel, S; Serrano-Mollar, A, 2013)	3.28
"Losartan-treated pups exhibited disturbances in renal function and structure that persisted into adulthood. "	( The role of oxidative stress in renal injury induced in rats by losartan exposure during lactation. Coimbra, TM; Costa, RS; da Silva, CG; Francescato, HD; Marin, EC, 2014)	2.08
"Losartan treatment significantly decreased the development of hypertension induced by >L-NAME and decreased left ventricular hypertrophy in untreated rats."	( N(G)-nitro-L-arginine methyl ester-induced hypertension and natriuretic peptide gene expression: inhibition by angiotensin II type 1 receptor antagonism. Jolma, P; Kalliovalkama, J; Pörsti, I; Ruskoaho, H; Suo, M; Tolvanen, JP; Vuolteenaho, O, 2002)	1.04
"Losartan treatment in patients with essential hypertension did not modify the percent change in LMCA diameter caused by sublingual administration of nitroglycerin (23.2 +/- 14.0% vs."	( Angiotensin receptor antagonist losartan improves endothelial function of epicardial coronary arteries in patients with essential hypertension. Chang, Q; Deng, YB; Li, CL; Yang, HY, 2002)	1.32
"Losartan treatment was started when serum creatinine rose above 4.0 mg/dl."	( Progression of renal failure delayed by use of losartan in a case of IgA nephropathy. Iseki, K; Takishita, S, 2002)	1.29
"Losartan treatment failed to alter these levels significantly."	( Effect of chronic treatment with losartan on streptozotocin induced diabetic rats. Goyal, RK; Murali, B, 2002)	1.32
"Losartan treatment resulted in a highly significant reduction in the mean sitting diastolic blood pressure. "	( An open comparative clinical trial to assess the efficacy and safety of losartan versus enalapril in mild to moderate hypertension. Adhikari, PM; Bhat, P; Chowta, KN; Chowta, MN, 2002)	1.99
"Losartan treatment also decreased REM AT1R Bmax by 55%."	( Growth hormone regulation of glomerular AT1 angiotensin receptors in adult uninephrectomized male rats. Lee, S; Mok, KY; Mulroney, SE; Sandberg, K; Sweeny, JM; Zheng, W, 2003)	1.04
"In Losartan treatment group, all of MPA, 24 hours urine protein count, kidney weight/body weight and Ccr decreased, compared with those of model group; ET-1 in blood and urine decreased too, especially the decreasing of ET-1 in urine (P < 0.01)."	( [Protective effect of angiotensin II receptor blockage on rats with experimental diabetes nephropathy in early stage]. Fan, J; Liu, X; Mi, X; Xu, G; Yang, L, 2003)	0.83
"Losartan treatment significantly prevented all these changes except STZ-induced hypoinsulinemia."	( Effect of chronic treatment with losartan on streptozotocin-induced renal dysfunction. Goyal, RK; Murali, B; Umrani, DN, 2003)	1.32
"Losartan treatment reduced the increased BBB permeability to EB dye in the brain regions of diabetic hypertensive rats treated with epinephrine (p < 0.05)."	( Effect of losartan on the blood-brain barrier permeability in diabetic hypertensive rats. Arican, N; Elmas, I; Kalayci, R; Kaya, M; Korkut, F; Küçük, M; Kudat, H, 2003)	1.44
"Losartan treatment (2 mg/ml in drinking water, daily) was started at 4 weeks and continued for 12 weeks."	( Antioxidant enzyme gene expression in congestive heart failure following myocardial infarction. Farahmand, F; Kaur, K; Khaper, N; Li, T; Singal, PK, 2003)	1.04
"Losartan treatment after myocardial infarction reduced the incidence of cMI from 30.4 to 4.5% and scar size from 1.52 +/- 0.07 to 0.94 +/- 0.11 cm2 respectively."	( Losartan inhibits myosin isoform shift after myocardial infarction in rats. Davidoff, AW; Elkassem, S; Saito, K; ter Keurs, HE; Zhang, ML, 2003)	2.48
"Losartan treatment caused a significant decrease of sICAM-1 levels at the end of the first month of treatment (300.2 +/-64.4 ng/mL, p<0.05), but the values reverted to the basal levels at the following time points."	( Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients. Altavilla, D; Bonaiuto, M; Campo, GM; Campo, S; Castaldo, M; Cinquegrani, M; Fontana, L; Saitta, A; Sardo, MA, )	1.13
"Losartan treatment lowered significantly LPO in kidney tissue after 2 and 4 weeks of treatment compared with untreated and atenolol-treated animals and induced the decrease of excretion of isoprostanes in urine at the end of the study."	( Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure. Aunapuu, M; Kullissaar, T; Ots, M; Pechter, U; Riispere, Z; Vihalemm, T; Zilmer, K; Zilmer, M, 2004)	1.3
"Losartan pretreated-rats presented diminished FN abundance in homogenates of cortex tissue from ischemic rats with or without reperfusion."	( Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function. Barrilli, A; Elías, MM; Menacho, M; Molinas, S; Petrini, G, 2004)	2.49
"5.Losartan treatment prevents the development of hypertension but not all vascular changes observed after ouabain treatment."	( Ouabain-induced hypertension alters the participation of endothelial factors in alpha-adrenergic responses differently in rat resistance and conductance mesenteric arteries. Alonso, MJ; Balfagón, G; Rossoni, LV; Salaices, M; Vassallo, DV; Xavier, FE, 2004)	0.88
"Losartan-treated rats exhibited a significantly less marked reduction in vascular perfusion and a significantly lesser extent of tissue hypoxia."	( The scar neovasculature after myocardial infarction in rats. Ansari, R; Kiani, MF; Postlethwaite, AE; Sun, Y; Wang, B; Weber, KT, 2005)	1.05
"Losartan-based treatment led to trends toward lower all-cause mortality (30 vs."	( Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005)	1.26
"Losartan treatment reduced lesion area at the aortic sinus, although differences were only significant in female mice."	( Differential effects of angiotensin II on atherogenesis at the aortic sinus and descending aorta of apolipoprotein-E-deficient mice. Catanzaro, DF; Catanzaro, SE; Chen, R; Dansky, HM; Hu, L; Zhou, Y, 2005)	1.05
"Losartan treatment throughout the 4-week post-transplantation period had negative effects on islet revascularisation as well as on islet graft insulin release. "	( Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucose-stimulated insulin secretion in revascularised syngeneic mouse islet grafts. Carlsson, PO; Kampf, C; Lau, T; Leung, PS; Olsson, R, 2005)	1.77
"Losartan treatment but not lisinopril increased cardiac tissue levels of Ang II and Ang-(1-7), whereas none of the treatments had an effect on cardiac neprilysin mRNA."	( Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Averill, DB; Brosnihan, KB; Chappell, MC; Diz, DI; Ferrario, CM; Gallagher, PE; Jessup, J; Tallant, EA, 2005)	1.05
"Losartan and enalapril treatment elevated plasma levels of AngI and Ang-(1-7) while AngII increased only in losartan-treated rats."	( Divergent regulation of circulating and intrarenal renin-angiotensin systems in response to long-term blockade. Basso, N; Diz, DI; Ferder, LF; Ferrario, CM; Kasper, SO; Kurnjek, ML; Paglia, N, )	0.85
"Losartan plus L-NAME treatment caused an increase in plasma ACE activity above control."	( Effects of losartan on blood pressure, oxidative stress, and nitrate/nitrite levels in the nitric oxide deficient hypertensive rats. Ahmad, M; Al-Shabanah, OA; Khattab, M; Raza, M, 2004)	1.43
"Losartan pretreatment inhibited both the vasoconstriction and the activation of ERK1/2 and p38."	( Pollutant particles produce vasoconstriction and enhance MAPK signaling via angiotensin type I receptor. Carter, JD; Dailey, LA; Huang, YC; Li, Z, 2005)	1.05
"Losartan treatment of patients with LVH decreased the CV as well as renal risk to a level similar to that of patients without LVH."	( Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Boner, G; Brenner, BM; Cooper, ME; Crow, RS; de Zeeuw, D; Dickson, T; Kowey, PR; McCarroll, K; Parving, HH; Shahinfar, S, 2005)	1.26
"The losartan treatment had no effect on renal TGF-beta1 expression."	( Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats. Akgun, H; Dursun, N; Gunduz, Z; Koc, N; Okur, H; Ozturk, F, 2005)	1.05
"Losartan pretreatment attenuated (0.01>p) the increase in cholesterol content and synthesis and restored and enhanced the AT1 angiotensin II receptor gene expression."	( Effect of losartan pretreatment on kidney lipid content after unilateral obstruction in rats. Alvarez, S; Carrizo, L; Manucha, W; Oliveros, L; Valles, P, 2005)	1.45
"Losartan treatments prevented EC training-induced increases in muscle wet and dry weights compared to untreated rats."	( AT1 receptors are necessary for eccentric training-induced hypertrophy and strength gains in rat skeletal muscle. McBride, TA, 2006)	1.06
"Losartan was the only treatment that induced alpha1 subunit expression."	( Role of angiotensin type-1 and angiotensin type-2 receptors in the expression of vascular integrins in angiotensin II-infused rats. Amiri, F; Brassard, P; Schiffrin, EL; Thibault, G, 2006)	1.06
"Oral losartan treatment delayed the onset of diabetes, and reduced hyperglycemia and glucose intolerance in db/db mice, but did not affect the insulin sensitivity of peripheral tissues."	( Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Carlsson, PO; Chu, KY; Lau, T; Leung, PS, 2006)	0.79
"The losartan treatment improved hepatic necroinflammation and fibrosis in NASH patients."	( [Clinical utility of angiotensin II receptor antagonist]. Haneda, M; Nakamura, K; Yokohama, S, 2006)	0.81
"The losartan-treated group also showed significantly increased mean tubular diameter and interstitial area of the kidney (P<0.05)."	( AT1 antagonist modulates activin-like kinase 5 and TGF-beta receptor II in the developing kidney. Bae, IS; Choi, BM; Hong, YS; Kim, JH; Kim, MK; Lee, JW; Yim, HE; Yoo, KH, 2006)	0.81
"Losartan treatment augmented this difference (18.7 +/- 3.7 versus 4.6 +/- 1.7 mGU/ml, P < 0.01)."	( Blood pressure is the major driving force for plaque formation in aortic-constricted ApoE-/- mice. Bergström, G; Gan, LM; Johansson, ME; Skøtt, O; Wickman, A, 2006)	1.06
"Losartan treatment abolished the insulin resistance in burn as evidenced by an area under the curve for insulin and glucose insulin index lower than that in the burn placebo group and similar to that in the sham-burned group."	( Blockade of the renin-angiotensin system improves insulin sensitivity in thermal injury. Castle, SM; Daley, BJ; Enderson, BL; Karlstad, MD; Kasper, SO, 2006)	1.06
"Late losartan treatment had no effect on any of the parameters in either kidney, and PD-123319 had no effect on either kidney."	( Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat. Burt, LE; Chevalier, RL; Coleman, CM; Forbes, MS; Minor, JJ; Thornhill, BA, 2007)	0.79
"Losartan treatment also reduced AP-associated depletion of IkappaBbeta and elevation of phospho-NF-kappaB p65 protein expression as well as the enhanced nuclear kappaB binding activity and elevated levels of kappaB-related proteins."	( Angiotensin II type 1 receptor-dependent nuclear factor-kappaB activation-mediated proinflammatory actions in a rat model of obstructive acute pancreatitis. Chan, YC; Leung, PS, 2007)	1.06
"Losartan treatment was able to reduce all these parameters."	( Effect of angiotensin AT1 receptor antagonist on D-galactosamine-induced acute liver injury. Chan, H; Leung, PS; Tam, MS, 2007)	1.06
"Both losartan-treated and untreated renal ablation groups had glomerular enlargement and compensatory hyperfiltration and this was uninfluenced by losartan."	( Angiotensin II receptor blockade blocker pre-treatment largely prevents injury from gradual renal ablation in rats. Jeong, HJ; Kim, KH; Kim, Y; Mauer, M; Park, HW; Rozen, S; Shin, MH, 2007)	0.79
"Losartan treatment significantly increased SOD activities (82.94 +/- 4.62 U/mg protein vs 67.78 +/-8.02 U/mg protein; P < 0.01) and decreased MDA levels (30.54 +/- 5.89 nmol/mg protein vs 48.75 +/- 8.09 nmol/mg protein, P < 0.01) compared with the hyperoxia exposure group 21 days after exposure."	( [Effect of losartan on lung fibrosis in neonatal rats with hyperoxia-induced chronic lung disease]. Chen, N; Li, JJ; Xue, XD, 2007)	1.45
"Losartan-treatment making AT1 blockade decreased Col I mRNA to 71.8% in cardiac fibroblasts, AT2 blockade from PD123319-treatment decreased Col I mRNA to 81.5%, co-treatment of both AT1 and AT2 blockade decreased Col I mRNA to 50.9% ; the AT1 blockade with Losartan-treatment decreased TIMP-1 mRNA to 88.1% in cardiac fibroblasts, AT2 blockade by PD123319-treatment decreased TIMP-1 mRNA to 75.4%, Both AT1 and AT2 blockade by co-treatment decreased TIMP-1 mRNA to 44.1%."	( [The influence of angiotensin II receptor blockade on the expressions of Col I and TIMP-1 mRNA in cardiac fibroblast of adult rat]. Gao, GD; Jiang, XY, 2007)	1.78
"Losartan treatment reduced renal outcomes in proteinuric patients with type 2 diabetes in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. "	( ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. Brenner, BM; Cooper, ME; de Zeeuw, D; Liu, N; Lunceford, J; Lyle, PA; Parving, HH; Remuzzi, G; Rossing, P; Shahinfar, S; Wong, PH, 2008)	2.09
"Losartan-treated (LOS group, n = 10) and untreated rats served as controls (n = 11)."	( Hyperinsulinemic rats are normotensive but sensitized to angiotensin II. Alexanderson, C; Andersson, IJ; Bergström, G; Holmäng, A; Johansson, ME; Skøtt, O, 2008)	1.07
"Losartan treatment and exercise training were initiated 1 week after infarction and continued for 8 weeks, either as a single intervention or combined."	( Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats. Erikson, JM; Ji, L; Lao, S; Powers, AS; Wan, W; Xu, X; Zhang, JQ; Zhao, W, 2008)	1.07
"Losartan treatment produced a significant reduction in LVH in AI rats without affecting the systolic blood pressure."	( Effects of losartan, an angiotensin II antagonist, on the development of cardiac hypertrophy due to volume overload. Ishiye, M; Nakashima, M; Uematsu, T; Umemura, K, 1995)	1.4
"Losartan treatment prevented both blood pressure elevation and hyperinsulinemia in fructose-fed rats but not elevation of plasma triglycerides."	( Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat. Cachofeiro, V; Lahera, V; Maeso, R; Navarro-Cid, J; Perez-Vizcaino, F; Ruilope, LM; Tamargo, J, 1995)	1.4
"Losartan treatment initiated 3 weeks after aortic banding and continued for 3 more weeks resulted in a slight but significant reduction in the extent of cardiac hypertrophy (45.6% hypertrophy in controls and 35.6% hypertrophy in losartan-treated animals, p < 0.05, n = 11 and 10, respectively)."	( Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal. Mohabir, R; Strosberg, AM; Young, SD, 1994)	1.01
"Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure."	( Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995)	1.25
"Both losartan and enalapril treatments maintained conscious BP at comparably lowered levels compared to control animals (116 +/- 6 mm Hg and 113 +/- 2 mm Hg vs."	( Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats. Fitzgibbon, WR; Hutchison, FN; Imamura, A; Lacy, ER; Mackenzie, HS; Ploth, DW, 1995)	0.75
"Losartan treatment, captopril treatment and losartan+captopril treatment all significantly and effectively protected against an increase in the percentage of focal glomerular sclerosis."	( Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. Abe, K; Fu, LP; Kanazawa, M; Kohzuki, M; Obara, K; Saito, T; Yasujima, M; Yoshida, K, 1995)	1.27
"With losartan pretreatment, DPCPX did not cause significant changes in RA and delta P."	( Effects of selective A1 receptor blockade on glomerular hemodynamics: involvement of renin-angiotensin system. Jackson, EK; Munger, KA, 1994)	0.74
"Losartan pretreatment (without versus with losartan) significantly potentiated DPMA-induced reductions in renal (-13 +/- 2% versus -22 +/- 4%, P < .05) and mesenteric (-11 +/- 2% versus -23 +/- 4%, P < .05) vascular resistances, resulting in a greater depressor response (-7 +/- 2 versus -18 +/- 3 mm Hg, P < .05)."	( Angiotensin subtype 1 blockade selectively potentiates adenosine subtype 2-mediated vasodilation. Cox, BF; Kitzen, JM; Perrone, MH; Smits, GJ, 1993)	1.01
"Losartan treatment increased PRA during the first 4 weeks, but this effect was not sustained."	( Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. Camargo, MJ; Campbell, WG; James, GD; Laragh, JH; Pecker, MS; Timmermans, PB; von Lutterotti, N, 1993)	1.01
"Losartan treatment of CRF rats before the removal of colonic tissues reversed the basal net secretion of urate to net absorption."	( Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. Freel, RW; Hatch, M; Shahinfar, S; Vaziri, ND, 1996)	1.26
"In losartan-treated MI rats, BKI increased (p < 0.05) UNa 42% and FENa 60%, whereas indomethacin increased (p < 0.05) UNa 79% and FENa 85%."	( Relative contribution of angiotensin II, bradykinin, and prostaglandins to the renal effects of converting enzyme inhibition in rats after chronic myocardial infarction. Deck, CC; Gaballa, MA; Raya, TE, 1996)	0.81
"Losartan treatment in pulmonary hypertensive rats caused a significant 2-fold increase of ACE activity in the hypertrophied right (p < 0.005) but not in the left ventricle."	( Effect of losartan on right ventricular hypertrophy and cardiac angiotensin I-converting enzyme activity in pulmonary hypertensive rats. Fernandez-Alfonso, MS; Ganten, D; Kreutz, R; Paul, M, 1996)	1.42
"Losartan treatment of the cells was able to partially block (approximately 50%) the AII- as well as C-ANF4-23-mediated inhibitions of adenylyl cyclase that are completely lost by AII pretreatment."	( Modulation of ANF-R2/ANP-C receptors by angiotensin II in vascular smooth muscle cells. Anand-Srivastava, MB; Palaparti, A, 1996)	1.02
"Losartan and enalapril treatments decreased blood pressure and induced complete regression of LVH in this model of renovascular hypertension. "	( Regression of left ventricular hypertrophy in experimental renovascular hypertension: diastolic dysfunction depends more on myocardial collagen than it does on myocardial mass. Cespedes, C; Dussaillant, GR; Gonzalez, H; Jalil, JE, 1996)	1.74
"Losartan treatment also resulted in a three-fold increase in cardiac AT1 mRNA levels in both the 4-day and 3-week treatment groups compared to controls."	( Developmental regulation of angiotensin type 1 and 2 receptor gene expression and heart growth. Everett, AD; Fisher, A; Harris, M; Tufro-McReddie, A, 1997)	1.02
"No losartan-treated patients discontinued due to cough compared with 14 in the captopril group."	( Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Chang, PI; Cowley, AJ; Deedwania, PC; Martinez, FA; Meurers, G; Ney, DE; Pitt, B; Segal, R; Snavely, DB; Thomas, I, 1997)	1.13
"Losartan treatment was associated with significant attenuation of MMP activities in cardiomyopathic samples at 65 and 120 days."	( Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan. Dixon, IM; Jasmin, G; Ju, H; Reid, NL; Scammell-La Fleur, T; Werner, JP, 1997)	1.24
"Losartan treatment resulted in a dose-dependent reduction in the media thickness and mediato-lumen ratio in small arteries from the four vascular beds studied on the wire myograph and in pressurized mesenteric small arteries."	( Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR. Li, JS; Schiffrin, EL; Sharifi, AM, 1997)	1.02
"Losartan treatment reduces albuminuria at least as effectively as enalapril, suggesting that glomerular leakage of albumin is profoundly affected by the effects angiotensin II."	( Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Dollerup, J; Jensen, HA; Mogensen, CE; Nielsen, B; Nielsen, S, 1997)	2.46
"Losartan treatment increased plasma renin activity about sevenfold and renal renin messenger RNA (mRNA) levels about fivefold and decreased systolic blood pressure from 118 to 95 mmHg. "	( Role of sympathetic nerves for the stimulation of the renin system by angiotensin II receptor blockade. Kees, F; Krämer, BK; Kurtz, A; Wagner, C, 1997)	1.74
"Losartan treatment decreased arterial pressure from 120 +/- 3 to 93 +/- 5 mmHg and increased the afferent (from 0.95 +/- 0.21 to 2.22 +/- 0.42% delta afferent vagal nerve activity/mmHg mean right atrial pressure, P < 0.05) and overall gain (from -1.14 +/- 0.19 to -4.20 +/- 0.39% delta renal sympathetic nerve activity/mmHg mean right atrial pressure, P < 0.05) of the cardiac baroreflex."	( Angiotensin receptor antagonist improves cardiac reflex control of renal sodium handling in heart failure. DiBona, GF; Jones, SY; Sawin, LL, 1998)	1.02
"Losartan treatment did not influence the increase in urinary excretion of sodium during infusion of atrial natriuretic factor, whereas enalapril treatment significantly attenuated this increase (P < 0.01)."	( Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers. Hertenberg, F; Smits, P; Vervoort, G; Wetzels, JF, 1998)	1.02
"Losartan-treated rats showed reduced tail pressure (104+/-3 versus 117+/-3 mm Hg in the vehicle group)."	( Chronic AT1 receptor blockade alters aortic nerve activity in hypertension. dos Santos, CM; Krieger, EM; Michelini, LC; Moreira, ED, 1998)	1.02
"Losartan treatment resulted in stimulation of active renin and decrease of plasma and urinary kallikrein activity."	( Losartan in Cushing's syndrome. Andrewa, M; Angelova-Gateva, P; Natchev, E; Orbetzova, M; Torbova, S; Tzingilev, D; Vergilova, J; Wipperrnann, M; Zacharieva, S, 1998)	2.46
"Losartan treatment comparably reduced blood pressure and increased plasma concentration of nitrates in rats of both age groups. "	( Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998)	2.05
"Losartan treatment reduced blood pressure levels and enhanced dose-related Ach-relaxations and urinary nitrites in both groups."	( Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR. Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998)	1.3
"Losartan treatment was used to determine the role of angiotensin II (AngII) AT1 receptors in the inhibition of nNOS expression in 5/6 Nx."	( Downregulation of neuronal nitric oxide synthase in the rat remnant kidney. Burns, KD; Fryer, JN; Levine, DZ; Roczniak, A, 1999)	1.02
"Losartan and enalapril treatments completely inhibited the increase of systolic blood pressure occurring with ageing in SHR. "	( Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats. Kähönen, M; Kalliovalkama, J; Magga, J; Pörsti, I; Romppanen, H; Ruskoaho, H; Tolvanen, JP; Vuolteenaho, O, 1999)	1.75
"Both losartan and enalapril treatments also augmented arterial potassium relaxation in spontaneously hypertensive rats, suggesting enhanced function of Na+,K+-ATPase, but this effect could not be attributed to changes in circulating s"	( Arterial responses in vitro and plasma digoxin immunoreactivity after losartan and enalapril treatments in experimental hypertension. Doris, PA; Kähönen, M; Kalliovalkama, J; Pekki, A; Pörsti, I; Tolvanen, JP; Voipio, J; Wu, X; Ylitalo, P, 2000)	1
"Losartan treatment was associated with a modest reduction of cardiac 4-hydroxyproline concentration, and a significant reduction of both MMP-1 and MMP-2 activities."	( Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. Dixon, IM; Hao, J; Reid, NL; Roth, JC, 2000)	1.03
"Losartan treatment significantly improved contractile recovery to 84% (P <."	( Losartan improves recovery of contraction and inhibits transient inward current in a cellular model of cardiac ischemia and reperfusion. Ferrier, GR; Howlett, SE; Louch, WE, 2000)	2.47
"Losartan-treated rats drank 1.1 +/- 0.4 ml of water compared with 5.9 +/- 0.77 ml (P < 0.002) drank by control animals, despite a similar body weight loss in the two groups."	( Central angiotensin receptor blockade impairs thermolytic and dipsogenic responses to heat exposure in rats. Hübschle, T; Mathai, ML; McKinley, MJ, 2000)	1.03
"Losartan treatment was well tolerated in terms of adverse events, heart rate, and blood pressure response, and there were no significant changes in serum creatinine or potassium. "	( Combined treatment with losartan and an ACE inhibitor in mild to moderate heart failure: results of a double-blind, randomized, placebo-controlled trial. Cowley, AJ; Hampton, JR; Harrison, M; Houghton, AR, 2000)	2.06
"Losartan alone treated animals had no postnatal increase in either MABP or RSNA, responses similar to those seen in nontreated sheep delivered at the same gestational age."	( Glucocorticoid modulation of cardiovascular and autonomic function in preterm lambs: role of ANG II. Bedell, KA; Segar, JL; Smith, OJ, 2001)	1.03
"in Losartan-treated hearts we observed a significant reduction of postischemic contractile dysfunction, CK release and myocardial ultrastructural damage; postischemic FITC-albumin extravasation was significantly reduced respect to controls. "	( MK-954 (losartan potassium) exerts endothelial protective effects against reperfusion injury: evidence of an e-NOS mRNA overexpression after global ischemia. Barbacane, RC; Barsotti, A; Conti, P; De Caterina, R; Di Napoli, P; Palka, G; Spina, R; Stuppia, L; Taccardi, AA, 2001)	1.37
"The losartan-treated group also had a marked reduction in mesangial proliferation and less glomerular sclerosis and less reduced vascular wall thickness in renal small arteries and arterioles."	( Renoprotective effect of angiotensin II receptor antagonists in experimental chronic renal failure. Avinoach, I; Ben-David, A; Eliahou, H; Matas, Z; Shahar, C; Shahmurov, M; Zimlichman, R, )	0.61
"Only losartan treatment reduced ex vivo platelet adhesion to a synthetic surface."	( Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001)	0.98
"In losartan treatment TPR for systolic and diastolic AP were 61.5 and 61.3%, respectively, IS made up 0.74 +/- 0.13 and 0.64 +/- 0.09, respectively. "	( [Evaluation of the evenness of the antihypertensive effect of losartan and captopril by using a 24-hour monitoring of arterial pressure]. Deev, AD; Gorbunov, VM; Metelitsa, VI; Savina, LV, 2001)	1.17
"Losartan treatment improved sexual satisfaction from an initial 7.3 to 58.5% (chi2; P = 0.001)."	( Sexual dysfunction in hypertensive patients treated with losartan. Argaya Roca, M; Aznar Vicente, J; Ferrario, CM; Llisterri, JL; Lozano Vidal, JV; Pol Bravo, C; Sanchez Zamorano, MA, 2001)	1.28
"In losartan-treated patients, CVF decreased from 5.65+/-2.03% to 3.96+/-1.46% (P<0.01) and PIP from 127+/-30 to 99+/-26 microgram/L (P<0.01)."	( Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Díez, J; González, A; Larman, M; López, B; Martínez Ubago, JL; Querejeta, R; Varo, N, 2001)	0.82
"Losartan treatment during 6 months also increased NOS activity in aortic smooth muscle (SM)."	( Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging. Basso, N; González Bosc, LV; Kurnjek, ML; Müller, A; Terragno, NA, 2001)	1.03
"Losartan treatment induced a significant reduction in basal pressure but did not interfere with the development of hypertension (similar pressure increases of 24% and 28% over control values in losartan and vehicle groups, respectively)."	( Chronic AT(1) receptor blockade alters autonomic balance and sympathetic responses in hypertension. Bezerra, SM; dos Santos, CM; Krieger, EM; Michelini, LC; Moreira, ED, 2001)	1.03
"Losartan treatment significantly decreased both AUC(glucose)and AUC(insulin)values."	( Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats. Goyal, RK; Murali, B, 2001)	1.3
"Losartan treatment normalized expression of NKCC2 and decreased expression of the vasopressin-regulated water channel aquaporin-2."	( Losartan treatment normalizes renal sodium and water handling in rats with mild congestive heart failure. Christensen, S; Janjua, NR; Jonassen, TE; Marcussen, N; Nielsen, S; Skøtt, O; Staahltoft, D, 2002)	2.48
"In losartan-treated patients, both cardiomyocyte and noncardiomyocyte apoptosis decreased (P<0.05)."	( Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Díez, J; Fortuño, MA; González, A; Larman, M; López, B; Querejeta, R; Ravassa, S, 2002)	0.83
"Losartan-treated rabbits revealed a reduction in immunohistochemical expression of MMP-1, whereas TIMP-2 expression became localized to the intima."	( Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-kappa B by losartan in hypercholesterolemic rabbits. Chen, H; Li, D; Mehta, JL, 2002)	1.26
"Losartan-treated ANG II-infused rats exhibited normalized apoptosis, bax, caspase 3 activity, and AT(1) receptors."	( Effect of AT(1) receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension. Diep, QN; El Mabrouk, M; Schiffrin, EL; Yue, P, 2002)	1.04
"Losartan or placebo treatment was initiated two days before balloon injury in the SHR aorta."	( Losartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury. deBlois, D; Hamet, P; Lemay, J, 2000)	2.47
"Losartan treatment in patients with essential hypertension did not modify the percentage change in the left main coronary artery diameter caused by sublingual administration of nitroglycerin (23.2 14.4% versus 27.2 13.5, P=0.2)."	( Effects of the angiotensin receptor antagonist losartan on the response of the left main coronary artery to cold pressor test in patients with essential hypertension as assessed by echocardiography. Deng, YB; Li, CL; Wang, DW; Yang, HY, 2002)	1.29
"In losartan-treated rats, plasma renin and angiotensin II concentration were increased between 4- and 7-fold at the end of both treatment periods."	( Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure. Beattie, EC; MacPherson, F; Morton, JJ, )	0.92
"Losartan treatment greatly suppressed the myointimal proliferative response.7."	( Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan. Azuma, H; Hamasaki, H; Niimi, Y, 1992)	1.22
"Treatment with losartan, an angiotensin receptor inhibitor, decreases MYOSIN IIB levels and impedes HPS lung fibroblast migration in vitro."	( Dysregulated myosin in Hermansky-Pudlak syndrome lung fibroblasts is associated with increased cell motility. Bishop, K; Bodine, SPM; El-Chemaly, S; Gochuico, BR; Handin, R; Imani, J; Lamattina, AM; Ma, DD; Malicdan, MCV; Maynard, DM; Nwokeji, A; Perrella, MA; Rosas, IO; Shrestha, S; Sood, R; Stump, B; Testa, LC; Young, LR, 2022)	1.06
"Co-treatment with losartan prevented changes on PWV, β-index, and elastic modulus in iron-overloaded rats."	( Blockade of angiotensin AT Ávila, RA; Botelho, T; Dos Santos, L; Fidelis, HG; Goes, SCE; Mageski, JGA; Marques, VB, 2020)	0.88
"Treatment with losartan or spironolactone alone significantly reduced various CKD-associated features."	( Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats. Aggarwal, D; Singh, G, 2020)	0.9
"Treatment with losartan or LRRC55 siRNA suppressed LRRC55 expression, prevented BK channel activation, and attenuated podocyte injury in animal models of FSGS, DN, and MN."	( Upregulated LRRC55 promotes BK channel activation and aggravates cell injury in podocytes. Bao, H; Chen, L; Han, R; Hu, S; Liu, Z; Qin, W; Shi, J; Tang, Z; Xu, X; Zeng, C; Zhang, M; Zhu, X, 2021)	0.96
"Treatment with losartan caused significant recovery of blood flow and decreased PBR and glandular epithelial area as well as tissue MDA, IL-6, and bFGF levels in the SHR ventral prostate without affecting blood pressure."	( Therapeutic effects of losartan on prostatic hyperplasia in spontaneously hypertensive rats. Higashi, Y; Karashima, T; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T, 2021)	1.27
"pretreatment with losartan, a selective AT-1 receptor antagonist, reduced the pressor and the tachycardic responses caused by RS."	( The AT-1 Angiotensin Receptor is Involved in the Autonomic and Neuroendocrine Responses to Acute Restraint Stress in Male Rats. Antunes-Rodrigues, J; Belém-Filho, IJA; Brasil, TFS; Corrêa, FMA; Fortaleza, EAT, 2022)	1.04
"Treatment with losartan (0.6 g/L) prevented the increase in PWV, blood pressure, and vascular stiffness in miR-181a1/b1-/- mice."	( miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling. Adachi, H; Berkowitz, DE; Biswas, D; Das, S; Dunkerly-Eyring, B; Flavell, RA; Henao-Mejia, J; Hori, D; Nomura, Y; Santhanam, L; Steenbergen, C; Steppan, J, 2017)	0.79
"Treatment with losartan suppressed both blood pressure elevation and augmentation of systolic blood pressure variability in rats infused with angiotensin II at 7 and 14 days."	( Inhibitory effects of losartan and azelnidipine on augmentation of blood pressure variability induced by angiotensin II in rats. Jiang, D; Kato, J; Kawagoe, Y; Kitamura, K; Kuwasako, K, 2017)	1.11
"Treatment with Losartan and to a lesser extent the combination therapy resulted in diminished graft take, increased wound contraction and poorer scar outcome."	( Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds. Akershoek, JJ; Beelen, RHJ; Boekema, BKHL; Brouwer, KM; Middelkoop, E; Ulrich, MMW; Vlig, M, 2017)	1.1
"Treatment with losartan suppressed the development of liver fibrosis induced by the CDAA diet, and reduced hepatic periostin expression."	( Periostin cross‑reacts with the renin‑angiotensin system during liver fibrosis development. Aihara, Y; Douhara, A; Kaji, K; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Okura, Y; Sawada, Y; Seki, K; Takeda, K; Yoshiji, H, 2017)	0.79
"Treatment with losartan, aliskiren, or both exerted similar antihypertensive effects."	( Direct renin inhibition is not enough to prevent reactive oxygen species generation and vascular dysfunction in renovascular hypertension. Casarini, DE; Ceron, CS; Fernandes, FB; Guimaraes, DA; Martins-Oliveira, A; Oliveira, DMM; Pinheiro, LC; Rizzi, E; Tanus-Santos, JE; Tirapelli, CR, 2018)	0.82
"Treatment with losartan reduced urinary protein excretion and blood lipids (triglyceride and cholesterol) dose-dependently in both studies. "	( Losartan improves renal function and pathology in obese ZSF-1 rats. Donnelly-Roberts, D; Gopalakrishnan, M; Leys, L; McGaraughty, S; Namovic, M; Nikkel, A; Su, Z; Widomski, D, 2018)	2.28
"Treatment with losartan (15 mg/kg) alone and in combination with a low dose of methotrexate (MTX 0.25 mg/kg/3 days) significantly suppressed the progression of CIA."	( Losartan suppresses the inflammatory response in collagen-induced arthritis by inhibiting the MAPK and NF-κB pathways in B and T cells. Chen, X; Guo, Y; Huang, W; Körner, H; Wang, X; Wei, W; Wu, H; Zhang, P, 2019)	2.3
"Treatment with losartan resulted in a significant reduction in left atrial fibrosis and AF duration (P<.01)."	( Losartan affects the substrate for atrial fibrillation maintenance in a rabbit model. Gu, TX; Liu, HG; Wang, C; Zhang, GW; Zhao, Y, )	1.91
"The treatment of losartan results in significantly reduced atrial fibrosis and AF vulnerability. "	( Losartan affects the substrate for atrial fibrillation maintenance in a rabbit model. Gu, TX; Liu, HG; Wang, C; Zhang, GW; Zhao, Y, )	1.91
"Treatment with losartan may preserve some features of kidney structure in American Indians with type 2 diabetes and microalbuminuria."	( Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Bennett, PH; Fufaa, G; Hanson, RL; Jones, LI; Knowler, WC; Lemley, KV; Lovato, T; Myers, BD; Nelson, RG; Weil, EJ; Yee, B, 2013)	1.13
"Treatment with losartan for MI rats significantly attenuated upregulated AT1R but not AT2R."	( Protection of renal impairment by angiotensin II type 1 receptor blocker in rats with post-infarction heart failure. Cai, M; Chen, Y; Geng, D; Mai, Z; Wang, J; Wen, Z, 2013)	0.73
"Treatment with losartan decreased neutrophil recruitment, hypernociception and the production of TNF-α, IL-1β and chemokine (C-X-C motif) ligand 1 in mice subjected to AIA."	( Mechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis. Bader, M; Barroso, LC; Coelho, FM; Costa, VV; Oliveira, ML; Queiroz-Junior, CM; Santos, RA; Silva, AC; Silva, TA; Silveira, KD; Sousa, LF; Teixeira, MM; Vieira, AT, 2013)	0.95
"Treatment with losartan significantly attenuated desmin- and p16(ink4a)-positive podocytes, restored podocin mRNA expression, and decreased blood cystatin C levels."	( Angiotensin II receptor blocker attenuates intrarenal renin-angiotensin-system and podocyte injury in rats with myocardial infarction. Cai, MY; Chen, YX; Geng, DF; Huang, H; Jin, DM; Mai, Z; Wang, JF; Wen, ZZ, 2013)	0.73
"Treatment with losartan significantly blocked TAC-induced vascular inflammation and macrophage accumulation."	( Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade. Brasier, AR; Cao, JM; Geng, L; Guo, S; Kuang, SQ; Kwartler, CS; Milewicz, DM; Peters, AM; Prakash, SK; Villamizar, C, 2013)	0.73
"Treatment with losartan, an angiotensin-II receptor-1 blocker, may reduce aortic dilatation rate in Marfan patients."	( Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. de Waard, V; den Hartog, AW; Franken, R; Groenink, M; Marquering, HA; Mulder, BJ; Radonic, T; Scholte, AJ; Spijkerboer, AM; Timmermans, J; van den Berg, MP; Zwinderman, AH, 2013)	2.17
"Treatment with losartan reduced left ventricular dysfunction and prevented increased extracellular volume fraction, indicating that T1 mapping is sensitive to pharmacological prevention of fibrosis."	( T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy. Fiedler, LR; Gsell, W; Habib, J; McSweeney, SJ; Prasad, SK; Price, AN; Schneider, MD; Stuckey, DJ; Thin, MZ, 2014)	0.74
"Rats treated with losartan present memory deficits and decreases in spine-density."	( Losartan-induced hypotension leads to tau hyperphosphorylation and memory deficit. Gong, CX; Hu, J; Liu, X; Luo, H; Wang, JZ; Wang, XC; Wang, Z; Xia, Y; Yu, G; Zeng, K; Zhou, XW, 2014)	2.17
"Treatment with losartan induced a significant increase of creatinine and urea clearance, as well as HDL."	( Losartan improved antioxidant defense, renal function and structure of postischemic hypertensive kidney. Ćirović, S; Grujić Milanović, J; Ivanov, M; Jovović, Đ; Marković-Lipkovski, J; Mihailović-Stanojević, N; Miloradović, Z, 2014)	2.18
"Treatment with losartan during the course of testosterone exposure significantly attenuated testosterone-induced hypertension."	( Gestational exposure to elevated testosterone levels induces hypertension via heightened vascular angiotensin II type 1 receptor signaling in rats. Chinnathambi, V; Hankins, GD; More, AS; Sathishkumar, K; Yallampalli, C, 2014)	0.74
"Treatment with losartan lowered systolic arterial pressure in S-P467L (132.2 ± 6.9 mmHg) to a level similar to untreated non-transgenic mice."	( Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension. Carrillo-Sepulveda, MA; Davis, DR; Grobe, JL; Keen, HL; Sigmund, CD, 2014)	0.74
"Treatment with losartan was initiated at a daily dose of 0.75 mg/kg."	( Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan. Ayyavoo, A; Cutfield, WS; Derraik, JG; Hofman, PL, 2014)	0.96
"Co-treatment with losartan significantly attenuated the release of sEng and sEng mRNA expression in the trophoblast cells."	( Autoantibodies isolated from patients with preeclampsia induce soluble endoglin production from trophoblast cells via interactions with angiotensin II type 1 receptor. Chishima, F; Kobayashi, Y; Suzuki, M; Takahashi, H; Yamamoto, T, 2015)	0.74
"Treatment with losartan was safe, suggesting that it can be used for other indications in patients with hypertrophic cardiomyopathy, irrespective of obstructive physiology."	( Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Ahtarovski, K; Axelsson, A; Bundgaard, H; Corell, P; Havndrup, O; Ho, C; Iversen, K; Jensen, M; Langhoff, L; Norsk, J; Vejlstrup, N, 2015)	1
"A pretreatment of losartan led to a marked reduction in CD80 expression on pulmonary DC (P < 0.05 vs ALI)."	( [Effects of losartan on pulmonary dendritic cells in lipopolysaccharide- induced acute lung injury mice]. Liu, J; Qiu, H; Yang, Y; Yu, T; Zhang, P, 2014)	1.1
"Pretreatment with Losartan (an AT1 receptor blocker) attenuated the AngII-induced expression of TLR4 and inflammatory cytokines."	( Angiotensin II-induced hypertensive renal inflammation is mediated through HMGB1-TLR4 signaling in rat tubulo-epithelial cells. Ebenezer, PJ; Francis, J; Nair, AR; Saini, Y, 2015)	0.74
"Mice treated with losartan or enalapril and untreated controls were infected intraperitoneally with the virus, and macrophages were analyzed."	( Losartan and enalapril decrease viral absorption and interleukin 1 beta production by macrophages in an experimental dengue virus infection. Durán, A; Hernández-Fonseca, JP; Mosquera, J; Valero, N, 2015)	2.18
"Treatment with losartan used, the selective antagonist of angiotensin II type I receptor could improve the cardiac function of TAC rats."	( [Preliminary Study of Necroptosis in Cardiac Hypertrophy Induced by Pressure Overload]. Fu, H; Liu, X; Lu, L; Qin, Y; Tang, X; Wu, W; Zhao, M, 2015)	0.76
"Treatment with losartan alone did not suppress tumor growth; In contrast, treatment with doxorubicin alone decreased tumor growth; losartan and doxorubicin were administered in combination, had a synergistic effect that the tumor growth was much more inhibited. "	( Losartan improves the distribution and efficacy of doxorubicin in CT26 tumor. Hu, SQ; Li, XY; Liu, JX; Wang, LY; Xiao, L, 2015)	2.21
"Treatment with losartan had no effect on cardiac function or exercise capacity compared with placebo. "	( Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial. Axelsson, A; Bundgaard, H; Havndrup, O; Ho, CY; Iversen, K; Jensen, M; Kofoed, KF; Norsk, J; Vejlstrup, N, 2016)	1.1
"Treatment with losartan, an angiotensin II receptor antagonist, decreased the collagen density and fiber length in the TIC, consistent with the known activity of this drug."	( Implantable tissue isolation chambers for analyzing tumor dynamics in vivo. Bazou, D; Gruionu, G; Gruionu, LG; Huang, P; Maimon, N; Munn, LL; Onita-Lenco, M, 2016)	0.77
"Treatment with losartan significantly attenuated aortic AS, inhibited ER stress and reduced aortic inflammation."	( Renin-angiotensin system activation accelerates atherosclerosis in experimental renal failure by promoting endoplasmic reticulum stress-related inflammation. Gan, H; Tang, W; Yang, J; Yu, X; Zhang, X, 2017)	0.79
"Treatment with losartan also resulted in significant decrease of the collagen density in the myocardial tissues."	( [Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. Bai, SC; Deng, LH; Huang, P; Su, L; Wen, YW; Wu, ZL; Xu, DL, 2008)	1.04
"Co-treatment with losartan and carvedilol reduced the renal vasoconstrictor responses to exogenously administered vasoactive agents but to a lesser extent than losartan or carvedilol alone."	( Influence of sympathetic and AT-receptor blockade on angiotensin II and adrenergic agonist-induced renal vasoconstrictions in spontaneously hypertensive rats. Abdulla, MH; Abdullah, NA; Johns, EJ; Khan, MA; Sattar, MA, 2009)	0.68
"Treatment with losartan during lactation provoked changes in renal function and structure associated with alterations in AT1 and type 2 AII (AT2) receptors and p-JNK and p-p38 expression in the kidney."	( Roles of mitogen-activated protein kinases and angiotensin II in renal development. Balbi, AP; Coimbra, TM; Costa, RS; Francescato, HD; Marin, EC, 2009)	0.69
"Treatment with losartan or carvedilol blunted the renal vasoconstrictor/vasodilator responses to sympathomimetics which was attenuated with the combined treatment."	( Chronic treatment with losartan and carvedilol differentially modulates renal vascular responses to sympathomimetics compared to treatment with individual agents in normal Wistar Kyoto and spontaneously hypertensive rats. Abdallah, HH; Abdulla, MH; Abdullah, NA; Johns, EJ; Khan, MA; Sattar, MA, 2009)	1
"Treatment with losartan resulted in significant decreases in plasma ANF and N-terminal proANF, whereas BNP did not change."	( Cardiac secretion of atrial and brain natriuretic peptides in acute ischaemic heart failure in pigs: effect of angiotensin II receptor antagonism. Djøseland, O; Hall, C; Karlberg, BE; Klinge, R, 1997)	0.64
"Treatment with Losartan and PD123319 in controls reduced MKP-1 and elevated ERK1/2 phosphorylation to the level observed in BS/GS patients treated with PD123319."	( Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. Calò, LA; D'Angelo, A; Davis, PA; Mormino, P; Pagnin, E; Pessina, AC; Schiavo, S, 2010)	0.7
"Treatment with losartan, a medicine that lowers blood pressure by blocking angiotensin II receptor type 1 receptor, can protect the retinal vasculature against hypertensive vascular injury by inhibiting apoptosis of vascular cells and by preventing hypertensive retinopathy."	( Protection of retinal vasculature by losartan against apoptosis and vasculopathy in rats with spontaneous hypertension. Cai, J; Chen, B; Fang, F; Geng, YJ; Huang, X; Qu, J; Shi, X; Wang, S; Yang, D; Zhang, M, 2010)	0.99
"Treatment with losartan will be compared with no additional treatment after 3 years of follow-up."	( Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Baars, MJ; de Witte, P; Groenink, M; Mulder, BJ; Radonic, T; Zwinderman, AH, 2010)	2.14
"Treatment with losartan potassium or enalapril maleate was not associated with a statistically significant change in CRAE or CRVE."	( Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus. Donnelly, SM; Gardiner, R; Goodyer, P; Klein, BE; Klein, R; Mauer, M; Myers, CE; Sinaiko, AR; Strand, T; Suissa, S; Zinman, B, 2010)	0.7
"Pretreatment with losartan but not the A-779 abolished the effects of Ang II, while A-779 but not the losartan eliminated the effects of Ang-(1-7)."	( Angiotensin-(1-7) and angiotension II in the rostral ventrolateral medulla modulate the cardiac sympathetic afferent reflex and sympathetic activity in rats. Gao, J; Gao, XY; Han, Y; Shi, Z; Yuan, N; Zhou, LM; Zhu, GQ, 2010)	0.68
"Pretreatment with losartan (10(-5) M) or LY294002 (50 microM) could significantly suppress these effects of Ang II."	( Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway. Cai, L; Chen, X; Fu, S; Sui, G; Yang, Y; Zhao, Y, 2010)	0.68
"The treatment with losartan ameliorated all of the above alterations."	( Reduction of inducible nitric oxide synthase via angiotensin receptor blocker prevents the oxidative retinal damage in diabetic hypertensive rats. de Faria, JB; de Faria, JM; Rosales, MA; Silva, KC, 2010)	0.68
"Oral treatment with losartan reduces iNOS expression and reestablishes the redox status, thus ameliorating the early markers of DR in a model of diabetes and hypertension."	( Reduction of inducible nitric oxide synthase via angiotensin receptor blocker prevents the oxidative retinal damage in diabetic hypertensive rats. de Faria, JB; de Faria, JM; Rosales, MA; Silva, KC, 2010)	0.68
"Treatment with losartan resulted in a down-regulation of GPDH in WT and TG."	( Changes in metabolic profile and population of skeletal muscle fibers of mice overexpressing calsequestrin: influence of losartan. Adams, V; Günther, S; Jones, LR; Kusche, T; Neumann, J; Punkt, K, 2011)	0.92
"Treatment with losartan significantly decreased the effects of Ang III, except for cardiomyocyte protein synthesis."	( Effects of angiotensin III on protein, DNA, and collagen synthesis of neonatal cardiomyocytes and cardiac fibroblasts in vitro. Tang, CS; Wang, HX; Wang, W; Zeng, XJ; Zhang, LK; Zhang, QF, 2010)	0.7
"Pre-treatment with losartan, an antagonist of the angiotensin type I (AT₁) receptor, abolished NFκB activation by angiotensin II and caerulein in a dose-dependent manner."	( Co-operative effects of angiotensin II and caerulein in NFκB activation in pancreatic acinar cells in vitro. Chan, YC; Leung, PS, 2011)	0.69
"Pretreatment with losartan (10 mg·kg(-1)·day(-1) in drinking water for 3 wk) significantly reduced protein expression of NAD(P)H oxidase subunits (p22(phox) and p47(phox)) in the PVN of diabetic rats."	( Enhanced angiotensin II-mediated central sympathoexcitation in streptozotocin-induced diabetes: role of superoxide anion. Bidasee, KR; Mayhan, WG; Patel, KP; Zheng, H, 2011)	0.69
"The treatment with losartan not only inhibited structural and functional changes, but also the frequencies and titres of AT1R-AA was significantly lower (P < 0.05) than RVH group."	( [Effect of losartan on produce of sera autoantibodies to angiotensin II-1 receptor in renovascular hypertension rats]. Jiao, XY; Liu, YX; Liu, ZB; Zhao, RR; Zhi, JM, 2003)	1.03
"Treatment with losartan completely prevented the impaired autoregulation and pressure-natriuresis relationship as well as the development of hypertension in I3C-induced rats."	( Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. Cervenka, L; Chábová, VC; Hammock, BD; Honetschlägerová, Z; Husková, Z; Hwang, SH; Imig, JD; Kopkan, L; Kramer, HJ; Kujal, P; Sporková, A; Tesař, V; Vernerová, Z, 2011)	0.71
"Treatment with losartan (15 mg/kg/day; n = 9) similarly mitigated signs of cardiac oxidative stress, but impairments in diastolic function persisted when compared with untreated rats (n = 7)."	( Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats. Carter, CS; Groban, L; Kassik, KA; Lin, MS; Lindsey, S; Machado, FS; Wang, H, 2012)	0.95
"• Treatment with losartan mediated an insignificant reduction in mean bladder weight (68.1 ± 9.1 mg vs 93.2 ± 11.7 mg, P= 0.10), but a significant reduction in detrusor muscle thickness (median 2 vs 3, P= 0.02)."	( Angiotensin II type 1 (AT-1) receptor inhibition partially prevents the urodynamic and detrusor changes associated with bladder outlet obstruction: a mouse model. Comiter, C; Phull, HS, 2012)	0.71
"Treatment with losartan significantly attenuated TAC-induced cardiac hypertrophy, in parallel with decreased expression of RANKL, TNF-α, IL-1α, and IL-1β."	( Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation. Abel, ED; Ahn, J; Kim, HS; Kim, J; Lee, SH; Lee, WS; Min, JK; Ock, S; Oh, GT; Oh, JG; Park, H; Park, WJ; Rho, J; Son, JW; Yang, DK, 2012)	0.72
"Treatment with losartan for 2weeks produced depressor effect, restored the reduced anandamide transporter activity, decreased the plasma anandamide level and increased the plasma level and mRNA expression of CGRP in SHRs."	( Decreased anandamide transporter activity and calcitonin gene-related peptide production in spontaneously hypertensive rats: role of angiotensin II. Hu, CP; Li, D; Li, SX; Li, YJ; Luo, D; Pan, W; Shi, RZ; Yang, TL; Zhang, GG, 2012)	0.72
"Treatment with losartan suppresses the differential expression of mitochondrial ATP synthase subunit d, GRP75, selenium-binding protein 1 etc. "	( Effect of losartan on the glomerular protein expression profile of type 2 diabetic KKAy mice. Fan, QL; Feng, JM; Jiang, Y; Liu, XD; Ma, JF; Wang, LN; Yang, G, )	0.89
"Treatment with losartan and paricalcitol reduced fibrosis (paricalcitol 1.6±0.3% and losartan 2.9±0.6%, both p<0.05 vs."	( The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. Cannon, MV; de Boer, RA; Mahmud, H; Meems, LM; Ruifrok, WP; Silljé, HH; van Gilst, WH; Voors, AA, 2012)	0.72
"Treatment with losartan 100 and 150 mg lowered GFR by 4 ml/min/1.73 m(2) (P<0.05)."	( Optimal dose of losartan for renoprotection in diabetic nephropathy. Andersen, S; Deinum, J; Juhl, TR; Parving, HH; Rossing, P, 2002)	1
"Treatment with losartan reverses this aldosterone-induced decrease in pump function, and coadministration with MR antagonists produces an additive effect on pump function, consistent with a beneficial effect of MR blockade in patients with hypertension and congestive heart failure treated with angiotensin type 1 receptor antagonists."	( Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia. Funder, JW; Mardini, M; Mihailidou, AS; Raison, M, 2002)	0.65
"Treatment with losartan was associated with lower risk of development of diabetes within each of the four quartiles of the risk score."	( Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H, 2002)	0.93
"Pretreatment with losartan and [Sar1, Ala8] ANG II completely abolished the water and sodium intake, and the pressor increase (0.5 +/- 0.2, 1.1 +/- 0.2, 0.5 +/- 0.2, and 0.8 +/- 0.2 ml, and 1.2 +/- 3.9, 31 +/- 4.6 mmHg, respectively, N = 9-12), whereas losartan blunted the urinary and sodium excretion induced by ANG II (13.9 +/- 1.0 ml and 187 +/- 10 micro Eq/120 min, respectively, N = 9)."	( Interaction between paraventricular nucleus and septal area in the control of physiological responses induced by angiotensin II. Camargo, LA; Saad, WA; Santos, TA; Simões, S, 2002)	0.64
"Treatment with losartan not only reduced the incidence of ESRD, but also can result in substantial cost savings in the European Union."	( Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Brenner, B; Carides, GW; Gerth, WC; Hannedouche, T; Martinez-Castelao, A; Remuzzi, G; Shahinfar, S; Viberti, G, 2002)	2.1
"Treatment with losartan--an angiotensin (AT1) receptor antagonist, 2 mg/kg, po for 6 weeks decreased the blood glucose levels by 16.5%."	( Effect of chronic treatment with losartan on streptozotocin induced diabetic rats. Goyal, RK; Murali, B, 2002)	0.94
"Pretreatment with losartan was associated with the increase in the level of CYA much higher than with CYA treatment alone."	( Effects of combination of cyclosporine with losartan or enalapril on kidney function in uremic rats. Azzadin, A; Buczko, W; Małyszko, J; Małyszko, JS; Myśliwiec, M; Tankiewicz, A, )	0.72
"Treatment with losartan in patients with type 2 diabetes and nephropathy not only reduced the incidence of ESRD, but also resulted in substantial cost savings."	( Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Alexander, CM; Brenner, BM; Carides, GW; Cook, JR; Dasbach, EJ; Gerth, WC; Herman, WH; Keane, WF; Shahinfar, S, 2003)	2.11
"Treatment with losartan or captopril normalized the water intake and urine excretion of VDR-null mice."	( Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. Kong, J; Li, YC, 2003)	0.66
"Treatment with losartan significantly decreased the plasma level of TGF-beta1, 24-hour urinary protein and serum uric acid (p < 0.05)."	( Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. el-Agroudy, AE; el-Sawy, EA; Foda, MA; Ghoneim, MA; Hassan, NA; Ismail, AM; Mousa, O, )	0.47
"Treatment with losartan prevented these changes."	( Effect of chronic treatment with losartan on streptozotocin-induced renal dysfunction. Goyal, RK; Murali, B; Umrani, DN, 2003)	0.94
"Treatment with losartan increased left ventricular ejection fraction (baseline vs."	( Effects of angiotensin II type 1 receptor antagonist, losartan, on ventilatory response to exercise and neurohormonal profiles in patients with chronic heart failure. Hisatome, I; Igawa, O; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C, 2004)	0.91
"Pretreatment with losartan into the PVN decreased in a dose-dependent manner the urine, sodium, and potassium excretions induced by MSA administration of adrenaline (50 ng), while PVN PD123319 was without effect."	( Interaction between paraventricular nucleus and medial septal area on the renal effects induced by adrenaline. de Arruda Camargo, LA; de Souza Villa, P; Saad, WA, 2004)	0.65
"Treatment with losartan may be a viable approach for controlling neointimal hyperplasia at locations (eg, grafts) that are accessible during a surgical procedure."	( Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury. Molnar, K; Moon, MC; Yau, L; Zahradka, P, 2004)	0.97
"Treatment with losartan resulted in a significant decrease in blood markers of hepatic fibrosis, plasma TGF-beta1 and serum ferritin concentration concurrently with an improvement in serum aminotransferase levels."	( Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Aso, K; Haneda, M; Hasegawa, T; Miyokawa, N; Nakamura, K; Okada, M; Okamoto, S; Tokusashi, Y; Yokohama, S; Yoneda, M, 2004)	0.66
"Treatment with losartan in patients with type 2 diabetes and nephropathy in the RENAAL study not only reduces the incidence of ESRD, but is also estimated from a U.S. "	( Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. Alexander, CM; Carides, GW; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2004)	2.12
"Treatment with losartan completely blocked the sodium appetite, as well as the induction of Fos-ir in these brain regions."	( Role of angiotensin in body fluid homeostasis of mice: effect of losartan on water and NaCl intakes. Crews, EC; Rowland, NE, 2005)	0.91
"Treatment with losartan resulted in a significant increase in the urinary Zn/creatinine ratio (from 0.020 +/- 0.004 microg/mg to 0.034 +/- 0.005 microg/mg, P = .02), which was further increased by the losartan/hydrochlorothiazide combination (from 0.034 +/- 0.005 microg/mg to 0.053 +/- 0.008 microg/mg, P = .03). "	( The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study. Berman, S; Dishy, V; Golik, A; Koren-Michowitz, M; Weissgarten, J; Yona, O; Zaidenstein, R, 2005)	1.04
"Treatment with losartan causes an increase in urinary Zn excretion and induces Zn deficiency in patients with hypertension. "	( The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study. Berman, S; Dishy, V; Golik, A; Koren-Michowitz, M; Weissgarten, J; Yona, O; Zaidenstein, R, 2005)	1.04
"Treatment with losartan is associated with a reduction in proteinuria, a delay in the onset of ESRD, and no increased risk of cardiovascular events in this pre-ESRD population."	( Losartan and end-organ protection--lessons from the RENAAL study. Brenner, BM; Dickson, TZ; Kowey, PR; Shahinfar, S; Zhang, Z, 2005)	2.11
"Pretreatment with losartan decreased shunt-induced pulmonary vascular resistance and medial thickness by 51% and 35%, respectively."	( Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. Brimioulle, S; Fesler, P; Hubloue, I; Huez, S; Kerbaul, F; Naeije, R; Remmelink, M; Rondelet, B; Salmon, I; Van Beneden, R, 2005)	0.88
"Treatment with losartan resulted in a significant decrease in the Cornell product (-6.2%) and Sokolow-Lyon voltage (-6.3%)."	( Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Boner, G; Brenner, BM; Cooper, ME; Crow, RS; de Zeeuw, D; Dickson, T; Kowey, PR; McCarroll, K; Parving, HH; Shahinfar, S, 2005)	0.88
"Treatment with losartan in patients with type 2 diabetes and nephropathy not only reduced the within-trial incidence of ESRD but is projected to result in lifetime reductions in ESRD, increased survival, and overall cost savings to public institutions in Mexico."	( The impact of losartan on the lifetime incidence of ESRD and costs in Mexico. Arredondo, A; Burke, TA; Carides, GW; Lemus, E; Querol, J, )	0.84
"Treatment with losartan for 3 or 14 days resulted in a slight decrease in mean arterial blood pressure (3 days, 92 +/- 1 mmHg; and 14 days, 99 +/- 2 mmHg) compared with vehicle (109 +/- 3 and 125 +/- 4 mmHg, respectively)."	( Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density. Greene, AS; Munzenmaier, DH, 2006)	0.67
"Treatment with losartan in patients with type 2 diabetic nephropathy not only reduced the incidence of ESRD among Asian patients, but resulted in direct medical cost savings in countries or regions representing Asia."	( Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. Burke, TA; Carides, GW; Chan, J; Choi, YJ; Han, DC; Hwang, SJ; Seng, WK; Teong, CC, 2005)	2.12
"Pretreatment with losartan (10(-8) - 10(-6) mmol/L) significantly inhibited the increased levels of ADMA, LDH and TNF-alpha, attenuated the decreased levels of NO and the decreased activity of DDAH induced by ox-LDL (P < 0.05)."	( [Protective effect of losartan on injury induced by ox-LDL in endothelial cells and the relationship with asymmetric dimethylarginine]. Chen, MF; Sun, ZL; Xie, QY; Yang, TL, 2006)	0.97
"Treatment with losartan plus CT in patients with type 2 diabetes and nephropathy reduced the within-trial incidence of ESRD and is projected to result in lifetime reductions in ESRD and associated costs, and increased survival, versus placebo."	( The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. Alexander, CM; Brenner, BM; Carides, GW; Dasbach, EJ; Gerth, WC; Herman, WH; Keane, WF; Shahinfar, S, 2006)	1.05
"Treatment with losartan for 4 additional weeks did not significantly modify hypertension (168 mmHg) either the degree of tubulo-interstitial lesions; in contrast, a significant regression of ischemic and sclerotic glomerular lesions was observed."	( [Renal hemodynamics and development of renal fibrotic lesions during hypertension]. Boffa, JJ; Chatziantoniou, C; Dussaule, JC; Flamant, M; Placier, S, )	0.47
"Treatment with losartan or enalapril had no effect either on arterial pressure or cardio-renal alterations."	( [Renin-angiotensin system inhibition and cardiac and renal alteration induced by a high sodium diet in rat]. Jover, B; Mimran, A; Rugale, C, )	0.47
"Treatment with losartan, captopril, and the TRx prevented the rhEPO-induced increased in systolic BP."	( Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME, 2006)	0.67
"Treatment with losartan (+/- HCTZ) was well tolerated and led to a substantial decrease in blood pressure and associated stroke risk."	( Impact of losartan on stroke risk in hypertensive patients in primary care. Bestehorn, K; Wahle, K, 2007)	1.08
"Pretreatment with Losartan attenuated ventilator-induced lung injury and prevented the increase in total protein, the number of apoptotic cells, W/D ratio, MPO, and neutrophil counts caused by high volume ventilation."	( Losartan attenuates ventilator-induced lung injury. Feng, D; Li, K; Wang, L; Wu, Q; Yao, S, 2008)	2.11
"Treatment with losartan (30 mg/kg) for 14 days significantly lowered blood pressure, elevated the plasma level of NO, and decreased the plasma concentration of ADMA in SHR."	( Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats. Deng, HW; Jiang, DJ; Li, D; Li, NS; Li, YJ; Luo, D; Wang, S; Xia, K, 2007)	0.9
"Treatment with losartan did not affect serum lipid levels or systolic blood pressure but did reduce the aortic surface lesion area and mean intimal thickness."	( Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan. Li, GS; Li, JJ; Li, NX; Peng, J; Wang, J; Xu, HX, 2007)	0.87
"Treatment with Losartan resulted in severe renal abnormalities."	( Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney. Ciuffo, GM; Forneris, ML; Fuentes, LB; Sánchez, SI; Seltzer, AM, 2008)	0.69
"Treatment with losartan led to dose-dependent vasodilation. "	( Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. DeKock, M; Dickstein, K; Fleck, E; Gottlieb, S; Kostis, J; LeJemtel, T; Levine, B, 1994)	0.88
"Pretreatment with Losartan, an AII receptor antagonist, did not modify the changes in BP, RBF, and RVR induced by L-NAME.(ABSTRACT TRUNCATED AT 250 WORDS)"	( Angiotensin II: endothelium-derived nitric oxide interaction in conscious rats. Beierwaltes, WH; Newman, JM; Sigmon, DH, 1994)	0.61
"Pretreatment with losartan icv eliminated the increase in SpNA observed during the heating period in the saline trial."	( Modulation of autonomic nervous system adjustments to heat stress by central ANG II receptor antagonism. Kregel, KC; Stauss, H; Unger, T, 1994)	0.61
"Pretreatment with losartan had no effect on the responses to nitroglycerin, whereas the responses to nifedipine either were not affected or were attenuated (percent change in mesenteric vascular resistance: without losartan pretreatment, -30 +/- 1%; with losartan pretreatment, -24 +/- 2%, P < .05)."	( Angiotensin subtype 1 blockade selectively potentiates adenosine subtype 2-mediated vasodilation. Cox, BF; Kitzen, JM; Perrone, MH; Smits, GJ, 1993)	0.61
"Pretreatment with losartan completely abolished the pressor and cardiac baroreflex responses to Ang II."	( Role of AT1 receptors in the resetting of the baroreflex control of heart rate by angiotensin II in the rabbit. Chou, L; Reid, IA; Wong, J, 1993)	0.61
"Treatment with losartan tended to decrease each of these toward the level of controls."	( Effect of chronic treatment with losartan potassium (DuP 753) on the elevation of blood pressure during chronic exposure of rats to cold. Brummermann, M; Cade, JR; Fregly, MJ; Rossi, F; Van Bergen, P, 1993)	0.91
"Treatment with losartan was compared to untreated controls, in rats with experimental infarction and sham-operated animals."	( The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cicutti, N; Kolar, F; Korecky, B; Papousek, F; Rakusan, K; Sladek, T; Sladkova, J, 1996)	0.63
"Treatment with losartan decreased the LVEDP, the relaxation constant tau and RVSP in the infarcted hearts."	( The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cicutti, N; Kolar, F; Korecky, B; Papousek, F; Rakusan, K; Sladek, T; Sladkova, J, 1996)	0.63
"Pre-treatment with losartan, however, had no significant effect on systemic vascular resistance although losartan compared to placebo resulted in a significant (P < 0.05) reduction in mean arterial pressure at an SaO2 75-80%: 78 +/- 2 vs 87 +/- 2 mmHg."	( Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade. Cargill, RI; Kiely, DG; Lipworth, BJ, 1995)	0.61
"Treatment with losartan or enalapril significantly decreased blood pressure and induced complete regression of LVH."	( Regression of left ventricular hypertrophy in experimental renovascular hypertension: diastolic dysfunction depends more on myocardial collagen than it does on myocardial mass. Cespedes, C; Dussaillant, GR; Gonzalez, H; Jalil, JE, 1996)	0.63
"Pre-treatment with Losartan completely blocked subsequent AngII-induced reductions in CBF, while both PD123177 and Divalinal failed to inhibit this response."	( Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Harding, JW; Kramár, EA; Wright, JW, 1997)	0.62
"Pretreatment with losartan (10(-8)-10(-5) mol/l) inhibited the contractile response of U46619 and shifted the concentration-response curve to the right in dose-dependent manner."	( Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. Brosnihan, KB; Ferrario, CM; Li, P, 1997)	0.89
"Pretreatment with losartan alone did not affect AUC(plasma epinephrine) (113+/-17 nmol x h/L), while pretreatment with PD123319 tended to reduce the response (87+/-10 nmol x h/L; P=.08 versus vehicle)."	( AT1 and AT2 receptor blockade and epinephrine release during insulin-induced hypoglycemia. Frandsen, E; Ibsen, H; Petersen, JS; Worck, RH, 1998)	0.62
"Treatment with losartan or irbesartan also reduced the chemotactic activity of isolated glomeruli from nephritic animals."	( AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Helmchen, U; Schneider, A; Stahl, RA; Wolf, G, )	0.47
"Pretreatment with losartan, an angiotensin II AT1 receptor antagonist (10.8 nmol/rat into the third ventricle 10 min before central cadmium administration) inhibits the natriuretic effect of this metal, being unable to reverse its kaliuretic effect."	( Natriuretic and kaliuretic effects of central acute cadmium administration in rats. Castro, L; De Castro-e-Silva, E; De Paula, S; Fregoneze, JB; Gonzalez, V; Lima, AK; Luz, CP; Marinho, CA; Nascimento, T; Oliveira, P; Santana Júnior, P; Sarmento, C, 1998)	0.62
"Pretreatment with losartan (10 microM) significantly reduced U46619-induced, concentration-dependent washed platelet aggregation."	( Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. Brosnihan, KB; Ferrario, CM; Li, P, 1998)	2.07
"Pretreatment with losartan abolished the significant difference between the two groups."	( The brain is a possible target for an angiotensin-converting enzyme inhibitor in the treatment of chronic heart failure. Kawada, T; Miyano, H; Sato, T; Shishido, T; Sugimachi, M; Sunagawa, K; Yoshimura, R, 1998)	0.62
"Treatment with losartan increased the magnitude of relaxations in response to acetylcholine for rings from rats in both groups, but increased the magnitude of relaxations in response to nitroprusside only for rings from senescent spontaneously hypertensive rats."	( Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1998)	0.95
"Pretreatment with losartan, a selective angiotensin II AT1 receptor antagonist (10.8 nmol/rat into the third ventricle 10 min before central lead injection), inhibits lead-induced natriuretic and kaliuretic effects."	( Central lead administration induces natriuretic and kaliuretic effects in rats. Castro, L; De Castro-e-Silva, E; De Oliveira, IR; De Paula, S; Fregoneze, JB; Gonzalez, V; Lima, AK; Luz, CP; Marinho, CA; Nascimento, T; Oliveira, P; Santana, P; Sarmento, C, 1998)	0.62
"Pretreatment with losartan attenuated the N(omega)-nitro-L-arginine methyl ester (L-NAME)-induced increase in total peripheral resistance by 26% and also blunted the fall in CI (28%) and stroke volume."	( Role of angiotensin II in modulating the hemodynamic effects of nitric oxide synthesis inhibition. Carbonell, LF; Fenoy, FJ; Hernández, I; Quesada, T, 1999)	0.63
"Treatment with losartan (50 mg) was introduced."	( Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Campistol, JM; Clesca, PH; Iñigo, P; Jimenez, W; Lario, S; Oppenheimer, F; Rivera, F, 1999)	2.09
"The treatment with losartan significantly decreased the plasma levels of TGF-beta1 (P < 0.05) and endothelin (P < 0.05) in all patients."	( Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Campistol, JM; Clesca, PH; Iñigo, P; Jimenez, W; Lario, S; Oppenheimer, F; Rivera, F, 1999)	2.07
"Pretreatment with losartan (40 mg/kg/d) did not improve insulin action in the SHR."	( Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan. Caldiz, CI; de Cingolani, GE, 1999)	0.84
"Treatment with losartan for 3 mo had no effect on LV mass measured by echo (141+/-5 vs."	( Losartan improves diastolic ventricular filling of hypertensive patients with diastolic dysfunction. Ayoub, JC; Costa, OM; de Parma, AH; Delgado, AS; Parro, A; Takakura, IT; Vitola, JV, 1999)	2.09
"Treatment with losartan significantly attenuated the rise in systolic blood pressure induced by L-NAME (p < 0.01)."	( Renal and vascular effects of chronic nitric oxide synthase inhibition: involvement of endothelin 1 and angiotensin II. D'Amours, M; Grose, JH; Larivière, R; Lebel, M, 1999)	0.64
"Treatment with losartan or enalapril reduced left ventricular ANP mRNA and IR-ANP in both strains, and ventricular BNP mRNA levels in SHR rats."	( Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats. Kähönen, M; Kalliovalkama, J; Magga, J; Pörsti, I; Romppanen, H; Ruskoaho, H; Tolvanen, JP; Vuolteenaho, O, 1999)	0.64
"Rats treated with losartan had significantly higher levels of angiotensin II in their plasma."	( Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. Browne, AE; Chatterjee, K; Chou, TM; Lee, RJ; Parmley, WW; Pulukurthy, S; Sievers, RE; Sudhir, K; Sun, Y; Zhu, B, 2000)	0.88
"Treatment with losartan (10 mg/kg/day) began 1 week post-MI and moderate treadmill exercise (25 m/min, 60 min/day, 5 days/week) was initiated 2 weeks post-MI."	( Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodelling in rats. Apstein, CS; Eberli, FR; Jain, M; Liao, R; Ngoy, S; Whittaker, P, 2000)	0.65
"Treatment with losartan is therefore an option for first-line therapy in all patients with hypertension, particularly those who are not well managed with or who are intolerant of their current therapy."	( Losartan: a review of its use, with special focus on elderly patients. McClellan, KJ; Simpson, KL, 2000)	2.09
"Treatment with losartan significantly reduced diastolic (DBP) and systolic BP (SBP) (P < 0.0001)."	( Influence of self-measurement of blood pressure on the responder rate in hypertensive patients treated with losartan: results of the SVATCH Study. Standard vs Automatic Treatment Control of COSAAR in Hypertension. Brignoli, R; Hess, L; Vetter, W, 2000)	0.86
"Co-treatment with losartan prevented all changes."	( Unchanged cardiac angiotensin II levels accompany losartan-sensitive cardiac injury due to nitric oxide synthase inhibition. Boer, P; Braam, B; Gröne, H; Hohbach, J; Joles, JA; Koomans, HA; Verhagen, AM, 2000)	0.88
"Treatment with losartan attenuated aortic intimal proliferation and markedly decreased the enhanced LOX-1 expression."	( Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Chen, H; Inoue, K; Li, D; Mehta, JL; Sawamura, T, 2000)	0.87
"Pretreatment with losartan had little effect on baseline MAP, but increased plasma renin activity, and virtually eliminated the pressor response to Ang II infusion."	( Effect of losartan on angiotensin II-mediated endothelin and prostanoid excretion in humans. Gopalakrishnan, V; McNeill, JR; Quest, DW; Wilson, TW, 2000)	1.03
"Treatment with losartan reduced collagen volume fraction by 49% to 4.9+/-2.9%."	( Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Bachireddy, P; Entman, M; Evans, A; Lim, DS; Lutucuta, S; Marian, AJ; Roberts, R; Youker, K, 2001)	0.65
"Treatment with losartan reversed interstitial fibrosis and the expression of collagen 1alpha (I) and transforming growth factor-beta1 in the hearts of cTnT-Q(92) mice. "	( Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Bachireddy, P; Entman, M; Evans, A; Lim, DS; Lutucuta, S; Marian, AJ; Roberts, R; Youker, K, 2001)	0.66
"Pre-treatment with losartan prevented the acute rise in the mid-frequency oscillations in SBP and partially reduced the low-frequency component observed at 2 and 4 days."	( Acute and chronic alterations in blood pressure variability following experimental subarachnoid haemorrhage. Elghozi, J; Fassot, C; Friberg, P; Lambert, E; Lambert, G, 2001)	0.63
"Treatment with losartan 1 month after five-sixths nephrectomy in male WKY rats resulted in reduced blood pressure, similar to that of the verapamil-treated group."	( Renoprotective effect of angiotensin II receptor antagonists in experimental chronic renal failure. Avinoach, I; Ben-David, A; Eliahou, H; Matas, Z; Shahar, C; Shahmurov, M; Zimlichman, R, )	0.47
"Treatment with losartan reduced the number of activated platelets in SHRSP independently of its blood pressure effects."	( Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001)	0.87
"Treatment with losartan decreases TGF-beta1 plasma values and UAE in type 2 diabetes mellitus patients with high baseline TGF-beta1 levels, suggesting that TGF-beta1 may be a marker to detect patients who may particularly benefit from renin-angiotensin system blockade."	( Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Campistol, JM; Esmatjes, E; Flores, L; Iñigo, P; Lario, S; Ruilope, LM, 2001)	1.07
"Treatment with losartan decreased systolic blood pressure (141 +/- 3 vs 135 +/- 4 mm Hg, P =.04) and increased plasma renin activity (1.2 +/- 0.4 vs 2.7 +/- 0.5 ng/mL/h, P =.001). "	( Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Brown, M; Csako, G; Fleischer, TA; Koh, KK; Mincemoyer, R; Prasad, A; Quyyumi, AA; Schenke, WH; Selvaggi, TA, 2001)	0.66
"Treatment with losartan significantly prevented the raise in cholesterol, creatinine, urea and blood urea nitrogen levels."	( Effect of chronic treatment with losartan on streptozotocin induced diabetic nephropathy. Goyal, RK; Murali, B, 2001)	0.93
"Treatment with losartan in the NIDDM rats caused a significant decrease in insulin levels and reduction in elevated fasting and fed glucose levels."	( Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats. Goyal, RK; Murali, B, 2001)	0.92
"Treatment with losartan, FK506, or cyclosporine partially prevented aldosterone-induced cardiac hypertrophy and fibrosis."	( Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Demura, M; Mabuchi, H; Takeda, Y; Usukura, M; Yoneda, T, 2002)	0.65
"Treatment with losartan, an angiotensin II AT(1) receptor antagonist, decreased BP in two-renin gene mice but not in one-renin gene mice."	( Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes. Brunner, HR; Burnier, M; Clément, S; Gabbiani, G; Hummler, E; Nussberger, J; Wang, Q, 2002)	0.65
"Treatment with Losartan (10 mg/kg per day) lowered blood pressure markedly."	( Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Fukuchi, S; Hashimoto, S; Mizuno, K; Niimura, S; Ohtsuki, M; Sanada, H; Tani, M; Watanabe, H, 1992)	1.01
"Treatment with Losartan normalized glomerular filtration rate, but not filtration fraction or renal vascular resistance."	( Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Antunes, E; de Nucci, G; Lovisolo, SM; Ribeiro, MO; Zatz, R, 1992)	0.62

Excerpt	Reference	Relevance
" There were no adverse effects on the F1 generation as assessed by mortality, clinical signs, weight gain, external examinations, developmental signs, behavioral tests, and gross or microscopic examination of the kidney."	( Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. Allen, HL; Cukierski, MA; Eydelloth, RS; Manson, JM; Robertson, RT; Spence, SG, 1995)	0.5
" Overall, losartan, whether administered alone or in combination with a low dose of hydrochlorothiazide (HCTZ), was effective and well-tolerated in these clinical trials, with an incidence of adverse experiences similar to that of placebo."	( Efficacy and safety of losartan. Goldberg, A; Sweet, C, 1995)	1
"1%) were the clinical adverse experiences most often reported in patients treated with losartan."	( Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Dunlay, MC; Goldberg, AI; Sweet, CS, 1995)	0.81
" Losartan was well tolerated in this trial, with an adverse event profile similar to placebo and enalapril."	( An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. Bradstreet, TE; Byyny, RL; Merrill, DD; Sweet, CS, 1996)	1.46
" The most frequently reported adverse events were headache, upper respiratory tract infection, dizziness, and asthenia/fatigue, but only dizziness occurred more frequently (> or = 1%) in the losartan-treated groups."	( Clinical safety and tolerability of losartan. Weber, M, )	0.6
" Safety was assessed by recording spontaneously reported or observed adverse experiences and clinical laboratory measurements."	( A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Cifkova, R; Harron, DW; Karpov, YA; Lepe, L; Oigman, W; Roca-Cusachs, A, 1997)	0.52
" The percentage of patients reporting a clinical adverse experience considered drug-related by the investigator was 13% in the captopril group and 10% in the losartan group."	( A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Cifkova, R; Harron, DW; Karpov, YA; Lepe, L; Oigman, W; Roca-Cusachs, A, 1997)	0.71
" The number of patients with the side effect of cough was higher following captopril."	( A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Cifkova, R; Harron, DW; Karpov, YA; Lepe, L; Oigman, W; Roca-Cusachs, A, 1997)	0.52
"Treatment of hypertensive patients with fixed-dose combination therapy consisting of losartan and hydrochlorothiazide (HCTZ) has several potential benefits over monotherapy with each of the individual components: more effective blood pressure control, a reduction in the likelihood of adverse effects, and facilitation of patients staying on therapy due to a simple once-daily regimen."	( Safe and effective management of hypertension with fixed-dose combination therapy: focus on losartan plus hydrochlorothiazide. Benedict, CR, )	0.58
" We saw the fetal toxic effects of oligohydramnios (decreased amniotic fluid), fetal pulmonary hypoplasia, fetal hypoplastic skull bones, and subsequent fetal death."	( Losartan and fetal toxic effects. Hagiwara, A; Ijiri, R; Saji, H; Yamanaka, M, 2001)	1.75
" Drug-related adverse experiences occurred in 30 patients (22."	( Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Aurup, P; Goldberg, A; Oparil, S; Snavely, D, 2001)	0.62
"To study the effect of losartan potassium in the treatment of mild to moderate hypertension and to compare its efficacy and adverse effect profile with enalaparil maleate."	( Evaluation of efficacy and safety of losartan potassium in the treatment of mild to moderate hypertension as compared to enalapril maleate. Babu, A; Bhaduri, J; Kamath, S; Kumar, TR; Raju, BS; Rao, M; Shobha, JC, 2000)	0.89
" Safety was assessed by determining the incidence of clinical and laboratory Adverse events and evaluating mean changes in pulse, body weight, electrocardiographic parameters, and laboratory test results."	( Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Alderman, M; Alexander, J; Ceesay, P; Espenshade, M; Flack, JM; Goldberg, A; Gradman, A; Green, S; Kraus, WE; Lester, FM; Pratt, JH; Saunders, E; Vargas, R, 2001)	0.58
" The incidence of clinical adverse events was comparable in the 3 treatment groups."	( Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Alderman, M; Alexander, J; Ceesay, P; Espenshade, M; Flack, JM; Goldberg, A; Gradman, A; Green, S; Kraus, WE; Lester, FM; Pratt, JH; Saunders, E; Vargas, R, 2001)	0.58
"Angioedema is an uncommon but potentially life-threatening adverse event associated with ACE inhibitor therapy which is believed to be due to potentiation of the vascular effects of bradykinin."	( Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Howes, LG; Tran, D, 2002)	0.31
" Thus, combination therapy of losartan/hydrochlorothiazide seems useful in the treatment of elderly hypertension, showing additive BP lowering effect without metabolic adverse effects."	( [Efficacy and safety of combination therapy with losartan and hydrochlorothiazide in elderly hypertension]. Abe, I; Eto, K; Iida, M; Tsuchihashi, T, 2002)	0.86
" Details of any adverse event reported or noted during the treatment with the combination were recorded in the appropriate section of the case record form, whether considered treatment related or not, as reported by the patients."	( Efficacy and safety of losartan-amplodipine combination--an Indian postmarketing surveillance experience. Gokhale, N; Pawar, D; Shahani, S, 2002)	0.63
" Adverse effects were recorded."	( An open comparative clinical trial to assess the efficacy and safety of losartan versus enalapril in mild to moderate hypertension. Adhikari, PM; Bhat, P; Chowta, KN; Chowta, MN, 2002)	0.55
" Adverse events reported with losartan were mild."	( An open comparative clinical trial to assess the efficacy and safety of losartan versus enalapril in mild to moderate hypertension. Adhikari, PM; Bhat, P; Chowta, KN; Chowta, MN, 2002)	0.84
" Safety was assessed in both studies by the incidence of adverse experiences."	( Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment. Dickson, TZ; Lin, CC; Lo, MW; Ramjit, D; Ritter, MA; Shahinfar, S; Snavely, D; Zagrobelny, J, 2003)	0.56
" Adverse effects were also evaluated."	( Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. Ellis, D; Grosso, MJ; Janosky, JE; Moritz, ML; Reitz, S; Vats, A, 2003)	0.55
" Thirteen children had adverse effects potentially ascribed to losartan; most of these either improved or resolved with dosage adjustment or resulted in its discontinuation in 9 of the 52 children (17%)."	( Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. Ellis, D; Grosso, MJ; Janosky, JE; Moritz, ML; Reitz, S; Vats, A, 2003)	0.79
" Tolerability and safety was assessed by physical examination, laboratory parameters and evaluation of adverse events."	( Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study. Ballary, C; Desai, A; Dongre, N; Samra, SS, 2003)	0.55
" In summary, according to this retrospective pilot study, DALI-LDL-apheresis was shown for the first time to be safe and effective in patients on ARA medication."	( Efficacy and safety of DALI-LDL-apheresis in two patients treated with the angiotensin II-receptor 1 antagonist losartan. Bosch, T; Wendler, T, 2004)	0.53
" Adverse effects (one serious) led to discontinuation of losartan in five children (11%)."	( Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Ellis, D; Janosky, JE; Moritz, ML; Vats, A, 2004)	0.81
" Adverse events with the two treatments were comparable (telmisartan vs."	( Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Bai, J; Cai, NS; Cheng, NN; Fan, WH; Guo, JX; Guo, JZ; Ke, YN; Lu, ZY; Sheng, LH; Tang, B; Zhu, JR, 2004)	0.59
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" We tested for effect modification by age of the effect of losartan on the incidence of the predefined end points (doubling of serum creatinine, end-stage renal disease [ESRD], or death) and the risk of adverse events."	( Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Avorn, J; Brenner, BM; Cooper, ME; Shahinfar, S; Winkelmayer, WC; Zhang, Z, 2006)	0.58
" We found no evidence that older patients were more likely to experience adverse events from losartan such as a rise in serum creatinine or hyperkalemia than younger patients."	( Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Avorn, J; Brenner, BM; Cooper, ME; Shahinfar, S; Winkelmayer, WC; Zhang, Z, 2006)	0.55
" Underuse of ACEI and ARB therapy in elderly patients because of the perceived lack of efficacy or a greater risk of adverse events appears unjustified."	( Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Avorn, J; Brenner, BM; Cooper, ME; Shahinfar, S; Winkelmayer, WC; Zhang, Z, 2006)	0.33
" (4) The incidence of study drug-related adverse events (AEs) in olmesartan group (10."	( [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. Cai, NS; Chen, YZ; Fan, WH; Guo, JX; He, B; Huang, J; Ke, YN; Li, XL; Ma, H; Wu, ZG; Zhu, DL; Zhu, JR, 2006)	0.58
"This study shows that olmesartan medoxomil, at oral dose of 20 mg-40 mg once daily was effective and safe for hypertension treatment and the hypotensive effect was superior to losartan potassium (50 mg-100 mg once daily)."	( [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. Cai, NS; Chen, YZ; Fan, WH; Guo, JX; He, B; Huang, J; Ke, YN; Li, XL; Ma, H; Wu, ZG; Zhu, DL; Zhu, JR, 2006)	0.78
" There were no significant differences in the incidences of clinical and laboratory drug-related adverse events between any of the combination groups and the placebo group."	( Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hirayama, Y; Matsuoka, H; Nonaka, K; Ogihara, T; Saruta, T; Suzuki, H; Takahashi, K; Toki, M, 2007)	0.57
" Adverse drug reactions occurred in 1,081 of the 29,850 patients."	( Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2008)	0.63
"To evaluate the evidence for temporal reporting patterns, such as the Weber effect, in spontaneous post-marketing adverse event (AE) reports submitted to the Food and Drug Administration (FDA), for four members of the angiotensin II receptor blockers drug class (ARBs)."	( Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect. Dal Pan, GJ; Governale, LA; Hammad, TA; McAdams, MA; Swartz, L, 2008)	0.35
"1%) were the most commonly reported clinical adverse experiences in patients treated with losartan."	( Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. Dunlay, MC; Goldberg, AI; Sweet, CS, 1995)	0.81
" Adverse effects related to the treatment during the study were reported in a total of 9 patients (0."	( [The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study]. Ceypová, K; Hauser, T; Kristenová, P; Krupicka, J, 2008)	0.61
"Losartan in the form of Lozap or Lozap is a safe and effective treatment of patients with hypertensive disease."	( [The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study]. Ceypová, K; Hauser, T; Kristenová, P; Krupicka, J, 2008)	2.05
" Main outcome parameters were the systolic (SBP) and diastolic (DBP) blood pressure reduction, the rate of normalized patients at study end compared to baseline, and the number and type of adverse events (AEs)."	( Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: observational, prospective study in primary care. Bestehorn, K; Bönner, G; Jung, C; Smolka, W, 2009)	0.66
" Clinical and laboratory adverse events were reported for 29 patients (11%), but serious abnormalities were not observed."	( One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Ayabe, T; Eto, T; Etoh, T; Ichiki, Y; Kato, J; Kita, T; Kitamura, K; Tamaki, N; Yokota, N, 2010)	0.62
" The adverse effects included dry cough (seven [19."	( Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. Lee, KO; Liew, CF; Lim, P; Mukherjee, JJ; Tan, F, 2010)	0.36
"Dual blockade of the RAAS is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy."	( Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. Lee, KO; Liew, CF; Lim, P; Mukherjee, JJ; Tan, F, 2010)	0.36
"The authors aimed to test the hypothesis that xenon anesthesia limits adverse hypotensive effects of losartan during acute hemorrhage."	( Xenon/remifentanil anesthesia protects against adverse effects of losartan on hemodynamic challenges induced by anesthesia and acute blood loss. Boemke, W; Francis, RC; Klein, A; Philippi-Höhne, C; Pickerodt, PA; Reyle-Hahn, MS, 2010)	0.81
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
"Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events."	( Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F; Rossing, P, 2010)	0.59
" Adverse event rates were similar between treatments, irrespective of CKD stage."	( Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F; Rossing, P, 2010)	0.59
" Adverse event incidence was low and comparable between losartan and placebo/amlodipine groups."	( Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Gleim, GW; Lam, C; Le Bailly De Tilleghem, C; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2011)	0.93
" No serious adverse events occurred in any of the 3 groups."	( Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study. Chen, P; Chen, X; Huang, S; Li, Y; Lie, C; Liu, S; Miao, L; Wang, L; Wu, X; Xie, Y; Zhang, A, 2011)	0.62
"Efficacy of losartan versus atenolol in the prevention of progressive dilation of the aorta, improved aortic distensibility, and prevention of adverse events (aortic dissection or rupture, cardiovascular surgery, or death) will be assessed in this study."	( [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome]. Centeno, J; Cortina, J; Evangelista, A; Forteza, A; García, D; García-Dorado, D; Gutiérrez, L; Rodríguez-Palomares, J; Sánchez, V; Sanz, P; Teixidó, G, 2011)	1.02
" Since these adverse effects did not disappear after the return to Preminent(®) at the end of Stage C, we performed an additional 3-month follow-up (extended stage)."	( Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study). Inoue, A; Kuwano, T; Mitsutake, R; Miura, S; Morii, J; Saku, K; Shiga, Y; Uehara, Y, 2011)	0.6
"Single-pill fixed-dose combination therapy using Preminent(®) showed significant 24-h BP-lowering effects and was safe when compared with CodioMD(®)."	( Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study). Inoue, A; Kuwano, T; Mitsutake, R; Miura, S; Morii, J; Saku, K; Shiga, Y; Uehara, Y, 2011)	0.6
" There were 38 adverse events in 20 patients (21."	( Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind Chae, SC; Cho, SY; Hong, TJ; Jeong, JW; Jung, JW; Kang, SM; Kim, CH; Kim, JJ; Kim, MH; Kwon, J; Park, CG; Park, SH; Shin, DG; Yang, JY; Yoon, JH; Youn, JC, 2011)	0.61
" Serious adverse events were more frequent in E (2."	( Efficacy and safety of early versus late titration of fixed-dose irbesartan/hydrochlorothiazide: ACTUAL study. Aoun, J; Girerd, X; Rosenbaum, D, 2011)	0.37
" Metabolic parameters maintained a limited range of changes after 3 years, and adverse events were markedly decreased after 1-year treatment."	( Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study). Ayabe, T; Eto, T; Etoh, T; Ichiki, Y; Kato, J; Kita, T; Kitamura, K; Tamaki, N; Yokota, N, 2012)	0.63
" Olmesartan and LOS were well tolerated, and the most common treatment-emergent adverse event was headache."	( Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension. Chavanu, KJ; Flack, JM; Graff, A; Li, W, 2012)	0.64
" At least one adverse event occurred in 141 (1."	( [Effectiveness and safety of losartan and its combination with hydrochlorothiazide in patients with hypertension: in result study]. Glezer, MG; Saĭgitov, RT, 2012)	0.67
"In patients with heart failure and reduced left ventricular ejection fraction (HFrEF), renin-angiotensin-aldosterone system blockade reduces morbidity and mortality, but comes at an increased risk of adverse events (AEs)."	( Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. Dickstein, K; Francis, G; Kiernan, MS; Komajda, M; Konstam, MA; Martinez, FA; Neaton, JD; Wentworth, D; Zannad, F, 2012)	0.38
" Safety parameters were assessed according to the percentage of adverse events and metabolic effects of therapy."	( [Postmarketing study of efficacy and safety of losartan during the treatment of patients with mild and moderate hypertension: LOTAR (corrected) study]. Burmazović, S; Dimković, N; Krstić, N; Lazarević, K; Micić, D; Milanović, S; Vasilijević, Z; Zorić, S, )	0.39
" Adverse events were rare and metabolic effect was favorable."	( [Postmarketing study of efficacy and safety of losartan during the treatment of patients with mild and moderate hypertension: LOTAR (corrected) study]. Burmazović, S; Dimković, N; Krstić, N; Lazarević, K; Micić, D; Milanović, S; Vasilijević, Z; Zorić, S, )	0.39
" Losartan is a safe and metabolically neutral medication."	( [Postmarketing study of efficacy and safety of losartan during the treatment of patients with mild and moderate hypertension: LOTAR (corrected) study]. Burmazović, S; Dimković, N; Krstić, N; Lazarević, K; Micić, D; Milanović, S; Vasilijević, Z; Zorić, S, )	1.3
" The incidence of adverse reactions was not different among the 3 groups (P>0."	( Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial. Chang, M; Chen, X; Ding, XQ; Fu, P; Guan, GJ; Hao, L; He, LQ; He, YN; Hu, Z; Li, P; Lin, HL; Lin, S; Liu, ZS; Mei, CL; Miao, LN; Wang, JQ; Wang, L; Wang, R; Wu, XF; Xie, RJ; Xing, CY; Yin, AP; Yuan, FH; Zhang, AP; Zhang, L; Zhang, M; Zhao, JY; Zhou, CH, 2014)	0.4
" Drug-related adverse events with an incidence ⩾ 2% in the L100/H12."	( Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials. Azuma, K; Fujimoto, G; Fujita, KP; Hanson, ME; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2014)	0.71
" Adverse events were assessed."	( Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015)	0.7
" However, the side effects of, and adverse reactions to, these agents reduce the benefits to patients."	( Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial. Cai, GY; Chen, XM; Deng, YY; Fang, JA; He, YN; Kou, J; Lin, HL; Nie, LF; Wu, J; Xie, YS; Yang, HT, 2014)	0.4
"No medical treatment has been reliably shown to halt or reverse disease progression in hypertrophic cardiomyopathy, but the results of several pilot studies have suggested beneficial effects of angiotensin II receptor blockers on left ventricular hypertrophy and fibrosis, which are predictive of an adverse outcome."	( Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Ahtarovski, K; Axelsson, A; Bundgaard, H; Corell, P; Havndrup, O; Ho, C; Iversen, K; Jensen, M; Langhoff, L; Norsk, J; Vejlstrup, N, 2015)	0.66
" Deaths and adverse reactions were absent barring clinically insignificant side effects in 28 of the 160 patients (17."	( [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013)	0.68
"Losartan and amlodipine are effective and safe agents for AH therapy."	( [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013)	2.12
" We evaluated the impact of 3 generic angiotensin II receptor blockers commercialization on adverse events: hospitalizations or emergency room consultations."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.46
" Rates of adverse events for losartan, valsartan, and candesartan users (N=136 177) aged ≥66 years were calculated monthly, 24 months before and 12 months after generics commercialization."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.75
"Among generic users, immediate or delayed differences in adverse events rates were observed right after generic commercialization for 3 antihypertensive drugs."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.46
" High adherence rates and few adverse effects were observed in Very-Elderly patients receiving combination (n = 32) and high-dose (n = 34) therapies and in Young/Elderly patients receiving combination (n = 69) and high-dose (n = 66) therapies."	( Losartan/hydrochlorothiazide combination is safe and effective for morning hypertension in Very-Elderly patients. Anegawa, T; Fukuda, K; Fukumoto, Y; Imaizumi, T; Iwamoto, Y; Kai, H; Kajimoto, H; Uchiwa, H, 2018)	1.92
"The aim of current study was to assess the effectiveness of losartan 50 mg in reducing blood pressure among post-dialysis euvolemic hypertensive patients, observing their survival trends and adverse events during the course of study."	( Safety and Efficacy of Losartan 50 mg in Reducing Blood Pressure among Patients with Post-Dialysis Euvolemic Hypertension: A Randomized Control Trial. Adnan, AS; Aftab, RA; Khan, AH; Khan, TM; Sulaiman, SAS, 2017)	1.01
" Adverse drug reactions (ADRs) were monitored."	( Comparison of Effect of Enalapril and Losartan Monotherapy on Quality of Life and Safety of Stage 1 Hypertensive Patients. Gupta, LK; Maharshi, V; Rehan, HS; Yadav, M, 2016)	0.71
" The oral tolerability and toxicity studies depicted that the developed hydrogels were safe up to 3800 mg/kg body weight and caused no hematological or histopathological changes when compared with the control group."	( Synthesis, Characterization and Safety Profiling of Eudragit-Based pHResponsive Hydrogels: A Promising Platform for Colonic Delivery of Losartan Potassium. Buabeid, MA; Khan, SA; Mahmood, S; Mannan, A; Murtaza, G; Ullah, K, 2019)	0.72
" Propensity scores were generated, and differences in BP and adverse events (angioedema, acute kidney injury, hyperkalemia) between BID/QDay groups were analyzed within dosing cohorts using inverse propensity of treatment-weighted regression models."	( Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. Botts, SR; Delate, T; Derington, CG; Kao, DP; King, JB; Kroehl, M; Trinkley, KE, 2020)	0.82
" Prospective cohort consisted of de novo initiation of losartan and continuation for a minimum of 7 days and assessed for adverse events (AKI, hyperkalemia, transaminitis, hypotension) and clinical outcomes (change in SpO2/FiO2 and inflammatory markers, need for ICU admission and mechanical ventilation)."	( Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: A feasibility study. Ahmad, S; Bolotova, O; Chaudhri, I; Koraishy, FM; Mallipattu, SK; Marcos, LA; Sahib, H; Skopicki, H; Yoo, J, 2020)	1.08
" Activation of the renin-angiotensin system (RAS) and associated inflammations may exacerbate the toxic effects of tacrolimus."	( Evaluation of the Effect of Captopril and Losartan on Tacrolimus-induced Nephrotoxicity in Rats. Abeyat, H; Behmanesh, MA; Poormoosavi, SM; Sangtarash, E, 2021)	0.89
" The number of adverse events was low (22 in the losartan group and 20 in the placebo group) with no differences between treatment groups."	( Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Barnes, J; Ben-Shlomo, Y; Blair, PS; Clegg, SL; Coulthard, E; Fox, NC; Howden, B; Jarutyte, L; Kehoe, PG; Lane, JA; Malone, IB; Mutsaerts, HJ; Nielsen, C; Passmore, P; Sudre, CH; Taylor, J; Thai, NJ; Thomas, DL; Turner, N; Wilkinson, I; Wilson, A, 2021)	1.19
" At the same time, it alleviates disease-related symptoms, reduces the influence of cytokine levels, and has fewer adverse reactions, making it more conducive to disease recovery."	( Meta-analysis of the effectiveness and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of chronic glomerulonephritis. Chen, XF; Feng, PF; Sheng, N; Zhu, LX, 2022)	0.95
" Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension."	( Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension. Cho, DK; Cho, GY; Cho, JM; Heo, JH; Hong, SJ; Jeong, MH; Jung, JA; Kim, DH; Kim, SH; Kim, SY; Kim, W; Kwon, K; Lee, HY; Lee, JB; Lim, SW; Park, K; Park, S; Pyun, WB; Rha, SW; Rhee, MY; Shin, J; Sung, KC, 2023)	0.91
" The numbers of patients with adverse drug reactions (ADRs) were compared as safety variables."	( A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023)	1.11
" Five patients showed clear adverse reactions, with abdominal or gastrointestinal discomfort."	( [Efficacy, safety, and mechanism of Huangkui Capsules in treating chronic kidney disease: Meta-analysis and integrative bioinformatics]. Liu, Y; Lyu, J; Wang, FP; Xie, YM; Zhang, L, 2023)	0.91

Excerpt	Reference	Relevance
" The acute pharmacodynamic actions of intravenous (i."	( Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Berman, RS; Bradstreet, DC; Jallard, N; Saenz, A; Sweet, CS; Weidler, DJ, 1994)	0.29
" Absorption was rapid, with peak plasma levels observed within 1 hr, and the Cmax and area under the concentration vs."	( The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. Christ, DD; Hart, SD; Lam, GN; Quon, CY; Wong, PC; Wong, YN, 1994)	0.51
" The mean values of Cmax and AUC0-infinity increased in a dose-dependent manner."	( Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Nakashima, M; Ohtawa, M; Saitoh, K; Takayama, F; Yoshinaga, T, 1993)	0.51
" The lack of pharmacokinetic or pharmacodynamic interaction between warfarin and losartan observed in this investigation suggests that a clinically important interaction between these drugs is unlikely to occur in patients requiring concomitant administration of both drugs."	( Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. Bjornsson, TD; Deutsch, PJ; Goldberg, MR; Kong, AN; Osborne, B; Tomasko, L; Waldman, SA, 1995)	1.96
"To support the use of a combination of losartan, a highly specific and selective AT1 angiotensin II receptor antagonist, and hydrochlorothiazide for treatment of hypertension, a pharmacokinetic drug interaction study was conducted."	( Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. Capra, NL; Goldberg, MR; Hsieh, JY; Lin, CC; Lo, MW; McCrea, JB; Tomasko, L, 1995)	0.81
" for 6 days) on the pharmacokinetics and pharmacodynamic effects of the angiotensin II receptor antagonist, losartan (100 mg)."	( Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. Bradstreet, TE; Goldberg, MR; Höglund, P; Lo, MW; Ritter, MA, 1995)	0.74
" This study indicates a predictable plasma concentration-effect relationship of EXP3174 in rats which would be helpful in designing more rational dosing schemes for pharmacodynamic studies."	( Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan. Christ, DD; Lam, GN; Wong, PC; Wong, YN, 1996)	0.5
"The pharmacokinetic and pharmacodynamic properties of nonpeptide angiotensin antagonists in humans are reviewed in this paper."	( Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Biollaz, J; Brunner, HR; Buclin, T; Csajka, C, 1997)	0.3
" After concomitant administration with fluconazole, losartan AUC(0-t) and Cmax were significantly increased 66% and 30%, respectively, compared with those values for losartan alone."	( Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Blum, RA; Boike, SC; Etheredge, R; Ilson, B; Jorkasky, DK; Kazierad, DJ; Martin, DE; Tenero, DM, 1997)	0.79
" The pharmacodynamic activities of losartan and EXP3174 were determined during constant intravenous infusion as the degree of inhibition of angiotensin II-induced increase in the diastolic pressure."	( Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model. Bai, SA; Christ, DD; Hellyer, P; Lankford, SM; Plummer, D, 1997)	0.83
" Furthermore, the half-life of Ang II in rats pretreated with saline or losartan was significantly greater than that measured in the other three groups."	( Role of AT1 and AT2 receptors in the plasma clearance of angiotensin II. Brosnihan, KB; Chappell, MC; Ferrario, CM; Iyer, SN, 1998)	0.53
" In vehicle-treated SD, SHR and TG+ the half-life (t1/2) of Ang-(1-7) averaged 10+/-1, 10+/-1, and 9+/-1 seconds, respectively."	( Converting enzyme determines plasma clearance of angiotensin-(1-7). Chappell, MC; Ferrario, CM; Ganten, D; Iyer, SN; Yamada, K, 1998)	0.3
" The authors found that fluvastatin did not significantly change the steady-state AUC0-24 or half-life of losartan or E3174."	( The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. Hinderliter, AL; Meadowcroft, AM; Patterson, JH; Pieper, JA; Williamson, KM, 1999)	0.77
"The pharmacodynamic effects of a single oral dose of 16 mg candesartan cilexetil are greater than those of 50 mg losartan and 8 mg candesartan cilexetil."	( Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan. Azizi, M; Chatellier, G; Guyene, TT; Ménard, J, 1999)	0.75
"Patients were administered losartan 100 mg/day for 7 days, and after the seventh and final dose pharmacokinetic parameters were determined for both losartan and its active metabolite E-3174."	( Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. Gehr, TW; Halstenson, CE; Keane, WF; Sica, DA, 2000)	0.86
" Significant differences were observed in some of the pharmacokinetic parameters of losartan and its metabolite E3174 after losartan administration with and without co-administered GJ."	( Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Avni, B; Dishi, V; Gips, M; Golik, A; Scapa, E; Soback, S; Weissgarten, Y; Zaidenstein, R, 2001)	0.78
"Single-dose pharmacokinetic study."	( Losartan and E3174 pharmacokinetics in cytochrome P450 2C91/1, 1/2, and 1/3 individuals. Blaisdell, JA; Goldstein, JA; Hinderliter, AL; Lee, CR; Pieper, JA, 2003)	1.76
"Plasma and urine samples were collected for 24 hours, and losartan and E3174 pharmacokinetic data were compared across the three genotypes."	( Losartan and E3174 pharmacokinetics in cytochrome P450 2C91/1, 1/2, and 1/3 individuals. Blaisdell, JA; Goldstein, JA; Hinderliter, AL; Lee, CR; Pieper, JA, 2003)	2.01
"The aim of this work was to develop lead pharmacodynamic hybrids, NO-sartans, possessing the characteristics of a typical AT1-antagonist and of a "slow NO donor", by adding NO-donor side chains to losartan."	( NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs. Balsamo, A; Breschi, MC; Calderone, V; Digiacomo, M; Martelli, A; Martinotti, E; Minutolo, F; Rapposelli, S, 2004)	0.51
"The pharmacokinetic profiles of two brands of losartan 50 mg tablets were compared in 24 healthy adult volunteers after a single oral dose in a randomized cross-over study."	( Comparative pharmacokinetics of two tablet formulations of Losartan: bioequivalence assessment. Dham, R; Mahmood Alam, S; Salem, II; Tamimi, JJ; Zaman, Q, 2005)	0.83
" Finally, some relevant pharmacokinetics and metabolic properties of the database of 53 compounds are calculated using the VolSurf and MetaSite software to allow the simultaneous characterization of pharmacodynamic and pharmacokinetics properties of the chemical space of angiotensin II receptor antagonists."	( Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. Berellini, G; Cruciani, G; Mannhold, R, 2005)	0.33
" E 3174 is 10- to 40-fold more potent than its parent compound and its estimated terminal half-life ranges from 6 to 9 hours."	( Clinical pharmacokinetics of losartan. Gehr, TW; Ghosh, S; Sica, DA, 2005)	0.62
" Under fed conditions, treatment C had no significant effect on the AUC(0-t) and Cmax of losartan and E-3174."	( The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects. Guilbaud, R; Kambhampati, SR; Lee, J; Marier, JF; Mathew, P; Moberly, J; Salazar, DE, 2006)	0.8
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" In the LOS group, the maximum concentration (C(max)) and area under the concentration curve (AUC) of losartan were significantly higher than in the LOS+BUC group."	( The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Fukumoto, K; Kato, R; Kobayashi, M; Takagi, M; Tanaka, K; Ueno, K, 2008)	0.79
"The pharmacokinetic parameters for losartan and E3174 changed inconsequentially across the range of renal insufficiency."	( The pharmacokinetics of losartan in renal insufficiency. Furtek, CI; Gehr, TW; Halstenson, CE; Keane, WF; Lipschutz, K; Lo, MW; Ritter, MA; Shahinfar, S; Shaw, WC; Sica, DA, 1995)	0.88
" These pharmacokinetic alterations do not warrant dose adjustment in the face of renal insufficiency."	( The pharmacokinetics of losartan in renal insufficiency. Furtek, CI; Gehr, TW; Halstenson, CE; Keane, WF; Lipschutz, K; Lo, MW; Ritter, MA; Shahinfar, S; Shaw, WC; Sica, DA, 1995)	0.6
" This method was successfully applied for pharmacokinetic study after oral administration of irbesartan (300 mg) to 23 Korean healthy male volunteers."	( HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. Bae, SK; Cho, DY; Kim, EY; Kim, MJ; Liu, KH; Shim, EJ; Shin, JG; Shon, JH, 2009)	0.35
"To determine whether, when losartan was used in combination with soy extract, a significant pharmacokinetic interaction would be observed in healthy female volunteers."	( Effect of soy extract administration on losartan pharmacokinetics in healthy female volunteers. Chen, Y; Fan, L; Guo, D; Hu, DL; Li, Z; Peng, XJ; Qian, RH; Wang, G; Xiao, CQ; Zhou, HH, 2009)	0.92
" In vivo pharmacokinetic study of PNP-H showed a significant increase in bioavailability (1."	( Proniosomal transdermal therapeutic system of losartan potassium: development and pharmacokinetic evaluation. Ali, A; Anwer, MK; Khar, RK; Shakeel, F; Shams, MS; Taha, EI; Thakur, R, 2009)	0.61
" The present method was successfully applied to the pharmacokinetic study of irbesartan after oral dose of irbesartan (150 mg tablet) to male healthy volunteers."	( Hydrophilic interaction chromatography-tandem mass spectrometric analysis of irbesartan in human plasma: application to pharmacokinetic study of irbesartan. Ji, HY; Lee, HS; Lee, HW; Lee, KC; Park, ES, 2009)	0.35
" Meanwhile, the CYP2C91/3 genotype group had significant differences in t(1/2) and Cmax of E3174 compared with the CYP2C91/1 group."	( Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Chen, BL; Fan, L; Hu, DL; Li, Q; Li, Z; Liu, J; Liu, ZQ; Tan, ZR; Tu, JH; Wang, G; Wang, LS; Zhang, W; Zhou, HH, 2009)	0.6
" Based on the 90% confidence interval of the individual ratios for Cmax and AUC0-inf, it was concluded that the test formulation is bioequivalent to the reference Hyzaar formulation with respect to the rate and extent of absorption of both LOS and HCTZ."	( Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics. Andraus, MH; Azevedo, CP; Borges, BC; Borges, NC; Moreira, RF; Moreno, RA; Salvadori, MC, 2009)	0.64
" The medicated films were evaluated for physical properties, in vitro drug release studies, in vitro skin permeation studies, and pharmacodynamic studies."	( Pharmacodynamics of a losartan transdermal system for the treatment of hypertension. Alam, MI; Ali, A; Aqil, M; Shams, MS; Sultana, Y, 2010)	0.68
" The pharmacodynamic studies were carried out using tail cuff method in Wistar albino rats."	( Pharmacodynamics of a losartan transdermal system for the treatment of hypertension. Alam, MI; Ali, A; Aqil, M; Shams, MS; Sultana, Y, 2010)	0.68
"The pharmacokinetic parameters of losartan and EXP-3174 were determined after oral administration of losartan (9 mg/kg) to rats in the presence or absence of myricetin (0."	( Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. Choi, DH; Choi, JS; Li, C, 2010)	0.88
" The pharmacokinetic parameters of losartan were significantly altered by myricetin compared with the control."	( Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. Choi, DH; Choi, JS; Li, C, 2010)	0.88
"To meet the requirements for marketing a new generic product, the study was designed to compare the pharmacokinetic parameters and relative bioavailability of a new generic losartan potassium 50-mg tablet (test formulation) with a branded 50-mg tablet (reference formulation) in healthy Chinese male volunteers."	( Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Jia, JY; Li, SJ; Liu, GY; Liu, Y; Liu, YM; Lu, C; Qi, YL; Weng, LP; Yu, C; Zhang, MQ, 2010)	0.8
" Pharmacokinetic parameters, including C(max), AUC(0-36), and AUC(0-infinity), were calculated."	( Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Jia, JY; Li, SJ; Liu, GY; Liu, Y; Liu, YM; Lu, C; Qi, YL; Weng, LP; Yu, C; Zhang, MQ, 2010)	0.61
" No period, formulation, or sequence effects were observed for any pharmacokinetic parameter, except for a significant subject effect."	( Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Jia, JY; Li, SJ; Liu, GY; Liu, Y; Liu, YM; Lu, C; Qi, YL; Weng, LP; Yu, C; Zhang, MQ, 2010)	0.61
" Pharmacokinetic parameters, such as C(max), t(max), and AUC were estimated."	( Pharmacokinetics of a losartan potassium released from a transdermal therapeutic system for the treatment of hypertension. Alam, MI; Ali, A; Aqil, M; Shakeel, F; Shams, MS; Sultana, Y, 2010)	0.68
" Pharmacokinetic parameters of losartan and EXP-3174 in rats were determined after oral and intravenous administration of losartan (9 mg/kg) without and with HMG-CoA reductase inhibitors (1 mg/kg)."	( Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Choi, DH; Choi, JS; Yang, SH, 2011)	0.89
" After normalization by weight, no ethnicity-based difference was noted in the pharmacokinetic parameters of losartan."	( Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China. Guo, T; Xia, DY; Yang, L; Zhao, LS, 2012)	0.91
" Pharmacokinetic (PK) parameters along with liver and muscle tissue levels were collected, and their contributions to total V(ss) were calculated."	( The impact of hepatic uptake on the pharmacokinetics of organic anions. Gardiner, P; Paine, SW, 2011)	0.37
" Saliva and plasma samples were collected for 3-5 half-life values of sitagliptin, cinacalcet, metformin, montelukast, tolterodine, hydrochlorothiazide (HCT), lornoxicam, azithromycin, diacerhein, rosuvastatin, cloxacillin, losartan and tamsulosin after oral dosing."	( Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. Arafat, T; Idkaidek, N, 2012)	0.56
" CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3."	( Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Abad-Santos, F; Cabaleiro, T; López-Rodríguez, R; Novalbos, J; Ochoa, D; Prieto-Pérez, R; Román, M; Talegón, M; Wojnicz, A, 2013)	0.65
" rosea resulted in a statistically significant increase of the following pharmacokinetic parameters for losartan: the maximum plasma concentration (C(max)), the area under the curve (AUC) and the apparent total body clearance (CL/F)."	( Pharmacokinetic interaction between losartan and Rhodiola rosea in rabbits. Batzias, G; Niopas, I; Spanakis, M; Vizirianakis, IS, 2013)	0.88
" rosea significantly alters the pharmacokinetic properties of losartan after concurrent oral administration to rabbits."	( Pharmacokinetic interaction between losartan and Rhodiola rosea in rabbits. Batzias, G; Niopas, I; Spanakis, M; Vizirianakis, IS, 2013)	0.91
" The purpose of this study was to investigate the pharmacokinetic properties of typical ARBs in the dog."	( Pharmacokinetics of angiotensin II receptor blockers in the dog following a single oral administration. Baek, IH; Kwon, KI; Lee, BY; Lee, ES, 2013)	0.39
" Plasma concentrations of losartan and EXP3174 were determined by LC-MS at designated points after drug administration, and the main pharmacokinetic parameters were estimated."	( Influence of compound danshen tablet on the pharmacokinetics of losartan and its metabolite EXP3174 by liquid chromatography coupled with mass spectrometry. Chai, Y; Ma, W; Sun, S; Wang, B; Yuan, Y; Zhang, G; Zhang, H; Zhao, L, 2013)	0.93
" Meanwhile, the Cmax of amlodipine, losartan and EXP3174 were reduced by 11."	( The influence of food on the pharmacokinetics of amlodipine and losartan after single-dose of its compound tablets in healthy chinese subjects. Guo, R; Li, R; Lv, C; Wang, B; Wang, X; Wei, C; Yao, H, 2014)	0.92
" The pharmacokinetic parameters AUC0-t, AUC0-∞, Cmax, tmax, and other pharmacokinetics parameters were determined from plasma concentration-time profiles for both test and reference formulations of losartan/hydrochlorothiazide 50 + 12."	( Pharmacokinetic comparison and bioequivalence evaluation of losartan/ hydrochlorothiazide tablet between Asian Indian and Japanese volunteers. Jain, R; Khuroo, A; Kumar, S; Kurachi, K; Monif, T; Reyar, S; Singla, AK, 2014)	0.83
" The ratios of least square means for AUC0-t and Cmax and the affiliated 90% confidence intervals were within acceptance range recommended by PMDA."	( Pharmacokinetic comparison and bioequivalence evaluation of losartan/ hydrochlorothiazide tablet between Asian Indian and Japanese volunteers. Jain, R; Khuroo, A; Kumar, S; Kurachi, K; Monif, T; Reyar, S; Singla, AK, 2014)	0.64
" Although Asian Indian and Japanese volunteers are ethnically different, results of these studies indicate that pharmacokinetic parameters of Asian Indian and Japanese volunteers are comparable to each other in terms of bioavailability of losartan, losartan carboxylic acid and hydrochlorothiazide."	( Pharmacokinetic comparison and bioequivalence evaluation of losartan/ hydrochlorothiazide tablet between Asian Indian and Japanese volunteers. Jain, R; Khuroo, A; Kumar, S; Kurachi, K; Monif, T; Reyar, S; Singla, AK, 2014)	0.83
" Pharmacokinetic parameters of losartan and EXP-3174 were determined after oral administration of losartan (9 mg/kg) to rats in the presence or absence of licochalcon A (0."	( Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Choi, DH; Choi, JS, 2013)	0.93
" The developed and validated method was successfully applied for estimating the pharmacokinetic parameters of LP following oral administrations of a single 10 mg LP/kg to rabbits and it could be concluded that the method can be applied to clinical trials."	( A new spectrofluorimetric method for determination of losartan potassium in rabbit plasma and its application to pharmacokinetic study. Demirkaya-Miloglu, F; Kadioglu, Y; Yaman, ME, 2015)	0.67
"To evaluate felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions (PK-DDIs) involving cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp)."	( Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Doogue, MP; Miners, JO; Polasek, TM; Rowland, A; Snyder, BD, 2014)	0.4
" The described method was successfully applied to preclinical pharmacokinetic studies of analytes after an oral administration of mixture of MET (1 mg/kg) and LOS (10 mg/kg) in rats."	( Simultaneous Determination and Pharmacokinetics of Metolazone, Losartan and Losartan Carboxylic Acid in Rat Plasma by HPLC-ESI-MS-MS. Dubey, R; Ghosh, M; Muthukrishnan, V; Sinha, BN, 2015)	0.66
" The method was successfully applied to a clinical pharmacokinetic study of febuxostat in humans after oral administration of a single dose of febuxostat at 40, 80 and 120 mg."	( Simultaneous determination of febuxostat and its three active metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in Chinese healthy volunteers. Di, X; Liu, Y; Mao, Z; Wang, X; Wu, Y, 2015)	0.42
" In this study, the pharmacokinetic (PK) interaction between RG and losartan, an antihypertensive drug, was examined."	( Negligible Pharmacokinetic Interaction of Red Ginseng and Losartan, an Antihypertensive Agent, in Sprague-Dawley Rats. Jang, HJ; Kim, KB; Kim, YS; Ryu, SH, 2015)	0.9
" Male Sprague-Dawley rats were randomly assigned to 3 groups: LST, LST+SA-B and LST+Tan IIA, and the main pharmacokinetic parameters were estimated after oral administration of LST, LST+SA-B and LST+Tan IIA."	( Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9. Wang, R; Wang, Y; Yu, X; Yuan, Y; Zhang, H, 2016)	0.66
" The pharmacokinetic parameters of losartan and its metabolite on the background of 4-day afabazole administration 5 mg/kg dose were not significantly different from analogous values calculated for the control group of rats."	( [EVALUATION OF THE PHARMACOKINETIC INTERACTION OF AFOBAZOLE WITH CYP2C9 ENZYME DRUG SUBSTRATE OF CYTOCHROME P450]. Gribakina, OG; Kolyvanov, GB; Litvin, AA; Shevchenko, RV; Smirnov, VV; Zherdev, VP, 2015)	0.69
" The plasma concentrations of losartan and EXP3174 were determined by LC-MS, and the main pharmacokinetic parameters were calculated."	( The effect of tripterygium glucoside tablet on pharmacokinetics of losartan and its metabolite EXP3174 in rats. Hu, Y; Shi, H; Shi, W; Ye, S; Zhang, H; Zhou, X, 2017)	0.98
" The aim of this study was to develop a population pharmacokinetic model for losartan and its active metabolite (EXP-3174) in order to describe the effect of gastric emptying on their disposition."	( Modelling gastric emptying: A pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-3174. Karalis, V; Karatza, E, 2020)	1.01
" The comparative pharmacokinetic study was performed to compare the profile of an FDC tablet formulation of amlodipine/losartan/rosuvastatin with that of concomitant administration of a currently marketed FDC tablet of amlodipine/losartan with a rosuvastatin tablet."	( Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers. Chung, JY; Jang, IJ; Jung, JA; Kim, YI; Park, SI; Yoon, DY, 2020)	1
" Blood samples were collected for up to 144 h post dose for pharmacokinetic evaluations."	( Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers. Chung, JY; Jang, IJ; Jung, JA; Kim, YI; Park, SI; Yoon, DY, 2020)	0.79
"We confirmed the pharmacokinetic equivalence of the FDC and LC treatments."	( Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers. Chung, JY; Jang, IJ; Jung, JA; Kim, YI; Park, SI; Yoon, DY, 2020)	0.79
" The impact of gastric emptying on pharmacokinetic parameters was investigated by applying principal component analysis to the individual parameter estimates."	( Investigating the Impact of Gastric Emptying on Pharmacokinetic Parameters Using Delay Differential Equations and Principal Component Analysis. Karalis, V; Karatza, E, 2021)	0.62
" Principal component analysis unveiled the impact of gastric emptying on the pharmacokinetic parameters."	( Investigating the Impact of Gastric Emptying on Pharmacokinetic Parameters Using Delay Differential Equations and Principal Component Analysis. Karalis, V; Karatza, E, 2021)	0.62
" The objective of this study was to compare the pharmacokinetic (PK) profiles of HCP1401, a fixed-dose combination of amlodipine 5 mg, losartan 100 mg, and chlorthalidone 25 mg, with the separate components (loose combination) of amlodipine/losartan 5/100 mg and chlorthalidone 25 mg."	( Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan and Chlorthalidone Compared to Concurrent Administration of the Separate Components. Choi, Y; Chung, JY; Jeon, I; Jung, J; Moon, SJ; Park, SI; Yu, KS, 2022)	1.17
" Possible pharmacodynamic and pharmacokinetic interactions were observed for, following single-dose as well as multiple-dose treatment protocols in normal and alloxan-induced diabetes in albino Wistar rats and rabbits."	( Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits. Anilkumar, KV; Nagaraju, B, )	0.38
" In vivo pharmacokinetic studies were carried out in rabbits."	( Formulation and Pharmacokinetic Evaluation of Ethyl Cellulose/HPMC-Based Oral Expandable Sustained Release Dosage of Losartan Potassium. Fazli, AA; Khan, NA; Raza, SN; Sheikh, FA; Wani, TU, 2022)	0.93

Excerpt	Reference	Relevance
"The antihypertensive effects and the tolerability of losartan and enalapril given alone or in combination with hydrochlorothiazide (HCTZ) were compared in a multicenter, double-blind, randomized, parallel-group, 16-week clinical trial."	( Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Edelman, JM; Haggert, B; Liss, C; Townsend, R, )	0.67
" In that way, administration of inhibitors of the angiotensin-converting enzyme combined with antagonists of receptors to angiotensin II has, been shown to considerably improve the endothelial function in CCi patients, which fact will, we believe, help in raising clinical effectiveness of the above combined medication."	( [Effects of inhibitors of angiotensin-converting enzyme combined with antagonists of angiotensin II receptors on endothelial function in patients with chronic cardiac insufficiency]. Bondarenko, TI; Korzh, AN; Raĭnina, IV, )	0.13
"The purpose of this study was to assess the antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide (HCTZ) in African American adults with mild to moderate hypertension."	( Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Alderman, M; Alexander, J; Ceesay, P; Espenshade, M; Flack, JM; Goldberg, A; Gradman, A; Green, S; Kraus, WE; Lester, FM; Pratt, JH; Saunders, E; Vargas, R, 2001)	0.8
" This study was aimed at assessing the effects of losartan or its combination with quinapril on the cardiac nervous system and neurohormonal status in essential hypertension."	( Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Doi, O; Ishikawa, J; Nawada, R; Obayashi, K; Sakata, K; Tamekiyo, H; Yoshida, H, 2002)	0.96
"A prospective, randomized, 3-period crossover study was conducted in 16 healthy volunteers with phenytoin alone, phenytoin in combination with losartan, and losartan alone."	( Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. Fischer, JD; Fischer, TL; Goldstein, JA; Graff, DW; Greenwood, R; Parnell, KJ; Patterson, JH; Pieper, JA; Rodgers, JE, 2002)	0.82
" However, losartan combined with ET had no additional effect on BP, baroreflex sensitivity or left ventricular hypertrophy when compared with losartan alone."	( Effects of losartan combined with exercise training in spontaneously hypertensive rats. Azevedo, LF; Barretto, AC; Brum, PC; Junqueira, CM; Mattos, KC; Negrão, CE; Rondon, MU, 2003)	1.11
" We aimed to clarify the effects of losartan and its combination with hydrochlorothiazide on 24-h blood pressures (BPs), central hemodynamics and microcirculation in essential hypertension (EH)."	( Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension. Bulatov, VA; Os, I; Podzolkov, VI; Son, EA, 2003)	0.85
"Forty patients with mild to moderate EH were randomly allocated to receive losartan 50 mg (group I) or losartan 50 mg in combination with hydrochlorothiazide, 12."	( Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension. Bulatov, VA; Os, I; Podzolkov, VI; Son, EA, 2003)	0.81
" Losartan and its combination with hydrochlorothiazide improved main parameters of microcirculation."	( Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension. Bulatov, VA; Os, I; Podzolkov, VI; Son, EA, 2003)	1.49
"Losartan monotherapy and losartan in combination with hydrochlorothiazide are effective antihypertensive agents."	( Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension. Bulatov, VA; Os, I; Podzolkov, VI; Son, EA, 2003)	2.02
"Simvastatin combined with losartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy with either drug in hypercholesterolemic, hypertensive patients."	( Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Ahn, JY; Ahn, TH; Choi, IS; Chung, WJ; Han, SH; Kang, MH; Koh, KK; Quon, MJ; Seo, YH; Shin, EK, 2004)	0.91
"Our objective was to investigate the frequency of potential drug-drug interactions between the prodrugs losartan, codeine, and tramadol and drugs known to inhibit their activation in hospitalized patients."	( Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Laine, K; Tirkkonen, T, 2004)	0.54
"This study was performed to ascertain whether losartan combined with pioglitazone is superior to losartan alone in delaying the progression of chronic renal failure in patients with type 2 diabetic nephropathy."	( Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. Jin, HM; Pan, Y, 2007)	0.89
"Renoprotection conferred by losartan combined with pioglitazone is superior to that conferred by losartan alone in subjects with type 2 diabetic nephropathy."	( Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. Jin, HM; Pan, Y, 2007)	0.93
"Our aim was to test the hypothesis that angiotensin II receptor blockade combined with exercise training after myocardial infarction (MI) could attenuate post-MI left ventricular remodelling and preserve cardiac function."	( Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats. Erikson, JM; Ji, L; Lao, S; Powers, AS; Wan, W; Xu, X; Zhang, JQ; Zhao, W, 2008)	0.35
" Cardiac function was preserved in rats receiving exercise training, and the beneficial effect was further improved by exercise combined with losartan treatment in comparison to the MISed group."	( Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats. Erikson, JM; Ji, L; Lao, S; Powers, AS; Wan, W; Xu, X; Zhang, JQ; Zhao, W, 2008)	0.55
"We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension."	( A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. Abate, N; Chen, E; Creager, MA; Galet, V; Jia, G; Julius, S; Lerman, A; Lyle, PA; Oparil, S; Pool, J; Tershakovec, AM, 2008)	0.95
" This study evaluates irbesartan in relation to commonly used alternative hypertension therapies losartan and valsartan given in combination with hydrochlorothiazide (HCTZ) in the general hypertensive population in Greece."	( Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011)	0.59
"Based on efficacy data from clinical trials and lower attainment costs in various hypertensive patient populations, irbesartan in combination with HCTZ compares favorably with losartan and valsartan in combination with HCTZ in the Greek setting."	( Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011)	0.56
" Drug-drug interactions were investigated when nebivolol was coadministered to subjects classified as poor CYP2D6 metabolizers and extensive CYP2D6 metabolizers who were receiving other drugs commonly administered to patients with hypertension or compounds metabolized by cytochrome P450 (CYP) 2D6."	( Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. Gorski, JC; Lindamood, C; Ortiz, S; Rackley, R; Shaw, A, 2011)	0.37
" The protein levels for MnSOD were significantly elevated by exercise training in combination with losartan treatment."	( Exercise training combined with angiotensin II receptor blockade reduces oxidative stress after myocardial infarction in rats. Erikson, JM; Ji, LL; Powers, AS; Wan, W; Xu, X; Zhang, JQ; Zhao, W, 2010)	0.58
" Administered with losartan 100 mg or alone, ISMN lowered AIx, demonstrating that acute effects of a nitrate donor are much larger than those of an ARB even when administered with an ARB."	( Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressure. Bolognese, JA; Feig, PU; Herman, GA; Kaufman, R; McCarthy, JM; Miller, DL; Nunes, I; Salotti, D; Smith, WB, )	0.69
"Few have tried to prove the effectiveness of mizoribine combined with losartan for adult IgA nephropathy patients in a randomized controlled trial."	( Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study. Chen, P; Chen, X; Huang, S; Li, Y; Lie, C; Liu, S; Miao, L; Wang, L; Wu, X; Xie, Y; Zhang, A, 2011)	0.86
"A multicenter, randomized, controlled, 12-month study was performed to evaluated the efficacy and safety of mizoribine combined with losartan for adult IgA nephropathy."	( Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study. Chen, P; Chen, X; Huang, S; Li, Y; Lie, C; Liu, S; Miao, L; Wang, L; Wu, X; Xie, Y; Zhang, A, 2011)	0.83
" The aim of this study was to evaluate the effects of losartan or amlodipine alone or combined with simvastatin on hepatic steatosis degree, and on insulin sensitivity in normocholesterolemic, hypertensive patients with nonalcoholic hepatic steatosis."	( Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2012)	1.02
" The purpose of the study was to assess the efficacy and safety of losartan and its fixed combination with hydrochlorothiazide (HCTZ) in patients with hypertension."	( [Effectiveness and safety of losartan and its combination with hydrochlorothiazide in patients with hypertension: in result study]. Glezer, MG; Saĭgitov, RT, 2012)	0.91
"We evaluated the effects of RU28318 (RU), a selective mineralocorticoid receptor (MR) antagonist, Captopril (Capt), an angiotensin converting enzyme inhibitor, and Losartan (Los), an angiotensin receptor blocker, alone or in combination with ischemia/reperfusion- (I/R-) induced cardiac dysfunction in hearts obtained from normal and diabetic rats."	( RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes. Akhtar, S; Al-Rashdan, I; Babiker, F; Benter, IF; Yousif, M, 2013)	0.59
" Therefore, the potential pharmacokinetic drug-drug interactions between sucroferric oxyhydroxide and selected drugs commonly taken by dialysis patients were investigated."	( Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. Chong, E; Kalia, V; Willsie, S; Winkle, P, 2014)	0.64
"Systemic exposure based on AUC0-∞ for all drugs, and AUC0-24 for all drugs except omeprazole (for which AUC 0-8 h was measured), was unaffected to a clinically significant extent by the presence of sucroferric oxyhydroxide, irrespective of whether sucroferric oxyhydroxide was administered with the drug or 2 h earlier."	( Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. Chong, E; Kalia, V; Willsie, S; Winkle, P, 2014)	0.64
"There is a low risk of drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, digoxin and warfarin."	( Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. Chong, E; Kalia, V; Willsie, S; Winkle, P, 2014)	0.87
"In this study, we characterized the drug-drug interactions of losartan (LOS) and glimepiride (GLP) using recombinant cytochrome P450 (CYP) 2C9 enzymes (CYP2C91, CYP2C93, CYP2C913, and CYP2C916)."	( Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C91, 2C93, 2C913, and 2C916 in vitro. Cai, J; Cai, JP; Chen, SZ; Dai, DP; Geng, PW; Hu, GX; Pan, PP; Shen, LB; Xu, SS, 2014)	0.95
"To evaluate felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions (PK-DDIs) involving cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp)."	( Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Doogue, MP; Miners, JO; Polasek, TM; Rowland, A; Snyder, BD, 2014)	0.4
"To estimate effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension."	( [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013)	0.95
" Losartan was used at a dose of 50-100 mg/24 h for 8 weeks (stage 1) and thereafter from week 9 to 26 (stage 2) in combination with amlodipine (5-10 mg/24 hr) if the desired AP level (< 140/90 mmHg) was not achieved."	( [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013)	1.59
"The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG)."	( Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. Jiang, XS; Liu, L; Ning, N; Tan, MH; Wei, P; Xiao, WY; Yi, D; Zhou, L, 2016)	0.94
" We tested the curative potential of the non brain-penetrant ACEi enalapril (3 mg/kg/day) administered for 3 months either alone or in combination with the brain penetrant ARB losartan (10 mg/kg/day) in aged (∼15 months) transgenic mice overexpressing a mutated form of the human amyloid-β protein precursor (AβPP, thereafter APP mice)."	( Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease. Aboulkassim, T; Hamel, E; Imboden, H; Nicolakakis, N; Ongali, B; Tong, XK, 2016)	0.89
" The new model is useful for estimating the risk of drug interaction in clinical practice when AST-120 is used in combination with other drugs."	( Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs. Kotegawa, T; Koya, Y; Machi, Y; Namiki, N; Shobu, Y; Uchida, S, 2016)	0.43
"To evaluate the capacity for modafinil to be a perpetrator of metabolic drug-drug interactions by altering cytochrome P450 activity following a single dose and dosing to steady state."	( Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Mangoni, AA; Rowland, A; Sorich, MJ; van Dyk, M; Warncken, D, 2018)	0.48
"These data support consideration of the risk of clinically relevant metabolic drug-drug interactions perpetrated by modafinil when this drug is co-administered with drugs that are primarily cleared by CYP2C19 (single modafinil dose or steady state modafinil dosing) or CYP3A4 (steady state modafinil dosing only) catalysed metabolic pathways."	( Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Mangoni, AA; Rowland, A; Sorich, MJ; van Dyk, M; Warncken, D, 2018)	0.48
" In addition, the renoprotection of DPP4i combined with ARBs was independent of glycemic control."	( Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy. An, Y; Ge, YC; Jiang, S; Liu, J; Qiu, DD; Shi, JS; Zhou, ML, 2018)	0.48
" The effect of losartan and enalapril alone and in combination with sodium valproate on seizures, cognition, cardiac histopathology, and serum brain-derived neurotropic factor (BDNF) levels were determined."	( Effects of enalapril and losartan alone and in combination with sodium valproate on seizures, memory, and cardiac changes in rats. Arava, S; Gupta, YK; Joshi, D; Katyal, J, 2019)	1.17
" Sodium valproate alone or in combination with losartan or enalapril prevented kindled seizures."	( Effects of enalapril and losartan alone and in combination with sodium valproate on seizures, memory, and cardiac changes in rats. Arava, S; Gupta, YK; Joshi, D; Katyal, J, 2019)	1.07
" This study confirmed that the Inje cocktail approach was able to detect relevant drug-drug interactions impacting further development of ASP8477 and future therapeutic use."	( A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels. Collins, C; Ernault, E; Fuhr, R; Gangaram-Panday, S; Passier, P; Treijtel, N; van Bruijnsvoort, M, 2019)	0.51
" Participants were divided into six treatment groups based on the hypertensive drug therapy they were using; lisinopril, losartan or valsartan alone or in combination with hydrochlorothiazide (A, B and C group respectively) or combination of lisinopril, losartan or valsartan with/without hydrochlorothiazide together with amlodipine (D, E and F respectively)."	( Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness. Hebibovic, S; Jatic, Z; Rustempasic, E; Skopljak, A; Sukalo, A; Valjevac, A, 2019)	0.72
"These data suggest that lisinopril/lisinopril + hydrochlorothiazide, losartan/losartan + hydrochlorothiazide and valsartan/valsartan + hydrochlorothiazide alone or in combination with amlodipine are equally effective and well tolerated for the reduction of both systolic and diastolic blood pressure and improve arterial stiffness in patients with essential hypertension."	( Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness. Hebibovic, S; Jatic, Z; Rustempasic, E; Skopljak, A; Sukalo, A; Valjevac, A, 2019)	0.75
"In this review, we intended to highlight the role of drug-drug interactions involving angiotensin II receptor antagonists with antiepileptic drugs accompanied by a brief characteristic of the role of RAS in neuroinflammation."	( A review of clinically significant drug-drug interactions involving angiotensin II receptor antagonists and antiepileptic drugs. Czuczwar, SJ; Rusek, M, 2020)	0.56
" Thus, we aim to evaluate whether losartan potassium combined with KLX is more effective than losartan potassium in DKD treatment and to provide validated evidence for the application of KLX in the treatment of DKD."	( Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial. Bai, L; Li, F; Li, J; Qu, L; Wang, Q; Wei, F; Wei, J; Wu, R; Yan, W, 2020)	1.1
" Here we leverage dogs with spontaneous OS to determine losartan's safety and pharmacokinetics associated with monocyte pharmacodynamic endpoints, and assess its antitumor activity, in combination with the kinase inhibitor toceranib."	( Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. Chow, L; Coy, JW; Das, S; Dow, SW; Gustafson, DL; Haines, L; Kurihara, JN; Mathias, A; Palmer, E; Regan, DP; Thamm, DH, 2022)	2.41
"Losartan inhibits the CCL2-CCR2 axis, and in combination with toceranib, exerts significant biological activity in dogs with metastatic osteosarcoma, supporting evaluation of this drug combination in patients with pediatric osteosarcoma."	( Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. Chow, L; Coy, JW; Das, S; Dow, SW; Gustafson, DL; Haines, L; Kurihara, JN; Mathias, A; Palmer, E; Regan, DP; Thamm, DH, 2022)	3.61
"Inhibition of SGLT2 in combination with an angiotensin II receptor blocker effectively improved BP salt sensitivity by reducing renal expression levels of sodium transporters including NHE3 and NKCC2, which eventually led to improvement of BP salt sensitivity and cardiorenal protection."	( Cardiorenal protective effects of sodium-glucose cotransporter 2 inhibition in combination with angiotensin II type 1 receptor blockade in salt-sensitive Dahl rats. Ali, Y; Dohi, K; Ito, H; Ito, M; Katayama, K; Okamoto, R; Zhe, Y, 2022)	0.72
"To conduct a systematic review of the efficacy and safety of Shenyankangfu tablets in combination with losartan potassium in the treatment of chronic glomerulonephritis."	( Meta-analysis of the effectiveness and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of chronic glomerulonephritis. Chen, XF; Feng, PF; Sheng, N; Zhu, LX, 2022)	1.16
"We searched PubMed, Embase, Cochrane Library, CNKI, WanFang Data, and WeiPu for comparative studies on Shenyankangfu tablets in combination with losartan potassium in the treatment of chronic glomerulonephritis."	( Meta-analysis of the effectiveness and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of chronic glomerulonephritis. Chen, XF; Feng, PF; Sheng, N; Zhu, LX, 2022)	1.15
"It is safer to treat chronic glomerulonephritis with Shyenyankangfu tablets in combination with losartan potassium."	( Meta-analysis of the effectiveness and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of chronic glomerulonephritis. Chen, XF; Feng, PF; Sheng, N; Zhu, LX, 2022)	1.16
"Rotator cuff repair combined with oral losartan and BMS of the greater tuberosity showed improved pullout strength and a highly organized tendon matrix in this rabbit chronic injury model."	( Losartan in Combination With Bone Marrow Stimulation Showed Synergistic Effects on Load to Failure and Tendon Matrix Organization in a Rabbit Model. Altintas, B; Dornan, G; Fukase, N; Gao, X; Huard, J; Kashyap, R; Lacheta, L; Miles, JW; Millett, PJ; Murata, Y; Philippon, M; Ravuri, S; Tashman, S; Utsunomiya, H, 2023)	2.62

Excerpt	Reference	Relevance
" Although these compounds are absorbed after oral dosing, their bioavailability was less than desired."	( Rationale for the chemical development of angiotensin II receptor antagonists. Carini, DJ; Chiu, AT; Duncia, JV; Johnson, AL; Timmermans, PB; Wells, GJ; Wexler, RR; Wong, PC, 1992)	0.28
" Using GR117289, a compound with moderate bioavailability (20%) in man as a lead, we pursued a strategy aimed at enhancing bioavailability."	( Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability. Dowle, MD; Hobson, JE; Jack, TI; Judd, DB; Middlemiss, D; Panchal, TA; Pass, M; Ross, BC; Scopes, DI; Tranquillini, E, 1994)	0.29
" Further study of 4a in Goldblatt (2K-1C) rats showed the compound to have oral bioavailability and to be an efficacious and potent compound in a high renin form of hypertension."	( Pyrido[2,3-d]pyrimidine angiotensin II antagonists. Antane, M; Antane, S; Bender, R; Collini, MD; Ellingboe, JW; Hartupee, D; McCallum, J; Nguyen, TT; Park, CH; White, V, 1994)	0.29
" bioavailability of single doses of 5 to 20 mg/kg was low, 23 to 33%, and independent of the dose."	( The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. Christ, DD; Hart, SD; Lam, GN; Quon, CY; Wong, PC; Wong, YN, 1994)	0.51
" In contrast, analogous substitution of the benzimidazole moiety with basic heterocycles resulted in potent AII antagonists which were also well absorbed after oral application."	( 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. Entzeroth, M; Hasselbach, KM; Hauel, NH; Mihm, G; Narr, B; Ries, UJ; van Meel, JC; Wienen, W; Wittneben, H, 1993)	0.29
" Renin inhibitors are theoretically more attractive than ACE inhibitors because of their specificity, and renin inhibitors with adequate oral bioavailability are now available."	( Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system. Brunner, HR; Nussberger, J; Waeber, B, 1993)	0.29
"With regard to oral bioavailability and estimates of oral angiotensin II blocking activity, the animal models were reasonably good predictors of the human response."	( How well have animal studies with losartan predicted responses in humans? Nelson, EB; Sweet, CS, 1993)	0.57
"In order to improve the oral bioavailability (BA) of 2-butyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimid azole - 7-carboxylic acid (3: CV-11194) and 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (4: CV-11974), novel angiotensin II (AII) receptor antagonists, chemical modification to yield prodrugs has been examined."	( Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. Furukawa, Y; Inada, Y; Kato, T; Kohara, Y; Kubo, K; Naka, T; Nishikawa, K; Shibouta, Y; Yoshimura, Y, 1993)	0.29
" Although 71 was active orally only at a 10-fold higher dose level, good oral bioavailability was demonstrated for a monoacidic analogue 62."	( Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles. Ashton, WT; Cantone, CL; Chang, LL; Chang, RS; Chen, TB; Faust, KA; Hutchins, SM; Lotti, VJ; MacCoss, M; Strelitz, RA, 1993)	0.29
" The oral bioavailability of losartan tablets was 33%."	( Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Bjornsson, TD; Furtek, CI; Goldberg, MR; Lo, MW; Lu, H; McCrea, JB, 1995)	0.91
"We wished to determine whether enhanced bioavailability of bradykinin (BK) and vasodilatory prostaglandins contribute to renovascular and sodium-handling effects of angiotensin-converting enzyme (ACE) inhibition after myocardial infarction (MI)."	( Relative contribution of angiotensin II, bradykinin, and prostaglandins to the renal effects of converting enzyme inhibition in rats after chronic myocardial infarction. Deck, CC; Gaballa, MA; Raya, TE, 1996)	0.29
" In other pharmacokinetic studies, it has been reported that bioavailability of losartan is about 33%, and its absorption is excellent."	( The clinical pharmacology of losartan in Japanese subjects and patients. Nakashima, M; Umemura, K, 1996)	0.81
"The effects of structural modifications on the membrane permeability of angiotensin II (Ang II) receptor antagonists and the usefulness of in vitro and in situ intestinal absorption models in predicting in vivo absorption or bioavailability were investigated."	( Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption. Aungst, BJ; Eyermann, CJ; Huang, SM; Ribadeneira, MD, 1996)	0.29
"Permeation coefficients (Pa) across Caco-2 cell monolayers correlated well with both in situ absorption rate constants (ka) and in vivo bioavailability or % absorption."	( Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption. Aungst, BJ; Eyermann, CJ; Huang, SM; Ribadeneira, MD, 1996)	0.29
" Charge, solvation energy, and hydrogen bonding are predominant determinants of intestinal permeability and oral bioavailability of these compounds."	( Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption. Aungst, BJ; Eyermann, CJ; Huang, SM; Ribadeneira, MD, 1996)	0.29
" Previous receptor antagonists for angiotensin II are angiotensin-like peptides with limitations of short duration, lack of oral bioavailability and partial agonistic activity."	( Historical development of losartan (DuP 753) and angiotensin II receptor subtypes. Timmermans, PB; Wong, PC, 1996)	0.59
" This might be ascribed to their improved bioavailability by increased lipophilicity."	( Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. Imamiya, E; Inada, Y; Kohara, Y; Kubo, K; Naka, T; Wada, T, 1996)	0.29
" Bioavailability of TA-606 was 11 times higher than that of 606A in Sprague-Dawley rats, with consistent hypotensive potencies in spontaneously hypertensive rats (SHRs)."	( Pharmacologic profile of TA-606, a novel angiotensin II-receptor antagonist in the rat. Hashimoto, Y; Hayashida, K; Kaji, H; Kurosawa, Y; Minami, K; Murata, S; Narita, H; Ohashi, R, 1998)	0.3
" Average bioavailability was 36%."	( Pharmacokinetics of intravenous and oral losartan in patients with heart failure. Colucci, WS; Emmert, SE; Furtek, CI; Lo, MW; Lu, H; Ritter, MA; Rucinska, E; Toh, J; Uretsky, BF, 1998)	0.57
" The absolute extent of oral bioavailability of losartan, F, (32."	( Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. Baik, EJ; Jung, YS; Lee, HJ; Lee, SH; Moon, CH, 1998)	0.88
"06 mg/kg), thus indicating a poor oral bioavailability in rats."	( In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist. Kwon, KJ; Lee, BH; Seo, HW; Shin, HS; Yoo, SE, 1999)	0.3
" We hypothesized that both ACE inhibitor (ACEI) and angiotensin II type 1 receptor antagonist (AT(1)-A) increase bioavailability of nitric oxide (NO) by reducing oxidative stress in the vessel wall, possibly by increasing EC-SOD activity."	( Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Ahlersmann, D; Christoph, A; Drexler, H; Hornig, B; Kohler, C; Landmesser, U; Spiekermann, S; Tatge, H, 2001)	0.31
" CONCLUSIONS-Four weeks of therapy with ramipril or losartan improves endothelial function to similar extents in patients with CAD by increasing the bioavailability of NO."	( Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Ahlersmann, D; Christoph, A; Drexler, H; Hornig, B; Kohler, C; Landmesser, U; Spiekermann, S; Tatge, H, 2001)	0.56
" This response is achieved by metaplastic transformation of arteriolar smooth muscle cells, a major mechanism to control renin bioavailability and blood pressure homeostasis."	( Ren1d and Ren2 cooperate to preserve homeostasis: evidence from mice expressing GFP in place of Ren1d. Carretero, O; Gomez, RA; Kim, HS; Lopez, ML; Pentz, ES; Smithies, O, 2001)	0.31
" This mechanism may be independent of direct AIIRA effects and may be due, in part, to increased bioavailability of nitric oxide."	( Effects of chronic subdepressor dose of angiotensin II type 1 receptor antagonist on endothelium-dependent vasodilation in patients with congestive heart failure. Arakawa, N; Hiramori, K; Nakamura, M; Saito, S; Sugawara, S; Yoshida, H, 2002)	0.31
" Thus NO bioavailability is impaired in SHR owing to an ANG II-mediated increase in superoxide production in association with enhanced expression of NAD(P)H oxidase components, despite increased expression of eNOS."	( Oxidant stress in kidneys of spontaneously hypertensive rats involves both oxidase overexpression and loss of extracellular superoxide dismutase. Adler, S; Huang, H, 2004)	0.32
"Two trials were performed in different groups of volunteers with the aim to compare the bioavailability of 50 mg losartan tablets (Sarvas as test and an originator product as reference formulation; study 1) and losartan/hydrochlorothiazide (50 mg/12."	( Combination of losartan and hydrochlorothiazide: in vivo bioequivalence. Alpan, RS; Erenmemisoglu, A; Koytchev, R; Ozalp, Y; van der Meer, MJ, 2004)	0.89
" Compound 21, with a bioavailability of 20-30% after oral administration and a half-life estimated to 4 h in rat, induces outgrowth of neurite cells, stimulates p42/p44(mapk), enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats."	( Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. Alterman, M; Beaudry, H; Botoros, M; Fändriks, L; Gallo-Payet, N; Hallberg, A; Holm, M; Johansson, B; Karlén, A; Mahalingam, AK; Nyberg, F; Pettersson, A; Plouffe, B; Wallinder, C; Wan, Y; Wu, X, 2004)	0.32
"To compare the bioavailability of two potassic losartan immediate release tablet (50 mg) formulations (Losartan from Laboratórios Cristália Ltd."	( Comparative bioavailability of two losartan formulations in healthy human volunteers after a single dose administration. Barrientos-Astigarraga, RE; Caliendo, G; De Nucci, G; Marcondes Rezende, V; Medeiros Silva, R; Mendes, GD; Oliveira, CH; Perissutti, E; Prado Galuppo, M; Santagada, V, 2006)	0.87
" BOLD-MRI demonstrated significant changes in medullary and cortical oxygen bioavailability in allografts with CAN."	( BOLD-MRI assessment of intrarenal oxygenation and oxidative stress in patients with chronic kidney allograft dysfunction. Becker, BN; Djamali, A; Fain, SB; Grist, TM; Hullett, DH; Lipscomb, RC; Muehrer, RJ; Reese, S; Sadowski, EA; Samaniego-Picota, M; Smavatkul, C; Vidyasagar, A, 2007)	0.34
"The bioavailability of a new losartan preparation (2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium salt, CAS 114798-26-4) was compared with the reference preparation of the drug in 24 healthy male volunteers, aged between 19 and 32."	( Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. Bienert, A; Brzezińiski, R; Drobnik, L; Dubai, V; Dyderski, S; Grześkowiak, E; Olejniczak-Rabinek, M; Szałek, E; Wolc, A, 2006)	0.92
" These drugs also increased the bioavailability of CSA."	( Comparative interaction of few antihypertensive drugs with cyclosporine-A in rats. Inamdar, MN; Kumar, NP; Venkataraman, BV, 2007)	0.34
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
" Remarkably, the least permeable 7c showed both permeability and oral bioavailability (80%) higher than losartan, but its terminal half-life was shorter."	( Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems. Anzini, M; Cappelli, A; Caselli, G; Ferrari, F; Gallelli, A; Giordani, A; Giorgi, G; Giuliani, G; Makovec, F; Mennuni, L; Mohr, Gl; Nannicini, C; Peris, W; Valenti, S; Vomero, S, 2008)	0.56
"We investigated the effects of co-administration of an angiotensin-converting enzyme inhibitor (ACEI) and angiotensin type 1 receptor blocker (ARB) on nitric oxide (NO) bioavailability in genetically hyperlipidemic rabbits with our newly developed NO sensor."	( Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits. Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Yoshida, K, 2008)	0.35
" We suggest that ADMA activates the local renin-angiotensin system, and the angiotensin II released activates NAD(P)H oxidase; superoxide produced interferes with the bioavailability of NO, resulting in diminished flow-induced dilation, a mechanism that may contribute to the development of arteriolar dysfunction and increased tone associated with elevated ADMA levels."	( ADMA impairs nitric oxide-mediated arteriolar function due to increased superoxide production by angiotensin II-NAD(P)H oxidase pathway. Koller, A; Lotz, G; Racz, A; Veresh, Z, 2008)	0.35
" In vivo pharmacokinetic study of PNP-H showed a significant increase in bioavailability (1."	( Proniosomal transdermal therapeutic system of losartan potassium: development and pharmacokinetic evaluation. Ali, A; Anwer, MK; Khar, RK; Shakeel, F; Shams, MS; Taha, EI; Thakur, R, 2009)	0.61
" Additionally, the influence of optimized GRDDS on the bioavailability of Losartan and the formation extent of active metabolite E3174 by CYP2C9 polymorphism was investigated."	( Development of swelling/floating gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose for Losartan and its clinical relevance in healthy volunteers with CYP2C9 polymorphism. Chen, RN; Ho, HO; Sheu, MT; Yu, CY, 2010)	0.79
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" These findings may explain the known interaction of telmisartan with digoxin and suggest that it may modulate the bioavailability of drugs whose absorption is restricted by P-gp and possibly also by BCRP or MRP2."	( Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J, 2010)	0.36
"The enhanced bioavailability of losartan may be mainly due to inhibition of the CYP3A4- and CYP2C9-mediated metabolism of losartan in the small intestine or in the liver, and the P-glycoprotein efflux pump in the small intestine by myricetin."	( Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. Choi, DH; Choi, JS; Li, C, 2010)	0.88
" The relative bioavailability of a newly developed tablet compared with an established branded formulation has not been reported in a Chinese population."	( Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Jia, JY; Li, SJ; Liu, GY; Liu, Y; Liu, YM; Lu, C; Qi, YL; Weng, LP; Yu, C; Zhang, MQ, 2010)	0.61
"To meet the requirements for marketing a new generic product, the study was designed to compare the pharmacokinetic parameters and relative bioavailability of a new generic losartan potassium 50-mg tablet (test formulation) with a branded 50-mg tablet (reference formulation) in healthy Chinese male volunteers."	( Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Jia, JY; Li, SJ; Liu, GY; Liu, Y; Liu, YM; Lu, C; Qi, YL; Weng, LP; Yu, C; Zhang, MQ, 2010)	0.8
" The relative bioavailability of the test formulation to the reference formulation was 93."	( Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Jia, JY; Li, SJ; Liu, GY; Liu, Y; Liu, YM; Lu, C; Qi, YL; Weng, LP; Yu, C; Zhang, MQ, 2010)	0.61
" A comparable AUC(0-24h), shortened T(max) and a significant increase in the plasma C(max) of EXP3174 were observed following oral administration of EXP3174-pivoxil (as EXP3174, 1 mg/kg) compared with those of losartan (as EXP3174, 5 mg/kg) in rats, suggesting faster absorption and a 5-fold enhancement in the bioavailability of EXP3174."	( The physicochemical properties, in vitro metabolism and pharmacokinetics of a novel ester prodrug of EXP3174. Choi, HG; Kim, HK; Lee, GS; Lee, WS; Seo, KH; Woo, JS; Yan, YD; Yong, CS, 2010)	0.55
" John's wort extracts containing hyperforin increase the expression of CYP-enzymes and P-glycoprotein mainly in the gut and liver which leads to a clinically relevant decrease of the bioavailability of CYP and P-glycoprotein substrates."	( [Pharmacokinetic drug interactions by herbal drugs: Critical evaluation and clinical relevance]. Unger, M, 2010)	0.36
" Moreover, the increased reactivity to PHE promoted by Gd was endothelium-dependent, reducing NO bioavailability and involving an increased stimulation of angiotensin-converting enzyme and angiotensin II AT1 receptors."	( Gadolinium increases the vascular reactivity of rat aortic rings. Angeli, JK; Casali, EA; Fürstenau, CR; Ramos, DB; Sarkis, JJ; Souza, DO; Stefanon, I; Vassallo, DV, 2011)	0.37
" Consequently, the absolute bioavailability (F) of losartan after oral administration with simvastatin was significantly increased by 59."	( Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Choi, DH; Choi, JS; Yang, SH, 2011)	0.86
"The aim of the work is to modify the solubility and bioavailability of Losartan potassium, by employing noneffervescent floating drug delivery (tablet dosage forms)."	( Formulation and evaluation of non-effervescent floating tablets of losartan potassium. Gangadharappa, HV; Getyala, A; Kumar, TM; Prasad, MS; Reddy, MP, 2013)	0.86
" Besides, its cholesterol-lowering effect, the ability of simvastatin to ameliorate endothelial dysfunction through increasing NO bioavailability and through suppression of oxidative stress and vascular inflammation may play an important role in these effects."	( Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein. Abdel-Zaher, AO; Abudahab, LH; Elbakry, MH; Elkoussi, AE; Elsayed, EA, 2014)	0.65
"Randomized, open-label, crossover, bioavailability studies were conducted separately in healthy Asian Indian and Japanese volunteers."	( Pharmacokinetic comparison and bioequivalence evaluation of losartan/ hydrochlorothiazide tablet between Asian Indian and Japanese volunteers. Jain, R; Khuroo, A; Kumar, S; Kurachi, K; Monif, T; Reyar, S; Singla, AK, 2014)	0.64
"The results of these bioavailability studies indicate that the test formulation of losartan/hydrochlorothiazide 50 + 12."	( Pharmacokinetic comparison and bioequivalence evaluation of losartan/ hydrochlorothiazide tablet between Asian Indian and Japanese volunteers. Jain, R; Khuroo, A; Kumar, S; Kurachi, K; Monif, T; Reyar, S; Singla, AK, 2014)	0.87
" Consequently, the absolute bioavailability of losartan in the presence of licochalcon A increased significantly (2."	( Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Choi, DH; Choi, JS, 2013)	0.9
"Our study provides novel evidence that chronic ethanol intake increases blood pressure, induces vascular oxidative stress and decreases nitric oxide (NO) bioavailability through AT1-dependent mechanisms."	( Angiotensin type 1 receptor mediates chronic ethanol consumption-induced hypertension and vascular oxidative stress. Antunes-Rodrigues, J; Ceron, CS; Coelho, EB; Mecawi, AS; Passaglia, P; Tirapelli, CR, 2015)	0.42
" Drug bioavailability was not reduced after voluntary ingestion, suggesting that this method is highly effective for chronic oral administration of losartan to laboratory rodents."	( Voluntary Oral Administration of Losartan in Rats. Afonso, RA; Diogo, LN; Faustino, IV; Monteiro, EC; Pereira, SA; Santos, AI, 2015)	0.9
" Moreover, levocetirizine attenuated the elevated renal levels of TNF-α and TGF-β1, ameliorated renal oxidative stress and restored NO bioavailability in diabetic kidney."	( Comparison of the effects of levocetirizine and losartan on diabetic nephropathy and vascular dysfunction in streptozotocin-induced diabetic rats. Anbar, HS; Gameil, NM; Shehatou, GS; Suddek, GM, 2016)	0.69
" C3435T, G2677T and C1236T polymorphic alleles of the MDR1 gene encoding the transporter have been shown to alter the transport, bioavailability and efficacy of certain drugs."	( Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients. Babaoglu, MO; Bozkurt, A; Cevik, L; Göktaş, MT; Gumus, E; Guven, GS; Kalkışım, S; Karaca, Ö; Pepedil, F; Yasar, U, 2016)	0.65
" Spironolactone, but not losartan, restored NO bioavailability in association with lower endothelial nitric oxide synthase-derived superoxide production, increased endothelial nitric oxide synthase dimerization, and aortic HSP90 upregulation."	( Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue. Alonso, MJ; Clerici, SP; Davel, AP; Jaffe, IZ; Palacios, R; Rossoni, LV; Vassallo, DV; Victorio, JA, 2016)	0.74
" Both single treatments significantly improved systemic and kidney antioxidant defense, bioavailability of renal nitric oxide, reduced kMMP-1 protein expression and renal injury, thus retarded CKD progression."	( Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy. Grujic-Milanovic, J; Ivanov, M; Jovovic, D; Karanovic, D; Markovic-Lipkovski, J; Mihailovic-Stanojevic, N; Miloradovic, Z; Vajic, UJ; Zivotic, M, 2016)	0.72
" Generic drug equivalence is evaluated through comparative bioavailability studies."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.46
" However, this widely used AT1 antagonist presents low bioavailability and needs once or twice a day dosage."	( A long-lasting oral preformulation of the angiotensin II AT1 receptor antagonist losartan. Braga, ANG; De Paula, WX; Denadai, ÂML; Frezard, F; Pinheiro, SVB; Santos, RAS; Shastri, VP; Sinisterra, RD, 2018)	0.71
" But due to its lower bioavailability and extensive hepatic metabolism its therapeutic index reduces down."	( Cytotoxicity of Graphene Oxide (GO) and Graphene Oxide Conjugated Losartan Potassium (GO-LP) on Neuroblastoma (NB41A3) Cells. Joshi, P; Kaur, R; Singh, M; Singh, SP; Verma, S, 2018)	0.72
" Losartan carboxylic acid (LCA), the potent AT1 blocker metabolite of losartan, suffers from poor bioavailability and brain access."	( Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats. Prusty, S; Sahu, PK; Singh, VK; Subudhi, BB, 2018)	1.63
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Since 2003, bioavailability regulations of TGF-ß through fibrillin alterations have been presumed of being the culprit mechanisms for aortic aneurysm development."	( Initial Angiotensin Receptor Blocker Response in Young Marfan Patients Decreases After 3 Years of Treatment. Heno, J; Michel-Behnke, I; Pees, C, 2022)	0.72
" LP and VPH have low bioavailability and long half-life."	( Losartan Potassium and Verapamil Hydrochloride Compound Transdermal Drug Delivery System: Formulation and Characterization. Chen, WB; Chen, YS; Liu, YQ; Qin, ZC; Sun, YY; Zhang, SY, 2022)	2.16

Excerpt	Relevance	Reference
" Losartan (15 mg/kg/day) resulted in a rightward shift of the AII pressor dose-response curve by a factor of 32-40."	( Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. Cleutjens, JP; Daemen, MJ; Schoemaker, RG; Smits, JF; van Krimpen, C, 1992)	1.19
" Losartan's long duration of action is documented by ratios of trough (end of 24-h dosing interval) to peak antihypertensive effects, which are consistently above 50%."	( Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. Weber, MA, 1992)	1.43
" Ninety percent of K+/86Rb accumulation was blocked by ouabain, and the dose-response curve of inhibition by ouabain was monophasic (IC50, approximately 80 microM), suggesting the role of a single type of Na+/K+ pump (alpha-isoenzyme) in 86Rb accumulation by rat glomerulosa cells."	( Angiotensin-II inhibits Na+/K+ pump in rat adrenal glomerulosa cells: possible contribution to stimulation of aldosterone production. Balla, T; Csordás, G; Enyedi, P; Hajnóczky, G; Hunyady, L; Kalapos, MP; Spät, A, 1992)	0.28
" In pithed rats, BIBS 39 dose dependently shifted the dose-response curve of AII to the right without affecting the maximal response."	( Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists. Entzeroth, M; Van Meel, JC; Wienen, W; Zhang, J, 1992)	0.28
" The inhibitory effect of EXP3174 (1 mg/kg iv) was not overcome by angiotensin II in the range of doses studied, and the shift to the right of the dose-response curve was nonparallel, suggesting that the blockade was noncompetitive."	( Inhibitory effects of DuP 753 and EXP3174 on responses to angiotensin II in pulmonary vascular bed of the cat. Hood, JS; Kadowitz, PJ; Kaye, AD; McMahon, TJ; Minkes, RK; Nossaman, BD, 1992)	0.28
" EXP3174 is a major metabolite generated after the oral dosing of 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H- tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole, potassium salt in rats."	( Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. Carini, DJ; Chiu, AT; Duncia, JV; Johnson, AL; Price, WA; Timmermans, PB; Wexler, RR; Wong, PC, 1990)	0.28
" caused dose-dependent parallel rightward shifts of the dose-response curves (DBP and LVdP/dtmax) without altering the maximal responses to AII."	( Effect of various angiotensin receptor antagonists on cardiovascular responses to angiotensin II in pithed rats. Pfaffendorf, M; van Zwieten, PA; Zhang, J, 1994)	0.29
") shifted dose dependently the dose-response curve of angiotensin II to the right without affecting the maximal response."	( Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action. Cazaubon, C; Chatelain, P; Christophe, B; Libon, R; Manning, A; Nisato, D, 1995)	0.29
" In this small sample of hypertensive patients, losartan monotherapy and losartan-hydrochlorothiazide (HCTZ) combination therapy were associated with modest reductions in systolic, diastolic and mean arterial BPs; significant changes were observed only at the peak dosing interval."	( Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. Bauer, IH; Lau-Sieckman, A; Reams, GP; Wu, Z, 1995)	0.94
" In this protocol after salt depletion, losartan caused a transient increase in urea and creatinine (143 +/- 40 microML) 8 h after dosing as compared with placebo (105 +/- 13 microM)."	( Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers. Doig, JK; MacFadyen, RJ; Reid, JL; Sweet, CS, 1995)	0.82
" A dose-response relationship to losartan was observed in this patient population."	( Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Goldberg, AI; Pratt, JH; Soffer, BA; Sweet, CS; Wiens, B; Wright, JT, 1995)	0.96
" Losartan, but not PD123177, shifted the dose-response curves for AII to the right in a parallel manner."	( Hemodynamic effects of angiotensin II and the influence of angiotensin receptor antagonists in pithed rabbits. Pfaffendorf, M; van Zwieten, PA; Zhang, J, 1995)	1.2
"The in vitro protein binding characteristics of the prototypical angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174 were determined by ultrafiltration with plasma from naive donors, volunteers dosed with losartan, and purified human plasma proteins."	( Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174. Christ, DD, 1995)	0.74
" Losartan is as effective as other commonly used antihypertensive agents, but it permits convenient dosing and is better tolerated."	( The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension. Lacourcière, Y, 1995)	1.47
" Our results indicate a BP and plasma renin dose-response relation for the orally active angiotensin II (AII) receptor blocker losartan in normotensive subjects with an activated RAS."	( Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man. Doig, JK; Lees, KR; MacFadyen, RJ; Reid, JL; Sweet, CS, 1993)	0.73
" In genetic and renal hypertensive rats, the antihypertensive effect induced after acute dosing of SR 47436 was similar to that observed after losartan and enalapril."	( Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models. Canals, F; Cazaubon, C; Galindo, G; Lacour, C; Nisato, D; Segondy, D, 1994)	0.49
") dosing in humans."	( Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans. Birnbock, H; Doig, JK; Jones, CR; MacFadyen, RJ; Reid, JL, 1995)	0.29
"By clinical sphygmomanometer measurements at the end of the 24-hour or 12-hour dosing intervals (trough), all three losartan dosages were significantly more effective than placebo at decreasing systolic and diastolic blood pressures."	( Blood pressure effects of the angiotensin II receptor blocker, losartan. Byyny, RL; Faison, EP; Goldberg, AI; Nelson, EB; Pratt, JH; Snavely, DB; Weber, MA, 1995)	0.74
" Meclofenamate and N omega-nitro-L-arginine methyl ester shifted the dose-response curve for ANG IV to the left in a manner similar to that observed with ANG II and ANG III."	( Analysis of responses to ANG IV: effects of PD-123319 and DuP-753 in the pulmonary circulation of the rat. Feng, CJ; Kadowitz, PJ; Kaye, AD; Nossaman, BD, 1995)	0.29
" Losartan but not PD123177 caused parallel rightward shifts of the dose-response curve of angiotensin II for dP/dtmax in the aortic blood pressure controlled pithed rat without altering the maximal response."	( Positive inotropic action of angiotensin II in the pithed rat. Pfaffendorf, M; van Zwieten, PA; Zhang, J, 1993)	1.2
" Dose-response curves to CPA were shallower and maximal responses were weaker than those produced by the other agonists."	( Interactions of adenosine A1 receptor-mediated renal vasoconstriction with endogenous nitric oxide and ANG II. Barrett, RJ; Droppleman, DA, 1993)	0.29
" We found that saralasin or DuP 753, but not the kinin antagonist, displaced the dose-response curve to the right."	( Oxytocic effect of trypsin on the isolated rat uterus. Castillo, G; Esteban, S; Orce, G, 1994)	0.29
" Group 2 (n = 5) was treated with enalapril at a dosage of 50 mg/l in drinking water starting at 6 weeks of age."	( Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. Baba, N; Sakemi, T, 1993)	0.29
"We studied healthy volunteers dosed with placebo, enalapril and losartan 4-6 h before measurement of forearm blood flow by venous occlusion plethysmography."	( Clinical pharmacology of angiotensin and bradykinin in human forearm vasculature. Cockcroft, JR; Goldberg, MR; Ritter, JM; Sciberras, DG, 1993)	0.52
", the blockade was overcome and the dose-response curves for angiotensin II were shifted to the right in a parallel manner."	( Analysis of the inhibitory effects of DuP 753 and EXP 3174 on responses to angiotensin II in the feline hindquarters vascular bed. Bellan, JA; Kadowitz, PJ; Minkes, RK; Osei, SY, 1993)	0.29
" In subjects given losartan, respective decreases (systolic/diastolic) from run-in in supine blood pressure 6 hours after dosing were (mean +/- SD), compared with the placebo run-in day, first dose: -8."	( Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Barchowsky, A; Bjornsson, TD; Bradstreet, TE; Goldberg, MR; Lo, MW; McCrea, J; McWilliams, EJ; Tanaka, W, 1993)	1
" A dose-response curve was performed for EPO at 0, 10, 100, 1,000, and 10,000 mU/mL."	( Erythropoietin-induced antinatriuresis mediated by angiotensin II in perfused kidneys. Aronoff, GR; Brier, ME; Bunke, CM; Lathon, PV, 1993)	0.29
" Although plasma inactive renin concentrations did not change acutely after losartan dosing on day 1 or 42 they did increase from 27."	( Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms. Goldberg, MR; Katz, SA; Opsahl, JA, 1995)	0.81
" This study was designed to investigate whether losartan at likely dosage levels would alter the anticoagulant response to warfarin."	( Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. Bjornsson, TD; Deutsch, PJ; Goldberg, MR; Kong, AN; Osborne, B; Tomasko, L; Waldman, SA, 1995)	1.99
" A total of 179 patients with a pretreatment mean baseline BP of 172 +/- 17/112 +/- 18 mm Hg enrolled in the trial and BP was recorded 24 h after dosing at baseline and weeks 2, 4, 8 and the final week (10-12 weeks)."	( Losartan potassium as initial therapy in patients with severe hypertension. Chrysant, S; Dunlay, MC; Fitzpatrick, V; Francischetti, EA; Goldberg, AI; Sweet, CS, 1995)	1.73
" Efficacy should be demonstrated not only in the conventional clinical setting, but also throughout the full 24 h day, including the important early morning hours near the end of dosing intervals."	( Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent. Neutel, JM; Smith, DH; Weber, MA, 1995)	0.29
" In spontaneously hypertensive rats (SHR), repeated daily oral dosing of XR510, losartan, and enalapril at 30 mg/kg/day decreased BP similarly."	( Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype. Bernard, R; Crain, EJ; McCall, DE; Quan, ML; Saye, JM; Smith, RD; Watson, CA; Wexler, RR; Wong, PC; Zaspel, AM, 1995)	0.52
" In the presence of PD 123319 (10(-5) M) ANG dose-response curve was shifted to the left with no change in the maximal effect."	( Angiotensin II receptor subtypes and phosphoinositide hydrolysis in rat adrenal medulla. Garrido, MR; Israel, A; Saavedra, JM; Strömberg, C; Torres, M; Tsutsumi, K, 1995)	0.29
" Pharmacokinetic data and clinical trials are reviewed, as well as adverse reactions, drug interactions, and dosing guidelines."	( Angiotensin II receptor antagonists: the prototype losartan. Porter, JA; Schaefer, KL, 1996)	0.55
" The dosage of losartan was 50 mg/day."	( Effects of losartan on renal function in patients with essential hypertension. Berra, N; Fauvel, JP; Laville, M; Madonna, O; Pozet, N; Velon, S; Zech, P, 1996)	1.04
" Following daily oral dosing of 135 mg/kg/day on GD6-15, fetal drug levels were negligible."	( Toxicokinetic analysis of losartan during gestation and lactation in the rat. Baldwin, CL; Berna, RA; Eydelloth, RS; Lee, LL; Mattson, BA; Spence, SG; Zacchei, AG, 1996)	0.59
" No initial dosage adjustment is necessary in the elderly and patients with renal impairment (even those on dialysis)."	( Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. Goldberg, AI; Mallion, JM, 1996)	0.57
" Once-daily dosing with losartan has been documented to be safe."	( Losartan: first of a new class of angiotensin antagonists for the management of hypertension. Carr, AA; Prisant, LM, 1996)	2.04
" In contrast, the single dosing of all agents failed to show antinociceptive effect."	( Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Miyazaki, M; Okunishi, H; Song, K; Takai, S; Tanaka, T, 1996)	0.29
" To this end, we studied dose-response curves of phenylephrine (10(-9) to 10(-5) mol/L) in the presence and absence of losartan (10(-9), 10(-7), and 10(-5) mol/L) in SHR aortic rings."	( Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors. Cachofeiro, V; Lahera, V; Maeso, R; Muñoz-García, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1996)	1.95
" This study indicates a predictable plasma concentration-effect relationship of EXP3174 in rats which would be helpful in designing more rational dosing schemes for pharmacodynamic studies."	( Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan. Christ, DD; Lam, GN; Wong, PC; Wong, YN, 1996)	0.5
" Losartan has a sustained duration of action, permitting once-daily dosing in many patients, and lacks partial agonist activity."	( The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Gavras, HP; Salerno, CM, )	1.3
" Further data are needed on the use of losartan potassium in patients with renal impairment before accepting the recommendation that dosage adjustment is not necessary."	( A risk-benefit assessment of losartan potassium in the treatment of hypertension. Burrell, LM, 1997)	0.86
" The characterisation of their pharmacokinetic-pharmacodynamic relationships deserves further refinement for designing optimal therapeutic regimens and proposing dosage adaptations in specific conditions."	( Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Biollaz, J; Brunner, HR; Buclin, T; Csajka, C, 1997)	0.3
" Continuously administered AII (150 microg/kg) induced PE in most cases, while a bolus injection of the same dosage did not."	( Angiotensin II-induced pulmonary edema in a rabbit model. Koike, Y; Mineshita, S; Sanaka, M; Shimakura, K; Wang, L; Yamamoto, T, 1997)	0.3
" Serial blood samples were collected over one dosing interval on study days 10 and 20 for measurement of plasma concentrations of eprosartan, losartan, and E-3174 (the active metabolite of losartan)."	( Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Blum, RA; Boike, SC; Etheredge, R; Ilson, B; Jorkasky, DK; Kazierad, DJ; Martin, DE; Tenero, DM, 1997)	0.74
" In isolated rabbit aorta, KRH-594 caused nonparallel shifts to the right of the dose-response curve to AII and decreased the maximal response with a pK(B) of 10."	( Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist. Amano, H; Hashimoto, K; Hirata, T; Inokuma, K; Mikoshiba, I; Okuhira, M; Tamura, K, 1997)	0.3
" In contrast, the angiotensin II type 1 receptor antagonist losartan, at a dosage that did not lower blood pressure, did not attenuate the increase in urinary excretion of sodium."	( Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers. Hertenberg, F; Smits, P; Vervoort, G; Wetzels, JF, 1998)	0.54
" After 6 weeks of treatment, the daily dosage was doubled in patients whose sitting diastolic blood pressure (SiDBP) remained > or = 90 mm Hg."	( A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Cifkova, R; Harron, DW; Karpov, YA; Lepe, L; Oigman, W; Roca-Cusachs, A, 1997)	0.52
" At the 48-week follow-up of the Evaluation of Losartan in the Elderly (ELITE) Study, the AT1 receptor antagonist losartan (at a dosage of 50 mg/day) was found to be superior to captopril 50 mg 3 times daily in terms of its effects on total mortality, total mortality and/or hospitalisation for CHF, and hospitalisation for any reason."	( The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study. Aronow, WS, 1998)	0.77
" Dose-response curves to angiotensin II of blood pressure show a tenfold higher potency for HR 720 to compete for angiotensin II, thereby decreasing the maximum effects when compared with losartan."	( Effects of the AT1 antagonist HR 720 in comparison to losartan on stimulated sympathetic outflow, blood pressure, and heart rate in pithed spontaneously hypertensive rats. Dendorfer, A; Dominiak, P; Häuser, W; Nguyen, T, 1998)	0.74
"1 mumol/L) had no alpha 1-adrenoceptor antagonist effect but altered the mode of action of the alpha 1-adrenoceptor antagonist doxazosin: PD123319 changed doxazosin from a competitive to a non-competitive antagonist, as evidenced by the reduced slope of the dose-response curve for the alpha 1-adrenoceptor agonist phenylephrine."	( Effect of angiotensin II receptor blockade on the interaction between enalaprilat and doxazosin in rat tail arteries. Marwood, JF, )	0.13
" It has been formulated and marketed as a tablet dosage from (COZAAR)."	( Determination of losartan and its degradates in COZAAR tablets by reversed-phase high-performance thin-layer chromatography. Brooks, MA; Gilbert, RE; Ip, DP; McCarthy, KE; Tsai, EW; Wang, Q, 1998)	0.64
"We evaluated the effects on cardiovascular structure of the angiotensin-converting enzyme (ACE) inhibitor enalapril and of the angiotensin II receptor blocker losartan, administered either at hypotensive or nonhypotensive dosage in spontaneously hypertensive rats (SHR)."	( Effects of losartan and enalapril on small artery structure in hypertensive rats. Agabiti Rosei, E; Bettoni, G; Castellano, M; Guelfi, D; Muiesan, ML; Mulvany, MJ; Pasini, G; Piccoli, A; Porteri, E; Rizzoni, D, 1998)	0.89
" On repeated dosing for 21 days in SHRs, SK-1080 significantly reduced blood pressure without inducing tachycardia and tolerance throughout the dosing period."	( In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist. Kwon, KJ; Lee, BH; Seo, HW; Shin, HS; Yoo, SE, 1999)	0.3
" This dose of losartan shifted the in vivo dose-response curve of the angiotensin II-induced elevation of left ventricular systolic pressure (LVSP) to the right."	( Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats. Baba, HA; Bauer, M; Irlbeck, M; Iwai, T; Schmid, KW; Zimmer, HG, 1999)	0.66
" Clinical evaluations and laboratory tests were performed (1) before CEI treatment (basal) and after (2) CEI alone (CEI, 12 weeks); (3) the combination of CEI and LOS, the latter at a dosage of 50 mg/d (CEI + LOS, 4 weeks); (4) LOS alone (LOS; 50 mg/d; 12 weeks); (5) the combination of LOS and CEI (LOS + CEI, 4 weeks, at the same dosage as CEI + LOS); and (6) a doubled dose of either CEI alone or LOS alone for 4 weeks."	( Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Andreucci, M; Balletta, MM; De Nicola, L; Minutolo, R; Pisani, A; Russo, D; Savino, FA, 1999)	0.54
" Losartan has been worldwide marketed as the first orally active AT1 receptor antagonist with once-daily dosing for treatment of hypertension."	( [Pharmacological properties and its significance in clinical practice]. Ikemoto, F; Nishikibe, M, 1999)	1.21
" No such correlation was detected for each single dose of candesartan cilexetil but a dose-response relationship was present when both doses were combined."	( Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan. Azizi, M; Chatellier, G; Guyene, TT; Ménard, J, 1999)	0.53
" Each patient received 50 mg of losartan or 5 mg of felodipine ER once daily, and the dosage was adjusted to double the initial level at week 6 if necessary."	( Comparison of antihypertensive efficacy and tolerability of losartan and extended-release felodipine in patients with mild to moderate hypertension. Cherng, WJ; Hsieh, IC; Hung, KC; Hung, MJ; Lin, FC; Wang, CH; Wen, MS; Wu, D, 1999)	0.83
"Losartan decreased serum uric acid and increased uric acid excretion without increasing urinary dihydrogen urate, the primary risk factor for acute urate nephropathy, during 21 days of dosing in hypertensive patients with thiazide-induced hyperuricemia."	( Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Carides, AD; Coe, FL; Nakagawa, Y; Parks, JH; Shahinfar, S; Simpson, RL; Thiyagarajan, B; Umans, JG, 1999)	2.15
" In these studies, ambulatory blood pressure monitoring is continued throughout the dosing interval and beyond in order to determine when systolic and diastolic blood pressure increase into the hypertensive range."	( Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. Dell'Oro, R; Grassi, G; Mancia, G; Turri, C, 1999)	0.52
"The purpose of this double-blind, forced titration study was to compare the antihypertensive effect duration of candesartan cilexetil, which has a longlasting binding to the human AT1-receptor, to that of losartan on ambulatory BP (ABP) not only during the 24-h dosing interval but also during the day of a missed dose intake."	( A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Lo Asmar, R; Lacourcière, Y, 1999)	0.72
" Each drug effectively lowers blood pressure during once daily administration to patients with mild to moderate hypertension, with candesartan cilexetil requiring the lowest dosage and providing dose-dependent efficacy."	( Newly emerging pharmacologic differences in angiotensin II receptor blockers. Oparil, S, 2000)	0.31
" A low dosage of fosinopril (5 mg/kg/d) that was still adequate to reduce their plasma ACE activity and LDL propensity to lipid peroxidation was insufficient to lower their blood pressure."	( The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Attias, J; Breslow, JL; Brodsky, S; Coleman, R; Hayek, T; Keidar, S; Smith, J, 1999)	0.52
"The U46619-stimulated platelet aggregation was significantly inhibited by losartan in a dose-response manner."	( [Effect of losartan on human platelet activation by thromboxane A2]. Casado, S; Castilla, C; Farré, J; Gómez, J; Guerra, JI; Jiménez, AM; López-Farré, A; Marcos, P; Montón, M; Núñez, A; Rico, L; Rodríguez-Feo, JA; Sánchez De Miguel, L, 2000)	0.93
" In the second experiment, furosemide injection was preceded by treatment with a higher dose of CAP; this dosage blocks the peripheral and central formation of angiotensin II."	( Activation of renal afferent pathways following furosemide treatment. II. Effect Of angiotensin blockade. Fitch, GK; Weiss, ML, 2000)	0.31
" No dosage adjustment is required in elderly or in patients with mild to moderate renal dysfunction, and the risk of first-dose hypotension is low."	( Losartan: a review of its use, with special focus on elderly patients. McClellan, KJ; Simpson, KL, 2000)	1.75
"The pharmacokinetics of losartan and E-3174 are minimally altered in ESRD; thus, dosage adjustment is not required in the presence of advanced dialysis-dependent renal failure."	( Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. Gehr, TW; Halstenson, CE; Keane, WF; Sica, DA, 2000)	0.87
" In addition, the numerically larger smoothness index with losartan suggested a more homogeneous antihypertensive effect throughout the 24-hour dosing interval."	( Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators. Aroca Martinez, GJ; Bunt, AM; Carbajal, ET; Cuevas, JH; Dumortier, T; Garcia, LH; Hitzenberger, G; Lara Teran, J; Leao Neves, P; Middlemost, SJ; Monterroso, VH; Rodriguez Chavez, V; Smith, RD; Vogel, DR, )	0.58
" Changes in the dose-response curve to platelet aggregation induced by the thrombin receptor-activating peptide SFLRRN-NH2 were determined in 9 patients (56% men, 72% white; mean age 52."	( Inhibition of platelet aggregability by losartan in essential hypertension. Brosnihan, KB; Ferrario, CM; Levy, PJ; Owen, J; Smith, R; Yunis, C, 2000)	0.57
" Dose-response curves to bradykinin (0."	( Acute administration of nicotine impairs the hypotensive responses to bradykinin in rats. Calegari, V; do Prado, JF; Moreno, H; Paganelli, MO; Tanus-Santos, JE; Toledo, JC, 2001)	0.31
" In this study we investigated the importance of drug dosing in mediating these differences by comparing the AT(1)-receptor blockade induced by 3 doses of valsartan with that obtained with 3 other antagonists at given doses."	( Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Brunner, HR; Burnier, M; Centeno, C; Maillard, MP; Nussberger, J; Würzner, G, 2002)	0.31
" Possible reasons for lack of ARB superiority include insufficient dosing of ARB, differences in effects mediated through angiotensin II type 2 receptors, interaction with beta-blockers, and bradykinin-mediated effects specific to ACE inhibitors."	( Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn? Pitt, B, 2002)	0.31
"Two new rapid reproducible and economical spectrophotometric methods are described for the determination of Losartan potassium in bulk and in synthetic mixture for solid dosage forms."	( A rapid colorimetric method for the determination of Losartan potassium in bulk and in synthetic mixture for solid dosage form. Giridhar, R; Prabhakar, AH, 2002)	0.78
" Acute losartan dosing to 2K-1C rats decreased platelet adhesion to fibrillar collagen(24."	( The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan. Buczko, W; Chabielska, E; Kucharewicz, I; Matys, T; Pawlak, D; Rólkowski, R, 2000)	0.99
" Losartan improved the shifted circadian BP rhythm towards the active phase in a dose-dependent manner, whereas the improvement caused by 1 and 3 mg/day of benazepril was less effective than the same dosage of losartan."	( Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP. Hayasaki-Kajiwara, Y; Iwasaki, T; Nakajima, M; Naya, N; Shimamura, T, 2002)	1.61
" Angiotensin II (Ang II) antagonistic effects were determined in vivo from rightward shifts in Ang II dose-response curves for diastolic blood pressure (BP) and dose ratios were calculated."	( The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man. Belz, GG; Breithaupt-Grögler, K; Butzer, R; Fuchs, W; Hausdorf, C; Mang, C, 2000)	0.31
"This study was conducted in 19 patients with mild or moderate essential hypertension randomised open trial to evaluate the influence of potassium losartan dosed 50 mg per day on blood pressure, metabolic processes and left ventricular heart function."	( [Estimation of blood pressure, selected biochemical parameters and indices of left ventricular heart function in patients with mild or moderate essential hypertension treated with potassium losartan]. Badowski, R; Cieślik, P; Haczkiewicz, P; Hefczyc, J; Hrycek, A; Scieszka, J, 2001)	0.7
" Analysis of dose-response curves to Ang III in forskolin-treated CTAL demonstrated that the maximal [Ca2+]i response was significantly increased without altering the EC50."	( Potentiation of [Ca2+]i response to angiotensin III by cAMP in cortical thick ascending limb. Corvol, P; Hus-Citharel, A; Llorens-Cortes, C; Marchetti, J, 2002)	0.31
"We studied the effects of a chronotherapeutic delivery system of verapamil (controlled-onset extended release [COER]-24 system) dosed at bedtime versus conventional morning administration of both enalapril and losartan on the blood pressure (BP), heart rate, and the heart rate systolic BP product during the first 4 hours after awakening in a placebo-controlled, forced-titration trial."	( Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Anders, RJ; Calhoun, D; Mansoor, GA; Sica, DA; White, WB, 2002)	0.69
"Bedtime administration of an agent designed to parallel the circadian rhythm of BP and heart rate led to significantly greater early morning hemodynamic effects compared with other conventional once-daily antihypertensive agents dosed in the morning."	( Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Anders, RJ; Calhoun, D; Mansoor, GA; Sica, DA; White, WB, 2002)	0.51
" Of these 708 patients 643 patients received once daily dosage of the combination whereas 10 patients received 1/2 daily, 13 patients received 1 1/2 daily and 42 patients received 1 twice daily dosage of the combination."	( Efficacy and safety of losartan-amplodipine combination--an Indian postmarketing surveillance experience. Gokhale, N; Pawar, D; Shahani, S, 2002)	0.63
" Higher dosage of losartan had deleterious effects in BDL rats."	( Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. Calès, P; Chappard, D; Croquet, V; Douay, O; Gallois, Y; Moal, F; Oberti, F; Roux, J; Veal, N; Vuillemin, E; Wang, J, 2002)	0.92
" The selected studies were included in a meta-analysis of the dose-response relationship for each drug."	( The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Elmfeldt, D; Meredith, P; Olofsson, B, 2002)	0.31
" Further research is necessary to determine which AT1RBs and which dosing regimens are optimal."	( Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. Mancini, GB, 2002)	0.31
" Of those who received a dosage adjustment, a significantly greater percentage of amlodipine-treated patients (59%) than losartan/HCTZ-treated patients (42%) reached BP goal at the last visit (p=0."	( The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. Grimm, RH; Kloner, RA; Phillips, RA; Weinberger, M, )	0.61
" Patients were administered either losartan or placebo, each in addition to conventional antihypertensive therapy, with dosage adjustments as necessary to achieve a target blood pressure of less than 140/less than 90 mm Hg."	( Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. Keane, WF; Lyle, PA, 2003)	0.6
" While the biphenyltetrazole compound candesartan dissociated slowly and behaved as an insurmountable antagonist for WT-AT(1), it dissociated swiftly and only produced a rightward shift of the angiotensin Ang II- and -IV dose-response curves for inositol phosphate (IP) accumulation in cells expressing N111G."	( Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors. Hunyady, L; Kersemans, V; Le, MT; Szaszák, M; Vanderheyden, PM; Vauquelin, G, 2003)	0.32
" During the last six hours of the dosing interval, telmisartan 40 mg/HCTZ 12."	( Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Byrne, M; Gil-Extremera, B; Lacourcière, Y; Mueller, O; Williams, L, 2003)	0.54
" Alterations in losartan dosing in CYP2C91/2 and 1/3 individuals does not appear necessary."	( Losartan and E3174 pharmacokinetics in cytochrome P450 2C91/1, 1/2, and 1/3 individuals. Blaisdell, JA; Goldstein, JA; Hinderliter, AL; Lee, CR; Pieper, JA, 2003)	2.11
" Both drugs provided effective control over the 24-h dosing interval."	( Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study. Kolloch, RE; Meinicke, TW; Neutel, JM; Plouin, PF; Schumacher, H, 2003)	0.67
"To compare the ability of telmisartan and losartan to reduce mean diastolic blood pressure (DBP) during the last 6 h of the 24-h dosing interval in a prospectively planned meta-analysis of ambulatory blood pressure monitoring (ABPM) data from two independent studies."	( Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Cramer, MJ; Hettiarachchi, R; Koval, S; Neutel, JM; Smith, DH, 2003)	0.86
" During the last 6 h of the 24-h dosing interval, telmisartan produced greater reductions in each of the observed hourly mean ambulatory DBP values."	( Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Cramer, MJ; Hettiarachchi, R; Koval, S; Neutel, JM; Smith, DH, 2003)	0.6
"Telmisartan 40/80 mg is superior to losartan 50/100 mg in controlling DBP and SBP during the last 6 h of the 24-h dosing interval."	( Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Cramer, MJ; Hettiarachchi, R; Koval, S; Neutel, JM; Smith, DH, 2003)	0.88
" Then, it is a good alternative to existing methods for determining Losartan potassium in tablets provided that the pharmaceutical dosage form does not contain hydrochlorothiazide as second drug."	( Development and validation of an UV derivative spectrophotometric determination of Losartan potassium in tablets. Lastra, OC; Lemus, IG; Pérez, RF; Sánchez, HJ, 2003)	0.78
" However, ET has no synergistic effect on BP in established hypertension when combined with losartan, at least at the dosage used in this investigation."	( Effects of losartan combined with exercise training in spontaneously hypertensive rats. Azevedo, LF; Barretto, AC; Brum, PC; Junqueira, CM; Mattos, KC; Negrão, CE; Rondon, MU, 2003)	0.93
" Criteria used in the assessment includes: need to change dosage for an ARB included in the Pharmacotherapeutic Guide, and blood pressure changes after drug interchange."	( [Therapeutic interchange between angiotensin II receptor blockers in institutionalized elderly patients. Implimenting a protocol]. de la Vega Ortega, A; Faus Felipe, VJ; Martínez Martínez, MA; Martínez Romero, G; Peris Martí, JF, )	0.13
"001) and the other periods of the 24-h interval compared with the levels achieved by the previous treatment, indicating a clear dose-response relationship."	( Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Lacourcière, Y; Poirier, L, 2003)	0.56
"5 and L 100/HCTZ 25 provided greater reductions in clinic and ABP than HCTZ monotherapies, with a clear dose-response relationship with regard to ABP."	( Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Lacourcière, Y; Poirier, L, 2003)	0.56
" Ligustrazine with the dosage of 80 mg twice a day was given to 25 patients in the treatment group by intravenous perfusion besides the medicine used in the control group."	( [Effect of ligustrazine on proliferative glomerulonephritis]. Tang, X, 2003)	0.32
" Brain hexamethylpropyleneamine oxime single photon emission computed tomography (HMPAO SPECT) was performed before dosing and at the estimated time of peak drug effect (6-8 h after the first dose)."	( The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke. Bolster, A; Hilditch, TE; Lees, KR; Nazir, FS; Overell, JR; Reid, JL, 2004)	0.68
" In dose-finding experiments in non-hypertrophied isolated perfused hearts, we performed dose-response curves of losartan and enalaprilat studying monophasic action potential duration at 90% repolarisation (MAPD(90%)) and ventricular fibrillation (VF) threshold."	( Losartan but not enalaprilat acutely reduces reperfusion ventricular tachyarrhythmias in hypertrophied rat hearts after low-flow ischaemia. Beier, K; Bellahcene, M; Buser, PT; Butz, S; Driamov, S; Remondino, A; Zaugg, CE; Ziegler, A, 2004)	1.98
" Dose-response curves were established for the noradrenaline-induced (10(-12) to 10(-7) mol/kg) increase of diastolic blood pressure in pithed rats treated with tubocurarine, propranolol, and atropine."	( Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation. Dendorfer, A; Dominiak, P; Raasch, W; Ziegler, A, 2004)	0.32
"In the present study, we established dose-response relationships between central administration of 4-hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl (Tempol, a superoxide dismutase mimetic) and the level of renal sympathetic nerve discharge (SND) and tested the hypothesis that intracerebroventricular (icv) Tempol pretreatment would attenuate centrally mediated changes in SND produced by icv ANG II administration."	( Central Tempol alters basal sympathetic nerve discharge and attenuates sympathetic excitation to central ANG II. Fels, RJ; Helwig, BG; Kenney, MJ; Lu, N; Parimi, S, 2004)	0.32
" Dosage was doubled at week 4 and hydrochlorothiazide was added at week 12 if blood pressure response was inadequate."	( Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Stumpe, KO, 2004)	0.32
" A first-derivative UV spectroscopic method and HPLC were developed for the determination of losartan in the tablet dosage form."	( A comparative study of first-derivative spectrophotometry and high-performance liquid chromatography applied to the determination of losartan potassium in tablets. Ansari, M; Baradaran, M; Kazemipour, M; Khosravi, F, 2004)	0.75
" Twenty-four-hour ambulatory blood pressure monitoring (ABPM) allows accurate assessment of a patient's hypertension and risk for cardiovascular events, and provides the most accurate measure of an antihypertensive agent's efficacy throughout a 24-hour dosing interval."	( Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Dubiel, R; Jones, M; Smith, DH, 2005)	0.53
"This article presents clinical data which suggest that the current dosage of losartan 50 to 100 mg/day may not be the optimum in many cases, especially if used as monotherapy in the treatment of proteinuria and we may have to increase to 200 mg/day."	( ATRA therapy restores normal renal function and renal reserve and prevents renal failure. Chan, CM; Lau, YK; Wong, KS; Woo, KT, 2005)	0.56
"This was a multicenter, randomized, double-blind, dose-response study."	( A double-blind, dose-response study of losartan in hypertensive children. Ahmed, T; Blumer, J; Briazgounov, I; Cano, F; Gleim, G; Miller, K; Santoro, EP; Shahinfar, S; Soffer, BA; Vogt, B; Zhang, Z, 2005)	0.6
"A total of 61 renal units in 32 patients with hypertension were studied in two groups based on the losartan dosage (50 mg in group A and 100 mg in group B)."	( Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing. Altun, B; Caner, B; Cil, B; Ergün, EL; Günay, EC; Hekimoğlu, B; Oztürk, MH; Salanci, BV; Uğur, O, 2005)	1.99
" The recommended dosage of losartan 50 mg/day can be administered without regard to food."	( Clinical pharmacokinetics of losartan. Gehr, TW; Ghosh, S; Sica, DA, 2005)	0.92
" It was concluded that losartan and perindopril similarly alter taste sensitivity during repeated dosing of the drugs."	( Comparative study of taste disturbance by losartan and perindopril in healthy volunteers. Araki, N; Fujimura, A; Ioka, T; Sugimoto, K; Tsuruoka, S; Wakaumi, M, 2005)	0.9
" This suggests that, in patients with hypertension, it may be important to maintain the efficacy of antihypertensive medication over the 24-h dosing interval, especially in the risky early morning hours."	( Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Chrysant, SG; Littlejohn, TW; Neutel, JM; Singh, A, 2005)	0.58
" The primary end point was the reduction from baseline in mean ambulatory DBP over the last 6 hours of the dosing interval."	( Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, pros Lacourcière, Y; Neutel, JM; Schumacher, H, 2005)	0.53
"5, including during the last 6 hours of the dosing interval."	( Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, pros Lacourcière, Y; Neutel, JM; Schumacher, H, 2005)	0.53
" Reduction in diastolic load was significantly greater with irbesartan/HCTZ than with losartan/HCTZ as was mean ambulatory systolic BP during the last 4 h of the dosing interval."	( Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. Neutel, JM; Smith, D, )	0.56
" Dose-response curves for Ang II were obtained in an isolated perfused kidney preparation comparing groups of SRAC pregnant and non-pregnant rats in the presence and absence of losartan (AT1 antagonist) or PD123319 (AT2 antagonist)."	( Renal vascular responses in an experimental model of preeclampsia. Bobadilla Lugo, RA; López Sanchez, P; Pérez-Alvarez, VM; Robledo, LA, 2005)	0.52
" Corresponding dosage of Losartan can also alleviate the motion capability and type I collagen content of hPSCs compared with AngII treatment and non-treatment control groups."	( Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells. Liu, WB; Wang, XP; Wu, K; Zhang, RL, 2005)	0.89
" Therefore, administration of AST-120 60 minutes after losartan under fed conditions may be preferred over other dosing regimens for CKD patients."	( The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects. Guilbaud, R; Kambhampati, SR; Lee, J; Marier, JF; Mathew, P; Moberly, J; Salazar, DE, 2006)	0.82
" Losartan was given at the dosage of 25-50 mg/day."	( Losartan, an angiotensin-II receptor antagonist, retards the progression of advanced renal insufficiency. Fujita, T; Kumasaka, R; Murakami, R; Nakamura, M; Nakamura, N; Okumura, K; Osawa, H; Shimada, M; Shirato, K; Yamabe, H, 2006)	2.69
"The aim of the present research work was to systemically device a model of factors that would yield an optimized sustained release dosage form of an anti-hypertensive agent, losartan potassium, using response surface methodology by employing a 3-factor, 3-level Box-Behnken statistical design."	( Release modulating hydrophilic matrix systems of losartan potassium: optimization of formulation using statistical experimental design. Chopra, S; Motwani, SK; Patil, GV, 2007)	0.79
" If the subject's seating diastolic blood pressure (SeDBP) was still >or=90 mm Hg, the dosage was doubled for another 4 weeks; for those subjects whose SeDBP was <90 mm Hg after 4-week treatment, the initial dosage remained unchanged and the treatment continued until completion of the study."	( [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. Cai, NS; Chen, YZ; Fan, WH; Guo, JX; He, B; Huang, J; Ke, YN; Li, XL; Ma, H; Wu, ZG; Zhu, DL; Zhu, JR, 2006)	0.58
" Models were adjusted for demographic, clinical, physician, and hospital characteristics; models were also adjusted for dosage categories, which were represented by time-dependent variables."	( Angiotensin II receptor blockers for the treatment of heart failure: a class effect? Behlouli, H; Hudson, M; Humphries, K; Pilote, L; Sheppard, R; Tu, JV, 2007)	0.34
" NO levels in serum and 24-hour urine were determined at baseline and after 6 weeks of daily dosing with losartan (50-100 mg)."	( Effect of losartan therapy on endothelial function in hypertensive patients. Armas-Hernández, MJ; Armas-Padilla, MC; Cammarata-Segura, R; Guerrero, J; Hernández-Hernández, R; Israili, ZH; Pacheco, B; Sosa-Canache, B; Valasco, M, )	0.75
" Patients received open-label treatment with a conventional dosage of benazepril (10 mg/d), individual uptitration of benazepril (median 20 mg/d; range 10 to 40), a conventional dosage of losartan (50 mg/d), or individual uptitration of losartan (median 100 mg/d; range 50 to 200)."	( Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. Chen, PY; Guo, ZJ; Hou, FF; Jiang, JP; Liang, M; Xie, D; Zhang, WR; Zhang, X, 2007)	0.74
" After a 3-month, open-label, run-in period during which patients received 100 mg of losartan daily, patients were randomly assigned to receive 6 months of treatment with aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months) or placebo, in addition to losartan."	( Aliskiren combined with losartan in type 2 diabetes and nephropathy. Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F, 2008)	0.88
"DM2 patients were dosed with losartan (100 mg/d) and urines were collected at week 8 and 12."	( [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics]. Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007)	0.9
"The results of HEAAL should facilitate selection of an optimal dosing regimen for losartan in patients with symptomatic heart failure who are intolerant of ACE-inhibitors."	( Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor. Dickstein, K; Drexler, H; Guptha, S; Justice, SJ; Komajda, M; Konstam, MA; Malbecq, W; Martinez, FA; Neaton, JD; Poole-Wilson, PA; Riegger, GA, 2008)	0.81
" Dose-response curves were constructed for dopamine and isoprenaline that induced falls or increases in renal blood flow, respectively."	( Inhibition of Ang II and renal sympathetic nerve influence dopamine-and isoprenaline-induced renal haemodynamic changes in normal Wistar-Kyoto and spontaneously hypertensive rats. Abdulla, MH; Abdullah, NA; Anand Swarup, KR; Hazim, AI; Johns, EJ; Khan, MA; Rathore, HA; Sattar, MA, 2008)	0.35
" Non-responders after a 6-week treatment period had the dosage doubled for both study drugs until the end of study (week 12)."	( Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. Bradstreet, DC; Goldberg, AI; Halasz, S; Lim, NY; Madonna, O; Makris, L; Mallion, JM; Sweet, CS, 1995)	0.54
" There was no dose-response effect of losartan."	( Regression of glomerular injury by losartan in experimental diabetic nephropathy. Fujihara, CK; Machado, FG; Malheiros, DM; Silva, LF; Teles, F; Ventura, BH; Zatz, R, 2009)	0.9
" There were no dose-response renal effects of losartan."	( Inhibition of the renin-angiotensin system: is more better? Anderson, S; Komers, R, 2009)	0.61
" Dose-response relationships were determined in terms of reduction/elevation in the magnitude of renal blood flow in response to intrarenal arterial injection of dopamine, phenylephrine and isoprenaline."	( Chronic treatment with losartan and carvedilol differentially modulates renal vascular responses to sympathomimetics compared to treatment with individual agents in normal Wistar Kyoto and spontaneously hypertensive rats. Abdallah, HH; Abdulla, MH; Abdullah, NA; Johns, EJ; Khan, MA; Sattar, MA, 2009)	0.66
" These results indicate that effects on cardiac load by peripheral AT(1) receptor blockade or the pharmacokinetic profile of subcutaneous versus oral dosing do not contribute to the different cardiac effects of central versus systemic AT(1) receptor blockade post-MI."	( Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats post-myocardial infarction. Ahmad, M; Huang, BS; Leenen, FH; Tan, J, 2009)	0.35
"The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria."	( Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009)	0.54
" Special testing suggests that NBC at adequate dosing increases insulin sensitivity, lowers HbA1C, decreases activity of the RAS, at least in part, through ACE inhibition, enhances NO activity, and is without signs of toxicity."	( Long-term metabolic effects of different doses of niacin-bound chromium on Sprague-Dawley rats. Bagchi, D; Echard, B; Perricone, NV; Preuss, HG, 2010)	0.36
"Both drugs differ in their oral bioavailability, potential for food interactions, degree of metabolism, dosing interval, time to peak, volume of distribution and terminal half-life."	( Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan. Bramlage, P; Schindler, C, 2010)	0.56
" Here we treated the APP/PS1 transgenic mouse model of AD with the ARB losartan (10 mg/kg body weight) to determine whether blockade of the AT-II receptor subtype 1 (AT1-R) with intranasal losartan, using at a dosage far below its systemic antihypertensive dose, could maintain its neuroprotective effects independent of its systemic vasoactive action."	( Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Buadze, M; Danielyan, L; Frey, WH; Gleiter, CH; Hanson, LR; Klein, R; Schwab, M, )	0.65
"We obtained dose-response curve for the administration of complete extract and extract fractions."	( Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism. Badillo, FH; González-Cortazar, M; Herrera-Ruiz, M; Jiménez-Ferrer, E; Tortoriello, J, 2010)	0.36
" However, pharmacologic and dosing differences exist among the various ARBs, and these differences can potentially influence their individual effectiveness."	( Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Siragy, HM, 2010)	0.36
" In vivo absorption was investigated following regional intestinal dosing in rats, and the pharmacokinetics was determined using rats after a single oral administration."	( The physicochemical properties, in vitro metabolism and pharmacokinetics of a novel ester prodrug of EXP3174. Choi, HG; Kim, HK; Lee, GS; Lee, WS; Seo, KH; Woo, JS; Yan, YD; Yong, CS, 2010)	0.36
" This study included 15 subjects whose therapy was changed from a usual dosage of ARB to losartan 50mg/HCTZ 12."	( Effects of losartan/hydrochlorothiazide treatment, after change from ARB at usual dosage, on blood pressure and various metabolic parameters including high-molecular weight adiponectin in Japanese male hypertensive subjects. Hirose, H; Kawabe, H; Saito, I, 2011)	0.98
" Dose-response relationships for the elevation of mean arterial pressure or change in heart rate (HR) in response to intravenous injections of noradrenaline (NA), phenylephrine (PE), methoxamine (ME) and Ang II were determined."	( The effect of losartan and carvedilol on vasopressor responses to adrenergic agonists and angiotensin II in the systemic circulation of Sprague Dawley rats. Abdulla, MH; Abdullah, NA; Anand Swarup, KR; Johns, EJ; Khan, MA; Sattar, MA, )	0.49
"Two simple, accurate and reproducible spectrophotometric methods have been developed for the simultaneous estimation of Hydrochlorothiazide (Hctz), Atenolol (Atn) and Losartan potassium (Los) in combined tablet dosage forms."	( Simultaneous spectrophotometric estimation of Hydrochlorothiazide, Atenolol and Losartan potassium in tablet dosage form. Chavan, UB; Deshpande, AD; Dighe, SB; Jagdale, SN; Kothapalli, LP; Nanda, RK; Thomas, AB, 2009)	0.77
" Experiment lasted 11 days and dosing was via oral route."	( Pharmacologic inhibition of the renin-angiotensin system did not attenuate hepatic toxicity induced by carbon tetrachloride in rats. Adesanoye, OA; Bamidele, TO; Ekor, M; Kale, OE; Odewabi, AO; Oritogun, KS, 2011)	0.37
" The results of the study indicate that the isolated polysaccharide has good physicochemical and morphological characteristics and is suitable for use as a mucoadhesive sustain release polymer in pharmaceutical dosage forms, to alleviate the drawbacks of the conventional drug therapy of Losartan potassium."	( Isolation and evaluation of a polysaccharide from Prunus amygdalus as a carrier for transbuccosal delivery of Losartan potassium. Chandrasekar, MJ; Kumar, SM; Manikandan, D; Nanjan, MJ, 2011)	0.76
" The purpose of this study was to determine the relative effects of these three modes of pharmacological RAS inhibition in reducing atherosclerosis by determining the dose-response relationships."	( Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. Balakrishnan, A; Cassis, LA; Charnigo, R; Daugherty, A; Howatt, DA; Liau, G; Lu, H; Wu, C, 2012)	0.38
"6 mmHg), ABP in the last 4 hours of the dosing period (-21."	( Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ. Duprez, D; Ferdinand, K; Purkayastha, D; Samuel, R; Wright, R, 2011)	0.37
"The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension."	( Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study. Chae, SC; Cho, SY; Choi, YJ; Hong, BK; Hong, TJ; Jeong, JW; Kim, CH; Kim, JJ; Kim, MH; Kwan, J; Park, CG; Park, SH; Yang, JY; Youn, HJ, 2012)	0.83
" Doses were adjusted to equipotent inhibition of the renin-angiotensin system, determined via a dose-response quantifying plasma and renal renin expression."	( AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease. Baucke, J; Danser, AH; Divac, N; Fraune, C; Frenay, AR; Garrelds, IM; Hölzel, A; Jankowski, V; Krebs, C; Lange, S; Nguyen, G; Schwedhelm, E; Stahl, R; Streichert, T; van Goor, H; Velden, J; Wenzel, UO, 2012)	0.38
" This study examined the practical efficacy of a combination therapy of ARB with thiazide diuretics for lowering morning home blood pressure (MHBP) in comparison to high-dose ARB therapy in patients with morning hypertension administered an ordinal dosage of ARB."	( Losartan/hydrochlorothiazide combination therapy surpasses high-dose angiotensin receptor blocker in the reduction of morning home blood pressure in patients with morning hypertension. Hanayama, Y; Makino, H; Nakamura, Y; Uchida, HA, 2012)	1.82
"The aim of the work is to modify the solubility and bioavailability of Losartan potassium, by employing noneffervescent floating drug delivery (tablet dosage forms)."	( Formulation and evaluation of non-effervescent floating tablets of losartan potassium. Gangadharappa, HV; Getyala, A; Kumar, TM; Prasad, MS; Reddy, MP, 2013)	0.86
"5 mg) (ARB+D; n = 72) or a combination of amlodipine (5 mg) and the typical dosage of ARBs (ARB+C; n = 68) to evaluate the change in the BP, laboratory values and cognitive function."	( Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. Hasebe, N; Kikuchi, K; Koyama, S; Maruyama, J; Morimoto, H; Morita, K; Saijo, Y; Sano, H; Sasagawa, Y; Sato, N; Sumitomo, K; Takehara, N; Takeuchi, T, 2013)	0.39
"Monotherapy with losartan in a dosage of 50-100 mg applied during 8 weeks resulted in achieving target values of blood pressure in 65% of patient with mild and moderate hypertension, also including the patients with diabetes mellitus and impaired renal function."	( [Postmarketing study of efficacy and safety of losartan during the treatment of patients with mild and moderate hypertension: LOTAR (corrected) study]. Burmazović, S; Dimković, N; Krstić, N; Lazarević, K; Micić, D; Milanović, S; Vasilijević, Z; Zorić, S, )	0.73
"To assess antihypertensive duration of action of Losartán Cronos in patients with essential hypertension throughout a 24-h dosing interval, using ABPM and response rates, AASI and Smoothness Index."	( [Abpm and duration of the antihypertensive effect: a study with a new formulation of sustained release losartan (CRONOS)]. Bendersky, M; Caruso, G; Gomez, R; Juncos, L; Kotetzky, M; Lopez-Santi, R; Montaña, O; Penna, M; Piskorz, D; Waisman, GD, 2012)	0.59
" The methods were successfully applied for the determination of the studied drugs in pharmaceutical dosage forms with excellent recovery."	( Utility of 4-chloro-7-nitrobenzofurazan (NBD-CI) for the Spectrophotometric and spectrofluorometric determination of several antihistamine and antihypertensive drugs. Abd, el-HS; Colyer, CL; Hassan, WS; Shalaby, A, )	0.13
" Therefore, sucroferric oxyhydroxide may be administered concomitantly without the need to adjust the dosage regimens of these drugs."	( Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. Chong, E; Kalia, V; Willsie, S; Winkle, P, 2014)	0.64
" This study assessed the dose-response relationship, safety, and tolerability of losartan in hypertensive children aged 6 months to 6 years."	( A randomized, open-label, dose-response study of losartan in hypertensive children. Blaustein, RO; Dankner, WM; Lam, C; Massaad, R; McCrary Sisk, C; Santoro, EP; Shahinfar, S; Webb, NJ; Wells, TG, 2014)	0.88
" No dose-response relationship was established by the slope analysis on SBP (P=0."	( A randomized, open-label, dose-response study of losartan in hypertensive children. Blaustein, RO; Dankner, WM; Lam, C; Massaad, R; McCrary Sisk, C; Santoro, EP; Shahinfar, S; Webb, NJ; Wells, TG, 2014)	0.66
"7 mg/kg per day had clinically significant decreases from baseline in SBP and DBP, yet no dose-response relationship was evident."	( A randomized, open-label, dose-response study of losartan in hypertensive children. Blaustein, RO; Dankner, WM; Lam, C; Massaad, R; McCrary Sisk, C; Santoro, EP; Shahinfar, S; Webb, NJ; Wells, TG, 2014)	0.66
" Individual-level linkage of nationwide registries of hospitalization and drug dispensing in Denmark was used to describe patterns of ARB prescriptions and estimate dosage before and after November 2010."	( Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies. Gislason, GH; Kristensen, SL; Køber, L; Lamberts, M; Selmer, C; Torp-Pedersen, C; von Kappelgaard, LM, 2014)	0.4
" The boy underwent an experimental treatment with losartan at a dosage of 50 mg/day, orally."	( Positive effects of an angiotensin II type 1 receptor antagonist in Camurati-Engelmann disease: a single case observation. Boduroglu, K; Bonafe, L; Campos-Xavier, B; Dikoglu, E; Simsek-Kiper, PO; Superti-Furga, A; Unger, S; Utine, GE, 2014)	0.66
" The dosage was modulated according to the weekly weight."	( Novel mechanism of intra‑renal angiotensin II-induced sodium/proton exchanger 3 expression by losartan in spontaneously hypertensive rats. Cui, W; Fan, X; Gao, Y; Huang, J; Liu, K; Wang, W, 2014)	0.62
" (4) LPS dosing resulted in a rapid accumulation of DC in lung tissues and an up-regulated expression of CD80 in LPS-induced ALI."	( [Effects of losartan on pulmonary dendritic cells in lipopolysaccharide- induced acute lung injury mice]. Liu, J; Qiu, H; Yang, Y; Yu, T; Zhang, P, 2014)	0.78
"The aim of the present research work is to develop carbo-protein polymeric complex based sustain release microspheres of losartan potassium and investigate the ability of this dosage form to improve the flowability, compressibility and tableting properties of losartan potassium."	( Ionotropic Cross-linked Carbo-protein Micro Matrix System: An Approach for Improvement of Drug Release, Compaction and Tableting behavior of Losartan Potassium. Chakraborty, S; Ghosh, AK; Khandai, M, 2015)	0.83
" Downward dosage adjustment appeared essential and may have prevented hypotension-related pathology."	( Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker. Forsdyke, DR, 2015)	0.42
"The benefits of aggressive medication (the "J curve" phenomenon) being debated, the possibility of seasonal hypersensitivity, perhaps explicable in terms of differential signaling by countervailing receptors, should be taken into account when considering dosage adjustments in hypertensive subjects."	( Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker. Forsdyke, DR, 2015)	0.42
" Dose-response profile of resveratrol remains indeterminate and additional studies may be necessary to determine effective dosing in diabetes."	( Comparison of the anti-diabetic effects of resveratrol, gliclazide and losartan in streptozotocin-induced experimental diabetes. Bilgin, HM; Deniz Obay, B; Elbey, B; Şermet, A; Taşdemir, E; Yazgan, ÜC, 2015)	0.65
"Gavage is a widely performed technique for daily dosing in laboratory rodents."	( Voluntary Oral Administration of Losartan in Rats. Afonso, RA; Diogo, LN; Faustino, IV; Monteiro, EC; Pereira, SA; Santos, AI, 2015)	0.7
"Hypertensive patients who had not achieved their target blood pressure with at least 4 weeks of ARB therapy were randomly assigned to receive either a fixed-dose combination of losartan and HCTZ (losartan/HCTZ; n=110) or a combination of amlodipine and a typical ARB dosage (CCB/ARB; n=121) and followed for 24 weeks."	( Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients. Ishii, K; Ito, H; Iwakura, K; Kihara, H; Toh, N; Watanabe, H; Yoshikawa, J, 2016)	0.63
" Isolated primary adipocytes were incubated with different RAS blockers (aliskiren, captopril and losartan) in vitro for 24 h and lipolysis, lipogenesis and glucose oxidation capacities were determined in dose-response assays to a β-adrenergic agonist and to insulin."	( Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro. Andreotti, S; Caminhotto, Rde O; Campaãa, AB; Lima, FB; Sertié, RA, 2016)	0.65
" Free losartan could inhibit collagen, but it would cause hypotension at the dosage of 10 mg/kg/d."	( Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer. Gao, H; He, Q; Liu, J; Ma, L; Shi, K; Wang, Y; Xia, T; Yu, Q; Zhang, L; Zhang, Q, 2018)	2.4
"The REDEFINE is an investigator-initiated, multicenter, prospective, randomized, double-blind, placebo-controlled trial to study the effects of the angiotensin II receptor blocker losartan (target dosage of 150 mg once daily) in adult patients with TOF."	( Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system (REDEFINE) trial: Rationale and design of a randomized, double-blind, placebo-controlled clinical trial. Berbee, JK; Bokma, JP; Bouma, BJ; Kornaat, EM; Meijboom, FJ; Mulder, BJM; Post, MC; van Dijk, AP; van Melle, JP; Vliegen, HW; Winter, MM; Zwinderman, AH, 2017)	0.65
" The ANG II dose-response curve of the Af-Art was significantly enhanced in diabetic mice."	( Enhanced hemodynamic responses to angiotensin II in diabetes are associated with increased expression and activity of AT1 receptors in the afferent arteriole. Buggs, J; Jiang, S; Liu, R; Qu, HY; Song, J; Wang, L; Wei, J; Zhang, J, 2017)	0.46
"To evaluate the capacity for modafinil to be a perpetrator of metabolic drug-drug interactions by altering cytochrome P450 activity following a single dose and dosing to steady state."	( Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Mangoni, AA; Rowland, A; Sorich, MJ; van Dyk, M; Warncken, D, 2018)	0.48
"These data support consideration of the risk of clinically relevant metabolic drug-drug interactions perpetrated by modafinil when this drug is co-administered with drugs that are primarily cleared by CYP2C19 (single modafinil dose or steady state modafinil dosing) or CYP3A4 (steady state modafinil dosing only) catalysed metabolic pathways."	( Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Mangoni, AA; Rowland, A; Sorich, MJ; van Dyk, M; Warncken, D, 2018)	0.48
" The current study was designed to examine the treatment effects of losartan on obese ZSF-1 rats and to evaluate the impact of the onset of dosing on efficacy."	( Losartan improves renal function and pathology in obese ZSF-1 rats. Donnelly-Roberts, D; Gopalakrishnan, M; Leys, L; McGaraughty, S; Namovic, M; Nikkel, A; Su, Z; Widomski, D, 2018)	2.16
" Losartan (3, 10, 30 mg/kg) was dosed 3 or 9 weeks post-Unx and continued for 12 weeks."	( Losartan improves renal function and pathology in obese ZSF-1 rats. Donnelly-Roberts, D; Gopalakrishnan, M; Leys, L; McGaraughty, S; Namovic, M; Nikkel, A; Su, Z; Widomski, D, 2018)	2.83
"Controlled release dosage forms provide sustained therapeutics effects for prolonged period of time and improve patient compliance."	( Formulation and in vitro evaluation of directly compressed controlled release tablets designed from the Co-precipitates. Jan, SU; Khan, GM; Khan, KA; Mehsud, S; Rehman, A, 2018)	0.48
" The study focuses on the possibilities of controlled release of losartan potassium from microspheres in order to reduce the dosage frequency, and also provides information on the effect of the addition of excipients to the quality of the microspheres."	( FORMULATION AND EVALUATION OF MICROSPHERES CONTAINING LOSARTAN POTASSIUM BY SPRAY-DRYING TECHNIQUE. Balwierz, R; Jankowski, A; Jasinska, A; Marciniak, D; Pluta, J, 2016)	0.92
" The primary objective was to investigate the steroid dosage required to control brain oedema on the last day of RT in each arm."	( Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study. Carpentier, AF; Charissoux, M; Chinot, O; Cuzzubbo, S; Ducray, F; Hoang-Xuan, K; Le Rhun, E; Levy-Piedbois, C; Mandonnet, E; Portal, JJ; Psimaras, D; Quillien, V; Ricard, D; Sejalon, F; Thomas, L; Tibi, A; Ursu, R; Vicaut, E, 2019)	0.51
" No difference in the steroid dosage required to control brain oedema on the last day of RT, or one month after completion of RT, was seen between both arms."	( Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study. Carpentier, AF; Charissoux, M; Chinot, O; Cuzzubbo, S; Ducray, F; Hoang-Xuan, K; Le Rhun, E; Levy-Piedbois, C; Mandonnet, E; Portal, JJ; Psimaras, D; Quillien, V; Ricard, D; Sejalon, F; Thomas, L; Tibi, A; Ursu, R; Vicaut, E, 2019)	0.51
" Its dosage is related to the genetic characteristics of CYP2C9 enzymatic activity, which metabolizes losartan to its active form E-3174, responsible for the antihypertensive effect."	( [Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients]. Jalil Milad, R; Lagos Lucero, M; Pedreros-Rosales, C; Solari Gajardo, S, 2019)	0.97
" Furthermore, most preclinical antiepileptogenic studies lack information needed for translation, such as dose-blood level relationship, brain target engagement, and dose-response, and many use treatment parameters that cannot be applied clinically, for example, treatment initiation before or at the time of injury and dosing higher than tolerated human equivalent dosing."	( Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M, 2020)	0.56
" After the dietary intervention, animals were assigned to be treated with losartan at the 30 mg/kg/day dosage or kept untreated for an additional five weeks."	( Increased angiotensin II from adipose tissue modulates myocardial collagen I and III in obese rats. Cicogna, AC; Corrêa, CR; da Silva-Bertani, DCT; de Oliveira, EM; de Souza, SLB; de Tomasi, LC; Fernandes, T; Freire, PP; Mota, GAF; Padovani, CR; Sant'Ana, PG; Vileigas, DF, 2020)	0.79
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."	( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)	0.72
"Lisinopril and losartan manufacturer labels recommend twice-daily dosing (BID) if once-daily (QDay) is insufficient to lower blood pressure (BP)."	( Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. Botts, SR; Delate, T; Derington, CG; Kao, DP; King, JB; Kroehl, M; Trinkley, KE, 2020)	1.17
" Propensity scores were generated, and differences in BP and adverse events (angioedema, acute kidney injury, hyperkalemia) between BID/QDay groups were analyzed within dosing cohorts using inverse propensity of treatment-weighted regression models."	( Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. Botts, SR; Delate, T; Derington, CG; Kao, DP; King, JB; Kroehl, M; Trinkley, KE, 2020)	0.82
"Extemporaneous oral liquid preparations are commonly used when there is no commercially available dosage form for adjustable dosing."	( Investigation of the Physical, Chemical and Microbiological Stability of Losartan Potassium 5 mg/mL Extemporaneous Oral Liquid Suspension. Barlow, JW; Fitzgerald-Hughes, D; Foley, L; O'Connor, M; Ramtoola, Z; Toney, J, 2021)	0.85
" The results demonstrate that the codrug approach is a plausible strategy to develop a single molecular entity with combined AT1 and NEP activities, aiming at achieving improved pharmacokinetics, efficacy and dosage convenience, as well as reduced drug-drug interaction for hypertension patients."	( Design, synthesis and antihypertensive evaluation of novel codrugs with combined angiotensin type 1 receptor antagonism and neprilysin inhibition. Azevedo, H; Ferreira Junior, MA; Guimarães, CRW; Ishikawa, EE; Mascarello, A, 2021)	0.62
"To determine the dosage and beneficial effects of an IA injection of losartan on microfracture-mediated cartilage repair and normal cartilage homeostasis."	( The Beneficial Effect of an Intra-articular Injection of Losartan on Microfracture-Mediated Cartilage Repair Is Dose Dependent. Arner, JW; Gao, X; Huard, J; Logan, CA; Lowe, WR; Philippon, MJ; Ravuri, SK; Ruzbarsky, JJ; Scibetta, AC; Talwar, M; Utsunomiya, H; Zhu, D, 2021)	1.1
"An IA injection of losartan at an optimal dosage represents a novel microfracture enhancement therapy and warrants a clinical trial for future clinical applications."	( The Beneficial Effect of an Intra-articular Injection of Losartan on Microfracture-Mediated Cartilage Repair Is Dose Dependent. Arner, JW; Gao, X; Huard, J; Logan, CA; Lowe, WR; Philippon, MJ; Ravuri, SK; Ruzbarsky, JJ; Scibetta, AC; Talwar, M; Utsunomiya, H; Zhu, D, 2021)	1.2
" Losartan PK/PD studies in dogs revealed that a 10-fold-higher dose than typical antihypertensive dosing was required for blockade of monocyte migration."	( Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. Chow, L; Coy, JW; Das, S; Dow, SW; Gustafson, DL; Haines, L; Kurihara, JN; Mathias, A; Palmer, E; Regan, DP; Thamm, DH, 2022)	3.07
" We present the analysis of our single-center Marfan children and adolescents cohort to assess the influence of age, sex, degree of cardiovascular involvement and dosage on losartan effectivity."	( Initial Angiotensin Receptor Blocker Response in Young Marfan Patients Decreases After 3 Years of Treatment. Heno, J; Michel-Behnke, I; Pees, C, 2022)	0.91
" The classic treatment involves the simultaneous dosing of two antiplatelet drugs, aspirin and clopidogrel/prasugrel."	( Development of a DHA-Losartan hybrid as a potent inhibitor of multiple pathway-induced platelet aggregation. Choleva, M; Fragopoulou, E; Ganai, AM; Karpoormath, R; Kiriakidi, S; Mavromoustakos, T; Patha, TK; Tsiailanis, AD; Tzakos, AG; Vrettos, EI, 2022)	1.04
" Hypoglycemic activity of a combination of glimepiride + metformin was enhanced when losartan was co-administered as a single dosage schedule as well as a multiple dose schedule as indicated by a reduced blood glucose level and enhanced levels of insulin in rats as well as in rabbits."	( Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits. Anilkumar, KV; Nagaraju, B, )	0.61
"It can therefore be concluded, that in diabetics with hypertension as a comorbidity condition, co-administration of losartan with glimepiride + metformin should be avoided or the dosage of a combination of glimepiride + metformin needs to be tittered to avoid recurrence of hypoglycemic episodes."	( Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits. Anilkumar, KV; Nagaraju, B, )	0.59
" In current study, the potential of Raman spectroscopy has been investigated for qualitative and quantitative analysis of solid dosage form of Losartan potassium."	( Quantitative analysis of solid dosage forms of Losartan potassium by Raman spectroscopy. Akram, M; Irfan Majeed, M; Nawaz, H; Rashid, N; Saleem, M; Shafaq, S; Shakeel, S; Tariq, A; Ul Haq, A; Yaqoob, N; Zaki Abdul Bari, R; Zaman Nawaz, M, 2022)	1.18
"Controlled release matrices have predictable drug release kinetics, provide drugs for an extended period of time, and reduce dosing frequency with improved patient compliance as compared with conventional tablet dosage forms."	( Preparation of Losartan Potassium Controlled Release Matrices and In-Vitro Investigation Using Rate Controlling Agents. Ahmad, A; Al Hawaj, MA; Al Mohaini, M; Alsalman, AJ; Farid, A; Khan, GM; Khan, KA; Muzammal, M; Niazi, ZR; Shah, KU, 2022)	1.07

Role	Description
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
angiotensin receptor antagonist	A hormone antagonist that blocks angiotensin receptors.
endothelin receptor antagonist	A hormone antagonist that blocks endothelin receptors.
anti-arrhythmia drug	A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
biphenylyltetrazole	A member of the class of biphenyls that consists of a biphenyl ring system substituted by a tetrazole ring at an unspecified position.
imidazoles	A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Losartan Action Pathway	7	4
Renin-angiotensin pathway (COVID-19 Disease Map)	1	16

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	2.5119	0.0032	45.4673	12,589.2998	AID2517
Chain A, Cruzipain	Trypanosoma cruzi	Potency	39.8107	0.0020	14.6779	39.8107	AID1476
TDP1 protein	Homo sapiens (human)	Potency	18.8375	0.0008	11.3822	44.6684	AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	2.2880	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	0.1345	0.0002	21.2231	8,912.5098	AID743035
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	15.0916	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.2391	0.0002	14.3764	60.0339	AID720691
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	20.1363	0.0002	29.3054	16,493.5996	AID743069; AID743075; AID743080
G	Vesicular stomatitis virus	Potency	4.0893	0.0123	8.9648	39.8107	AID1645842
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	20.4223	0.0010	19.4141	70.9645	AID743094; AID743140
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	19.9526	0.0316	10.2792	39.8107	AID884; AID885
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	39.8107	0.2512	15.8432	39.8107	AID504327
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Interferon beta	Homo sapiens (human)	Potency	4.0893	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	4.0893	0.0123	8.9648	39.8107	AID1645842
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	14.1254	0.0096	10.5250	35.4813	AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	4.0893	0.0123	8.9648	39.8107	AID1645842
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	4.0893	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	9.0100	0.1100	7.1903	10.0000	AID1443990; AID1449628; AID1674183
Neprilysin	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0002	0.5422	6.7000	AID1515581
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	2.8820	0.0000	2.8005	10.0000	AID625248
Angiotensin-converting enzyme	Homo sapiens (human)	IC50 (µMol)	0.0190	0.0001	0.5336	10.0000	AID39767
Atrial natriuretic peptide receptor 3	Homo sapiens (human)	IC50 (µMol)	0.0018	0.0018	0.0019	0.0020	AID37844
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0190	0.0003	1.3833	8.4000	AID37698
Thromboxane A2 receptor	Homo sapiens (human)	IC50 (µMol)	20.0000	0.0011	0.7106	5.2000	AID1692292
Type-1A angiotensin II receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0247	0.0004	0.1555	3.8000	AID1292033; AID242697; AID37698; AID37699; AID37824; AID37830; AID37837; AID37841; AID37843; AID37844; AID37969; AID38298; AID39209; AID39351
Type-1A angiotensin II receptor	Rattus norvegicus (Norway rat)	Ki	0.0132	0.0002	0.1025	1.7000	AID1292033; AID239602; AID37973; AID39023; AID39331
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)	IC50 (µMol)	26.0000	0.0000	1.0680	10.0000	AID159637
Type-1B angiotensin II receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	1.7366	0.0004	0.1334	3.8000	AID242697; AID37673; AID37674; AID37686; AID37687; AID37696; AID37698; AID37699; AID37824; AID37830; AID37837; AID37841; AID37843; AID37844; AID37969; AID38298; AID39209; AID39350; AID39351
Type-1B angiotensin II receptor	Rattus norvegicus (Norway rat)	Ki	0.0212	0.0002	0.0521	1.1000	AID220640; AID239602; AID37705; AID37973; AID39331; AID39511
Adenosine receptor A2a	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0032	0.0012	0.4828	9.0000	AID1312219
Type-1 angiotensin II receptor	Homo sapiens (human)	IC50 (µMol)	0.0470	0.0002	0.0932	3.6000	AID1261025; AID1312219; AID1525517; AID39659; AID39663; AID644750; AID673037; AID673042; AID675418; AID736072; AID774875
Type-1 angiotensin II receptor	Homo sapiens (human)	Ki	0.0113	0.0002	0.1837	4.7000	AID1289936; AID1289953; AID1515578
Type-1 angiotensin II receptor	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	0.0250	0.0001	0.0913	0.5000	AID1897137; AID271575
Type-2 angiotensin II receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	28.0029	0.0010	0.3957	3.3000	AID38153; AID38161; AID38276; AID38284; AID39209; AID39351; AID39524; AID39631
Type-2 angiotensin II receptor	Rattus norvegicus (Norway rat)	Ki	0.0316	0.0001	0.0147	0.0316	AID39331
Type-2 angiotensin II receptor	Homo sapiens (human)	IC50 (µMol)	8.0038	0.0001	0.0289	0.2000	AID1277889; AID242700; AID644751; AID711559; AID774874
Squalene synthase	Rattus norvegicus (Norway rat)	Ki	0.0050	0.0050	0.6558	2.6000	AID1515578
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	IC50 (µMol)	26.0000	0.0000	1.1040	10.0000	AID159637
cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)	IC50 (µMol)	26.0000	0.0000	1.4651	10.0000	AID159637
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	IC50 (µMol)	26.0000	0.0000	1.1463	10.0000	AID159637
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)	IC50 (µMol)	13.0000	0.0000	2.0724	10.0000	AID159215
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)	IC50 (µMol)	13.0000	0.0003	1.9901	10.0000	AID159215
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	250.0000	0.0100	2.7656	10.0000	AID721754
Platelet glycoprotein VI	Homo sapiens (human)	IC50 (µMol)	4.0000	0.0020	1.5588	4.0000	AID1692277; AID1692278
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	IC50 (µMol)	1.1481	0.1047	2.7195	7.0795	AID977603
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	Ki	0.8900	0.0800	2.4688	9.8000	AID977604
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	35.0000	0.0040	1.9666	10.0000	AID1873192
Type-1 angiotensin II receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	0.0180	0.0180	0.0930	0.4300	AID39648
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	IC50 (µMol)	0.2884	0.0500	2.3797	9.7000	AID977600
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	Ki	0.1600	0.0440	1.3630	5.0000	AID977601
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Type-1A angiotensin II receptor	Rattus norvegicus (Norway rat)	Kd	0.0100	0.0000	0.0027	0.0100	AID412478
Type-1 angiotensin II receptor	Homo sapiens (human)	Kd	0.0033	0.0020	0.0039	0.0063	AID568789
Type-1 angiotensin II receptor	Oryctolagus cuniculus (rabbit)	Kd	0.0426	0.0001	0.0379	0.1995	AID1261034; AID307295; AID330797; AID37538; AID568923
Platelet glycoprotein VI	Homo sapiens (human)	Kd	170.0000	0.0411	0.0411	0.0411	AID1692279; AID459706
Type-1 angiotensin II receptor	Cavia porcellus (domestic guinea pig)	Kd	0.0126	0.0126	0.0126	0.0126	AID568923
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-dependent translocase ABCB1	Homo sapiens (human)	Km	245.0667	0.0140	3.7172	10.0000	AID679234; AID679255; AID681163
Thromboxane A2 receptor	Homo sapiens (human)	MEC	0.5000	0.5000	2.0000	5.0000	AID1692291
Type-1 angiotensin II receptor	Homo sapiens (human)	Affinity	0.0064	0.0005	0.0315	0.2300	AID243379
Type-1 angiotensin II receptor	Homo sapiens (human)	Kb	0.0060	0.0040	0.0060	0.0090	AID238111; AID263157; AID263158
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
kidney development	Neprilysin	Homo sapiens (human)
placenta development	Neprilysin	Homo sapiens (human)
proteolysis	Neprilysin	Homo sapiens (human)
peptide metabolic process	Neprilysin	Homo sapiens (human)
learning or memory	Neprilysin	Homo sapiens (human)
substance P catabolic process	Neprilysin	Homo sapiens (human)
bradykinin catabolic process	Neprilysin	Homo sapiens (human)
sensory perception of pain	Neprilysin	Homo sapiens (human)
protein catabolic process	Neprilysin	Homo sapiens (human)
lung development	Neprilysin	Homo sapiens (human)
hormone catabolic process	Neprilysin	Homo sapiens (human)
response to estrogen	Neprilysin	Homo sapiens (human)
creatinine metabolic process	Neprilysin	Homo sapiens (human)
amyloid-beta metabolic process	Neprilysin	Homo sapiens (human)
positive regulation of neurogenesis	Neprilysin	Homo sapiens (human)
neuropeptide processing	Neprilysin	Homo sapiens (human)
cellular response to cytokine stimulus	Neprilysin	Homo sapiens (human)
cellular response to UV-A	Neprilysin	Homo sapiens (human)
cellular response to UV-B	Neprilysin	Homo sapiens (human)
replicative senescence	Neprilysin	Homo sapiens (human)
amyloid-beta clearance	Neprilysin	Homo sapiens (human)
amyloid-beta clearance by cellular catabolic process	Neprilysin	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Neprilysin	Homo sapiens (human)
protein processing	Neprilysin	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
response to hypoxia	Angiotensin-converting enzyme	Homo sapiens (human)
kidney development	Angiotensin-converting enzyme	Homo sapiens (human)
blood vessel remodeling	Angiotensin-converting enzyme	Homo sapiens (human)
angiotensin maturation	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of renal output by angiotensin	Angiotensin-converting enzyme	Homo sapiens (human)
neutrophil mediated immunity	Angiotensin-converting enzyme	Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class I	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensin	Angiotensin-converting enzyme	Homo sapiens (human)
proteolysis	Angiotensin-converting enzyme	Homo sapiens (human)
spermatogenesis	Angiotensin-converting enzyme	Homo sapiens (human)
female pregnancy	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of blood pressure	Angiotensin-converting enzyme	Homo sapiens (human)
male gonad development	Angiotensin-converting enzyme	Homo sapiens (human)
response to xenobiotic stimulus	Angiotensin-converting enzyme	Homo sapiens (human)
embryo development ending in birth or egg hatching	Angiotensin-converting enzyme	Homo sapiens (human)
post-transcriptional regulation of gene expression	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of gene expression	Angiotensin-converting enzyme	Homo sapiens (human)
substance P catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
bradykinin catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of smooth muscle cell migration	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of vasoconstriction	Angiotensin-converting enzyme	Homo sapiens (human)
animal organ regeneration	Angiotensin-converting enzyme	Homo sapiens (human)
response to nutrient levels	Angiotensin-converting enzyme	Homo sapiens (human)
response to lipopolysaccharide	Angiotensin-converting enzyme	Homo sapiens (human)
mononuclear cell proliferation	Angiotensin-converting enzyme	Homo sapiens (human)
response to laminar fluid shear stress	Angiotensin-converting enzyme	Homo sapiens (human)
angiotensin-activated signaling pathway	Angiotensin-converting enzyme	Homo sapiens (human)
vasoconstriction	Angiotensin-converting enzyme	Homo sapiens (human)
hormone metabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
hormone catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
eating behavior	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of apoptotic process	Angiotensin-converting enzyme	Homo sapiens (human)
peptide catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of vasoconstriction	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of glucose import	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of synaptic plasticity	Angiotensin-converting enzyme	Homo sapiens (human)
lung alveolus development	Angiotensin-converting enzyme	Homo sapiens (human)
amyloid-beta metabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
arachidonic acid secretion	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of neurogenesis	Angiotensin-converting enzyme	Homo sapiens (human)
heart contraction	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of angiotensin metabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
hematopoietic stem cell differentiation	Angiotensin-converting enzyme	Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesis	Angiotensin-converting enzyme	Homo sapiens (human)
cellular response to glucose stimulus	Angiotensin-converting enzyme	Homo sapiens (human)
response to dexamethasone	Angiotensin-converting enzyme	Homo sapiens (human)
cell proliferation in bone marrow	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of calcium ion import	Angiotensin-converting enzyme	Homo sapiens (human)
response to thyroid hormone	Angiotensin-converting enzyme	Homo sapiens (human)
blood vessel diameter maintenance	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of hematopoietic stem cell proliferation	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of gap junction assembly	Angiotensin-converting enzyme	Homo sapiens (human)
cellular response to aldosterone	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylation	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of systemic arterial blood pressure	Angiotensin-converting enzyme	Homo sapiens (human)
skeletal system development	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
angiogenesis	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
blood vessel remodeling	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
osteoclast proliferation	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
response to ischemia	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
regulation of blood pressure	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
regulation of osteoblast proliferation	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
positive regulation of urine volume	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
positive regulation of nitric-oxide synthase activity	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
signal transduction	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
smooth muscle contraction	Thromboxane A2 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Thromboxane A2 receptor	Homo sapiens (human)
response to nutrient	Thromboxane A2 receptor	Homo sapiens (human)
response to xenobiotic stimulus	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of blood coagulation	Thromboxane A2 receptor	Homo sapiens (human)
response to testosterone	Thromboxane A2 receptor	Homo sapiens (human)
thromboxane A2 signaling pathway	Thromboxane A2 receptor	Homo sapiens (human)
response to ethanol	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of angiogenesis	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of smooth muscle contraction	Thromboxane A2 receptor	Homo sapiens (human)
cellular response to lipopolysaccharide	Thromboxane A2 receptor	Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesis	Thromboxane A2 receptor	Homo sapiens (human)
inflammatory response	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of blood pressure	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Thromboxane A2 receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Thromboxane A2 receptor	Homo sapiens (human)
cAMP catabolic process	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
signal transduction	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
sensory perception of smell	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
regulation of protein kinase A signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
cellular response to xenobiotic stimulus	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
cAMP-mediated signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
regulation of cell growth	Type-1 angiotensin II receptor	Homo sapiens (human)
kidney development	Type-1 angiotensin II receptor	Homo sapiens (human)
renin-angiotensin regulation of aldosterone production	Type-1 angiotensin II receptor	Homo sapiens (human)
maintenance of blood vessel diameter homeostasis by renin-angiotensin	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensin	Type-1 angiotensin II receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Type-1 angiotensin II receptor	Homo sapiens (human)
Rho protein signal transduction	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of vasoconstriction	Type-1 angiotensin II receptor	Homo sapiens (human)
calcium-mediated signaling	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of phospholipase A2 activity	Type-1 angiotensin II receptor	Homo sapiens (human)
low-density lipoprotein particle remodeling	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of renal sodium excretion	Type-1 angiotensin II receptor	Homo sapiens (human)
angiotensin-activated signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of cell population proliferation	Type-1 angiotensin II receptor	Homo sapiens (human)
symbiont entry into host cell	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of inflammatory response	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of inflammatory response	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of protein metabolic process	Type-1 angiotensin II receptor	Homo sapiens (human)
cell chemotaxis	Type-1 angiotensin II receptor	Homo sapiens (human)
phospholipase C-activating angiotensin-activated signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
blood vessel diameter maintenance	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of CoA-transferase activity	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Type-1 angiotensin II receptor	Homo sapiens (human)
inflammatory response	Type-1 angiotensin II receptor	Homo sapiens (human)
blood vessel remodeling	Type-2 angiotensin II receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by circulatory renin-angiotensin	Type-2 angiotensin II receptor	Homo sapiens (human)
angiotensin-mediated vasodilation involved in regulation of systemic arterial blood pressure	Type-2 angiotensin II receptor	Homo sapiens (human)
brain renin-angiotensin system	Type-2 angiotensin II receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messenger	Type-2 angiotensin II receptor	Homo sapiens (human)
brain development	Type-2 angiotensin II receptor	Homo sapiens (human)
regulation of blood pressure	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of heart rate	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of cell growth	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of phosphoprotein phosphatase activity	Type-2 angiotensin II receptor	Homo sapiens (human)
regulation of metanephros size	Type-2 angiotensin II receptor	Homo sapiens (human)
exploration behavior	Type-2 angiotensin II receptor	Homo sapiens (human)
nitric oxide-cGMP-mediated signaling	Type-2 angiotensin II receptor	Homo sapiens (human)
angiotensin-activated signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
vasodilation	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of blood vessel endothelial cell migration	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of neurotrophin TRK receptor signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
neuron apoptotic process	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of metanephric glomerulus development	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of branching involved in ureteric bud morphogenesis	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
inflammatory response	Type-2 angiotensin II receptor	Homo sapiens (human)
neutrophil homeostasis	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cAMP catabolic process	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
neutrophil chemotaxis	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
positive regulation of type II interferon production	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
positive regulation of interleukin-2 production	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
T cell receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
leukocyte migration	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cellular response to lipopolysaccharide	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cellular response to xenobiotic stimulus	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cellular response to epinephrine stimulus	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
regulation of cardiac muscle cell contraction	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
negative regulation of relaxation of cardiac muscle	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cAMP-mediated signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cAMP catabolic process	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
cAMP-mediated signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
regulation of heart rate	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP catabolic process	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of heart rate	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of type II interferon production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of interleukin-2 production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of interleukin-5 production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of peptidyl-serine phosphorylation	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of heart contraction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
T cell receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
establishment of endothelial barrier	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
adrenergic receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of cardiac muscle cell contraction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conduction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of relaxation of cardiac muscle	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP-mediated signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
angiogenesis	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of cell adhesion	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of angiogenesis	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cellular response to insulin stimulus	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of cell adhesion mediated by integrin	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of lipid catabolic process	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cAMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
oocyte maturation	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
lipid metabolic process	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
response to xenobiotic stimulus	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cAMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cGMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
regulation of meiotic nuclear division	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of apoptotic process	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of vascular permeability	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
positive regulation of vascular permeability	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
steroid hormone mediated signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of cAMP-mediated signaling	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
positive regulation of oocyte development	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
regulation of ribonuclease activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cellular response to cGMP	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
apoptotic signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
amino acid import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
proton transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
positive regulation of platelet aggregation	Platelet glycoprotein VI	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
platelet activation	Platelet glycoprotein VI	Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
collagen-activated signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
platelet aggregation	Platelet glycoprotein VI	Homo sapiens (human)
immune response-regulating signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
lipid transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid biosynthetic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate metabolic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transmembrane transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transepithelial transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
renal urate salt excretion	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
export across plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
cellular detoxification	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylserine binding	Neprilysin	Homo sapiens (human)
endopeptidase activity	Neprilysin	Homo sapiens (human)
metalloendopeptidase activity	Neprilysin	Homo sapiens (human)
protein binding	Neprilysin	Homo sapiens (human)
exopeptidase activity	Neprilysin	Homo sapiens (human)
zinc ion binding	Neprilysin	Homo sapiens (human)
peptide binding	Neprilysin	Homo sapiens (human)
protein homodimerization activity	Neprilysin	Homo sapiens (human)
oligopeptidase activity	Neprilysin	Homo sapiens (human)
cardiolipin binding	Neprilysin	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
endopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
carboxypeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
metalloendopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
calmodulin binding	Angiotensin-converting enzyme	Homo sapiens (human)
peptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
metallopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
exopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
tripeptidyl-peptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
peptidyl-dipeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
zinc ion binding	Angiotensin-converting enzyme	Homo sapiens (human)
chloride ion binding	Angiotensin-converting enzyme	Homo sapiens (human)
mitogen-activated protein kinase kinase binding	Angiotensin-converting enzyme	Homo sapiens (human)
bradykinin receptor binding	Angiotensin-converting enzyme	Homo sapiens (human)
mitogen-activated protein kinase binding	Angiotensin-converting enzyme	Homo sapiens (human)
metallodipeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
heterocyclic compound binding	Angiotensin-converting enzyme	Homo sapiens (human)
protein binding	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
G protein-coupled peptide receptor activity	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
natriuretic peptide receptor activity	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
peptide hormone binding	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
chloride ion binding	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
peptide binding	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
hormone binding	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
protein homodimerization activity	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
thromboxane A2 receptor activity	Thromboxane A2 receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Thromboxane A2 receptor	Homo sapiens (human)
protein binding	Thromboxane A2 receptor	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
cAMP binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
metal ion binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
angiotensin type I receptor activity	Type-1 angiotensin II receptor	Homo sapiens (human)
angiotensin type II receptor activity	Type-1 angiotensin II receptor	Homo sapiens (human)
protein binding	Type-1 angiotensin II receptor	Homo sapiens (human)
bradykinin receptor binding	Type-1 angiotensin II receptor	Homo sapiens (human)
protein heterodimerization activity	Type-1 angiotensin II receptor	Homo sapiens (human)
angiotensin type II receptor activity	Type-2 angiotensin II receptor	Homo sapiens (human)
protein binding	Type-2 angiotensin II receptor	Homo sapiens (human)
receptor antagonist activity	Type-2 angiotensin II receptor	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
calcium channel regulator activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cAMP binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
gamma-tubulin binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
transmembrane transporter binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
metal ion binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
metal ion binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
calcium channel regulator activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
enzyme binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
signaling receptor regulator activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
beta-2 adrenergic receptor binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
transmembrane transporter binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
metal ion binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
ATPase binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
scaffold protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
heterocyclic compound binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
protein binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
protein kinase B binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
metal ion binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
protein binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
nuclear estrogen receptor activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
metal ion binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
estrogen binding	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane signaling receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
protein binding	Platelet glycoprotein VI	Homo sapiens (human)
collagen binding	Platelet glycoprotein VI	Homo sapiens (human)
signaling receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
collagen receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
protein tyrosine kinase binding	Platelet glycoprotein VI	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cytoplasm	Neprilysin	Homo sapiens (human)
early endosome	Neprilysin	Homo sapiens (human)
trans-Golgi network	Neprilysin	Homo sapiens (human)
plasma membrane	Neprilysin	Homo sapiens (human)
brush border	Neprilysin	Homo sapiens (human)
focal adhesion	Neprilysin	Homo sapiens (human)
synaptic vesicle	Neprilysin	Homo sapiens (human)
cell surface	Neprilysin	Homo sapiens (human)
membrane	Neprilysin	Homo sapiens (human)
axon	Neprilysin	Homo sapiens (human)
dendrite	Neprilysin	Homo sapiens (human)
secretory granule membrane	Neprilysin	Homo sapiens (human)
cytoplasmic vesicle	Neprilysin	Homo sapiens (human)
neuronal cell body	Neprilysin	Homo sapiens (human)
neuron projection terminus	Neprilysin	Homo sapiens (human)
membrane raft	Neprilysin	Homo sapiens (human)
synapse	Neprilysin	Homo sapiens (human)
extracellular exosome	Neprilysin	Homo sapiens (human)
presynapse	Neprilysin	Homo sapiens (human)
plasma membrane	Neprilysin	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme	Homo sapiens (human)
extracellular region	Angiotensin-converting enzyme	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme	Homo sapiens (human)
lysosome	Angiotensin-converting enzyme	Homo sapiens (human)
endosome	Angiotensin-converting enzyme	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
external side of plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
basal plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
brush border membrane	Angiotensin-converting enzyme	Homo sapiens (human)
extracellular exosome	Angiotensin-converting enzyme	Homo sapiens (human)
sperm midpiece	Angiotensin-converting enzyme	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
plasma membrane	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
extracellular exosome	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
protein-containing complex	Atrial natriuretic peptide receptor 3	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
acrosomal vesicle	Thromboxane A2 receptor	Homo sapiens (human)
plasma membrane	Thromboxane A2 receptor	Homo sapiens (human)
nuclear speck	Thromboxane A2 receptor	Homo sapiens (human)
plasma membrane	Thromboxane A2 receptor	Homo sapiens (human)
nucleoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
plasma membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
ruffle membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
nucleus	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)
Golgi membrane	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
plasma membrane	Type-1 angiotensin II receptor	Homo sapiens (human)
membrane	Type-1 angiotensin II receptor	Homo sapiens (human)
plasma membrane	Type-1 angiotensin II receptor	Homo sapiens (human)
plasma membrane	Type-2 angiotensin II receptor	Homo sapiens (human)
plasma membrane	Type-2 angiotensin II receptor	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
centrosome	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
synaptic vesicle	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
postsynaptic density	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
Z disc	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
dendritic spine	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
excitatory synapse	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
gamma-tubulin complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
voltage-gated calcium channel complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
nucleus	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)
extracellular space	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
cilium	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
nucleus	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)
centrosome	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
plasma membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
apical plasma membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
voltage-gated calcium channel complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
calcium channel complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
nucleus	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
endoplasmic reticulum	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
Golgi apparatus	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cytosol	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
membrane	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
guanyl-nucleotide exchange factor complex	cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)
cytosol	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
membrane	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
cytosol	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane raft	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Platelet glycoprotein VI	Homo sapiens (human)
cell surface	Platelet glycoprotein VI	Homo sapiens (human)
extracellular exosome	Platelet glycoprotein VI	Homo sapiens (human)
tetraspanin-enriched microdomain	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (587)

Assay ID	Title	Year	Journal	Article
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID39659	In vitro inhibitory activity against angiotensin II receptor type 1, in human adrenal membrane preparations.	1995	Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19	Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.
AID717894	Displacement of [125I]Angiotensin-2 from angiotensin AT1 receptor in Sprague-Dawley rat VSMC after 60 mins by gamma counting	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID481444	Octanol-water partition coefficient, log P of the compound	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1312219	Displacement of [125I-Sar1-Ile8]Ang2 from human AT1 receptor expressed in HEK293 cell membrane incubated for 1 hr by gamma counting method	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Exploring new scaffolds for angiotensin II receptor antagonism.
AID174246	% decrease in blood pressure after 4 hours at a dose of 10 mg/kg in male rats by using Renal artery hypertensive model	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID168380	In vitro antihypertensive activity in renal hypertensive rat at 0.5 mg/kg after 24 hr of oral administration.	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID167567	Inhibition of angiotensin II induced contraction in rabbit aortic strips after 60 minutes contact with the compound	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1214180	Half life in human plasma expressing CYP2C81/1 polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID263159	Antihypertrophic activity in Wistar rat at 21.3 mg/kg, ip	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1214190	Half life in human plasma expressing CYP2C8*4 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214228	Cmax in men plasma at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID167384	pA2 value was determined by the compound's ability to antagonize the AII-induced contraction of rabbit aorta rings.	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Nonpeptide angiotensin II receptor antagonists: synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1- yl]phenyl]methyl]imidazole derivatives and their in vitro activity.
AID1214193	AUC in human plasma expressing CYP2C91/1 polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID174239	% decrease in blood pressure after 24 hours at a dose of 10 mg/kg in male rats by using Furosemide-treated spontaneous hypertensive model	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID1058232	Toxicity in renal spontaneously hypertensive rat model assessed as reduction of heart rate at 20 mg/kg, po measured at 8 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID307294	Displacement of [125I]angiotensin-2 from bovine adrenal cortex AT1 receptor	2007	Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10	Synthesis and biological activity of 2-alkylbenzimidazoles bearing a N-phenylpyrrole moiety as novel angiotensin II AT1 receptor antagonists.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID236277	Volume distribution was determined	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID39801	Evaluation of Angiotensin II antagonistic activity by displacement of [125I]-Sar Ile-AII at the rabbit aorta Angiotensin II receptor, type 1	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
AID1692294	Modulation of GP6 in human platelet-rich plasma reduction in collagen type 1-induced platelet aggregation preincubated for 15 mins followed by collagen-1 stimulation by optical aggregometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID671498	Antihypertensive activity in rat assessed as change in diastolic arterial pressure at 20 mg/kg, iv measured after 8 hrs (Rvb = 0.11 +/- 2.3 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID39808	In vitro antagonist activity against angiotensin II receptor type 1 in rabbit aorta using [125I]-Sar, Ile AII.	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1214232	Tmax in men plasma at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID717888	Antihypertensive activity in SHR rat assessed as decrease in mean arterial pressure at 10 mg/kg, po	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID446299	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood K- level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID330799	AUC in Sprague-Dawley rat at 3 mg/kg, iv	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID39350	Binding affinity against angiotensin II receptor in rat smooth muscle cell preparations	1991	Journal of medicinal chemistry, Oct, Volume: 34, Issue:10	Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives.
AID167369	Compound was tested for its antagonistic activity against angiotensin II-induced contractions in rabbit aorta	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID183922	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 5 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1058233	Toxicity in renal spontaneously hypertensive rat model assessed as reduction of heart rate at 20 mg/kg, po measured at 6 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID1339062	Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of CVX-induced platelet aggregation preincubated for 5 mins followed by CVX addition measured after 5 mins by turbidimetric method
AID1058246	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of systolic arterial pressure at 20 mg/kg, po measured at 6 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID1216824	Drug metabolism assessed as human recombinant CYP2C9-mediated semicarbazide adducts formation at 20 uM by LCMS-IT-TOF method	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID39807	In vitro antagonist activity against angiotensin II receptor type 1 in rabbit aorta using [125I]-Sar, Ile AII.	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.
AID37699	Inhibitory concentration was evaluated by measuring displacement of [3H]AII from rat liver Angiotensin II receptor, type 1	1996	Journal of medicinal chemistry, May-24, Volume: 39, Issue:11	Diphenylpropionic acids as new AT1 selective angiotensin II antagonists.
AID37698	Inhibitory concentration that gives 50% displacement of specific binding at labeled angiotensin II type 1 receptor in rat adrenal cortical membranes.	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID229950	IC50 ratio of AT2 receptor from rabbit aorta to AT1 receptor from rat midbrain.	1995	Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19	Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.
AID183751	Inhibitory activity against AII-Induced Pressor response at 10 mg/Kg at 6 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1129839	Displacement of [125I]-angiotensin 2 from angiotensin AT1 receptor in VSMC of Sprague-Dawley rat thoracic aorta after 60 mins by gamma-counting	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Design, synthesis and biological evaluation of new 5-nitro benzimidazole derivatives as AT1 antagonists with anti-hypertension activities.
AID671492	Antihypertensive activity in rat assessed as change in systolic arterial pressure at 20 mg/kg, iv measured after 4 hrs (Rvb = 4.72 +/- 3.4 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID1737443	Cytotoxicity against human HS5 cells assessed as cell death at 10 uM measured after 72 hrs by Propidium iodide stain based FACS analysis	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID39498	In vitro inhibitory activity against angiotensin II rabbit aorta AT1 receptor using radioligand [125I]-Sar Ile-AII	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID39631	In vitro inhibitory activity against angiotensin II rat midbrain AT2 receptor using radioligand [125I]-Sar Ile-AII	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID39351	Inhibition of radioligand [3H]angiotensin II binding to angiotensin II receptor of rat adrenal cortical membrane	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.
AID39648	Inhibition of [125I]angiotensin binding to a guinea pig adrenal membrane preparation which corresponds to Angiotensin II receptor, type 1	1993	Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9	New nonpeptide angiotensin II receptor antagonists. 3. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)pyridine derivatives.
AID39209	Displacement of [3H]-AII from the Angiotensin II receptor isolated from the liver of rats	1995	Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23	4-(Heteroarylthio)-2-biphenylyltetrazoles as nonpeptide angiotensin II antagonists.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID647625	Antioxidant activity assessed as trolox equivalent of ABTS radical scavenging activity relative to control	2012	European journal of medicinal chemistry, Apr, Volume: 50	New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: Ester, amide and amine linkers.
AID183065	Inhibition of AII pressor response expressed as peak inhibition in conscious normotensive rats at 1 mg/Kg i.v.	1993	Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17	Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.
AID364010	Antihypertensive activity against desoxycortisone-induced hypertension in rat assessed as decrease in mean arterial blood pressure at 5 mg/kg, ip	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Angiotensin II--AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives.
AID446293	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood LDH level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID364008	Antagonist activity at AT1 receptor in rat aorta	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Angiotensin II--AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives.
AID184398	Peak percent inhibition of Angiotensin II pressor response in conscious, normotensive rats at 3 mg/kg po (no. of animals treated)	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
AID271580	Terminal half life in Sprague-Dawley rat at 3 mg/kg, iv	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
AID37969	Tested for inhibitory concentration against AT1 receptor binding affinity in rat liver	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoro
AID717882	Antihypertensive activity in Sprague-Dawley rat renal hypertensive model assessed as decrease in mean arterial pressure at 10 mg/kg, po	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID1579127	Inhibition of [125I] Ang2 binding to AT1 receptor in Sprague-Dawley rat VSMC after 150 mins by gamma-counter method	2019	European journal of medicinal chemistry, Nov-01, Volume: 181	Design, synthesis and biological evaluation of AT
AID1214197	Clearance in human plasma expressing CYP2C91/1 polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID175104	Time to produce onset of action for inhibition of pressor response in conscious, normotensive rats 0.3 mg/kg po (no. of animals treated)	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
AID673042	Inhibition of angiotensin AT1 receptor	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.
AID1679337	Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as serum creatinine level at 20 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dose by ELISA (Rvb = 38.86 +/- 8.86 mmol/L)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
AID1214207	Clearance in human plasma expressing CYP2C9*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID125514	The compound was evaluated for the percentage of inhibition of A II pressor response in rhesus monkey for peroral administration.	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID127111	Inhibition of AII pressor response by the compound in conscious, normotensive monkey, at 10 (mg/kg) peroral dose	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID159215	Inhibition of guinea pig ventricular Phosphodiesterase 3 (PDE 3)	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds.
AID242919	Competitive antagonism of Angiotensin II receptor in endothelium removed isolated rat aortic ring	2005	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17	Design, synthesis, and evaluation of novelly substituted benzimidazole compounds as angiotensin II receptor antagonists.
AID1487363	Antagonist activity at human AT1 receptor expressed in CHO cells assessed as reduction in angiotensin 2-induced inositol phosphate accumulation by measuring dissociation rate constant preincubated with cells followed by compound washout and subsequent add	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID181931	Percent inhibition of angiotensin II (0.1 ug/kg iv) -induced pressor response 3h after administration of test compounds (1 mg/kg po) in conscious male Sprague-Dawley rats	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1679335	Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as urinary albumin level at 20 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dose by ELISA (Rvb = 244.98 +/- 44.98 ug)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
AID446289	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood cholesterol level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID172095	Change in mean arterial blood pressure in renal artery ligated hypertensive rats, orally dosed at 1 mg/kg	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.
AID1552806	Antagonist activity at AT1 receptor in rat portal vein assessed as reduction in potassium-induced contraction at 10 uM incubated for 1 min relative to control	2019	Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17	Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators.
AID37686	Concentration required to inhibit binding of radioligand [125I]AII to angiotensin II receptor, type 1 in rat adrenal glomerulosa tissue	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Nonpeptide angiotensin II receptor antagonists: synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1- yl]phenyl]methyl]imidazole derivatives and their in vitro activity.
AID1873192	Inhibition of ABCG2 (unknown origin) expressed in human HEK293-A cells membrane vesicles assessed inhibition of ABCG2-mediated urate transport activity by rapid filtration technique	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID774874	Displacement of [125I]-Sar1Ile8-angiotensin 2 from angiotensin 2 AT2 receptor (unknown origin) after 180 mins by gamma counting analysis	2013	European journal of medicinal chemistry, Nov, Volume: 69	Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.
AID192970	The compound was evaluated for the percentage of inhibition of A II pressor response in rat for intravenous administration	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID679610	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 uM, Losartan: 50 uM) in MDR1-expressing LLC-PK1 cells	2002	Life sciences, Feb-15, Volume: 70, Issue:13	Interaction of digoxin with antihypertensive drugs via MDR1.
AID656177	Acute toxicity in intragastrically dosed ICR rat	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.
AID183747	Inhibitory activity against AII-Induced Pressor response at 1 mg/Kg at 3 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1214187	Clearance in human plasma expressing CYP2C8*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID168381	In vitro antihypertensive activity in renal hypertensive rat at 0.5 mg/kg after 5 hr of oral administration.	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID675418	Displacement of 125[I-Sar1-Ile8]ANG II from human AT1 receptor expressed in HEK293 membranes after 1 hr by gamma counting	2012	European journal of medicinal chemistry, Sep, Volume: 55	The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives.
AID37673	Activity against high affinity Angiotensin II receptor, type 1 was measured from the ability to inhibit [125I]angiotensin II binding to rat uterine membrane.	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists.
AID37696	Inhibition of [125I]angiotensin-II binding to the angiotensin II receptor type 1 in rat uterine membranes	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists.
AID174245	% decrease in blood pressure after 4 hours at a dose of 10 mg/kg in male rats by using Furosemide-treated spontaneous hypertensive model	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1214226	AUC in men plasma at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID568792	Antihypertensive activity in iv dosed renal hypertensive rat model	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID977603	pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID330796	Displacement of [125I]Sar1,Ile8-Ang2 from AT1 receptor in Wistar rat hepatic membrane	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID1679336	Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as creatinine clearance rate at 20 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dose by ELISA (Rvb = 120.77 +/- 20.77 uL/min)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
AID39511	Displacement of [125I]-Sar1-Ile8-A II from rat adrenal Angiotensin-1 (AT-1) receptor	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.
AID1692290	Inhibition of [3H]-U46619 binding to TxA2 receptor in human platelet suspension at 0.7 uM incubated for 30 mins by liquid scintillation counting method relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID183756	Inhibitory activity against AII-Induced Pressor response at 3 mg/Kg at 1 hr	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID645200	Antihypertensive activity in iv dosed pithed rat model assessed as inhibition of angiotensin 2-induced pressor response by gould pressure transducer-coupled grass polygraphy	2012	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4	Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.
AID446271	Antihypertensive activity in Wistar rat assessed as normalization of L-NAME-induced aorta thickness at 10 mg/kg/day, po for 4 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID166799	In vitro functional potency by antagonism of angiotensin II induced contraction of isolated rabbit aorta	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Dihydropyrimidine angiotensin II receptor antagonists.
AID1261049	Toxicity in Kunming mouse at 1.8 g/kg, po assessed as mortality after 2 weeks	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID39767	Inhibitory activity against angiotensin I converting enzyme (ACE)	2000	Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3	Protease inhibitors: current status and future prospects.
AID247113	Maximal effect produced by the drug in human	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID671491	Antihypertensive activity in rat assessed as change in systolic arterial pressure at 20 mg/kg, iv measured after 2 hrs (Rvb = 8.20 +/- 6.2 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID271583	Tmax in Sprague-Dawley rat at 30 mg/kg, po	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
AID179579	In vitro antagonistic activity by displacement of [125I]-Sar1-Ile8-A II at the rat adrenal cortical aorta AT1 receptor	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
AID37538	Compound was evaluated for in vitro potency against angiotensin II receptor, type 1 in isolated rabbit aorta; value ranges from 8.27-8.70	1992	Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20	Discovery of a novel class of orally active, non-peptide angiotensin II antagonists.
AID1674183	Inhibition of human BSEP expressed in HEK293 cell membrane vesicles assessed as reduction in 3H-TCA uptake incubated for 5 mins by radiodetection method	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID977601	Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID127113	Inhibition of AII pressor response by the compound in conscious, normotensive monkey, at 3 (mg/kg) peroral dose; NA= Not active	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID238111	Antagonistic activity against Angiotensin II receptor type 1 in presence of eserin	2004	Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23	NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID37689	Inhibition of specific binding of [125I]angiotensin-II to angiotensin 1 receptor in rat lung membrane preparation	1993	Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25	6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships.
AID243379	Binding affinity for AT1 receptor	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID644750	Displacement of [125I]Sar1 Ile8-Ang 2 from angiotensin 2 AT1 receptor after 180 mins by gamma counting	2012	European journal of medicinal chemistry, Mar, Volume: 49	Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.
AID37676	Binding affinity for Angiotensin II receptor, type 1 measured by ability to displace [125I]- A II from its specific binding site in rat liver membrane	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
AID671493	Antihypertensive activity in rat assessed as change in systolic arterial pressure at 20 mg/kg, iv measured after 6 hrs (Rvb = 0.92 +/- 1.1 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID1261052	Toxicity in orally dosed Kunming mouse assessed as mortality after 2 weeks	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center.
AID37837	Inhibitory activity against Angiotensin II receptor type 1 in rat adrenal membrane	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID271575	Antagonist activity against AT1 receptor assessed as inhibition of Ang2-induced rabbit aortic strip contraction	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
AID176515	Compound was evaluated by intravenous administration to conscious rats for inhibition of pressor response induced by infusion of AII (n=3-10)	1993	Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9	New nonpeptide angiotensin II receptor antagonists. 3. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)pyridine derivatives.
AID1214211	Clearance in women plasma at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID127110	Inhibition of AII pressor response by the compound in conscious, normotensive monkey, at 0.3 (mg/kg) intravenous dose	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1679312	Antifibrotic activity in mouse MES-13 cells assessed as decrease in glucose-induced fibronectin protein level pretreated with glucose for 48 hrs followed by compound treatment relative to control	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
AID192971	The compound was evaluated for the percentage of inhibition of A II pressor response in rat for peroral administration.	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID383271	Antihypertensive effect in spontaneous hypertensive Wistar rat model assessed as maximum decrease in diastolic arterial pressure at 1.0 mg/kg, po after 80 mins	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Synthesis and antihypertensive effects of new methylthiomorpholinphenol derivatives.
AID237981	Percentage modification of drug adsorbed after administration to human	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID486402	Displacement of [125I]angiotensin 2 from AT1 receptor in rat liver membrane after 2 hrs by gamma counting	2010	Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12	Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.
AID37843	Inhibitory concentration against binding of [125I]angiotensin II to rat liver expressing Angiotensin II receptor	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoro
AID717885	Antihypertensive activity in SHR rat assessed as decrease in mean arterial pressure at 10 mg/kg, po measured for 7 hrs after dosing	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID37973	Displacement of [3H]angiotensin II from Angiotensin II type 1 receptor in rat adrenal cortical membrane	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	N-3-substituted pyrimidinones as potent, orally active, AT1 selective angiotensin II receptor antagonists.
AID38283	In vitro inhibitory activity against Angiotensin II receptor, type 2 in rat midbrain membrane preparations.	1995	Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19	Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.
AID1679334	Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as urine albumin to creatinine ratio at 20 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dose by ELISA (Rvb = 2.72 +/- 0.729 ug/mg)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
AID330797	Antagonist activity at AT1 receptor in KCl-contracted rabbit aortic strips after 60 mins	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID1058238	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of mean arterial pressure at 20 mg/kg, po measured at 4 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID645197	Antagonist activity at angiotensin 2 receptor type 1 in New Zealand White rabbit descending thoracic aorta rings assessed as inhibition of angiotensin 2-induced contraction preincubated for 30 mins prior angiotensin 2 challenge	2012	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4	Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.
AID1679323	Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as decrease in glomerular sclerosis lesions by measuring glomerular sclerosis index at 20 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dos	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
AID717880	Cytotoxicity against human LNCAP cells assessed as cell viability at 10 uM after 24 to 96 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID1214210	Clearance in men plasma at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID671502	Toxicity in rat assessed as change in heart rate at 20 mg/kg, iv measured after 8 hrs (Rvb = 2.12 +/- 20.6 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID183758	Inhibitory activity against AII-Induced Pressor response at 3 mg/Kg at 6 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID481446	Effective permeability across human jejunum	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID37844	Inhibitory concentration against [125 I]Ang II binding to rat pituitary membranes Angiotensin II receptor type 1 without 0.2% bovine serum albumin	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Design, synthesis, and biological activities of four angiotensin II receptor ligands with gamma-turn mimetics replacing amino acid residues 3-5.
AID39641	In vitro for inhibition of [125I]-angiotensin II (0.1 nM) binding to angiotensin II receptor type 1 in membrane fractions of bovine adrenal cortex	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID383256	Antihypertensive effect in anesthetized Wistar rat assessed as change mean arterial pressure at 10.0 mg/kg administered through femoral vein	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Synthesis and antihypertensive effects of new methylthiomorpholinphenol derivatives.
AID568937	Antagonist activity at angiotensin AT1 receptor in rat kidney homogenates	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID182895	In vivo inhibition of AII pressor response was measured in conscious, normotensive rats after po administration at dose 3.0 mg/kg	1995	Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19	Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.
AID239874	Competitive antagonism of Angiotensin II receptor in endothelium removed isolated rat aortic ring; (n = 5)	2005	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17	Design, synthesis, and evaluation of novelly substituted benzimidazole compounds as angiotensin II receptor antagonists.
AID271582	Cmax in Sprague-Dawley rat at 30 mg/kg, po	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
AID1214195	Half life in human plasma expressing CYP2C91/1 polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID183746	Inhibitory activity against AII-Induced Pressor response at 1 mg/Kg at 1 hr	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID717879	Antitumor activity against human LNCAP cells xenografted in athymic nude mouse assessed as relative tumor volume at 5 mg/kg/day dosed on day 8 measured at 4 weeks post implantation by caliper measurement (Rvb = 28.34 +/-2.05)	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID446291	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood calcium level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID1214233	Tmax in women plasma at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID37674	Binding affinity against angiotensin II receptor type 1 (AT1) from rat liver.	1993	Journal of medicinal chemistry, Jun-11, Volume: 36, Issue:12	Nonpeptide angiotensin II receptor antagonists. 1. Synthesis and in vitro structure-activity relationships of 4-[[[(1H-pyrrol-1-ylacetyl)amino]phenyl]methyl]imidazole derivatives as angiotensin II receptor antagonists.
AID39820	In vitro inhibitory activity against Angiotensin II receptor, type 1 in rabbit aorta membrane preparations.	1995	Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19	Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.
AID446297	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood urea level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1408901	Transactivation of human PPARgamma expressed in human MCF7 cells harboring pPPRE3-tk-luc reporter at 10 uM after 24 hrs by luciferase reporter gene assay relative to control	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.
AID446296	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood creatinine level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID1515591	Antagonist activity at AT1 receptor (unknown origin) by inositol phosphate accumulation assay relative to control
AID183923	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 7 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID568868	Antihypertensive activity in po dosed renal hypertensive rat model	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1214189	Cmax in human plasma expressing CYP2C8*4 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID446270	Antihypertensive activity in Wistar rat assessed as normalization of L-NAME-induced systolic blood pressure at 10 mg/kg/day, po for 4 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID166678	Antagonism of angiotensin-II mediated contraction of rabbit aortic rings expressed as pA2 (in vitro)	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists.
AID362091	Antagonist activity at HA-tagged mouse AT1a angiotensin 2 receptor expressed in HEK293T cells assessed as decrease in angiotensin 2-induced intracellular calcium uptake	2008	Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16	Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension.
AID1737436	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 10 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID647626	Antihypertensive activity against angiotensin-2-induced cell contraction in Wistar rat VSMC assessed as changes in planar cell surface area after 30 mins by planimetric technique	2012	European journal of medicinal chemistry, Apr, Volume: 50	New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: Ester, amide and amine linkers.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID166812	Antagonism against A-2 induced contraction of aortic rings from rabbit.	1996	Journal of medicinal chemistry, May-24, Volume: 39, Issue:11	Diphenylpropionic acids as new AT1 selective angiotensin II antagonists.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1214179	Cmax in human plasma expressing CYP2C81/1 polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID673037	Displacement of [125I]Sar1Ile8-Ang2 from angiotensin AT1 receptor after 180 mins by gamma counting	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.
AID1261025	Displacement of [125I]Sar1Ile8-Ang2 from human AT1 receptor expressed in CHO-K1 cell membranes after 180 mins	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center.
AID179987	Tested in vivo for effective dose (iv) that produces inhibition of pressor response to Angiotensin II in conscious normotensive rats	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoro
AID1214205	Half life in human plasma expressing CYP2C9*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID159637	Inhibitory effect in cAMP-specific Phosphodiesterase 4 (PDE 4) isolated from guinea pig ventricular tissue.	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds.
AID412478	Antagonist activity at AT1 receptor in rat aortic rings	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID568790	Displacement of radiolabeled angiotensin2 from angiotensin AT1 receptor in rat adrenal cortex membranes	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID10690	Area under curve was measured by using concentration Vs time	1994	Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4	Pyrido[2,3-d]pyrimidine angiotensin II antagonists.
AID1214186	Tmax in human plasma expressing CYP2C8*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID194611	Inhibition of AII pressor response by the compound in conscious, normotensive rats, at 0.3 (mg/kg) intravenous dose	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID18415	Oral bioavailability in rat	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID1586998	Displacement of [125I]-angiotensin-2 from AT1 receptor in Sprague-Dawley rat vascular smooth muscle cells after 150 mins by gamma counting method	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Design, Synthesis, and Biological Evaluation of 6-Benzoxazole Benzimidazole Derivatives with Antihypertension Activities.
AID1214192	Clearance in human plasma expressing CYP2C8*4 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID446263	Displacement of [125I]angiotensin II from angiotensin 2 receptor in Wistar rat VSMC cells by gamma-counter	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID1058247	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of systolic arterial pressure at 20 mg/kg, po measured at 4 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID1216820	Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 10 to 100 uM after 24 hrs by ATP assay	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID1294155	Displacement of [125I]-Sar1,Ile8-angiotensin 2 from AT1 receptor in Sprague-Dawley rat vascular smooth muscle cells after 150 mins by gamma counting analysis	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	N-Phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: Design, synthesis and biological evaluation.
AID1515581	Inhibition of NEP (unknown origin) preincubated for 10 mins followed by fluorogenic substrate addition and measured after 20 mins by fluorescence assay
AID681163	TP_TRANSPORTER: ATP hydrolysis in reconstituted proteoliposomes	1996	The Journal of biological chemistry, Feb-09, Volume: 271, Issue:6	Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity.
AID1214181	Tmax in human plasma expressing CYP2C81/1 polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID184364	Maximum percent change in A II supported mean arterial pressure 60 minutes following 3 mg/kg i.d. administration.	1994	Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4	Pyrido[2,3-d]pyrimidine angiotensin II antagonists.
AID242697	Displacement of [125I]-Ang II from rat liver membrane angiotensin II type 1 (AT1) receptor	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.
AID193103	Time from onset of action until significant (i.e., >=30%) inhibition of pressor response is no longer observed, at 1 (mg/kg) intravenous dose	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID1408902	Blocking activity at AT1 receptor in rat aortic vascular smooth muscle cells assessed as inhibition of angiotensin-2-induced calcium flux at 10 uM preincubated for 20 mins followed by angiotensin-2 addition by Fura-2-AM dye based scanning fluorometric met	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.
AID774873	Antagonist activity at angiotensin 2 receptor in Japanese white rabbit thoracic aorta assessed as inhibition of angiotensin 2-induced contraction after 60 mins by Schild plot analysis	2013	European journal of medicinal chemistry, Nov, Volume: 69	Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.
AID193088	Time from onset of action until significant (i.e., >= 30%) inhibition of pressor response no longer observed (0.3 mg/kg peroral route).	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
AID1058241	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of diastolic arterial pressure at 20 mg/kg, po measured at 6 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID1277889	Binding affinity to type-2 angiotensin-2 receptor (unknown origin)	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.
AID1261027	Antihypertensive activity in spontaneously hypertensive rat assessed as mean blood pressure at 10 mg/kg, po within 24 hrs by tail-cuff plethysmography	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center.
AID1674184	Toxicity in po dosed human assessed as maximum daily dose	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1289953	Displacement of [3H]-Angiotensin 2 from AT1 receptor in human PLC/PRF/5 cells after 20 mins by liquid scintillation counting	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.
AID1214178	AUC in human plasma expressing CYP2C81/1 polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1679338	Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as blood urea nitrogen level at 20 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dose by ELISA (Rvb = 11.22 +/- 1.22 mmol/L)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
AID755128	Antagonist activity at alpha1-adrenergic receptor in Wistar rat endothelium denuded thoracic aorta assessed as inhibition of phenylephrine-induced contraction preincubated for 30 mins prior to phenylephrine-challenge	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Design and synthesis of 6,7-dimethoxyquinazoline analogs as multi-targeted ligands for α1- and AII-receptors antagonism.
AID271576	Apparent permeability from apical to basolateral side of Caco-2 cell	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
AID671500	Toxicity in rat assessed as change in heart rate at 20 mg/kg, iv measured after 4 hrs (Rvb = -3.88 +/- 15.1 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID1058240	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of diastolic arterial pressure at 20 mg/kg, po measured at 8 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID486403	Displacement of [125I]angiotensin 2 from AT2 receptor in pig uterus membrane after 1.5 hrs by gamma counting	2010	Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12	Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.
AID755124	Antihypertensive activity in Wistar rat assessed as inhibition of angiotensin 2-induced pressor response at 0.36 to 0.72 micromol	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Design and synthesis of 6,7-dimethoxyquinazoline analogs as multi-targeted ligands for α1- and AII-receptors antagonism.
AID977600	pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID169534	Maximum fall in blood pressure (mmHg) in groups of four sodium-depleted rats, after administration of test compounds at the indicated dose (mg/kg, p.o.).	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.
AID184384	Peak percent inhibition of Angiotensin II pressor response in conscious, normotensive rats at 0.3 mg/kg iv (no. of animals treated)	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
AID1261051	Toxicity in Kunming mouse at 1.3 g/kg, po assessed as mortality after 2 weeks	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center.
AID446282	Plasma concentration in po dosed Wistar rat assessed as EXP-3174 level after 4 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID37691	In vitro antagonistic activity by displacement of [125I]-Sar1-Ile8-A II at the rat adrenal cortical aorta Angiotensin II receptor, type 1	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
AID184386	Peak percent inhibition of Angiotensin II pressor response in conscious, normotensive rats at 0.3 mg/kg po (no. of animals treated)	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
AID261361	Reduction of the systolic blood pressure in hypertensive Sprague-Dawley rat at 3 mg/kg, ip	2006	Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5	Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists.
AID446298	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood Na+ level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID194613	Inhibition of AII pressor response by the compound in conscious, normotensive rats, at 1 (mg/kg) intravenous dose	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID481442	Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1261034	Antagonist activity against AT1 receptor in Japanese White rabbit aortic strips assessed as reduction in angiotension-2-induced contractile response after 60 mins by Schild's plot analysis	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center.
AID1058242	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of diastolic arterial pressure at 20 mg/kg, po measured at 4 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID231155	Ratio of the of A II pressor responses in rhesus monkey, p.o./i.v.	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID330810	Tmax in Sprague-Dawley rat at 30 mg/kg, po	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID23693	Partition coefficient (logP)	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Nonpeptide angiotensin II receptor antagonists: synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1- yl]phenyl]methyl]imidazole derivatives and their in vitro activity.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1214204	Cmax in human plasma expressing CYP2C9*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID75342	Inhibition against human growth hormone secretagogue (GHS) receptor; No binding detected	2004	Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4	Recognition of privileged structures by G-protein coupled receptors.
AID673039	Antagonist activity at AT1 receptor in Japanese white rabbit thoracic aorta assessed as inhibition of KCl-induced contraction incubated 30 mins post KCl-induction for 1 hr	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.
AID38161	In vitro antagonist activity against angiotensin II type 2 (AT2) receptor in rat midbrain using [125I]- Sar, Ile AII.	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.
AID1129841	Antihypertensive activity in spontaneous hypersensitive Sprague-Dawley rat model assessed as reduction of blood pressure at 10 mg/kg, po measured for 1 to 24 hrs	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Design, synthesis and biological evaluation of new 5-nitro benzimidazole derivatives as AT1 antagonists with anti-hypertension activities.
AID568881	Binding affinity to angiotensin AT1 receptor in rat liver membranes	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1289936	Displacement of [3H]-Asp-{Nomega-[N-(4-propanoylaminobutyl)aminocarbonyl]}Arg-ValTyr-Ile-His-Pro-Phe-OH Tris(hydrotrifluoroacetate) from human AT1 receptor transfected in CHO cells co-expressing Galpha16-mtAEQ after 2 hrs by liquid scintillation counting	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.
AID177191	Effective dose that lowers the blood pressure 30 mmHg after intravenous administration	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.
AID174625	Duration of inhibition of AII pressor response no longer observed in conscious normotensive rats at 1 mg/Kg p.o.	1993	Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17	Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.
AID1216825	Drug metabolism assessed as human recombinant CYP2C9-mediated semicarbazide adducts formation at 20 uM by LC-MS/MS method	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID568788	Binding affinity to angiotensin AT1 receptor in bovine adrenal cortex membranes	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID193224	Time from onset of action until significant (i.e., >=30%) inhibition of pressor response is no longer observed, at 3 (mg/kg) intravenous dose	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID647627	Antihypertensive activity in Wistar rat assessed as decrease of L-NAME-induced systolic arterial pressure at 20 mg/kg, po administered with drinking water qd for 3 days by sphygmomanometer	2012	European journal of medicinal chemistry, Apr, Volume: 50	New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: Ester, amide and amine linkers.
AID263157	Antagonist activity against AT1 receptor after 20 min preincubation	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties.
AID1737435	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as intrinsic activity measured after 39 hrs by dual luciferase reporter assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1737437	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 20 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID237841	Oral bioavailability	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID671495	Antihypertensive activity in rat assessed as change in diastolic arterial pressure at 20 mg/kg, iv measured after 2 hrs (Rvb = 4.40 +/- 2.5 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID263158	Antagonist activity against AT1 receptor after 60 min preincubation	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties.
AID774875	Displacement of [125I]-Sar1Ile8-angiotensin 2 from angiotensin 2 AT1 receptor (unknown origin) after 180 mins by gamma counting analysis	2013	European journal of medicinal chemistry, Nov, Volume: 69	Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.
AID675419	Antagonist activity at AT1 receptor in rat uterus assessed inhibition of oxytocin/bradykinin-induced contraction	2012	European journal of medicinal chemistry, Sep, Volume: 55	The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives.
AID1261033	Antihypertensive activity in spontaneously hypertensive rat assessed as mean blood pressure at 30 mg/kg, po by tail-cuff plethysmography	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center.
AID1214198	AUC in human plasma expressing CYP2C9*2 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1679311	Antifibrotic activity in mouse MES-13 cells assessed as decrease in glucose-induced CTGF protein level pretreated with glucose for 48 hrs followed by compound treatment relative to control	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
AID38298	In vitro inhibition of specific binding of [125 I] A II to rat liver membrane.	1994	Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4	Pyrido[2,3-d]pyrimidine angiotensin II antagonists.
AID736071	Antagonist activity at Angiotensin 2 type-1 receptor in Wistar rat uterus assessed as suppression of ANG2-induced contraction	2013	European journal of medicinal chemistry, Apr, Volume: 62	Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers.
AID175106	Time to produce onset of action for inhibition of pressor response in conscious, normotensive rats at 0.3 mg/kg iv (no. of animals treated)	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID711559	Antagonist activity at angiotensin 2 receptor	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Synopsis of some recent tactical application of bioisosteres in drug design.
AID166916	Compound was tested for dose-related reduction of the mean blood pressure on boluses of different dose of 0.1 mg via ear vein	2002	Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18	Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3,5 side-chain bridges. Role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists.
AID38153	Activity against low affinity Angiotensin II receptor, type 2 was measured from the ability to inhibit [125I]angiotensin II binding to rat uterine membrane	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists.
AID1292036	Antihypertensive activity in spontaneous hypertensive rat model assessed as reduction in mean blood pressure at 10 mg/kg, po administered for 2 hrs	2016	Bioorganic & medicinal chemistry, May-01, Volume: 24, Issue:9	Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs.
AID481441	Aqueous diffusivity at 37C	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID174623	Duration of inhibition of AII pressor response no longer observed in conscious normotensive rats at 1 mg/Kg i.v.	1993	Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17	Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.
AID1214202	Clearance in human plasma expressing CYP2C9*2 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID599064	Plasma protein binding in human	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID644752	Antagonist activity at angiotensin 2 AT1 receptor in Japanese White rabbits thoracic aorta assessed as inhibition of KCl-indcuced contraction after 60 mins	2012	European journal of medicinal chemistry, Mar, Volume: 49	Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.
AID568870	Metabolic stability in iv and po dosed human assessed as conversion of EXP3174	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1692277	Antagonist activity at GP6 in human platelet assessed as reduction in collagen-induced platelet-aggregation preincubated for 60 secs followed by collagen stimulation by light transmission aggregometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID261359	Displacement of [125I]-Sar(1)Ile(8)-Ang 2 from human AT1 receptor in CHO cells	2006	Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5	Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists.
AID39503	In vitro binding affinity for angiotensin II AT1 receptor in rabbit aorta	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID1214201	Tmax in human plasma expressing CYP2C9*2 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214184	Cmax in human plasma expressing CYP2C8*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID568869	Oral bioavailability in rat	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID172096	Change in systolic arterial blood pressure in renal artery ligated hypertensive rats, orally dosed at 10 mg/kg	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.
AID167649	Antagonistic activity through inhibition of A II induced contractions on rabbit aortic strips	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
AID1058239	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of mean arterial pressure at 20 mg/kg, po measured at 1 hr by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID736072	Displacement of [125I-Sar1-Ile8]-ANG2 from human Angiotensin 2 type-1 receptor expressed in HEK293 cells after 1 hr by gamma counting analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers.
AID446290	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood triglyceride level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID1408904	Antihypertensive activity in angiotensin 2-induced Wistar rat hypertensive model assessed as reduction in angiotensin 2-induced mean arterial pressure at 6 x 10'-5mol/kg, iv	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.
AID166917	Compound was tested for dose-related reduction of the mean blood pressure on boluses of different dose of 0.2 mg via ear vein; value ranges from -40 to -60	2002	Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18	Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3,5 side-chain bridges. Role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists.
AID182769	In vivo inhibition of AII pressor response was measured in conscious, normotensive rats after intravenous administration at dose 1.0 mg/kg	1995	Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19	Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID263160	Inhibition of ADP-mediated platelet aggregation in Wistar rat platelet-rich plasma at 100 uM	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties.
AID89969	Inhibitory activity against Ang II-induced proliferation of human aortic smooth muscle cells in a dose dependent manner	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID717876	Cardiotoxicity in SHR rat assessed as effect on heart rate at 10 mg/kg, po	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID330804	Half life in Sprague-Dawley rat at 30 mg/kg, po	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID645198	Displacement of [125I]angiotensin 2 from angiotensin 2 receptor type 1 in Sprague-Dawley rat adrenal cortex membranes after 60 mins by gamma counting	2012	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4	Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.
AID184050	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 1 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID167560	Inhibition of all induced contractions of rabbit aortic rings	1991	Journal of medicinal chemistry, Oct, Volume: 34, Issue:10	Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives.
AID1339055	Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation preincubated for 5 mins followed by collagen addition measured after 5 mins by turbidimetric method
AID39501	In vitro antagonistic activity against Ang II (AT1) receptor was determined in rabbit aorta	1994	Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26	Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists.
AID446284	Plasma concentration in po dosed Wistar rat assessed as total drug level after 4 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID1214230	Half life in men plasma at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID598527	1-Octanol-sodium citrate buffer distribution coefficient, log D of the compound at pH 5.5 by shake-flask method	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID37705	Compound was evaluated for binding affinity against angiotensin II receptor, type 1 in rat liver	1992	Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20	Discovery of a novel class of orally active, non-peptide angiotensin II antagonists.
AID1552808	Inhibition of Cu2+ ion-induced oxidation of ascorbic acid by spectrophotometric analysis	2019	Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17	Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators.
AID182953	In vivo inhibitory activity against angiotensin II induced pressor response in anesthetized normotensive rats	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1214188	AUC in human plasma expressing CYP2C8*4 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID168382	In vitro antihypertensive activity in renal hypertensive rat at 0.5 mg/kg after 7 hr of oral administration.	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
AID183748	Inhibitory activity against AII-Induced Pressor response at 1 mg/Kg at 6 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1692279	Binding affinity to recombinant GP6 (unknown origin) at protein to compound ratio of 1 : 1 to 1 : 10 by 2D 15N-1H TROSY-HSQC NMR spectroscopy	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID412480	Antihypertensive effect in desoxycortisone acetate-induced hypertensive rat assessed as maximum decrease in mean arterial blood pressure at 5 mg/kg, ip after 6 hrs	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists.
AID671496	Antihypertensive activity in rat assessed as change in diastolic arterial pressure at 20 mg/kg, iv measured after 4 hrs (Rvb = 1.62 +/- 2.2 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID165371	Inhibitory concentration against [125I]angiotensin II(AII) induced contraction in rabbit aorta by 50%	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoro
AID167381	Inhibition of angiotensin II-induced contractions in rabbit aorta in vitro.	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID1214203	AUC in human plasma expressing CYP2C9*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214200	Half life in human plasma expressing CYP2C9*2 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214229	Cmax in women plasma at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID37824	In vitro inhibitory activity against rat Angiotensin II receptor, type 1 expressed in CHO cells	1999	Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22	Angiotensin II analogues encompassing 5,9- and 5,10-fused thiazabicycloalkane tripeptide mimetics.
AID39663	Inhibition against human angiotensin II receptor, type 1 (AG2-R)	2004	Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4	Recognition of privileged structures by G-protein coupled receptors.
AID13548	Area under curve gives the effective duration for the angiotensin II antagonist effect.	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	4-Diazinyl- and 4-pyridinylimidazoles: potent angiotensin II antagonists. A study of their activity and computational characterization.
AID481440	Dissociation constant, pKa of the compound	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID717878	Antitumor activity against human LNCAP cells xenografted in athymic nude mouse assessed as relative tumor volume at 10 mg/kg/day dosed on day 8 measured at 4 weeks post implantation by caliper measurement (Rvb = 28.34 +/-2.05)	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID598526	1-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID446262	Antioxidant activity assessed as inhibition of oxidation of chromogen (ABTS) measured per mmol/L of product by total antioxidant assay	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID1214196	Tmax in human plasma expressing CYP2C91/1 polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1692292	Modulation of TxA2 receptor in human platelets assessed as reduction in U46619-induced platelet aggregation preincubated for 5 min followed by U46619 stimulation	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID1214227	AUC in women plasma at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1058234	Toxicity in renal spontaneously hypertensive rat model assessed as reduction of heart rate at 20 mg/kg, po measured at 4 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID126971	Time from onset of action until significant (i.e., >=30%) inhibition of pressor response is no longer observed, at 0.3 (mg/kg) peroral dose	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID271578	AUC in Sprague-Dawley rat at 30 mg/kg, po	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
AID307295	Antagonist activity at AT1 receptor assessed inhibition of angiotensin-2-induced contraction of rabbit thoracic aortic rings	2007	Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10	Synthesis and biological activity of 2-alkylbenzimidazoles bearing a N-phenylpyrrole moiety as novel angiotensin II AT1 receptor antagonists.
AID1487379	Displacement of [3H]-candesartan from human AT1 receptor expressed in CHO cells assessed as residence time at 10 uM pre-incubated with cells followed by compound washout and subsequent addition of [3H]-candesartan up to 60 mins	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID568789	Antagonist activity at angiotensin AT1 receptor	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID177661	Effect on pressure response to angiotensin II receptor (AII) after (i.v.) administration of 1 mg/kg in anesthetized, ganglion blocked, AII-infused rat in vivo	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	N-3-substituted pyrimidinones as potent, orally active, AT1 selective angiotensin II receptor antagonists.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID177662	Effect on pressure response to angiotensin II receptor (AII) after intradermally administration of 1 mg/kg in anesthetized, ganglion blocked, A II- infused rat was determined in vivo	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	N-3-substituted pyrimidinones as potent, orally active, AT1 selective angiotensin II receptor antagonists.
AID330812	Oral bioavailability in Sprague-Dawley rat at 30 mg/kg	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID446281	Plasma concentration in po dosed Wistar rat assessed as losartan level after 4 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID1214191	Tmax in human plasma expressing CYP2C8*4 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID271581	Terminal half life in Sprague-Dawley rat at 30 mg/kg, po	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
AID1737434	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as maximal activation at 10 uM measured after 39 hrs by dual luciferase reporter assay relative to pioglitazo	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID446294	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood AST level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID721753	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID330800	AUC in Sprague-Dawley rat at 30 mg/kg, po	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID1058244	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of diastolic arterial pressure at 20 mg/kg, po measured at 1 hr by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID383257	Antihypertensive effect in anesthetized Wistar rat assessed as change systolic arterial pressure at 10.0 mg/kg administered through femoral vein	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Synthesis and antihypertensive effects of new methylthiomorpholinphenol derivatives.
AID174940	Time duration was determined from onset of the action till no response after (i.v.) administration of 1 mg/kg in anesthetized, ganglion blocked, A II- infused rat	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	N-3-substituted pyrimidinones as potent, orally active, AT1 selective angiotensin II receptor antagonists.
AID1261048	Toxicity in Kunming mouse at 2 g/kg, po assessed as mortality after 2 weeks	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID459706	Binding affinity to human N-terminal Ig-like domain D1D2 GPVI expressed in Escherichia coli DH5alpha by NMR spectroscopy	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI.
AID37542	Potency to antagonize the ability of angiotensin II to contract rabbit aorta	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID1216814	Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 25 to 100 uM after 24 hrs by WST-8 assay	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID1552810	Inhibition of AGE formation assessed as reduction in bovin serum albumin glycation at 1 mM incubated for 24 hrs in presence of glucose by spectrophotometric analysis relative to control	2019	Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17	Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators.
AID177192	Effective dose that lowers the blood pressure 30 mmHg after peroral administration	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.
AID193097	Time from onset of action until significant (i.e., >= 30%) inhibition of pressor response no longer observed (3 mg/kg peroral route)	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
AID644751	Displacement of [125I]Sar1 Ile8-Ang 2 from angiotensin 2 AT2 receptor after 180 mins by gamma counting	2012	European journal of medicinal chemistry, Mar, Volume: 49	Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.
AID175111	Time to produce onset of action for inhibition of pressor response in conscious, normotensive rats at 3 mg/kg po (no. of animals treated)	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID671499	Toxicity in rat assessed as change in heart rate at 20 mg/kg, iv measured after 2 hrs (Rvb = -2.22 +/- 10.5 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID220640	In vitro antagonistic potency against angiotensin II receptor using [125I]- Sar,Ile8-angiotensin II as the radioligand in rat adrenal cortical membranes	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Dihydropyrimidine angiotensin II receptor antagonists.
AID568876	Antagonist activity at angiotensin AT1 receptor in rat adrenal cortical membranes	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1515578	Displacement of Europium-labeled angiotensin-2 from human AT1 receptor expressed in CHOK1 cell membranes after 120 mins by DELFIA
AID1525517	Inhibition of ATR1 (unknown origin)	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group.
AID38284	Displacement of [1251][Sar1,IIe8]AII from rat midbrain angiotensin II (AT2) receptor	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.
AID1058250	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of mean arterial pressure at 20 mg/kg, po measured at 8 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID383276	Antihypertensive effect in spontaneous hypertensive Wistar rat model assessed as maximum decrease in heart rate per min at 1.0 mg/kg, po after 80 mins	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Synthesis and antihypertensive effects of new methylthiomorpholinphenol derivatives.
AID1058235	Toxicity in renal spontaneously hypertensive rat model assessed as reduction of heart rate at 20 mg/kg, po measured at 2 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID184186	In vivo concentration inhibiting angiotensin II (A II) induced pressor response in conscious normotensive rats 30 mins after oral administration of 2 uM/kg.	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	4-Diazinyl- and 4-pyridinylimidazoles: potent angiotensin II antagonists. A study of their activity and computational characterization.
AID671501	Toxicity in rat assessed as change in heart rate at 20 mg/kg, iv measured after 6 hrs (Rvb = 1.10 +/- 11.3 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID126974	Time from onset of action until significant (i.e., >=30%) inhibition of pressor response is no longer observed, at 10 (mg/kg) peroral dose	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID679255	TP_TRANSPORTER: transepithelial transport (basal to apical) in Caco-2 cells	2000	British journal of pharmacology, Mar, Volume: 129, Issue:6	Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers.
AID679524	TP_TRANSPORTER: inhibition of PAH uptake (PAH: 1 uM, Losartan: 100 uM) in Xenopus laevis oocytes	1999	Biochemical and biophysical research communications, Feb-16, Volume: 255, Issue:2	Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3).
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1129845	Antihypertensive activity in renal hypersensitive Sprague-Dawley rat model assessed as reduction of blood pressure at 10 mg/kg, po measured for 1 to 24 hrs	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Design, synthesis and biological evaluation of new 5-nitro benzimidazole derivatives as AT1 antagonists with anti-hypertension activities.
AID1058255	Displacement of [125I]-Ang-2 from AT1 receptor in rat liver membranes after 1.5 hrs	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID126976	Time from onset of action until significant (i.e., >=30%) inhibition of pressor response is no longer observed, at 3 (mg/kg) peroral dose; NA= Not active	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID271574	Displacement of [125I]Sar1,Ile8-Ang2 from AT1 receptor in rat hepatic membrane	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
AID1261050	Toxicity in Kunming mouse at 1.5 g/kg, po assessed as mortality after 2 weeks	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center.
AID39810	In vitro antagonistic activity for AT1 receptor by displacing 125I[Sar, ILe8]AII radioligand in rabbit aorta membrane using 0.2% bovine serum albumin (BSA)	1993	Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17	Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID271584	Oral bioavailability in Sprague-Dawley rat at 30 mg/kg, po	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
AID330807	Cmax in Sprague-Dawley rat at 30 mg/kg, po	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID185600	Percent peak inhibition of pressor response induced by exogenously administered AII at 3 mg/kg in 2 or more pithed rats.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.
AID37514	Displacement of [1251][Sar1,IIe8]AII from rabbit aorta Angiotensin II receptor, type 1	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.
AID1443995	Hepatotoxicity in human assessed as drug-induced liver injury	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1586999	Antihypertensive activity in rat spontaneous hypertensive model assessed as decrease in maximal mean blood pressure at 10 mg/kg, po qd measured up to 24 hrs	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Design, Synthesis, and Biological Evaluation of 6-Benzoxazole Benzimidazole Derivatives with Antihypertension Activities.
AID721754	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID38276	In vitro antagonist activity against angiotensin II receptor type 2 in rat midbrain using [125I]-Sar,Ile AII.	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.
AID261360	Reduction of the systolic blood pressure in normotensive Sprague-Dawley rat at 3 mg/kg, ip	2006	Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5	Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists.
AID174627	Duration of inhibition of AII pressor response no longer observed in conscious normotensive rats at 3 mg/Kg p.o.	1993	Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17	Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.
AID1058248	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of systolic arterial pressure at 20 mg/kg, po measured at 2 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID175108	Time to produce onset of action for inhibition of pressor response in conscious, normotensive rats at 1 mg/kg iv (no. of animals treated)	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID410428	Displacement of [125I]Ang2 from AT1 receptor in bovine adrenal cortex	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	Synthesis and biological activities of novel nonpeptide angiotensin II receptor antagonists based on benzimidazole derivatives bearing a heterocyclic ring.
AID177200	Intravenous effective dose required for lowering blood pressure in renal hypertensive rats (RHR)	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID37830	In vitro binding affinity for rat liver angiotensin II receptor type 1, determined by displacement of the specially bound [3H]AII radioligand	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.
AID1058236	Toxicity in renal spontaneously hypertensive rat model assessed as reduction of heart rate at 20 mg/kg, po measured at 1 hr by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID624608	Specific activity of expressed human recombinant UGT1A4	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID181933	Percent inhibition of angiotensin II (0.1 ug/kg iv) -induced pressor response 7 hr after administration of test compounds (1 mg/kg po) in conscious male Sprague-Dawley rats	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID1692278	Antagonist activity at GP6 in human platelet assessed as reduction in CRP-induced platelet-aggregation preincubated for 60 secs followed by collagen stimulation by light transmission aggregometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID1487362	Antagonist activity at human AT1 receptor expressed in CHO cells assessed as reduction in angiotensin 2-induced inositol phosphate accumulation by measuring dissociation rate constant preincubated with cells followed by compound washout in presence of los	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID1487367	Displacement of [3H]-candesartan from human AT1 receptor expressed in CHO cells assessed as dissociation rate constant at 10 uM pre-incubated with cells followed by compound washout and subsequent addition of [3H]-candesartan up to 60 mins	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
AID37687	Binding affinity for rat angiotensin II receptor, type 1	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID330798	Permeability from apical to basolateral side of human Caco-2 cell membrane	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID1579129	Anti-hypersensitive activity in spontaneous hypertensive rat assessed as reduction in blood pressure at 10 mg/kg, po	2019	European journal of medicinal chemistry, Nov-01, Volume: 181	Design, synthesis and biological evaluation of AT
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID183921	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 3 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID183757	Inhibitory activity against AII-Induced Pressor response at 3 mg/Kg at 3 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID167563	Compound was evaluated for antagonism of angiotensin II induced contraction of rabbit aorta rings.	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists.
AID174394	% decrease in blood pressure after 4 hours in male rats at a dose of 3 mg/kg by using Renal artery hypertensive model; IA means inactive	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID671497	Antihypertensive activity in rat assessed as change in diastolic arterial pressure at 20 mg/kg, iv measured after 6 hrs (Rvb = 1.04 +/- 1.1 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID39809	Displacement of [125I]-Sar1-Ile8-A II at the rabbit aorta angiotensin II receptor, type 1	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
AID1214231	Half life in women plasma at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID568923	Antagonist activity at angiotensin AT1 receptor in rabbit thoracic aortic rings	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID185594	Percent peak inhibition of pressor response induced by exogenously administered AII (submaximal dose (mg/kg) ) in groups of 2 or more pithed rats.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.
AID239885	pKa value against human Angiotensin II receptor type 1	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID239602	Displacement of [125I]-Ang II from rat liver membrane angiotensin II type 1 (AT1) receptor	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics.
AID446292	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood protein level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID184392	Peak percent inhibition of Angiotensin II pressor response in conscious, normotensive rats at 1 mg/kg iv (no. of animals treated)	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
AID183066	Inhibition of AII pressor response expressed as peak inhibition in conscious normotensive rats at 1 mg/Kg p.o.	1993	Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17	Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.
AID755120	Antihypertensive activity in Wistar rat assessed as inhibition of angiotensin 2-induced pressor response at 0.72 micromol pretreated with prazosin prior to compound administration	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Design and synthesis of 6,7-dimethoxyquinazoline analogs as multi-targeted ligands for α1- and AII-receptors antagonism.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID193101	Time from onset of action until significant (i.e., >=30%) inhibition of pressor response is no longer observed, at 0.3 (mg/kg) peroral dose	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID1515579	In vivo antagonist activity at AT1 receptor in Sprague-Dawley rat assessed as inhibition of angiotensin-2-induced pressor response at 3 mg/kg, iv treated for 5 mins at 15 mins post 2 doses of angiotensin-2 treatment at 15 minutes apart followed by ANP tre
AID39039	Inhibition of specific binding of [125I]angiotensin II (0.2 nM) to angiotensin II receptor in bovine adrenal cortex	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID1058254	Displacement of [125I]-Ang-2 from AT2 receptor in porcine myometrial membranes after 1.5 hrs	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID194763	Peak inhibition of A II pressor response in conscious normotensive rats after intravenous administration of 0.3 mg/kg of drug (4 animals treated)	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
AID1214182	Clearance in human plasma expressing CYP2C81/1 polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1216823	Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siScramble at 25 to 100 uM after 24 hrs by ATP assay	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID183750	Inhibitory activity against AII-Induced Pressor response at 10 mg/Kg at 3 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID39331	Tested for in vitro binding affinity against angiotensin II receptor of rat liver	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID237099	Time required for elimination of 50% of the compound	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID1692293	Inhibition of ADP-stimulated human platelet aggregation assessed as ADP light transmission at 50 uM preincubated for 5 min followed by ADP stimulation by light transmission aggregometry (Rvb = 62 +/- 3%)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID1692291	Modulation of TxA2 receptor in human platelet suspension assessed as lowest concentration that reduced U46619-induced platelet aggregation preincubated for 5 min followed by U46619 stimulation by light transmission aggregometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID194615	Inhibition of AII pressor response by the compound in conscious, normotensive rats, at 3 (mg/kg) intravenous dose	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID194614	Inhibition of AII pressor response by the compound in conscious, normotensive rats, at 1 (mg/kg) peroral dose	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
AID234499	Ratio of the of A II pressor responses in rat, p.o./i.v.	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID446288	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood glucose level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID673041	Toxicity against Photobacterium phosphoreum expressing T3 mutation after 15 mins by Microtox assay	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.
AID644754	Toxicity against Photobacterium phosphoreum T3 mutant assessed as inhibition of luminescence after 15 mins by microtox test	2012	European journal of medicinal chemistry, Mar, Volume: 49	Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.
AID183920	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 24 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1058253	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of mean arterial pressure at 20 mg/kg, po measured at 2 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID8003	Oral bioavailability in human	2000	Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3	Protease inhibitors: current status and future prospects.
AID166915	Compound was tested for dose-related reduction of the mean blood pressure on boluses of different dose of 0.05 mg via ear vein; value ranges from -20 to -40	2002	Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18	Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3,5 side-chain bridges. Role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists.
AID717881	Antiproliferative activity against human LNCAP cells assessed as reduction in Ang-2-induced increase in cell viability at 10 uM after 24 to 96 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID446295	Antihypertensive activity in L-NAME-induced Wistar rat assessed as decrease in blood ALT level at 20 mg/kg/day, po for last 4 weeks measured after 8 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID1214206	Tmax in human plasma expressing CYP2C9*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID671494	Antihypertensive activity in rat assessed as change in systolic arterial pressure at 20 mg/kg, iv measured after 8 hrs (Rvb = 1.26 +/- 1.6 mmHg)	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID39353	Ionization constant for the compound	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.
AID194768	Peak inhibition of A II pressor response in conscious normotensive rats after peroral administration of 0.3 mg/kg of drug (2 animals treated)	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
AID177204	Oral effective dose required for lowering blood pressure in renal hypertensive rats (RHR)	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID1058243	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of diastolic arterial pressure at 20 mg/kg, po measured at 2 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID1339047	Toxicity in Swiss albino mouse assessed as increase in bleeding time at 100 umol/kg, po
AID125515	The compound was evaluated for the percentage of inhibition of A II pressor response in rhesus monkeys for intravenous administration	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID1294157	Antihypertensive activity in SHR rat assessed as reduction in mean blood pressure at 10 mg/kg, po measured upto 24 hrs post dosing	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	N-Phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: Design, synthesis and biological evaluation.
AID1214199	Cmax in human plasma expressing CYP2C9*2 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1292033	Displacement of [125I]-Ang II from Angiotensin 2 type-1A receptor in rat vascular smooth muscle cells after 150 mins by gamma counting method	2016	Bioorganic & medicinal chemistry, May-01, Volume: 24, Issue:9	Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs.
AID679234	TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCK cells	2000	British journal of pharmacology, Mar, Volume: 129, Issue:6	Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers.
AID1552815	Inhibition of AGE formation assessed as reduction in reduction in bovin serum albumin glycation incubated for 24 hrs in presence of glucose by spectrophotometric analysis	2019	Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17	Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators.
AID977604	Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID39195	Binding affinity towards Angiotensin receptor from rabbit aorta	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.
AID167537	Compound was tested for its antagonistic activity against angiotensin II-induced contractions in rabbit aorta	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID183067	Inhibition of AII pressor response expressed as peak inhibition in conscious normotensive rats at 3 mg/Kg p.o.	1993	Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17	Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1897137	Displacement of [125I]Sar1,I1e8-AII from AT1 receptor in rabbit aorta membrane	2022	RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11	Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies.
AID194772	Peak inhibition of A II pressor response in conscious normotensive rats after peroral administration of 3 mg/kg of drug (4 animals treated)	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
AID193086	Time from onset of action until significant (i.e., >= 30%) inhibition of pressor response no longer observed (0.3 mg/kg intravenous route)	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
AID183919	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 2 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID568791	Displacement of radiolabeled angiotensin2 from angiotensin AT1 receptor in rat vascular smooth muscle	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID184209	Inhibitory effect on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 0.5 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1058245	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of systolic arterial pressure at 20 mg/kg, po measured at 8 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID1552816	Inhibition of AGE formation assessed as reduction in reduction in bovin serum albumin glycation incubated for 24 hrs in presence of glucose, Cu2+ by spectrophotometric analysis	2019	Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17	Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID330803	Half life in Sprague-Dawley rat at 3 mg/kg, iv	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID1552799	Inhibition of AGE formation assessed as reduction in reduction in bovin serum albumin glycation at 1 mM incubated for 24 hrs in presence of glucose, Cu2+ by spectrophotometric analysis relative to control	2019	Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17	Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators.
AID383259	Antihypertensive effect in anesthetized Wistar rat	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Synthesis and antihypertensive effects of new methylthiomorpholinphenol derivatives.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1214185	Half life in human plasma expressing CYP2C8*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID446264	Antihypertensive activity in Wistar rat assessed as normalization of L-NAME-induced systolic blood pressure at 20 mg/kg/day, po for 4 weeks	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID183749	Inhibitory activity against AII-Induced Pressor response at 10 mg/Kg at 1 hr	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID446267	Antihypertensive activity in Wistar rat assessed as normalization of L-NAME-induced heart weight at 20 mg/kg/day, po for 4 weeks in presence of L-NAME	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID671489	Displacement of [125I]AngII from type 1 angiotensin 2 receptor in bovine adrenal cortex	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID481439	Absolute bioavailability in human	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID39524	In vitro binding affinity for angiotensin II AT2 receptor in rat midbrain	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID1443990	Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell plasma membrane vesicles assessed as reduction in ATP-dependent [3H]-taurocholate uptake in to vesicles after 15 to 20 mins	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1214194	Cmax in human plasma expressing CYP2C91/1 polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID39812	In vitro antagonistic activity for angiotensin II receptor, type 1 by displacing 125I[Sar, ILe8 ]AII radioligand in rabbit aorta membrane without using bovine serum albumin (BSA)	1993	Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17	Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.
AID174941	Time duration was determined from onset of the action till no response after intradermal administration of 1 mg/kg in anesthetized, ganglion blocked, A II- infused rat	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	N-3-substituted pyrimidinones as potent, orally active, AT1 selective angiotensin II receptor antagonists.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1214183	AUC in human plasma expressing CYP2C8*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID182764	In vivo inhibitory percentage of pressor response induced by exogenous submaximal dose of angiotensin -II (1 mg/kg) administered iv to pithed rats	1996	Journal of medicinal chemistry, May-24, Volume: 39, Issue:11	Diphenylpropionic acids as new AT1 selective angiotensin II antagonists.
AID1339061	Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of CRP-XL-induced platelet aggregation preincubated for 5 mins followed by CRP-XL addition measured after 5 mins by turbidimetric method
AID193882	Effect on mean arterial pressure after oral dosing at 10 mg/kg to renal hypertensive rats	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoro
AID169538	Maximum fall in blood pressure in groups of four sodium-depleted rats, after peroral administration at the 3 mg/Kg	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.
AID383258	Antihypertensive effect in anesthetized Wistar rat assessed as change diastolic arterial pressure at 10.0 mg/kg administered through femoral vein	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Synthesis and antihypertensive effects of new methylthiomorpholinphenol derivatives.
AID182765	In vivo inhibitory percentage of pressor response induced by exogenous submaximal dose of angiotensin -II (3 mg/kg) administered iv to pithed rats	1996	Journal of medicinal chemistry, May-24, Volume: 39, Issue:11	Diphenylpropionic acids as new AT1 selective angiotensin II antagonists.
AID1443992	Total Cmax in human administered as single dose	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1277888	Displacement of 125I-[Sar1,Leu8] angiotensin-2 from rat type 1 angiotensin-2 receptor expressed in African green monkey COS7 cells after 24 hrs	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.
AID271577	AUC in Sprague-Dawley rat at 3 mg/kg, iv	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
AID39023	Binding affinity against angiotensin II receptor from rat liver; n=8	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID242700	Displacement of [125I]-Ang II from pig uterus membrane angiotensin II type 2 (AT2) receptor	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.
AID1443991	Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID37841	Inhibitory activity against Angiotensin II receptor, type 1 in rat vascular smooth muscle	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID383267	Antihypertensive effect in spontaneous hypertensive Wistar rat model assessed as maximum decrease in systolic arterial pressure at 1.0 mg/kg, po after 80 mins	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Synthesis and antihypertensive effects of new methylthiomorpholinphenol derivatives.
AID1058237	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of mean arterial pressure at 20 mg/kg, po measured at 6 hrs by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1058249	Antihypertensive activity in renal spontaneously hypertensive rat model assessed as reduction of systolic arterial pressure at 20 mg/kg, po measured at 1 hr by tail-cuff method relative to control	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
AID755127	Antagonist activity at angiotensin-2 receptor in Wistar rat endothelium denuded thoracic aorta assessed as inhibition of angiotensin 2-induced contraction preincubated for 30 mins prior to angiotensin 2-challenge	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Design and synthesis of 6,7-dimethoxyquinazoline analogs as multi-targeted ligands for α1- and AII-receptors antagonism.
AID515314	Octanol-water partition coefficient, log P of the compound	2010	European journal of medicinal chemistry, Oct, Volume: 45, Issue:10	Antihypertensive and antiarrhythmic properties of a para-hydroxy[bis(ortho-morpholinylmethyl)]phenyl-1,4-DHP compound: comparison with other compounds of the same kind and relationship with logP values.
AID1346995	Human AT1 receptor (Angiotensin receptors)	1993	Pharmacological reviews, Jun, Volume: 45, Issue:2	Angiotensin II receptors and angiotensin II receptor antagonists.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (0.01)	18.7374
1990's	1856 (26.73)	18.2507
2000's	2731 (39.33)	29.6817
2010's	1926 (27.74)	24.3611
2020's	429 (6.18)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,245 (17.22%)	5.53%
Reviews	464 (6.42%)	6.00%
Case Studies	222 (3.07%)	4.05%
Observational	10 (0.14%)	0.25%
Other	5,290 (73.16%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (360)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
An 8-week, Multicenter, Randomized, Double-blind, Factorial Phase II Study to Evaluate Dose-response Relationship of Amlodipine and Losartan Combination in Patients With Essential Hypertension. [NCT00942344]	Phase 2	320 participants (Actual)	Interventional	2007-05-31	Completed
A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension [NCT00568178]	Phase 3	306 participants (Actual)	Interventional	2007-06-01	Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide Tablets 100 mg/25 mg Under Fasting Conditions [NCT01102478]		30 participants (Actual)	Interventional	2005-02-28	Completed
Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis [NCT01115426]	Phase 4	20 participants (Actual)	Interventional	1997-01-31	Completed
Local Vasoconstriction in Postural Tachycardia Syndrome [NCT01210430]	Early Phase 1	74 participants (Actual)	Interventional	2010-07-31	Completed
An Open Label, Randomised, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. [NCT01218698]	Phase 1	0 participants	Interventional		Completed
A Prospective, Randomized, Open Label Blinded End Point (Probe), Crossover Study to Compare the Effects of Telmisartan and Losartan on Metabolic Profile of Renal Transplant Patients [NCT01224860]	Phase 2	20 participants (Actual)	Interventional	2009-01-31	Completed
A Clinical Trial to Assess the Efficacy and Safety of Losartan Versus Atenolol in the Prevention of Progressive Dilation of the Aorta in Patients With Marfan Syndrome. [NCT01145612]	Phase 3	140 participants (Actual)	Interventional	2008-10-31	Active, not recruiting
A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With Essential Hypertension [NCT00447603]	Phase 3	40 participants (Actual)	Interventional	2007-05-24	Terminated(stopped due to Achieving site readiness and enrolling the trial within a reasonable time)
A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects [NCT01197014]	Phase 1	72 participants (Anticipated)	Interventional	2010-09-30	Completed
Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke [NCT01198496]	Phase 4	5,000 participants (Anticipated)	Interventional	2010-10-31	Recruiting
Losartan as Anti-inflammatory Therapy to Augment F508del Cystic Fibrosis Transmembrane (CFTR) Recovery [NCT03206788]	Phase 2	7 participants (Actual)	Interventional	2017-11-11	Terminated(stopped due to due to slow enrollment and approval of the Trikafta for CF patients)
Exercise and Intensive Vascular Risk Reduction in Preventing Dementia [NCT02913664]	Phase 2/Phase 3	513 participants (Actual)	Interventional	2017-02-02	Completed
BP-EASE-A 12-Week, Multicenter, Open-Label, Randomized, Controlled Trial To Compare The Effectiveness of Losartan 50 mg/HCTZ 12.5 mg Titrated as Needed to Losartan 100 mg/HCTZ 25 mg or Valsartan 160 mg/HCTZ 25 mg, in Patients With Essential Hypertension W [NCT00546754]	Phase 3	808 participants (Actual)	Interventional	2007-05-01	Completed
A Randomized, Double-Blind, Parallel-Filter Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan-HCTZ Combination as Compared to Losartan Monotherapy in Patients With Essential Hypertension [NCT00307060]	Phase 3	274 participants (Actual)	Interventional	2004-12-01	Completed
An Open-label, Single Arm, Prospective Study to Evaluate the Safety and Anti-hypertensive Efficacy of Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg Combination in Patients With Mild to Moderate Essential Hypertension [NCT01431508]	Phase 4	15 participants (Actual)	Interventional	2007-08-01	Completed
A Randomized, Open-label, Comparative, Non-inferiority, Multicenter Study to Compare Efficacy of Losartan Potassium Group and Carvedilol Group on Arterial Stiffness in Essential Hypertension Patients [NCT00496834]	Phase 4	201 participants (Actual)	Interventional	2008-02-01	Completed
A Single Dose, 2-Period, 2-Treatment Bioequivalency Study of Losartan Potassium Tablets 100 mg Under Fed Conditions [NCT01216878]		40 participants (Actual)	Interventional	2004-09-30	Completed
A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome [NCT05843162]	Phase 4	116 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
"Single-center, Randomized, Five-way Crossover Study to Investigate Low-dose Combinations of Caffeine, Efavirenz, Losartan, Omeprazole, Metoprolol, Chlorzoxazone and Midazolam (Basel Cocktail) for Simultaneous Phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C1 [NCT01187862]	Phase 1	16 participants (Actual)	Interventional	2010-07-31	Completed
Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure [NCT01292694]	Phase 1	12 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to Could not enroll enough participants, and lost funding.)
A Pilot Study of N-of-1 Trials of Blood Pressure Medications in Adults With Hypertension [NCT02744456]	Early Phase 1	10 participants (Actual)	Interventional	2014-08-01	Completed
An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Fixed Dose Combination (FDC) of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Ver [NCT01218711]	Phase 1	0 participants	Interventional		Completed
The Multicenter, Randomized, Double Blind Phase 3 Clinical Trial to Compare Efficacy and Safety of Combination of Amlodipine and Losartan Compared to Amlodipine Monotherapy in Patients With Stage 2 Hypertension [NCT01127217]	Phase 3	149 participants (Actual)	Interventional	2009-05-31	Completed
Pharmacokinetic and Hemodynamic Interactions Between Amlodipine and Losartan in Humans [NCT03912285]	Phase 1	24 participants (Actual)	Interventional	2008-01-10	Completed
Effects of Intensive Vasodilating add-on Therapy on Peripheral Vascular Resistance and Coronary Flow Reserve in Patients With Essential Hypertension [NCT01180413]	Phase 4	48 participants (Actual)	Interventional	2010-12-31	Completed
Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients [NCT00398541]	Phase 3	41 participants (Actual)	Interventional	2005-03-01	Completed
A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension [NCT03276598]	Phase 4	233 participants (Actual)	Interventional	1999-11-25	Completed
The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study [NCT02676466]	Phase 2	289 participants (Actual)	Interventional	2016-04-26	Completed
A Randomized Clinical Trial of the N-of-1 Approach in Children With Hypertension [NCT03461003]	Phase 4	49 participants (Actual)	Interventional	2018-04-02	Completed
A Multi-center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Effects of Two Different Doses of Losartan on Morbidity and Mortality in Patients With Symptomatic Heart Failure Intolerant of ACE Inhibitor Treatment [NCT00090259]	Phase 3	3,834 participants (Actual)	Interventional	2001-12-19	Completed
EffecTs of Amlodipine and Other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases [NCT03082014]	Phase 3	101 participants (Actual)	Interventional	2018-02-22	Terminated(stopped due to completed for the primary study group of sporadic SVD patients, halted prematurely for the additional study group due to slow recruitment at 26 of 30 CADASIL patients in December 2022)
HYZAAR Versus Ramipril Diabetic Patients [NCT00480805]	Phase 3	312 participants (Actual)	Interventional	2001-08-08	Completed
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy [NCT00308347]	Phase 3	1,513 participants (Actual)	Interventional	1996-05-31	Completed
Effect of Potassium Losartan With Bedtime Dosing on Chronic Kidney Disease Patients With Nondipping Blood Pressure Pattern [NCT03603938]		189 participants (Anticipated)	Interventional	2018-11-01	Not yet recruiting
An Observational Study to Evaluate the Efficacy and Safety of Amosartan Plus Tablet in Uncontrolled Essential Hypertension Patients [NCT05462535]		4,785 participants (Actual)	Observational	2018-02-26	Completed
Effect of Fixed Triple Combination With Losartan-Amlodipin-HCTZ vs. Free Triple Combination on Blood Pressure Control [NCT03578042]	Phase 4	100 participants (Anticipated)	Interventional	2017-04-01	Recruiting
A Randomized, Placebo-Controlled, Double-Blind, Parallel Study of the Anti-Hypertensive Efficacy and Safety of Losartan Monotherapy as Compared to HCTZ Monotherapy and to the Combination of Losartan and HCTZ in Japanese Patients With Essential Hypertensio [NCT00092209]	Phase 3	840 participants	Interventional	2002-04-30	Completed
Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project [NCT00879879]		20 participants (Actual)	Interventional	2009-03-31	Completed
Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization [NCT04311177]	Phase 2	117 participants (Actual)	Interventional	2020-04-09	Completed
A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®] [NCT01307033]	Phase 3	278 participants (Actual)	Interventional	2011-03-29	Completed
An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hy [NCT00449111]	Phase 3	11 participants (Actual)	Interventional	2006-03-13	Terminated
Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease [NCT02373241]	Phase 2	1 participants (Actual)	Interventional	2015-04-30	Terminated(stopped due to Estimated GFR was determined not to be a reliable endpoint for this study. We identified significant variabilty in annual eGFR that it became inappropriate to randomize to a medication but use EGFR as the primary endpoint.)
Effect of the Administration of Losartan / Amlodipine in Fixed Combination Versus Losartan on Hemodynamic and Arterial Stiffness Parameters in Patients With Systemic Hypertension Grade 1 and 2 [NCT03626259]	Phase 4	28 participants (Anticipated)	Interventional	2018-08-06	Recruiting
Safety and Efficacy of Maximally Tolerated RAAS Blockade and Spironolactone Therapy on Urinary Proteinuria and Progression of Type II Diabetic Nephropathy in African Americans and Other Patient Cohorts. [NCT03502031]	Phase 4	72 participants (Anticipated)	Interventional	2018-10-01	Recruiting
Effect of Nighttime Losartan on Prognosis of Nocturnal Hypertension Patients Undergoing Continous Ambulatory Peritoneal Dialysis [NCT03692013]	Phase 4	68 participants (Anticipated)	Interventional	2018-12-01	Not yet recruiting
Renoprotection in Early Diabetic Nephropathy in Pima Indians [NCT00340678]	Phase 3	170 participants (Actual)	Interventional	1995-08-31	Completed
The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients [NCT01305850]	Phase 4	100 participants (Anticipated)	Interventional	2010-07-31	Recruiting
Pharmacokinetic Study of Propranolol, Losartan, and Eprosartan in Healthy Volunteers and Patients With Chronic Kidney Disease [NCT01087749]	Phase 1	24 participants (Actual)	Interventional	2010-03-31	Completed
Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition) [NCT01233635]	Phase 4	228 participants (Anticipated)	Interventional	2005-11-30	Terminated(stopped due to inadequate enrollment rate)
A Prospective, Randomised, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 or 80 mg p.o. Once Daily) and COZAAR® / LORZAAR® (Losartan) (50 or 100 mg p.o. Once Daily) in Patients With Mild-to-Moderate Hypertens [NCT02200653]	Phase 4	387 participants (Actual)	Interventional	2000-05-31	Completed
A Phase III, Randomized, Open-Label, Parallel-Group, Dose-Ranging Clinical Trial to Study the Safety and Efficacy of MK954/Losartan Potassium in Pediatric Patients With Hypertension [NCT00756938]	Phase 3	101 participants (Actual)	Interventional	2009-03-01	Completed
Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail [NCT05402397]	Phase 4	40 participants (Anticipated)	Interventional	2022-07-01	Recruiting
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control [NCT02521233]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Sponsor decision)
Matão Controlling Hypertension (MatCH Study): Rationale and Design. Project to Reduce Incidence of Arterial Hypertension in City of Matão, Brazil. [NCT03147092]	Early Phase 1	15,000 participants (Anticipated)	Interventional	2018-02-01	Not yet recruiting
Prognostic Effect of Isolated Nocturnal Hypertension Pattern With Nondialysis CKD [NCT03604003]		252 participants (Anticipated)	Interventional	2018-11-30	Not yet recruiting
The Role of Losartan in the Prevention of Early Structural Changes Associated With Radiation-Induced Heart Failure [NCT05607017]	Early Phase 1	10 participants (Anticipated)	Interventional	2023-10-15	Not yet recruiting
Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis-a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial [NCT02063100]	Phase 4	720 participants (Anticipated)	Interventional	2014-02-28	Recruiting
A Prospective, Randomized, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 & 80 mg QD) and COZAAR® (Losartan) (50 & 100 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Mon [NCT02200640]	Phase 4	333 participants (Actual)	Interventional	2000-03-31	Completed
INFLAMMATION AND DRUG METABOLISM - Does the Effect of Drugs Decrease When Patients With Type 2 Diabetes Initiate Antidiabetic Treatment? [NCT04504045]	Phase 1	10 participants (Actual)	Interventional	2020-09-01	Terminated(stopped due to Slow recruitment due to COVID-19, the study was stopped when recruited numbers fulfilled the pre-defined lower sample size.)
A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy [NCT02232776]	Phase 3	37 participants (Actual)	Interventional	2014-10-31	Completed
A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Different Doses of DuP 753 (MK0954) [NCT00882440]	Phase 3	576 participants (Actual)	Interventional	1990-12-31	Completed
Multicenter, Randomized, Open-label Trial to Assess the Efficacy of Sacubitril/Valsartan vs. Amlodipine/Losartan on Left Ventricular Remodeling in Patients With Chronic Severe Aortic Regurgitation [NCT05212597]	Phase 2	100 participants (Anticipated)	Interventional	2022-01-12	Recruiting
Post-Traumatic Stress Disorder and Cardiovascular Disease Risk: Role of Sympathetic Overactivity and Angiotensin II [NCT02560805]	Phase 2	134 participants (Anticipated)	Interventional	2015-10-31	Suspended(stopped due to Enrollment and study activities are temporarily suspended due to COVID-19.)
Bariatric Surgery and Pharmacokinetics of Losartan: BAR-MEDS Losartan [NCT03519893]		12 participants (Anticipated)	Observational	2016-11-02	Recruiting
The Effect of Continuing or Discontinuing ACE-I/ARBs Therapy on the Incidence of Contrast-induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Coronary Angiography; a Randomized Controlled Trial [NCT05271448]		600 participants (Anticipated)	Interventional	2021-06-01	Recruiting
Cardiorenal Effecs of Losartan in Kidney Transplant Recipients [NCT05243446]		740 participants (Anticipated)	Observational	2015-09-30	Recruiting
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid, and Tau in Older Adults (IPAT Study) [NCT05331144]	Phase 2	180 participants (Anticipated)	Interventional	2022-10-25	Recruiting
The Effects of Losartan and Spironolactone on Residual Renal Function Preservation in Peritoneal Dialysis Patients [NCT02190318]		96 participants (Anticipated)	Interventional	2013-11-30	Recruiting
[NCT01015937]		50 participants (Actual)	Interventional	2008-03-31	Completed
Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers; Open-label, Parallel Group [NCT02056743]	Phase 1	30 participants (Actual)	Interventional	2013-09-30	Completed
Adiponectin in Obese Women With T2DN and Effects by RAS Blocker [NCT00561704]		80 participants (Actual)	Interventional	2007-04-30	Completed
A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta [NCT06150560]	Phase 3	120 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME [NCT03878524]	Phase 1	2 participants (Actual)	Interventional	2020-04-01	Active, not recruiting
12 Week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Group Trial Comparing the Efficacy and Safety of 40 & 80 mg Telmisartan and 50 & 100 mg Losartan in the Treatment of 150 Pairs of Primary Hypertension Patients [NCT02269176]	Phase 3	330 participants (Actual)	Interventional	2000-07-31	Completed
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan (MK954, DuP753) in Patients With Mild to [NCT00887250]	Phase 3	366 participants (Actual)	Interventional	1991-12-31	Completed
A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Losartan After Oral Administration in Healthy Male Volunteer [NCT02212769]	Phase 1	12 participants (Actual)	Interventional	2014-08-31	Completed
The Effect of Losartan on Emotional Processing in Healthy Volunteers [NCT03434054]		30 participants (Actual)	Interventional	2016-06-01	Completed
Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Chloroquine + Low Dose Losartan Compared to Chloroquine Monotherapy in Subjects With SARS-CoV-2 Pneumonia [NCT04428268]	Phase 2	0 participants (Actual)	Interventional	2020-03-10	Withdrawn(stopped due to evidence showed chloroquine is not effective against COVID-19)
Losartan Effects on Emphysema Progression [NCT02696564]	Phase 4	220 participants (Actual)	Interventional	2017-05-23	Completed
A Single Dose, 2-Period, 2-Treatment Bioequivalency Study of Losartan Potassium Tablets 100 mg Under Fasted Conditions [NCT01216852]		40 participants (Actual)	Interventional	2004-08-31	Completed
An Open Label, Randomised, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. [NCT01218022]	Phase 1	0 participants	Interventional		Completed
An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Fixed Dose Combination (FDC) of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Ver [NCT01218724]	Phase 1	0 participants	Interventional		Completed
A PROBE (Prospective, Randomised, Open-label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80 mg Once Daily Compared With Losartan 50-100 mg Once Daily Over a Period of 12 Weeks, and of Telmisartan 80 mg + HCTZ 12.5 mg [NCT02172586]	Phase 4	363 participants (Actual)	Interventional	2000-01-31	Completed
The Effect of Ethosomal Gel Bearing Losartan 5% on The Patient and Observer Scar Assessment Scale Score, Degree of Erythema and Pigmentation, Surface Area, Thickness and Pliability of Human Keloids [NCT05893108]	Phase 1/Phase 2	46 participants (Anticipated)	Interventional	2024-03-30	Not yet recruiting
A Double-blind, Randomized, Parallel-group, Placebo-controlled Pilot Study to Investigate the Magnitude and Duration of Response and the Safety of MK0954 (50 mg Given Once or Twice Daily, or 100 mg Given Once Daily) Compared to Placebo Using Ambulatory Bl [NCT00886600]	Phase 3	122 participants (Actual)	Interventional	1991-05-31	Completed
A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide Tablets 100 mg/25 mg Under Fed Conditions [NCT01102465]		25 participants (Actual)	Interventional	2005-02-28	Completed
Double-blind, Randomized, Parallel-group, Dose Ranging, Multicenter Study to Evaluate the Efficacy and Safety of 2.5, 10, 35 and 50 mg AVE 7688 Once Daily, Using 100 mg Losartan-potassium Once Daily as Calibrator, for 12 Months Treatment, in Patients With [NCT00284128]	Phase 2/Phase 3	1,940 participants (Actual)	Interventional	2005-12-31	Completed
Angiotensin-II Receptor Antibody Blockade With Losartan in Patients With Lupus Nephritis [NCT03526042]		40 participants (Anticipated)	Interventional	2017-09-10	Recruiting
Phase 4 Study of the Renoprotective Efficacy of Aliskiren in Addition to Angiotensin II Receptor Blocker in Chronic Kidney Disease [NCT01150201]	Phase 4	80 participants (Anticipated)	Interventional	2009-07-31	Completed
Prevention of Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer [NCT01281787]	Phase 3	320 participants (Actual)	Interventional	2008-04-30	Completed
Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD): A Phase 2, Randomized, Placebo-Controlled Clinical Trial [NCT03467217]	Phase 2	83 participants (Actual)	Interventional	2018-10-02	Terminated(stopped due to Trial stopped for futility)
A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects [NCT01197001]	Phase 1	72 participants (Anticipated)	Interventional	2010-08-31	Completed
Biologically Regulated Marrow Stimulation by Blocking Fibrosis to Improve Cartilage Repair: A Randomized Double-Blind, Placebo-Controlled Study [NCT04212650]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2020-08-07	Terminated(stopped due to redesigned trial using another placebo controlled drug)
A Randomized, Open Label, Multiple Dose, Crossover Study to Investigate Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide(HCTZ) in Subjects With (Pre)Hypertension [NCT01198249]	Phase 1	23 participants (Actual)	Interventional	2010-09-30	Completed
[NCT02620306]	Phase 3	351 participants (Actual)	Interventional	2016-02-11	Completed
Influence of Losartan and Diphenhydramine on Emotional and Cognitive Functions in Healthy Human Subjects [NCT01321021]		80 participants (Actual)	Interventional	2011-03-31	Completed
Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile [NCT01320397]	Phase 2	240 participants (Anticipated)	Interventional	2011-05-31	Not yet recruiting
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan Cilexetil + Chlorthalidone (16mg + 12.5mg and 16mg + 25mg) Compared With HYZAAR® in Hypertension Control [NCT02521246]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Sponsor decision)
Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection [NCT04340557]	Phase 4	31 participants (Actual)	Interventional	2020-03-27	Completed
A Phase III, Randomized, Active-comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954A in Japanese Patients With Essential Hypertension Uncontrolled With the High Dose of Losartan Potassium [NCT01307046]	Phase 3	336 participants (Actual)	Interventional	2011-03-29	Completed
Randomized Open-label Trial to Evaluate the Effectiveness of Diet Management With a Losartan Titration Regimen Versus Losartan Titration Regimen Alone on Blood Pressure Reduction in Hypertensives. [NCT00739674]	Phase 3	992 participants (Actual)	Interventional	2008-02-01	Completed
Evaluate the Safety and Tolerability of Hyzaar(R) (Losartan 50 Mg/ Hydrochlorothiazide 12.5 Mg) In the Treatment of Hypertension [NCT00400218]	Phase 3	62 participants (Actual)	Interventional	2005-09-01	Completed
The Effect of Losartan on Emotional Memory in Healthy Volunteers [NCT03763409]		53 participants (Actual)	Interventional	2018-03-01	Completed
The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients [NCT05232370]	Phase 2	39 participants (Actual)	Interventional	2022-01-01	Completed
Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose [NCT00673790]	Phase 4	537 participants (Actual)	Interventional	2008-05-15	Completed
Two-Part,Multicenter,Randomized,Double-Blind,Placebo-Controlled,Study to Evaluate the Effect of Simvastatin,Losartan,and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised From Patients w/PAD [NCT00720577]	Early Phase 1	164 participants (Actual)	Interventional	2005-12-31	Completed
A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Renal Transplant [NCT00140907]	Phase 4	367 participants (Actual)	Interventional	2000-03-14	Completed
Efficacy of Losartan in Preventing Progression of COPD [NCT00720226]	Phase 4	106 participants (Actual)	Interventional	2008-07-31	Completed
The Effect of Losartan Versus Amlodipine-based Antihypertensive Therapy on Atherosclerotic Inflammatory Markers and Cerebrovascular Regulation in Ischemic Stroke Patients [NCT00754429]	Phase 4	40 participants (Actual)	Interventional	2004-06-30	Completed
The Efficacy and Safety of Losartan/Hydrochlorothiazide Combination Drug (Preminent) in Patients With Morning Hypertension [NCT00795847]	Phase 4	216 participants (Actual)	Interventional	2008-11-30	Completed
The Effect of Losartan on Emotion Regulation [NCT05828940]		41 participants (Actual)	Interventional	2019-10-01	Completed
Telmisartan Promotes the Differentiation of Monocytes Into Macrophages M2 in Diabetic Nephropathy? [NCT02768948]		20 participants (Actual)	Interventional	2017-05-05	Completed
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial [NCT02231125]	Phase 4	1,600 participants (Anticipated)	Interventional	2014-09-30	Recruiting
A Prospective, Randomized, Cross-over Study Evaluating the Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria [NCT02232763]	Phase 3	58 participants (Actual)	Interventional	2014-09-30	Completed
A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Losartan Given Once or Twice Daily in Patients With Mild to Moderate Hypertension [NCT00888355]	Phase 3	428 participants (Actual)	Interventional	1992-05-31	Completed
Effects of Low-Dose vs High-dose Losartan on Sympathetic Hyperactivity in Patients With Congestive Heart Failure [NCT02238457]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to Difficulty recruiting patients)
Camrelizumab Combined With Liposomal Doxorubicin and Losartan in the Treatment With Advanced or Locally Advanced Triple-negative Breast Cancer Who Have Received no More Than 1 Prior Line of Chemotherapy [NCT05097248]	Phase 2	52 participants (Anticipated)	Interventional	2021-10-31	Not yet recruiting
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease [NCT04394117]	Phase 4	787 participants (Actual)	Interventional	2020-06-19	Completed
Kidney Disease in Type 2 Diabetes Mellitus: Biomarker Discovery and Novel Therapeutics [NCT02410005]	Phase 2/Phase 3	56 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Logistic challenges)
Long - Term Effect of Quinapril or Losartan or Their Combination on Diabetic Autonomic Neuropathy and Left Ventricular Function Over a Period of 4 Years. A Radionuclide Ventriculography Study. [NCT05713396]	Phase 4	59 participants (Actual)	Interventional	2017-01-01	Completed
A Prospective Randomised Open-Label Blinded Endpoint Trial Comparing Telmisartan 80 mg and Losartan 50 mg + Hydrochlorothiazide 12.5 mg (Fixed Dose Combination) in Patients With Mild-to-Moderate Essential Hypertension Using Ambulatory Blood Pressure Monit [NCT02183701]	Phase 3	715 participants (Actual)	Interventional	1998-04-30	Completed
A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 100mg Versus Losartan 100mg in Patients With Essential Hypertension Not Controlled on Losartan Monotherapy [NCT00940680]	Phase 3	142 participants (Actual)	Interventional	2008-04-30	Completed
Effect of Aliskiren on Arterial Stiffness and Platelet Function in Patients With Type 2 Diabetes Mellitus, a Comparison With Losartan [NCT00732407]		40 participants (Anticipated)	Interventional	2008-09-30	Not yet recruiting
Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network) [NCT00429364]	Phase 3	608 participants (Actual)	Interventional	2007-01-31	Completed
A Double-Blind, Double Dummy, Randomized, Placebo-Controlled, Alternating Panel, Single Oral Rising Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of MK1809 in Healthy Young Volunteers [NCT01033318]	Phase 1	30 participants (Actual)	Interventional	2007-09-11	Completed
Window of Opportunity for Neoadjuvant Stroma Modification in Pancreatic Cancer [NCT05365893]	Early Phase 1	20 participants (Anticipated)	Interventional	2021-10-20	Recruiting
Comparison of the Efficacy of Olmesartan Medoxomil Versus Losartan on Diastolic Blood Pressure in Elderly and Very Elderly Patients With Essential Hypertension. [NCT00751751]	Phase 3	441 participants (Actual)	Interventional	2003-06-30	Completed
Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Continuous Ambulatory Peritoneal Dialysis Patients: An Open-Label Randomized-Controlled Trial [NCT03953950]	Phase 4	84 participants (Anticipated)	Interventional	2019-10-31	Not yet recruiting
A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essentia [NCT00219141]	Phase 3	460 participants (Actual)	Interventional	2005-10-31	Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
Comparison of Effects Between Calcium Channel Blocker and Diuretics in Combination With Angiotensin II Receptor Blocker on 24-hr Central Blood Pressure and Vascular Hemodynamic Parameters in Hypertensive Patients Multicenter, Double-blind, Active-controll [NCT02294539]	Phase 4	231 participants (Actual)	Interventional	2014-08-31	Completed
Rationale and Design of a Simple Randomized Trial Evaluating Losartan and Perindopril in Blacks Type 2 Diabetics Patients: the Cardiac and Renal Protection With Losartan or Perindopril (CARE-PLP) Trial [NCT04222686]	Phase 4	23 participants (Actual)	Interventional	2017-12-20	Completed
A Randomized, Comparator-controlled, Cross-over Intervention Study to Assess Renal Hemodynamics of Mono- and Combination Therapy With SGLT-2 Inhibitor Empagliflozin and RAS-inhibitor Losartan in Patients With Type 2 Diabetes Mellitus [NCT04238702]	Phase 4	24 participants (Actual)	Interventional	2020-11-04	Completed
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study) [NCT00555217]	Phase 3	1,448 participants (Actual)	Interventional	2008-07-31	Terminated(stopped due to It was stopped primarily because of safety concerns along with low conditional power to detect a treatment effect on the primary outcome.)
Clinical Protocol For A Double-Blind, Randomized, Active- Controlled Comparison Study Of The Antihypertensive Effect Of Eplerenone Versus Losartan In Patients With Mild To Moderate Hypertension [NCT00649311]	Phase 2	248 participants (Actual)	Interventional	2003-04-30	Terminated(stopped due to Poor enrollment; termination not due to safety reasons.)
Resveratrol's Effects in Diabetic Nephropathy [NCT02704494]	Early Phase 1	60 participants (Actual)	Interventional	2016-03-31	Completed
Effects Of Losartan On Myocardial Structure And Function And On Epicardial Fat Deposition In Diabetic Hypertensive Patients With Left Ventricular: Qualitative And Quantitative Alteration [NCT00659451]	Phase 3	100 participants (Anticipated)	Interventional	2008-04-30	Recruiting
Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients [NCT00669435]	Phase 4	75 participants (Anticipated)	Interventional	2008-04-30	Recruiting
"A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a Real-liFe GP sEtting in Sweden" [NCT00620178]		14,000 participants (Anticipated)	Observational	2008-03-31	Completed
Evaluation of Antihypertensive Activity of Valsartan and Amlodipine Compared to Losartan and Amlodipine Through Ambulatory Blood Pressure Monitoring in Moderate Hypertensive Patients in a Randomized, Controlled, Double-Blind Study [NCT00716950]	Phase 4	187 participants (Anticipated)	Interventional	2008-07-31	Recruiting
Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations. [NCT00683124]	Phase 3	291 participants (Anticipated)	Interventional	2008-07-31	Recruiting
A Randomized, Double-blind, Double-dummy, Multi-center Study to Investigate the Safety and Efficacy of Olmesartan Medoxomil Compared With Losartan Potassium in Patients With Mild to Moderate Essential Hypertension [NCT00856271]	Phase 3	287 participants (Actual)	Interventional	2004-08-31	Completed
A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 50mg Versus Amlodipine 10mg in Patients With Essential Hypertension Not Controlled on Amlodipine Monotherapy [NCT00940667]	Phase 3	185 participants (Actual)	Interventional	2008-05-31	Completed
The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients [NCT01041963]	Phase 4	90 participants (Anticipated)	Interventional	2009-06-30	Recruiting
Effect of Acute Angiotensin Receptor Blockade on Insulin Resistance and Selected Cytokines in Adipose Tissue in Type 2 Diabetes [NCT01011062]		23 participants (Actual)	Interventional	2004-01-31	Completed
A Comparison Between Diuretics and Angiotensin-receptor Blocker Agents in Patients With Stage I Hypertension: PREVER-treatment Study [NCT00971165]	Phase 3	655 participants (Actual)	Interventional	2010-07-31	Completed
Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes [NCT00981929]		412 participants (Anticipated)	Interventional	2009-09-30	Terminated(stopped due to Unexpected non-serious adverse events)
The Effect of Azilsartan in Patients With Diabetic Kidney Disease and Hypertension [NCT05753696]		106 participants (Anticipated)	Interventional	2023-04-01	Recruiting
Rosiglitazone Versus Rosiglitazone and Metformin (Avandamet) Versus Combination Rosiglitazone and Losartan in the Treatment of Nonalcoholic Steatohepatitis (NASH). A Prospective, Open-Label, Randomized Trial [NCT00699036]	Phase 2	165 participants (Anticipated)	Interventional	2007-04-30	Recruiting
Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers [NCT00782327]	Phase 3	22 participants (Actual)	Interventional	2009-11-01	Completed
[NCT02663141]	Phase 2	57 participants (Actual)	Interventional	2015-06-30	Completed
Losartan Improved Insulin Resistance and Decreased Inflammatory Cytokines in Patients With Chronic Heart Failure Treated With Angiotensin Converting Enzyme Inhibitors [NCT00663377]	Phase 4	16 participants (Anticipated)	Interventional	2006-04-30	Completed
A Randomized Trial to Establish the Effects of Combination Pill of Losartan Potassium and Hydrochlorothiazide on Medication Compliance Among Patients With High Blood Pressure. [NCT00670787]	Phase 3	207 participants (Actual)	Interventional	2008-06-30	Completed
Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure. [NCT00456963]	Phase 4	3,000 participants (Anticipated)	Interventional	2007-09-30	Terminated(stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.)
Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome [NCT00723801]	Phase 3	40 participants (Actual)	Interventional	2007-10-31	Completed
Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan [NCT00774904]		80 participants (Actual)	Interventional	2007-04-30	Completed
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Nebivolol Added To Antihypertensive Treatment With Lisinopril or Losartan in Patients With Hypertension. [NCT00734630]	Phase 4	491 participants (Actual)	Interventional	2008-08-31	Completed
An Open-label, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Amlodipine in Combination With Valsartan Compared to Losartan in Combination With Hydrochlorothiazide Given for 52 Weeks on the Regression of Left Ventricular Hypertrophy [NCT00446563]	Phase 3	90 participants (Actual)	Interventional	2007-03-31	Completed
Multicenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome [NCT00763893]	Phase 3	303 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to A similar publication has been released, suggesting a beneficial effect of sartans, and only 15 patients remained to be seen for their visit at 36 months.)
A Relative Bioavailability Study of 100/25 mg Losartan Potassium/Hydrochlorothiazide Tablets Under Fasting Conditions [NCT01149486]	Phase 1	20 participants (Actual)	Interventional	2004-01-31	Completed
The Effect of Losartan Treatment on Matrix Metalloproteinase Levels and Outcomes in Bicuspid Aortic Valve Patients [NCT01390181]		4 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to Due to low enrollment the decision was made to terminate study prior to final data collection for any individual.)
A Randomized, Double-blind, Losartan-controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg~120mg in Patients With Mild to Moderate Essential Hypertension [NCT00922480]	Phase 3	506 participants (Actual)	Interventional	2008-12-31	Completed
The Effect of Losartan on Atrial Fibrillation and Pacemaker Dependence in Sick Sinus Syndrome (SSS) Patients Receiving Physiological Pacemaker - A Prospective, Randomized, Multicenter Study in Taiwan [NCT00647257]		220 participants (Anticipated)	Interventional	2008-04-30	Recruiting
A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome [NCT00651235]	Phase 2	44 participants (Anticipated)	Interventional	2007-02-28	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, 4-Treatment, 3-Period, Incomplete Block, Balanced Crossover Study to Evaluate the Effects of a Single Dose of Aliskiren and Losartan on Renal Blood Flow Measurements in Healthy Male Subjects [NCT00856960]	Phase 1	12 participants (Actual)	Interventional	2010-01-31	Completed
Polypill Strategy for Prevention of Cardiomyopathy Among Patients With Diabetes at Risk of Heart Failure [NCT06143566]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2023-12-29	Not yet recruiting
Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics? [NCT00732966]		30 participants (Anticipated)	Interventional	2008-09-30	Not yet recruiting
Enhancing Fear Extinction Via Angiotensin Type 1 Receptor Inhibition: A Randomized Controlled Trial in Posttraumatic Stress Disorder [NCT02709018]		149 participants (Actual)	Interventional	2016-07-16	Completed
A Relative Bioavailability Study of Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets Under Non-Fasting Conditions [NCT01149473]	Phase 1	80 participants (Actual)	Interventional	2004-03-31	Completed
Pilot Trial: the Safety and Feasibility of Losartan Therapy for Treatment of Pulmonary Vein Stenosis in Pediatric Patients [NCT02769130]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2016-05-31	Suspended(stopped due to Due to Health Canada losartan recall, a new formulation being added to the protocol/ temporary suspension)
Hypertension Control Based on Home Systolic Pressure Study (HOSP Study) [NCT00198562]	Phase 4	2,600 participants (Anticipated)	Interventional	2000-04-30	Active, not recruiting
Benefit of Treatment With Losartan and Spironolactone on the Regulation of the Renin-angiotensin System in the Prognosis of Patients Infected With COVID-19 and Suffering From Acute Respiratory Distress Syndrome [NCT04643691]	Phase 2	90 participants (Anticipated)	Interventional	2020-09-11	Recruiting
A Prospective Multicenter Randomized Controlled Trial of Efficacy and Safety of Renal Denervation for Resistant Hypertension [NCT02900729]	Phase 3	254 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome [NCT00546052]	Phase 3	1,738 participants (Actual)	Interventional	2005-09-01	Completed
A Randomised, Controlled Trial of Losartan as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis [NCT01051219]	Phase 3	45 participants (Actual)	Interventional	2011-05-31	Completed
Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension [NCT00994617]	Phase 4	600 participants (Anticipated)	Interventional	2010-01-31	Recruiting
A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia [NCT04074551]	Phase 3	145 participants (Actual)	Interventional	2019-07-16	Completed
Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients [NCT05871333]	Phase 2	80 participants (Anticipated)	Interventional	2023-07-17	Recruiting
[NCT00530595]		0 participants	Interventional		Completed
NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial [NCT02817360]	Phase 4	2,400 participants (Anticipated)	Interventional	2016-02-29	Recruiting
A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects [NCT00949884]	Phase 4	941 participants (Actual)	Interventional	2009-08-31	Completed
A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors [NCT00140985]	Phase 4	97 participants (Actual)	Interventional	2000-02-29	Completed
A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension [NCT00931710]	Phase 4	488 participants (Actual)	Interventional	2009-07-31	Completed
Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment [NCT00701428]	Phase 4	90 participants (Actual)	Interventional	2008-06-30	Completed
An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatme [NCT02760615]	Phase 4	0 participants (Actual)	Interventional	2016-11-01	Withdrawn(stopped due to No enrollment)
[NCT01858623]		18 participants (Actual)	Interventional	2013-02-28	Completed
Comparative, Randomized,, Single Dose, Open-label, Crossover Bioequivalence Study of LOSANET AM PLUS 10mg/100mg/12.5 mg Tablets (One Tablet) of (PHARMALINE, Lebanon) Versus NORVASC 10mg Tablets (One Tablet) of (Pfizer Canada Inc., Kirkland (Quebec)) and H [NCT01713647]	Phase 1	39 participants (Actual)	Interventional	2012-10-31	Completed
Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment [NCT00151827]	Phase 3	393 participants (Actual)	Interventional	2003-08-31	Completed
A Pilot Project to Determine the Effect of Losartan (Cozaar) on Radiation-Induced Pulmonary Fibrosis in Patients With Non-Small Cell Lung Cancer [NCT00880386]		0 participants (Actual)	Interventional	2009-03-31	Withdrawn(stopped due to Study concept was not approved by NCI. Study was never activated. No enrollment)
Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial [NCT00813722]	Phase 4	400 participants (Actual)	Interventional	1999-03-31	Active, not recruiting
Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension [NCT00152633]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2005-09-30	Withdrawn(stopped due to No patient could be recruited.)
A Double-Blind, Randomized, Parallel, Efficacy Study Evaluating Losartan Potassium Alone or in Combination With Hydrochlorothiazide Versus Placebo in Obese Patients With Elevated Systolic and Diastolic Blood Pressure [NCT00289887]	Phase 3	261 participants (Actual)	Interventional	2006-02-28	Completed
A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Losartan Potassium in Healthy Male and Female Adults [NCT01324752]	Phase 1	36 participants (Actual)	Interventional	2011-03-31	Completed
An Open Label, Single Arm Prospective Study to Evaluate Efficacy and Safety of Losartan Based Therapy Reslio® (Losartan) and Resilo-h® (Losartan+Hydrochlorthiazide) in Diabetic and Uncontrolled Hypertensive Patients [NCT03978884]	Phase 4	0 participants (Actual)	Interventional	2019-06-01	Withdrawn(stopped due to Unable to effective arrange trial logistics)
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome [NCT00467831]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to insufficient enrollment)
Angiotensin II Blockade for the Prevention of Cortical Interstitial Expansion and Graft Loss in Kidney Transplant Recipients [NCT00067990]	Phase 4	153 participants (Actual)	Interventional	2002-12-31	Completed
Evaluation Of The Effect Of PF-05089771 On The Metabolism Of Multiple Cytochrome P450 And OATP1B1 Transporter Substrates [NCT01934569]	Phase 1	17 participants (Actual)	Interventional	2013-09-30	Completed
The COMPAriSon of Systolic Blood Pressure Variability and Central Blood Pressure of Calcium Channel Blocker (Amlodipine) in Comparison With Angiotensin Receptor Blocker (Losartan) in Patients With Essential Hypertension [NCT01964079]	Phase 4	144 participants (Actual)	Interventional	2013-04-30	Completed
Losartan Treatment for Sickle Cell Chronic Kidney Disease [NCT01989078]	Early Phase 1	24 participants (Actual)	Interventional	2012-12-31	Completed
The Role of the Renin-angiotensin System in Emotion-memory Interactions [NCT04606225]		60 participants (Anticipated)	Interventional	2020-10-10	Recruiting
The Role of the Renin-angiotensin System in Reward Reinforcement Learning [NCT04604938]		60 participants (Anticipated)	Interventional	2020-10-10	Recruiting
Multi-Center,Double-Blind,Randomized,Controlled Clinical Trial of Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3 [NCT00565396]		400 participants (Anticipated)	Interventional	2004-09-30	Active, not recruiting
Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System [NCT02010905]	Phase 2	120 participants (Anticipated)	Interventional	2013-12-31	Recruiting
Study of Vascular Responsiveness in Subjects With Polymorphisms of the Angiotensin II Type I Receptor Gene [NCT00001741]	Phase 1	200 participants	Interventional	1997-11-30	Completed
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? [NCT04606563]	Phase 3	341 participants (Actual)	Interventional	2020-10-09	Terminated(stopped due to DSMC recommendation due to futility)
Losartan Effects on the Emotion Processing in Humans [NCT04606212]		90 participants (Anticipated)	Interventional	2020-10-10	Recruiting
Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL) [NCT00237588]	Phase 4	25 participants	Interventional	2004-12-31	Completed
Losartan Effects on the Social Reward in Humans [NCT04604756]		90 participants (Anticipated)	Interventional	2020-10-10	Recruiting
Randomised Placebo Controlled Clinical Trial of Efficacy of MYOcardial Protection in Patients With Postacute inFLAMmatory Cardiac involvEment Due to COVID-19 [NCT05619653]	Phase 3	280 participants (Anticipated)	Interventional	2022-12-12	Recruiting
A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor 9-ING-41 and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Cancer [NCT05077800]	Phase 2	70 participants (Anticipated)	Interventional	2022-03-21	Recruiting
A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and [NCT01371747]	Phase 2	324 participants (Actual)	Interventional	2011-06-30	Completed
Early and Late Cardiac Effects of Arteriovenous Fistula Creation for Haemodialysis in End-stage Renal Failure and Their Possible Attenuation [NCT00602004]		52 participants (Anticipated)	Interventional	2006-10-31	Completed
Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis [NCT00805311]	Phase 4	400 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Due to the clear advantage of carotid endarterectomy)
A Randomized Clinical Trial to Evaluate the Effects of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI [NCT03632213]	Phase 2	10 participants (Actual)	Interventional	2018-11-07	Active, not recruiting
"The ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling (ALLMARK) Study" [NCT01176032]	Phase 4	74 participants (Actual)	Interventional	2010-06-30	Completed
A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients [NCT05637216]	Phase 2	40 participants (Anticipated)	Interventional	2023-08-17	Recruiting
Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension. [NCT00140959]	Phase 4	120 participants	Interventional	2003-02-01	Completed
Randomized, 2-way Crossover, Bioequivalence Study of Losartan 100 mg Tablets and Cozaar® Administered as 1 * 100 mg Tablet in Healthy Subjects Under Fasting Conditions [NCT01124162]	Phase 1	80 participants (Actual)	Interventional	2003-10-31	Completed
An Open-Label, Randomized, 2-Period Crossover Study to Evaluate the Bioequivalence After Administration of a Losartan 100-mg/Hydrochlorothiazide 12.5-mg Combination Tablet and the Coadministration of a Currently Marketed COZAAR™ 100-mg Tablet and MICROZID [NCT00953680]	Phase 1	77 participants (Actual)	Interventional	2004-04-30	Completed
Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency [NCT00630708]		309 participants (Anticipated)	Interventional	2008-02-29	Terminated(stopped due to Significant differences observed between groups.)
[NCT00533858]	Phase 4	160 participants (Anticipated)	Interventional	2007-09-30	Recruiting
A Double-Blind, Randomized, Placebo-Controlled, 5-Period Crossover Study to Evaluate the Effects of a Single Dose of Losartan, a Single Dose of Isosorbide Mononitrate (ISMN), and Single Doses of Losartan + ISMN on Central Blood Pressure Measurements in Mi [NCT00943852]	Phase 1	13 participants (Actual)	Interventional	2006-08-31	Completed
[NCT00561327]		0 participants	Observational	2007-09-30	Recruiting
The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension [NCT00185094]	Phase 4	60 participants	Interventional	2004-02-29	Completed
Multifactorial Intervention to Prevent Cardiovascular Disease in Patients With Early Rheumatoid Arthritis [NCT02246257]		300 participants (Anticipated)	Interventional	2014-09-30	Recruiting
Randomized, Phase 3, Multicenter, Open Label, Evaluating the Effect of the Treatment of Indapamide 1.5mg/Losartan 50mg and Indapamide 1.5mg/Losartan 100mg, Compared With Hyzaar® in the Treatment of Hypertension [NCT01620788]	Phase 3	636 participants (Anticipated)	Interventional	2019-11-27	Suspended(stopped due to Substancial amendment)
Qianyangyuyin Formula Prevent and Treat for Early Renal Injury in Hypertensive Patients [NCT04078711]	Phase 2/Phase 3	520 participants (Anticipated)	Interventional	2019-09-10	Not yet recruiting
Pharmacogenetic of the Antihypertensive Response to the Angiotensin II Blockers in Monotherapy or Associated to Hydrochlorothiazide [NCT00617877]		800 participants (Actual)	Interventional	2005-03-31	Completed
Phase II Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer: OVERPASS Trial [NCT05861336]	Phase 2	34 participants (Anticipated)	Interventional	2023-05-31	Not yet recruiting
Short-term add-on Therapy With Angiotensin Receptor Blocker for End-stage Inotrope-dependent Heart Failure Patients: B-type Natriuretic Peptide Reduction in a Randomized Clinical Trial [NCT01857999]	Phase 4	21 participants (Actual)	Interventional	2008-09-30	Completed
A Randomized Double-blind Study Assessing the Effects of Losartan Versus Atenolol on Pulse Wave Velocity and the Biophysical Properties of the Aorta in Patients With Marfan Syndrome [NCT00593710]	Phase 2	17 participants (Actual)	Interventional	2008-01-31	Completed
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605 [NCT02916602]	Phase 3	340 participants (Actual)	Interventional	2015-04-30	Completed
Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study [NCT00446862]		36 participants (Actual)	Observational	2007-03-31	Completed
A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration [NCT01302691]	Phase 3	327 participants (Actual)	Interventional	2011-01-01	Completed
Comparative Trial of Combination Therapy of ARB/Diuretic Versus ARB/CCB in Uncontrolled Hypertensive Patients With Monotherapy of ARB [NCT00492128]	Phase 4	196 participants (Actual)	Interventional	2007-09-30	Completed
Losartan Decreases Pulmonary Artery Pressure and Improves Exercise Capacity in Patients With Pulmonary Hypertension [NCT00519870]	Phase 3	0 participants	Interventional	2005-01-31	Completed
"A Randomized, Open-label, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover Bioequivalence Study of Test Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) of Pharmtechnology LLC, Republic of Belarus With Reference Cozaar® (C [NCT03459911]	Phase 1	66 participants (Actual)	Interventional	2018-02-16	Completed
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma [NCT01199978]	Phase 2	30 participants (Actual)	Interventional	2011-03-08	Active, not recruiting
Effects of Angiotensin Converting Enzyme Inhibitors on Patency of Arterio-Venous Fistulas: A Randomized Controlled Trial [NCT05132712]	Early Phase 1	100 participants (Anticipated)	Interventional	2021-10-01	Recruiting
Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) [NCT04328012]	Phase 2/Phase 3	15 participants (Actual)	Interventional	2020-04-06	Terminated(stopped due to difficult enrollment)
Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of COZAAR XQ in Usual Practice [NCT01041807]		669 participants (Actual)	Observational	2010-02-28	Completed
Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis. [NCT00298714]	Phase 4	20 participants	Interventional	2003-03-31	Completed
A Muticenter, Randomized, Double-blind, Parallel, Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension [NCT03897868]	Phase 2	248 participants (Actual)	Interventional	2019-03-21	Completed
INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan. [NCT01447654]	Phase 2	130 participants (Actual)	Interventional	2011-11-30	Completed
A Randomized, Double-Blind, Parallel-Group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5 mg in Comparison With Losartan 50 mg Plus Hydrochlorothiazide 12.5 mg in Taiwanese Patients With Mild to Moderate Hypertensi [NCT00133185]	Phase 3	31 participants	Interventional	2004-03-31	Completed
Renin Angiotensin System Blockage-DN (RASS) [NCT00143949]	Phase 2	285 participants (Actual)	Interventional	1997-03-31	Completed
[NCT00155064]	Phase 4	100 participants (Anticipated)	Interventional	2002-07-31	Completed
Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease: A Prospective, Phase II Study. [NCT05012631]	Phase 2	24 participants (Anticipated)	Interventional	2021-09-01	Recruiting
Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study [NCT01845688]		72 participants (Actual)	Interventional	2011-11-30	Completed
Telmisartan vs. Losartan in Hypertensive Patients With Impaired Glucose Tolerance: A Comparison of Their Antihypertensive, Metabolic, and Vascular Effects [NCT00407862]	Phase 4	24 participants	Interventional	2005-01-31	Completed
A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome [NCT00234858]	Phase 4	280 participants (Actual)	Interventional	2004-03-31	Completed
Randomized, 2-way Crossover, Bioequivalence Study of Losartan 100 mg Tablets and Cozaar® Administered as 1 * 100 mg Tablet in Healthy Subjects Under Fed Conditions [NCT01124175]	Phase 1	80 participants (Actual)	Interventional	2003-10-31	Completed
A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipi [NCT01541943]	Phase 3	356 participants (Actual)	Interventional	2012-03-31	Completed
Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects [NCT00388388]	Phase 2	1 participants (Actual)	Interventional	2007-03-31	Terminated(stopped due to Few subjects recruited, sponsor withdrew support.)
Compare Efficacy of the Angiotensin Converting Enzyme Inhibitor (ACEi) Lisinopril With Angiotensin II Receptor Antagonist Losartan (ARB) for the Cardiomyopathy of Duchenne Muscular Dystrophy [NCT01982695]		23 participants (Actual)	Interventional	2009-03-31	Completed
Comparison of Blood Pressure Lowering Effect Between Fimasartan and Losartan in the Hypertensive Patient During Night and Early Morning Time [NCT02958631]	Phase 4	40 participants (Anticipated)	Interventional	2014-11-30	Active, not recruiting
[NCT01806324]	Phase 1	30 participants (Actual)	Interventional	2012-04-30	Completed
Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial [NCT01805453]	Phase 3	80 participants (Actual)	Interventional	2013-03-29	Completed
A Randomized, Double-blinded, Placebo-controlled Study of Angiotensin II Receptor Blockade to Prevent Renal Dysfunction Following Liver Transplantation. [NCT00275639]	Phase 4	62 participants (Anticipated)	Interventional	2004-12-31	Completed
A Study of Muscle Strength Maintenance in Older Adults [NCT01989793]	Phase 2	37 participants (Actual)	Interventional	2013-07-31	Completed
The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure [NCT00223717]	Phase 1	152 participants (Actual)	Interventional	2001-01-31	Completed
Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan [NCT06108063]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2023-11-01	Recruiting
Comparative Effectiveness of Ambulatory Blood Pressure Monitoring vs Usual Care for Diagnosing and Managing Hypertension: A Pilot Study [NCT02121041]		28 participants (Actual)	Interventional	2014-05-31	Completed
Antihypertensive Effect of Different Doses of ROSTAFUROXIN in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile. [NCT03217825]	Phase 2	240 participants (Actual)	Interventional	2015-12-31	Completed
No Pharmacokinetic Interaction Between Chlorthalidone and Losartan, in Healthy Volunteers Under Fasting Conditions, Administered in Fixed Combination Against Individual Components Administered Jointly and Separately [NCT05090449]	Phase 1	36 participants (Actual)	Interventional	2019-05-01	Completed
Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas [NCT01276613]	Early Phase 1	18 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to Per memo from study team)
Novel Therapies for Resistant Focal Segmental Glomerulosclerosis [NCT00814255]	Phase 2	32 participants (Actual)	Interventional	2008-12-31	Completed
A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients [NCT03357653]	Phase 3	174 participants (Anticipated)	Interventional	2018-01-30	Not yet recruiting
Comparison of the Effects of Amlodipine and Losartan on Blood Pressure and Diurnal Variation in Hypertensive Stroke Patients [NCT01830517]	Phase 4	84 participants (Actual)	Interventional	2007-08-31	Completed
Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria [NCT00369538]	Phase 4	20 participants (Anticipated)	Interventional	2006-08-31	Suspended(stopped due to principle investigator moved, new investigators will join, insurance expired - project needs to be re-examined by an ethic committee)
ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension [NCT03295734]	Phase 2	213 participants (Anticipated)	Interventional	2018-05-29	Recruiting
An Eight-week, Randomized, Double-blind Multicenter Study to Compare the Efficacy and Safety of Amosartan® Tab 5/100mg Versus Cozaar® Plus Pro Tab in Patients With Essential Hypertension Uncontrolled With Losartan 100mg Monotherapy [NCT01828359]	Phase 4	199 participants (Actual)	Interventional	2010-08-31	Completed
Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis - a Prospective Randomized Long-Term Study [NCT00239096]	Phase 4	100 participants	Interventional	2005-09-30	Recruiting
An Open-label, Randomized, Single Dose, Three-way Crossover Study to Determine the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine (5mg) and Losartan (100mg) in Healthy Adult Male and Female Subjects Under Fasti [NCT01648231]	Phase 1	23 participants (Actual)	Interventional	2012-08-06	Completed
A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group 6-week Treatment Study Comparing Telmisartan Combined With Hydrochlorothiazide (40 mg/12.5 mg or 80 mg/12.5 mg) Tablets With Losartan Combined With Hydrochlorothiazide (50 mg/12.5 mg) [NCT00274638]	Phase 4	805 participants (Actual)	Interventional	2002-07-31	Completed
Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria [NCT00280215]	Phase 3	0 participants (Actual)	Interventional	2007-12-31	Withdrawn(stopped due to Inadequate number of patients, lack of funding)
A Phase II Study of the Effect of ACE Inhibitors on Pro-Angiogenic Hormones in Cancer Patients With Hypertension [NCT01234922]	Phase 2	6 participants (Actual)	Interventional	2011-02-28	Terminated(stopped due to slow accrual)
Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus [NCT00419835]	Phase 4	80 participants (Actual)	Interventional	2005-05-31	Completed
The Effects of Mycophenolate Mofetil on Renal Outcomes in Patients With Advanced IgA Nephropathy: a Randomized Open-label Study [NCT01854814]		238 participants (Actual)	Interventional	2013-07-31	Completed
[NCT00338091]		0 participants	Interventional	2002-01-31	Terminated
Treating the Endothelium to Restore Insulin Sensitivity [NCT00402194]		17 participants (Actual)	Interventional	2005-06-30	Completed
Comparison of Efficacy of Losartan/Spironolactone and Losartan/Enalapril on Urinary Albumin Excretion, Estimated Glomerular Filtration Rate, and Blood Pressure in Patients With Type 2 Diabetes Nephropathy [NCT01667614]	Phase 2	136 participants (Actual)	Interventional	2010-05-31	Completed
Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization [NCT04312009]	Phase 2	205 participants (Actual)	Interventional	2020-04-13	Completed
Phase 1/2 Prospective Double-blind, Placebo-controlled Randomized Clinical Trial Using Losartan to Treat Grade II and III Hamstring Strains [NCT02263729]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2016-08-10	Terminated(stopped due to The study was terminated due to difficulty identifying eligible participants and the expiration of funding.)
Efficacy of Losartan in the Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients. [NCT06135493]	Phase 2	84 participants (Anticipated)	Interventional	2023-12-12	Recruiting
Occult Cardiovascular Disease With Chronic Exposure to Secondhand Tobacco Smoke [NCT04715568]	Phase 4	100 participants (Anticipated)	Interventional	2021-03-30	Recruiting
Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial [NCT04343001]	Phase 3	0 participants (Actual)	Interventional	2020-10-31	Withdrawn(stopped due to Grant not obtained)
Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty [NCT04743063]		40,000 participants (Anticipated)	Observational	2021-01-14	Active, not recruiting
A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension [NCT02235909]	Phase 3	215 participants (Actual)	Interventional	2014-12-19	Completed
Investigation of MDR1 (Multi-Drug Resistance) Gene Polymorphism and Losartan Plasma Concentration in Patients Undergoing Hypertensive Episodes While Under Losartan Treatment: A Prospective, Case-Control Study [NCT05349825]		100 participants (Actual)	Observational [Patient Registry]	2017-10-23	Completed
An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19 [NCT04335123]	Phase 1	34 participants (Actual)	Interventional	2020-04-04	Completed
A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder [NCT03029091]	Phase 2	15 participants (Actual)	Interventional	2017-05-23	Completed
Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients With Blood Pressure Not Controlled by Amlodipine: Effects on Echocardiographic Parameters, Vascular Stiffness and Endothelial Function. [NCT01603940]	Phase 4	30 participants (Actual)	Interventional	2012-05-31	Completed
Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide Produced By Lab Hypermarcas S/A In Healthy Subjects [NCT01692717]	Phase 1	90 participants (Actual)	Interventional	2013-02-28	Completed
An Open Label Study to Assess the Efficacy of Losartan/HCTZ Combination Therapy in Patients With Essential Hypertension Who Were Inadequately Controlled on Current Antihypertensive Monotherapy [NCT00354991]	Phase 3	437 participants (Actual)	Interventional	2006-06-01	Completed
A Randomized, Open-label, 4-way Crossover Single Dose Clinical Trial to Investigate the Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 When Administered Alone and in Combination in Healthy Male Volunteers [NCT02387554]	Phase 1	33 participants (Actual)	Interventional	2014-08-31	Completed
Effects of Angiotensin Type 1 Receptor Blockade With Losartan on Insulin Sensitivity and Secretion in Subjects With Type 2 Diabetes and Nephropathy [NCT00361023]		25 participants	Interventional	2006-01-31	Completed
Confirmatory Study of the Efficacy and Safety of the Combination of Losartan / Chlorthalidone vs Losartan / Hydrochlorothiazide in the Treatment of Patients With Essential Arterial Hypertension [NCT04927299]	Phase 3	190 participants (Anticipated)	Interventional	2022-06-30	Recruiting
"A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker Olmesartan Medoxomil Versus Losartan in Patients With Mild to Moderate Essential Hypertension" [NCT00857285]	Phase 3	130 participants (Actual)	Interventional	2002-05-31	Completed
Double-Blind, Placebo-Controlled Study of the Long Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced Left Ventricular Hypertrophy in Non-Obstructive HCM [NCT00001534]		112 participants	Observational	1996-09-30	Completed
A Pilot Study of Losartan in the Treatment of Pediatric NAFLD [NCT01913470]	Phase 2	12 participants (Actual)	Interventional	2013-07-31	Completed
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]	Phase 4	2,414 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly [NCT01384591]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2011-07-31	Completed
Anti-Inflammatory Therapy to Augment CFTR Rescue in CF Patients [NCT03435939]	Early Phase 1	16 participants (Anticipated)	Interventional	2022-02-15	Recruiting
Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients (FOCUS) [NCT03946514]	Phase 4	300 participants (Anticipated)	Interventional	2018-09-01	Recruiting
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy [NCT01150461]	Phase 2	20 participants (Actual)	Interventional	2007-02-28	Completed
Losartan and Eprosartan Induce a Similar Effect on Oral Fructose-induced Rise in Serum Uric Acid Concentration in Patients With Metabolic Syndrome [NCT04954560]		16 participants (Actual)	Interventional	2008-01-01	Completed
Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer [NCT01821729]	Phase 2	50 participants (Actual)	Interventional	2013-07-31	Active, not recruiting
Multimodal Intervention to Reduce Cardiovascular Risk Among Hypertensive Older Adults [NCT01891513]		104 participants (Actual)	Observational	2014-01-31	Completed
Effect of Innovative Natural Dietary Formulation on Primary Hypertension and the Underlying Mechanism of Gut Microbiome Restoration: Pilot Study [NCT04403347]	Early Phase 1	90 participants (Anticipated)	Interventional	2021-07-08	Recruiting
A New Treatment Modality For Skeletal Muscles Sports Injuries; Losartan Combination With PRP [NCT05827484]	Phase 4	20 participants (Actual)	Interventional	2016-10-10	Completed
Development of High-throughput Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human [NCT01570569]	Phase 1	26 participants (Actual)	Interventional	2011-01-31	Completed
Fixed Dose Intervention Trial of New England Enhancing Survival in Serious Mental Illness Patients [NCT02188121]	Phase 4	227 participants (Actual)	Interventional	2015-02-28	Completed
A Multi-Center, Double Blind, Randomized and Non-Inferiority Clinical Study of Cilnidipine to Compare the Effects on Cerebral Blood Flow With Losartan in Patients With Ischemic Stroke Hypertension [NCT00325637]	Phase 3	250 participants (Actual)	Interventional	2005-01-31	Completed
A Clinical Treatment Trial Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis [NCT00981747]	Phase 2/Phase 3	12 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Funding was withdrawn.)
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV [NCT01852942]	Phase 2	52 participants (Actual)	Interventional	2014-09-30	Completed
[NCT00378443]		0 participants	Interventional	2006-01-31	Active, not recruiting
"An Open-label, Single-sequence Study of the Effect of Belatacept on the Pharmacokinetics of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam Administered as Inje Cocktail in Healthy Subjects" [NCT01766050]	Phase 4	45 participants (Actual)	Interventional	2013-01-31	Completed
Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea [NCT01637623]	Phase 2	87 participants (Actual)	Interventional	2012-06-30	Completed
Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty [NCT05157464]	Phase 4	0 participants (Actual)	Interventional	2023-09-01	Withdrawn(stopped due to Study was not initiated, no participants enrolled.)
Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial [NCT02049307]	Phase 2	108 participants (Actual)	Interventional	2014-10-16	Completed
Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy [NCT00362960]	Phase 3	300 participants	Interventional	2003-05-31	Completed
Combination Therapy With Pioglitazone and Losartan Provides Additional Renoprotection in Subjects With Type 2 Diabetic Nephropathy [NCT00364988]		60 participants (Actual)	Interventional	2005-01-31	Completed
The Effect of Losartan on the Recoverability of Renal Function in Anuric and Oliguric Patients With Unilateral Obstructed Kidney: A Double Blind Randomized Placebo-controlled Trial [NCT04278495]		96 participants (Actual)	Interventional	2014-09-01	Completed
Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation [NCT01529749]	Phase 4	48 participants (Actual)	Interventional	2012-02-29	Completed
A Phase II Trial of Losartan to Reverse Sickle Nephropathy [NCT01479439]	Phase 2	36 participants (Actual)	Interventional	2012-02-29	Completed
Improving Outcomes in Diabetic Nephropathy [NCT00381134]	Phase 2	92 participants (Anticipated)	Interventional	2003-07-31	Completed
Hypertension in Young Adults Trial [NCT05370599]	Phase 2	120 participants (Anticipated)	Interventional	2022-04-15	Recruiting
An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors [NCT03864042]	Phase 1	56 participants (Actual)	Interventional	2018-01-02	Active, not recruiting
A 12 Week, Open, Randomized, Parallel, Multicenter Study of Efficacy, Tolerability & Safety of Hydrochlorothiazide (+) Losartan Potassium Versus Amlodipine in Essential Hypertensive Patients. [NCT00157963]	Phase 4	174 participants (Actual)	Interventional	2005-02-05	Completed
Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19 [NCT04447235]	Phase 2	77 participants (Actual)	Interventional	2020-07-23	Terminated(stopped due to futility analysis has demonstrated no difference between arms)
Protocol Merck 318-00: A Double-Blind, Placebo-Controlled, Randomized, Parallel, Clinical Trial To Study The Effect Of Losartan Potassium On Endothelial Dysfunction And Insulin Resistance In Obese Patients With Impaired Fasting Glucose [NCT00675987]	Phase 4	53 participants (Actual)	Interventional	2007-05-31	Completed
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer [NCT03563248]	Phase 2	168 participants (Actual)	Interventional	2018-08-10	Active, not recruiting
SHAPER: A Phase 1 Study of Losartan and Hypofractionated Radiation Therapy After Induction Chemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer [NCT04106856]	Phase 1	20 participants (Anticipated)	Interventional	2019-08-08	Recruiting
NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic C [NCT04539808]	Phase 2	60 participants (Anticipated)	Interventional	2021-05-27	Recruiting
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis [NCT04815902]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2021-05-18	Active, not recruiting
Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan [NCT01271374]	Phase 4	80 participants (Anticipated)	Interventional	2010-04-30	Active, not recruiting
A Prospective, Multicentre, Randomized, Open Label, Evaluator-Blind, Phase IV Study to Evaluate the Effect on Improvement of Left Ventricular Hypertrophy by the Control of Blood Pressure in Hypertension Patients With Aortic Valve Disease [NCT03666351]	Phase 4	128 participants (Actual)	Interventional	2018-10-18	Completed
A Randomized Controlled Trial for Evaluating Protective Effects of Antioxidants (Selenium and Vitamins A, C and E), Calcium Channel Blocker (Verapamil) and Angiotensin Receptor Blocker (Losartan) Against Extracorporeal Shockwaves Lithotripsy Induced Renal [NCT01675362]	Phase 4	160 participants (Actual)	Interventional	2012-08-31	Completed
Angiotensin II Receptor Inhibition to Improve Microvascular Function in Women Who Have Had Preeclampsia [NCT04632589]	Early Phase 1	20 participants (Anticipated)	Interventional	2020-11-22	Recruiting
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt N [NCT00168857]	Phase 4	860 participants (Actual)	Interventional	2003-07-09	Completed
A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder. [NCT01808196]	Phase 2	6 participants (Actual)	Interventional	2013-10-10	Completed
An Open-label, Randomised, Single Dose, Three-way Crossover, Parallel Groups Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 to Respective Reference Dosages in H [NCT01797926]	Phase 1	102 participants (Actual)	Interventional	2013-05-23	Completed
The 8 Weeks, Multicenter, Randomized, Double-blind, Clinical Study To Evaluate Efficacy Of Treatment With Losartan/Amlodipine 100/5 mg Combination Compared To Amlodipine 10 mg Monotherapy In Hypertensive Patients Who Are Not Appropriately Respond To Amlod [NCT01277822]	Phase 4	334 participants (Actual)	Interventional	2011-05-30	Completed
Comparative Effects of add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on Serum NT-PRO BNP and Proteinuria in Type 2 Diabetics With Nephropathy [NCT03006952]	Phase 4	59 participants (Actual)	Interventional	2015-04-30	Completed
Effect of Angiotensin Receptor Blockers on Periodic Breathing During Sleep in Hypoxia [NCT03335904]	Phase 4	14 participants (Actual)	Interventional	2018-01-01	Completed
Flucloxacillin as an Inducer of CYP-enzymes [NCT04840641]	Phase 1	14 participants (Actual)	Interventional	2021-03-25	Completed
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol [NCT04349410]	Phase 2/Phase 3	1,800 participants (Actual)	Interventional	2020-04-11	Completed
Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study [NCT03951142]	Phase 2	165 participants (Anticipated)	Interventional	2019-10-01	Enrolling by invitation
Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. [NCT04662723]	Phase 4	878 participants (Anticipated)	Interventional	2023-05-01	Recruiting
Losartan Effects on the Extinction of Conditioned Fear in Humans [NCT03396523]		70 participants (Anticipated)	Interventional	2018-01-04	Recruiting
Sex Differences in the Dilatory Response of Compound 21 [NCT05576155]	Early Phase 1	24 participants (Actual)	Interventional	2022-10-03	Active, not recruiting
Open-label, Randomized, Multicenter, Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan), Manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, Tablets 60/120 mg and Cozaar® (Losartan), Manufactured by MERCK SHARP & DOHME B.V [NCT02248961]	Phase 3	179 participants (Actual)	Interventional	2014-05-31	Completed
A Phase I/Ib Study of Losartan in Combination With Sunitinib in the Treatment of Pediatric and Adult Patients With Relapsed or Refractory Osteosarcoma [NCT03900793]	Phase 1	41 participants (Anticipated)	Interventional	2019-08-26	Recruiting
Influence of Aliskiren on Albuminuria After Kidney Transplantation [NCT02446548]		18 participants (Actual)	Interventional	2013-03-31	Completed
Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis [NCT02416102]	Phase 4	31 participants (Actual)	Interventional	2016-03-31	Terminated(stopped due to Difficulty in recruitment)
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD [NCT03417388]	Phase 4	4,422 participants (Anticipated)	Interventional	2018-02-09	Recruiting
The SCCS Polypill Pilot Trial [NCT02278471]	Phase 2	303 participants (Actual)	Interventional	2015-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00067990 (2) [back to overview]	Doubling of Interstitium or Any ESRD
NCT00067990 (2) [back to overview]	Number of Participants With Cortical Interstitial Volume Expansion or Any ESRD
NCT00090259 (5) [back to overview]	Number of Participants That Were Hospitalized for Heart Failure
NCT00090259 (5) [back to overview]	Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization
NCT00090259 (5) [back to overview]	Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure
NCT00090259 (5) [back to overview]	Number of Participants That Experienced Cardiovascular Hospitalization
NCT00090259 (5) [back to overview]	Number of Participants That Died (Any Cause)
NCT00219141 (13) [back to overview]	Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular Stroke Volume as Measured by MRI From Baseline to End of Study (Week 36)
NCT00219141 (13) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Diastolic and Systolic Blood Pressure From Baseline to the End of the Study (Week 36)
NCT00219141 (13) [back to overview]	Change in the Left Ventricular Hypertrophy (LVH) Parameter Sokolow-Lyon Voltage as Measured by Electrocardiogram From Baseline to End of Study (Week 36)
NCT00219141 (13) [back to overview]	Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular Mass Index as Measured by MRI From Baseline to End of Study (Week 36)
NCT00219141 (13) [back to overview]	Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular Inferolateral Wall Thickness as Measured by MRI From Baseline to End of Study (Week 36)
NCT00219141 (13) [back to overview]	Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular End Systolic Volume as Measured by MRI From Baseline to End of Study (Week 36)
NCT00219141 (13) [back to overview]	Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular End Diastolic Volume as Measured by MRI From Baseline to End of Study (Week 36)
NCT00219141 (13) [back to overview]	Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular End Diastolic Mass as Measured by MRI From Baseline to End of Study (Week 36)
NCT00219141 (13) [back to overview]	Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular Ejection Fraction as Measured by MRI From Baseline to End of Study (Week 36)
NCT00219141 (13) [back to overview]	Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular Anteroseptal Wall Thickness as Measured by MRI From Baseline to End of Study (Week 36)
NCT00219141 (13) [back to overview]	Change in the Left Ventricular Hypertrophy (LVH) Parameter Diameter of Ascending Aorta as Measured by MRI From Baseline to End of Study (Week 36)
NCT00219141 (13) [back to overview]	Change in the Left Ventricular Hypertrophy (LVH) Parameter Cornell Voltage Duration Product as Measured by Electrocardiogram From Baseline to End of Study (Week 36)
NCT00219141 (13) [back to overview]	Change in Left Ventricular Mass Index (LVMI) From Baseline to End of Study (Week 36)
NCT00289887 (6) [back to overview]	Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 16
NCT00289887 (6) [back to overview]	Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8
NCT00289887 (6) [back to overview]	Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12
NCT00289887 (6) [back to overview]	Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
NCT00289887 (6) [back to overview]	Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 16
NCT00289887 (6) [back to overview]	Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8
NCT00340678 (2) [back to overview]	Number of Participants With Decline in GFR
NCT00340678 (2) [back to overview]	Glomerular Volume
NCT00402194 (2) [back to overview]	Insulin-stimulated Leg Glucose Uptake
NCT00402194 (2) [back to overview]	Leg Blood Flow Response to Insulin
NCT00429364 (26) [back to overview]	Adverse Drug Reactions Reported at the Baseline Visit
NCT00429364 (26) [back to overview]	Number of Participants With the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.
NCT00429364 (26) [back to overview]	Event Rate of the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.
NCT00429364 (26) [back to overview]	Annual Rate of Change in Body Mass Index for Age Z-score
NCT00429364 (26) [back to overview]	Number of Participants With Aortic-root Surgery.
NCT00429364 (26) [back to overview]	Number of Participants With Aortic Dissection.
NCT00429364 (26) [back to overview]	Number of Death.
NCT00429364 (26) [back to overview]	Event Rate of Death
NCT00429364 (26) [back to overview]	Event Rate of Aortic-Root Surgery
NCT00429364 (26) [back to overview]	Event Rate of Aortic Dissection.
NCT00429364 (26) [back to overview]	Annual Rate of Change in Body Mass Index
NCT00429364 (26) [back to overview]	Annual Rate of Change in Ascending-aorta-diameter Z Score, Adjusted by Body-surface-area.
NCT00429364 (26) [back to overview]	Annual Rate of Change in Arm Span to Height Ratio
NCT00429364 (26) [back to overview]	Annual Rate of Change in Aortic-annulus-diameter Z Score, Adjusted by Body-surface Area
NCT00429364 (26) [back to overview]	Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score
NCT00429364 (26) [back to overview]	Annual Rate of Change in Weight-for-height Z-score
NCT00429364 (26) [back to overview]	Annual Rate of Change in Weight-for-age Z-score
NCT00429364 (26) [back to overview]	Annual Rate of Change in Weight
NCT00429364 (26) [back to overview]	Annual Rate of Change in Height
NCT00429364 (26) [back to overview]	Annual Rate of Change in Upper to Lower Segment Ratio
NCT00429364 (26) [back to overview]	Annual Rate of Change in Total Aortic Proximal Regurgitant Jet Area Indexed to Body-surface-area
NCT00429364 (26) [back to overview]	Annual Rate of Change in the Absolute Diameter of the Ascending Aorta
NCT00429364 (26) [back to overview]	Annual Rate of Change in the Absolute Diameter of the Aortic Annulus
NCT00429364 (26) [back to overview]	Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Absolute Dimension
NCT00429364 (26) [back to overview]	Adverse Drug Reactions Reported During Routine Follow-up Surveillance
NCT00429364 (26) [back to overview]	Annual Rate of Change in Height-for-age Z-score
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI
NCT00446563 (15) [back to overview]	Percentage of Participants Achieving Target Blood Pressure at Week 52
NCT00446563 (15) [back to overview]	Percentage of Participants Who Experienced Adverse Events (AEs)
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP)
NCT00446563 (15) [back to overview]	Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)
NCT00446563 (15) [back to overview]	Change From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP)
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI
NCT00467831 (1) [back to overview]	Survival at 2 Years
NCT00496834 (4) [back to overview]	Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
NCT00496834 (4) [back to overview]	PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
NCT00496834 (4) [back to overview]	Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
NCT00496834 (4) [back to overview]	Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
NCT00546052 (13) [back to overview]	Absolute Change in Uric Acid Between Baseline and 52 Week Assessments
NCT00546052 (13) [back to overview]	Change in Body Mass Index Between Baseline and 52 Week Assessments
NCT00546052 (13) [back to overview]	Change in Diastolic Blood Pressure Between Baseline and 52 Week Assessments
NCT00546052 (13) [back to overview]	Change in Fasting Blood Glucose Between Baseline and 52 Weeks Assessments
NCT00546052 (13) [back to overview]	Change in Systolic Blood Pressure Between Baseline and 52 Week Assessments
NCT00546052 (13) [back to overview]	Change in Waist Circumference Between Baseline and 52 Week Assessments
NCT00546052 (13) [back to overview]	Percent Change in Triglycerides Between Baseline and 52 Week Assessments
NCT00546052 (13) [back to overview]	Change in Hemoglobin A1c Between 52 Weeks and Baseline
NCT00546052 (13) [back to overview]	Percent Change in High Density Lipoprotein-C Between Baseline and 52 Week Assessments
NCT00546052 (13) [back to overview]	Percent Change in Low Density Lipoprotein-C Between Baseline and 52 Week Assessments
NCT00546052 (13) [back to overview]	Target Blood Pressure
NCT00546052 (13) [back to overview]	Percent Change in Total Cholesterol Between Baseline and 52 Week Assessments
NCT00546052 (13) [back to overview]	Absolute Change in C Reactive Protein Between Baseline and 52 Week Assessments
NCT00546754 (13) [back to overview]	Number of Patients Achieving Target Blood Pressure at Week 6
NCT00546754 (13) [back to overview]	Number of Patients Achieving Target Blood Pressure at Week 12
NCT00546754 (13) [back to overview]	Time to Achieve Target Blood Pressure
NCT00546754 (13) [back to overview]	Change in Uric Acid From Baseline to Week 6
NCT00546754 (13) [back to overview]	Change in Systolic Blood Pressure From Baseline to Week 6
NCT00546754 (13) [back to overview]	Change in Systolic Blood Pressure From Baseline to Week 12
NCT00546754 (13) [back to overview]	Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 12
NCT00546754 (13) [back to overview]	Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 6
NCT00546754 (13) [back to overview]	Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 12
NCT00546754 (13) [back to overview]	Change in Diastolic Blood Pressure From Baseline to Week 12
NCT00546754 (13) [back to overview]	Change in Diastolic Blood Pressure From Baseline to Week 6
NCT00546754 (13) [back to overview]	Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 6
NCT00546754 (13) [back to overview]	Change in Uric Acid From Baseline to Week 12
NCT00555217 (2) [back to overview]	A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73mm in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73mm, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death
NCT00555217 (2) [back to overview]	A Renal Composite Endpoint, Defined as; Reduction in Estimated GFR of >50% (for Individuals With Baseline GFR <60) or Reduction in GFR of >30 (for Individuals With Baseline GFR >= GFR 60) or ESRD.
NCT00568178 (5) [back to overview]	Open Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36
NCT00568178 (5) [back to overview]	Open Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 36
NCT00568178 (5) [back to overview]	Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12
NCT00568178 (5) [back to overview]	Double-Blind Treatment Phase: Change From Baseline in Systolic Blood Pressure in Hypertensive Participants at Week 12
NCT00568178 (5) [back to overview]	Double-Blind Treatment Phase: Change From Baseline in Diastolic Blood Pressure in Hypertensive Participants at Week 12
NCT00673790 (2) [back to overview]	Plasma Glucose Level After an Oral Glucose Tolerance Test
NCT00673790 (2) [back to overview]	Trough Seated Diastolic Blood Pressure
NCT00675987 (9) [back to overview]	Change in hsCRP (High-sensitivity C-reactive Protein)
NCT00675987 (9) [back to overview]	Change in MCP-1 (Monocyte Chemoattractant Protein-1)
NCT00675987 (9) [back to overview]	Change in Ox-LDL (Oxidized Low-density Lipoprotein)
NCT00675987 (9) [back to overview]	Change in E-selectin
NCT00675987 (9) [back to overview]	Change in F2-isoprostanes
NCT00675987 (9) [back to overview]	Insulin Sensitivity Utilizing the Euglycemic Hyperinsulinemic Clamp
NCT00675987 (9) [back to overview]	Insulin Sensitivity Utilizing Endothelial Function as Assessed by Pulse Volume Amplitude
NCT00675987 (9) [back to overview]	Change in VCAM-1(Vascular Cell-adhesion Molecule-1)
NCT00675987 (9) [back to overview]	Change in Urine Albumin/Creatine
NCT00720226 (2) [back to overview]	Change in FEV1 (L)
NCT00720226 (2) [back to overview]	Change in Percent Emphysema on CT Scan
NCT00723801 (2) [back to overview]	Aortic Biophysical Properties - Pulse Wave Velocity
NCT00723801 (2) [back to overview]	Diastolic Function - Ejection Fraction
NCT00734630 (2) [back to overview]	Mean Seated Trough Cuff Diastolic Blood Pressure (DBP) at Week 12
NCT00734630 (2) [back to overview]	Mean Seated Trough Cuff Systolic Blood Pressure (SBP) at Week 12
NCT00739674 (11) [back to overview]	Change in Diastolic Blood Pressure From Baseline to Week 6
NCT00739674 (11) [back to overview]	Change in Systolic Blood Pressure From Baseline to Week 10
NCT00739674 (11) [back to overview]	Change in Systolic Blood Pressure From Baseline to Week 14
NCT00739674 (11) [back to overview]	Change in Systolic Blood Pressure From Baseline to Week 6
NCT00739674 (11) [back to overview]	Time to Achieve the Target Blood Pressure From Baseline
NCT00739674 (11) [back to overview]	Number of Patients Achieving Target Blood Pressure at Week 10 From Baseline
NCT00739674 (11) [back to overview]	Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline
NCT00739674 (11) [back to overview]	Number of Patients Achieving Target Blood Pressure at Week 40 From Baseline
NCT00739674 (11) [back to overview]	Number of Patients Achieving Target Blood Pressure at Week 6 From Baseline
NCT00739674 (11) [back to overview]	Change in Diastolic Blood Pressure From Baseline to Week 10
NCT00739674 (11) [back to overview]	Change in Diastolic Blood Pressure From Baseline to Week 14
NCT00756938 (4) [back to overview]	Mean Change From Baseline in Diastolic Blood Pressure
NCT00756938 (4) [back to overview]	Number of Participants Who Reported 1 or More Clinical and/or Laboratory Adverse Event(s)
NCT00756938 (4) [back to overview]	Number of Participants Who Were Discontinued From Study Due to a Clinical and/or Laboratory Adverse Event
NCT00756938 (4) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure
NCT00814255 (2) [back to overview]	Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR Defined as Greater Than 75 ml/Min/1.73m2 in Those With an Initial Value Above 90 OR Within 25% of Baseline for Remaining Patients
NCT00814255 (2) [back to overview]	Number of Participants With Adverse Events
NCT00857285 (1) [back to overview]	Mean Change of Sitting dBP From Baseline to Week 12
NCT00879879 (3) [back to overview]	Number of Participants With Stable, Improved, or Deteriorated Diffusion Capacity of Carbon Monoxide (DLCO) at 1 Year
NCT00879879 (3) [back to overview]	Number of Patients With Stable, Improved or Deteriorated 6-minute Walk Test Results at 1 Year
NCT00879879 (3) [back to overview]	Number of Participants With Stable or Improved Forced Vital Capacity (FVC) Response at 1 Year
NCT00882440 (3) [back to overview]	Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8
NCT00882440 (3) [back to overview]	Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8
NCT00882440 (3) [back to overview]	Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8
NCT00886600 (5) [back to overview]	Mean Change From Week 4 in Sitting Diastolic Blood Pressure (siDBP) Adding HCTZ 24 Hours After Morning Dose at Week 6
NCT00886600 (5) [back to overview]	Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) After Adding HCTZ 24 Hours After Morning Dose at Week 6
NCT00886600 (5) [back to overview]	Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4
NCT00886600 (5) [back to overview]	Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4
NCT00886600 (5) [back to overview]	Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4
NCT00887250 (6) [back to overview]	Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12
NCT00887250 (6) [back to overview]	Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6
NCT00887250 (6) [back to overview]	Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
NCT00887250 (6) [back to overview]	Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6
NCT00887250 (6) [back to overview]	Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 12
NCT00887250 (6) [back to overview]	Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6
NCT00888355 (13) [back to overview]	Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) as Week 12
NCT00888355 (13) [back to overview]	Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12
NCT00888355 (13) [back to overview]	Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
NCT00888355 (13) [back to overview]	Number of Patients Discontinued Due to CAEs
NCT00888355 (13) [back to overview]	Number of Patients Discontinued Due to LAEs
NCT00888355 (13) [back to overview]	Number of Patients Who Died
NCT00888355 (13) [back to overview]	Number of Patients With Clinical Adverse Experiences (CAEs)
NCT00888355 (13) [back to overview]	Number of Patients With Drug-related CAEs
NCT00888355 (13) [back to overview]	Number of Patients With Drug-related LAEs
NCT00888355 (13) [back to overview]	Number of Patients With Laboratory Adverse Experiences (LAEs)
NCT00888355 (13) [back to overview]	Number of Patients With Serious CAEs
NCT00888355 (13) [back to overview]	Number of Patients With Serious LAEs
NCT00888355 (13) [back to overview]	Categories of Antihypertensive Response in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
NCT00922480 (2) [back to overview]	Diastolic Blood Pressure Change
NCT00922480 (2) [back to overview]	Diastolic Blood Pressure Change
NCT00931710 (6) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure After 6 Weeks
NCT00931710 (6) [back to overview]	Change in Mean Sitting Systolic and Diastolic Blood Pressure After 12 Weeks
NCT00931710 (6) [back to overview]	Change in Mean Sitting Systolic Blood Pressure After 6 Weeks
NCT00931710 (6) [back to overview]	Cumulative Percentage of Patients With Incidence of Peripheral Edema Before or at the Corresponding Visit
NCT00931710 (6) [back to overview]	Cumulative Percentage of Treatment Responders
NCT00931710 (6) [back to overview]	Cumulative Percentage of Patients Achieving Blood Pressure Control
NCT00943852 (2) [back to overview]	Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg
NCT00943852 (2) [back to overview]	Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo
NCT00949884 (16) [back to overview]	Percentage of Participants Achieving Ambulatory Blood Pressure Goal of < 135/85 mmHg at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline to Week 2 in Trough, Cuff, Seated Blood Pressure
NCT00949884 (16) [back to overview]	Percentage of Participants Achieving Blood Pressure Goals at Week 4
NCT00949884 (16) [back to overview]	Percentage of Participants Achieving Blood Pressure Goals at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline to Week 8 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)
NCT00949884 (16) [back to overview]	Incremental Change From Week 4 to Week 8 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)
NCT00949884 (16) [back to overview]	Incremental Change From Week 4 to Week 8 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)
NCT00949884 (16) [back to overview]	Change From Baseline in Mean 24-Hour Ambulatory Blood Pressure at Week 4
NCT00949884 (16) [back to overview]	Change From Baseline in Mean 24-Hour Ambulatory Blood Pressure at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Ambulatory Blood Pressure During the Final 2, 4, and 6 Hours of the Dosing Interval at Week 4
NCT00949884 (16) [back to overview]	Change From Baseline to Week 8 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)
NCT00949884 (16) [back to overview]	Change From Baseline to Week 4 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)
NCT00949884 (16) [back to overview]	Change From Baseline to Week 4 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Ambulatory Blood Pressure During the Final 2, 4, and 6 Hours of the Dosing Interval at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Daytime (8am to 4pm) and Mean Nighttime (10pm to 6am) Ambulatory Blood Pressure at Week 4
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Daytime (8am to 4pm) and Mean Nighttime (10pm to 6am) Ambulatory Blood Pressure at Week 8
NCT00953680 (4) [back to overview]	Peak Plasma Concentration (Cmax) of HCTZ Following Single Dose Administration of Losartan/HCTZ or Losartan and HCTZ
NCT00953680 (4) [back to overview]	Peak Plasma Concentration (Cmax) for Losartan
NCT00953680 (4) [back to overview]	Area Under the Curve (AUC(0 to Infinity)) of HCTZ
NCT00953680 (4) [back to overview]	Area Under the Curve (AUC(0 to Infinity)) of Losartan
NCT00981747 (3) [back to overview]	Change in Shortness of Breath (SOB) Score
NCT00981747 (3) [back to overview]	Change in Six Minute Walk Distance in Meters
NCT00981747 (3) [back to overview]	Change in Forced Vital Capacity (FVC)
NCT01124162 (6) [back to overview]	Cmax of Losartan Carboxy Acid (Maximum Observed Concentration of Drug Substance in Plasma)
NCT01124162 (6) [back to overview]	Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma)
NCT01124162 (6) [back to overview]	AUC0-t of Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01124162 (6) [back to overview]	AUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01124162 (6) [back to overview]	AUC0-inf of Losartan (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01124162 (6) [back to overview]	AUC0-inf of Losartan Carboxy Acid(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01124175 (6) [back to overview]	Cmax of Losartan Carboxy Acid (Maximum Observed Concentration of Drug Substance in Plasma)
NCT01124175 (6) [back to overview]	Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma)
NCT01124175 (6) [back to overview]	AUC0-t of Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01124175 (6) [back to overview]	AUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01124175 (6) [back to overview]	AUC0-inf or Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01124175 (6) [back to overview]	AUC0-inf of Losartan (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01149473 (6) [back to overview]	Cmax of Losartan(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01149473 (6) [back to overview]	Cmax of Hydrochlorothiazide(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01149473 (6) [back to overview]	AUC0-t of Losartan(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01149473 (6) [back to overview]	AUC0-t of Hydrochlorothiazide(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01149473 (6) [back to overview]	AUC0-inf of Losartan(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01149473 (6) [back to overview]	AUC0-inf of Hydrochlorothiazide(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01149486 (9) [back to overview]	AUC0-inf of Losartan Carboxy Acid(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01149486 (9) [back to overview]	AUC0-inf of Hydrochlorothiazide(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01149486 (9) [back to overview]	AUC0-t of Losartan Carboxy Acid(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01149486 (9) [back to overview]	AUC0-t of Hydrochlorothiazide(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01149486 (9) [back to overview]	AUC0-inf of Losartan(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01149486 (9) [back to overview]	Cmax of Losartan(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01149486 (9) [back to overview]	Cmax of Losartan Carboxy Acid(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01149486 (9) [back to overview]	Cmax of Hydroclorothiazide(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01149486 (9) [back to overview]	AUC0-t of Losartan(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01150461 (2) [back to overview]	Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging.
NCT01150461 (2) [back to overview]	Percentage Change From Baseline in Left Ventricular Mass at 1 Year as Assessed by Magnetic Resonance Imaging.
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method) in Combination of Aliskiren With Amlodipine
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule in Combination of Aliskiren With Amlodipine
NCT01176032 (20) [back to overview]	Change From Baseline in Reduction of Left Ventricular Mass Index (LVMI)
NCT01176032 (20) [back to overview]	Change From Baseline of LVMI in Combination of Aliskiren With Amlodipine
NCT01176032 (20) [back to overview]	Change From Baseline in Biomarkers in Heart Disease
NCT01176032 (20) [back to overview]	Change From Baseline in Combination of Aliskiren With Amlodipine in Biomarkers of Heart Disease.
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LV End-diastolic Volume by Simpson's Rule, and LV End-systolic Volume by Simpson's Rule
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson)
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LV Ejection Fraction (Teicholz), and LV Ejection Fraction (Simpson) in Combination of Aliskiren With Amlodipine
NCT01176032 (20) [back to overview]	Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease
NCT01176032 (20) [back to overview]	Change From Baseline in Biomarker Such as Aldosterone (Aldo) in Heart Disease in Combination of Aliskiren With Amlodipine
NCT01176032 (20) [back to overview]	Change From Baseline in C-terminal Propeptide of Procollagen Type I (PICP)
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, LA (Left Atrium) Diameter in Combination of Aliskiren With Amlodipine
NCT01176032 (20) [back to overview]	Change From Baseline in Left Ventricular (LV) Function, Left Atrial Volume (Biplane Simpson's Method)
NCT01176032 (20) [back to overview]	Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With Satisfactory Response Rate
NCT01176032 (20) [back to overview]	Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Systolic Blood Pressure (SBP)
NCT01176032 (20) [back to overview]	Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Reduction in Diastolic Blood Pressure (DBP)
NCT01176032 (20) [back to overview]	Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Rate of Use of Added Antihypertensive Rescue Drugs
NCT01176032 (20) [back to overview]	Effectivness of Aliskiren in Controlling Blood Pressure Compare to Losartan in Terms of Patients With SBP < 140 mmHg and DBP < 90 mmHg Compared to Baseline
NCT01234922 (1) [back to overview]	Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter
NCT01277822 (8) [back to overview]	Percentage of Participants Who Had Peripheral Edema During the Study
NCT01277822 (8) [back to overview]	Percentage of Participants Who Achieve Target Blood Pressure at Week 4
NCT01277822 (8) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8
NCT01277822 (8) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4
NCT01277822 (8) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8
NCT01277822 (8) [back to overview]	Percentage of Participants Who Achieve Target Blood Pressure at Week 8
NCT01277822 (8) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 4
NCT01277822 (8) [back to overview]	Change From Baseline in Ankle Circumference at Week 8
NCT01302691 (7) [back to overview]	Percentage of Participants Who Experience ≥1 Adverse Event (AE)
NCT01302691 (7) [back to overview]	Change in Mean Trough Sitting Systolic Blood Pressure (SiSBP)
NCT01302691 (7) [back to overview]	Percentage of Participants Who Had Study Drug Stopped Due to an AE
NCT01302691 (7) [back to overview]	Percentage of Participants Who Experience ≥1 Serious Adverse Event (SAE)
NCT01302691 (7) [back to overview]	Percentage of Participants Who Experience ≥1 Drug-related SAE
NCT01302691 (7) [back to overview]	Percentage of Participants Who Experience ≥1 Drug-related AE
NCT01302691 (7) [back to overview]	Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)
NCT01307033 (3) [back to overview]	Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8
NCT01307033 (3) [back to overview]	Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8
NCT01307033 (3) [back to overview]	Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension)
NCT01307046 (3) [back to overview]	Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP)
NCT01307046 (3) [back to overview]	Percentage of Participants Who Experienced at Least One Adverse Event (AE)
NCT01307046 (3) [back to overview]	Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP)
NCT01371747 (9) [back to overview]	Mean Change in Serum Potassium From Week 52 or Last Patiromer Dose (if Occurred Before Week 52) to Follow-up Visits Plus 7 Days
NCT01371747 (9) [back to overview]	Proportion of Participants Achieving Serum Potassium Levels Within 3.5 to 5.5 mEq/L at Week 8 for Each Individual Starting Dose Group
NCT01371747 (9) [back to overview]	Proportions of Participants Achieving Serum Potassium Levels Within 3.8 to 5.0 mEq/L at Week 52 for Each Individual Starting Dose Group
NCT01371747 (9) [back to overview]	Time to First Serum Potassium Measurement of 4.0 - 5.0 mEq/L During Treatment Initiation Period for Each Individual Starting Dose Group
NCT01371747 (9) [back to overview]	Proportion of Participants Achieving Serum Potassium Levels Within 4.0 to 5.0 mEq/L at Week 8 for Each Individual Starting Dose Group
NCT01371747 (9) [back to overview]	Least Squares Mean Change in Serum Potassium From Baseline to Week 4 or Time of First Titration for Each Individual Starting Dose Group
NCT01371747 (9) [back to overview]	Least Squares Mean Change in Serum Potassium From Baseline to Day 3 During the Treatment Initiation Period for Each Individual Starting Dose Group
NCT01371747 (9) [back to overview]	Least Squares Mean Change in Serum Potassium From Baseline to Week 8 or Time of First Titration for Each Individual Starting Dose Group
NCT01371747 (9) [back to overview]	Mean Change in Serum Potassium From Baseline to Week 52 During the Long-term Maintenance Period for Each Individual Starting Dose Group
NCT01384591 (41) [back to overview]	Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 100% Effort at Baseline
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Mental Fatigue at Baseline
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Physical Fatigue After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Handgrip Fatigue of Non-dominant Hand as Measured by Handgrip Dynamometry After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Physical Fatigue at Baseline
NCT01384591 (41) [back to overview]	Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 100% Perceived Effort After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Vigor Fatigue at Baseline
NCT01384591 (41) [back to overview]	Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 100% Effort at Baseline
NCT01384591 (41) [back to overview]	Handgrip Fatigue of Dominant Hand as Measured by Handgrip Dynamometry at Baseline
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Handgrip Fatigue of Non-dominant Hand as Measured by Handgrip Dynamometry at Baseline
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Vigor Fatigue After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Handgrip Fatigue of Dominant Hand as Measured by Handgrip Dynamometry After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Total Score After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Total Score at Baseline
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Global Fatigue Score as Measured by Brief Fatigue Inventory at Baseline
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale After Handgrip Fatigue Test After Study Intervention
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale After Handgrip Fatigue Test at Baseline.
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale Before Handgrip Fatigue Test After Study Intervention
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale Before Handgrip Fatigue Test at Baseline.
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale After Handgrip Fatigue Test After Study Intervention
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale After Handgrip Fatigue Test at Baseline.
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale Before Handgrip Fatigue Test After Study Intervention
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale Before Handgrip Fatigue Test at Baseline.
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Emotional Fatigue After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Emotional Fatigue at Baseline
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale General Fatigue After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort at Baseline
NCT01384591 (41) [back to overview]	Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 100% Perceived Effort After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Global Fatigue Score as Measured by Brief Fatigue Inventory After Study Invention
NCT01384591 (41) [back to overview]	Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort at Baseline
NCT01384591 (41) [back to overview]	Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale General Fatigue at Baseline
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Mental Fatigue After All Doses of Study Intervention
NCT01431508 (1) [back to overview]	Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
NCT01479439 (3) [back to overview]	Change in Creatinine Clearance
NCT01479439 (3) [back to overview]	Change in UACR
NCT01479439 (3) [back to overview]	Categorical Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline
NCT01529749 (17) [back to overview]	Proportion of Patients With Changes in Levels of Proteins.
NCT01529749 (17) [back to overview]	Proportion of Patients With Changes in Levels of Metalloproteinases
NCT01529749 (17) [back to overview]	Proportion of Patients With Changes in Levels of CSF Cells.
NCT01529749 (17) [back to overview]	Proportion of Patients With 50% Reduction of Fibrosis in Lymphatic Tissue.
NCT01529749 (17) [back to overview]	Number of Participants With Adverse Events and Laboratory Abnormalities in the Different Groups.
NCT01529749 (17) [back to overview]	Changes in the CD4/CD8 Ratio in Peripheral Blood in Different Groups.
NCT01529749 (17) [back to overview]	Changes in CD4 CD38+ HLADR+ (%)
NCT01529749 (17) [back to overview]	Proportion of Patients With Improvement in Neuropsychological Test
NCT01529749 (17) [back to overview]	Proportion of Patients With Increased CD4 in Lymphatic Tissue.
NCT01529749 (17) [back to overview]	Proportion of Patients With Changes in Levels of beta2-microglobulin.
NCT01529749 (17) [back to overview]	Proportion of Patients With Increased CD4 in Peripheral Blood.
NCT01529749 (17) [back to overview]	Proportion of Patients With Reduced Intima-media Complex in Carotid Ultrasound in Different Groups.
NCT01529749 (17) [back to overview]	Proportion of Patients With Undetectable Plasma Viral Load in Different Groups
NCT01529749 (17) [back to overview]	Proportion of Patients With Undetectable Viral Load in Lymphatic Tissue in Different Groups
NCT01529749 (17) [back to overview]	Proportion of Patients With Changes in the Levels of D-dimer in Different Groups.
NCT01529749 (17) [back to overview]	Proportion of Patients With Changes in the Levels of CRP in Different Groups.
NCT01529749 (17) [back to overview]	Proportion of Patients With Changes in the Levels of IL-6 in Different Groups.
NCT01603940 (5) [back to overview]	Systolic Blood Pressure
NCT01603940 (5) [back to overview]	Diastolic Blood Pressure
NCT01603940 (5) [back to overview]	Endothelial Function
NCT01603940 (5) [back to overview]	Vascular Stiffness by Augmentation Index
NCT01603940 (5) [back to overview]	Vascular Stiffness
NCT01637623 (11) [back to overview]	Forearm Vascular Conductance
NCT01637623 (11) [back to overview]	Change in Muscle Sympathetic Nerve Activity Responses During Hypoxia
NCT01637623 (11) [back to overview]	Change in Minute Ventilation During Hypoxia
NCT01637623 (11) [back to overview]	Change in Minute Ventilation at Normoxia
NCT01637623 (11) [back to overview]	Cerebrovascular Conductance
NCT01637623 (11) [back to overview]	Change in Mean 24-Hour Blood Pressure (Mean Arterial Pressure)
NCT01637623 (11) [back to overview]	PERCENT Time Spent Below 88 PERCENT Oxygen Saturation
NCT01637623 (11) [back to overview]	Aortic Augmentation Index
NCT01637623 (11) [back to overview]	Change in Aortic Pulse Wave Velocity
NCT01637623 (11) [back to overview]	Apnea-Hypopnea Index
NCT01637623 (11) [back to overview]	Mean Change in PERCENT Vasodilation
NCT01766050 (36) [back to overview]	Ratio of 1'-Hydroxy-Midazolam AUC(0-T) to Midazolam AUC(0-T) and 1'-Hydroxy-Midazolam AUC(INF) to Midazolam AUC(INF), Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Ratio of 5-Dextrorphan AUC(0-T) to Dextromethorphan AUC(0-T) and 5-Dextrorphan AUC(INF) to Dextromethorphan AUC(INF), Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Ratio of 5-Hydroxyomeprazole AUC(0-T) to Omeprazole AUC(0-T) and 5-Hydroxyomeprazole AUC(INF) to Omeprazole AUC(INF) , Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC(INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Ratio of E-3174 AUC(0-T) to Losartan AUC(0-T) and E3174 AUC (INF) to Losartan AUC (INF) Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC(INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Ratio of Paraxanthine AUC(0-T) to Caffeine AUC(0-T) and Paraxanthine AUC (INF) to Caffeine AUC (INF), Corrected for Molecular Weight [MR_AUC(0-T) and MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	T-HALF of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without the Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Time of Maximum Observed Plasma Concentration (Tmax) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan, and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Tmax of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without the Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Adjusted Geometric Mean Cmax of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
NCT01766050 (36) [back to overview]	Adjusted Geometric Mean Cmax of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Adjusted Geometric Mean Cmax of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Adjusted Geometric Mean Cmax of Losartan With and Without the Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Adjusted Geometric Mean Maximum Drug Concentration (Cmax) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
NCT01766050 (36) [back to overview]	Mean Change From Baseline in Heart Rate at Study Discharge (Day 46±2 Days)
NCT01766050 (36) [back to overview]	Ratio of 1'-Hydroxy-Midazolam (Cmax) to Midazolam (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Ratio of 5-Dextrorphan (Cmax) to Dextromethorphan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Ratio of 5-Hydroxyomeprazole (Cmax) to Omeprazole (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Ratio of E-3174 (Cmax) to Losartan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Ratio of Paraxanthine (Cmax) to Caffeine (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Adjusted Geometric Mean Area Under the Concentration Time Curve (AUC) From Zero to Last Concentration (0-T) and AUC Extrapolated to Infinity (INF) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
NCT01766050 (36) [back to overview]	Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Losartan With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
NCT01766050 (36) [back to overview]	Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
NCT01766050 (36) [back to overview]	Apparent Total Body Clearance (CLT/F) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	AUC(0-T) of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	AUC(INF) of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Cmax of Inje Cocktail Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01766050 (36) [back to overview]	Mean Change From Baseline in Sitting Heart Rate - All Treated Participants
NCT01766050 (36) [back to overview]	Mean Change From Baseline in Sitting Systolic and Diastolic Blood Pressure - All Treated Participants
NCT01766050 (36) [back to overview]	Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Study Discharge (Day 46±2 Days)
NCT01766050 (36) [back to overview]	Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and AEs Leading to Discontinuation - All Treated Participants
NCT01766050 (36) [back to overview]	Number of Participants With Marked Hematology and Urinalysis Laboratory Abnormalities - All Treated Participants
NCT01766050 (36) [back to overview]	Number of Participants With Marked Serum Chemistry Laboratory Abnormalities - All Treated Participants
NCT01766050 (36) [back to overview]	Number of Participants With Out-of-Range Electrocardiogram Intervals - All Treated Participants
NCT01766050 (36) [back to overview]	Plasma Half-Life (T-HALF) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan, and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population
NCT01808196 (3) [back to overview]	Percent of Participants in Histologic Remission at 16 Weeks
NCT01808196 (3) [back to overview]	Change in Peak Eosinophil Count at 16 Weeks
NCT01808196 (3) [back to overview]	Change in Pediatric EoE Symptom Score at 16 Weeks
NCT01821729 (2) [back to overview]	Number of Participants With R0 Resection
NCT01821729 (2) [back to overview]	Progression-Free Survival
NCT01852942 (1) [back to overview]	Collagen Deposition in LT
NCT01913470 (7) [back to overview]	Change in Fatty Acid Levels From Baseline to End of Treatment (8 Weeks of Treatment)
NCT01913470 (7) [back to overview]	Change in Cholesterol Levels From Baseline to End of Treatment (8 Weeks of Treatment)
NCT01913470 (7) [back to overview]	Changes in Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations Between Baseline and End of Treatment
NCT01913470 (7) [back to overview]	Change in Aspartate Aminotransferase (AST) From Baseline to End of Treatment
NCT01913470 (7) [back to overview]	Change in Alanine Aminotransferase (ALT) From Baseline to End of Treatment (8 Weeks of Treatment)
NCT01913470 (7) [back to overview]	Changes in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) Between Baseline and End of Treatment (8 Weeks of Treatment)
NCT01913470 (7) [back to overview]	Change in Triglyceride Levels From Baseline to End of Treatment (8 Weeks of Treatment)
NCT01982695 (1) [back to overview]	Cardiac Ejection Fraction as Measured by Echocardiogram
NCT01989793 (9) [back to overview]	Number of Participants Experiencing Any Amount of Decrease in Frailty
NCT01989793 (9) [back to overview]	Fatiguability
NCT01989793 (9) [back to overview]	Number of Participants Experiencing Any Amount of Decrease in Frailty
NCT01989793 (9) [back to overview]	Change From Baseline in Isokinetic Strength
NCT01989793 (9) [back to overview]	Number of Participants Experiencing Any Amount of Decrease in Frailty
NCT01989793 (9) [back to overview]	Fatiguability
NCT01989793 (9) [back to overview]	Change From Baseline in Isokinetic Strength
NCT01989793 (9) [back to overview]	Change From Baseline in Isokinetic Strength
NCT01989793 (9) [back to overview]	Fatiguability
NCT02049307 (2) [back to overview]	Change in CD4+ Cell Count From Baseline to 12 Months.
NCT02049307 (2) [back to overview]	Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 12 Months
NCT02121041 (1) [back to overview]	24 Hour Blood Pressure Average at the End of 4 Month Participation.
NCT02188121 (2) [back to overview]	Change in Low Density Lipoprotein Levels
NCT02188121 (2) [back to overview]	Number of Participants on Adequate Cardiovascular Prevention Care (Defined as Taking a Statin and Angiotensin Medication)
NCT02248961 (7) [back to overview]	Change in Diastolic Blood Pressure (DBP) After 4 Weeks of Treatment
NCT02248961 (7) [back to overview]	Number of Subjects Who Responded on Therapy
NCT02248961 (7) [back to overview]	Change in DBP After 12 Weeks of Treatment
NCT02248961 (7) [back to overview]	Change in DBP After 8 Weeks of Treatment
NCT02248961 (7) [back to overview]	Change in SBP After 4 Weeks of Treatment
NCT02248961 (7) [back to overview]	Change in SBP After 8 Weeks of Treatment
NCT02248961 (7) [back to overview]	Change in Systolic Blood Pressure (SBP) After 12 Weeks of Treatment
NCT02278471 (6) [back to overview]	Systolic Blood Pressure
NCT02278471 (6) [back to overview]	Systolic Blood Pressure
NCT02278471 (6) [back to overview]	LDL Cholesterol
NCT02278471 (6) [back to overview]	LDL Cholesterol
NCT02278471 (6) [back to overview]	Medication Adherence
NCT02278471 (6) [back to overview]	Medication Adherence-Percentage of Pills Taken
NCT02373241 (3) [back to overview]	Feasibility as Measured by the Number of Patients That Accept Enrollment, Remain Adherent to Losartan, and Remain Adherent to Study Procedures.
NCT02373241 (3) [back to overview]	Number of Patients With Incident Hypertension
NCT02373241 (3) [back to overview]	Feasibility as Measured by the Number of Patients With Improvement in Nocturnal Blood Pressure While Receiving Losartan.
NCT02387554 (1) [back to overview]	AUClast
NCT02416102 (2) [back to overview]	Change in IL-8 Concentrations
NCT02416102 (2) [back to overview]	Percent Change in TGF-ß mRNA Expression
NCT02676466 (7) [back to overview]	Number of Participants Exhibiting Frailty
NCT02676466 (7) [back to overview]	Peak Torque of the Knee Extensor and Flexor Muscles
NCT02676466 (7) [back to overview]	Short Form Health Survey (SF-36) - Physical Component Score
NCT02676466 (7) [back to overview]	Changes in the Interleukin-6 Level Between Groups
NCT02676466 (7) [back to overview]	Short Physical Performance Battery (SPPB)
NCT02676466 (7) [back to overview]	Number of Participants Experiencing Major Mobility Disability
NCT02676466 (7) [back to overview]	Isometric Hand Grip Strength
NCT02696564 (11) [back to overview]	Change From Baseline in PROMIS-20a T-score
NCT02696564 (11) [back to overview]	Change From Baseline in CAT Score
NCT02696564 (11) [back to overview]	Number of COPD Exacerbations by Severity and Treatment Assignment
NCT02696564 (11) [back to overview]	Change in SGRQ Score: Impact
NCT02696564 (11) [back to overview]	Change From Baseline in SGRQ Score: Total
NCT02696564 (11) [back to overview]	Change From Baseline in SGRQ Score: Symptoms
NCT02696564 (11) [back to overview]	Change From Baseline in SGRQ Score: Activity
NCT02696564 (11) [back to overview]	Change From Baseline in Post-bronchodilator FEV1 Percent Predicted
NCT02696564 (11) [back to overview]	Change From Baseline in Pre-bronchodilator FEV1 Percent Predicted
NCT02696564 (11) [back to overview]	Change From Baseline in mMRC Dyspnea Scale
NCT02696564 (11) [back to overview]	Change in Mean pct950
NCT02709018 (2) [back to overview]	Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan.
NCT02709018 (2) [back to overview]	The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm.
NCT03029091 (7) [back to overview]	Change From Baseline in PEESS V2.0
NCT03029091 (7) [back to overview]	Percent of Participants in Complete and Partial Histologic Remission at 16 Weeks
NCT03029091 (7) [back to overview]	Number of Serious and Grade 3 or Higher Adverse Events
NCT03029091 (7) [back to overview]	Change From Baseline in Total Histology Scoring System
NCT03029091 (7) [back to overview]	Change From Baseline in Total Endoscopic Reference Score
NCT03029091 (7) [back to overview]	Change From Baseline in PedsQL EoE
NCT03029091 (7) [back to overview]	Change From Baseline in Peak Eosinophil Count
NCT03206788 (5) [back to overview]	Change in NPD to Assess CaCC Activity
NCT03206788 (5) [back to overview]	Change in FEV1
NCT03206788 (5) [back to overview]	Change in Sweat Chloride Concentration
NCT03206788 (5) [back to overview]	Change in NPD to Assess BK Activity
NCT03206788 (5) [back to overview]	Change in Nasal Potential Difference (NPD) to Assess CFTR Activity
NCT03461003 (5) [back to overview]	Number of Participants Who Reported That Side Effects From Medication Led Them to Discontinue Medication
NCT03461003 (5) [back to overview]	Change in Mean Wake Ambulatory Systolic Blood Pressure
NCT03461003 (5) [back to overview]	Patient Satisfaction With Intervention as Assessed by a Survey
NCT03461003 (5) [back to overview]	Change in Mean 24-hour Ambulatory Systolic Blood Pressure
NCT03461003 (5) [back to overview]	Number of Participants Who Self-reported Adherence to Intervention
NCT03467217 (17) [back to overview]	Change in Triglycerides at 24 Weeks Compared to Baseline
NCT03467217 (17) [back to overview]	Change in Serum Aspartate Aminotransferase AST at 24 Weeks Compared to Baseline AST
NCT03467217 (17) [back to overview]	Change in Serum Alanine Aminotransferase (ALT) From Baseline.
NCT03467217 (17) [back to overview]	Change in LDL Cholesterol at 24 Weeks Compared to Baseline
NCT03467217 (17) [back to overview]	Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) Compared to Baseline.
NCT03467217 (17) [back to overview]	Change in HDL Cholesterol at 24 Weeks Compared to Baseline
NCT03467217 (17) [back to overview]	Change in Gamma-glutamyl Transpeptidase (GGT) Compared to Baseline
NCT03467217 (17) [back to overview]	Change in Body Mass Index (BMI) at 24 Weeks Compared to Baseline.
NCT03467217 (17) [back to overview]	Change in ALT at 12 Weeks Compared to Baseline ALT
NCT03467217 (17) [back to overview]	Relative Change in Serum Alanine Aminotransferase (ALT) Compared to Baseline ALT
NCT03467217 (17) [back to overview]	Change in Pediatric Quality of Life Inventory (PedsQOL) Psychosocial Health Score at 24 Weeks Compared to Baseline
NCT03467217 (17) [back to overview]	Change in Total Cholesterol at 24 Weeks Compared to Baseline
NCT03467217 (17) [back to overview]	Change in Pediatric Quality of Life Inventory (PedsQOL) Physical Health Score at 24 Weeks Compared to Baseline
NCT03467217 (17) [back to overview]	Frequency of Adverse Events Over 24 Weeks
NCT03467217 (17) [back to overview]	Change in Weight at 24 Weeks Compared to Baseline
NCT03467217 (17) [back to overview]	Change in Waist-to-hip Ratio at 24 Weeks Compared to Baseline
NCT03467217 (17) [back to overview]	Change in Waist Circumference at 24 Weeks Compared to Baseline
NCT04212650 (6) [back to overview]	Patient Reported Outcomes Questionnaire - Western Ontario and McMaster Universities Osteoarthritis Index
NCT04212650 (6) [back to overview]	Patient Reported Outcomes Questionnaire - Numeric Rating Scale for Pain
NCT04212650 (6) [back to overview]	Patient Reported Outcomes Questionnaire - Hip Outcome Score
NCT04212650 (6) [back to overview]	Patient Reported Outcomes Questionnaire - Harris Hip Score
NCT04212650 (6) [back to overview]	Patient Reported Outcomes Questionnaire
NCT04212650 (6) [back to overview]	Incidence of Treatment-Emergent Adverse Events
NCT04311177 (11) [back to overview]	Change in Viral Load by Nasopharyngeal Swab at Day 15
NCT04311177 (11) [back to overview]	Change in Viral Load by Nasopharyngeal Swab at Day 9
NCT04311177 (11) [back to overview]	Count of Participants With an Emergency Department or Clinic Presentation
NCT04311177 (11) [back to overview]	Daily Maximum Temperature
NCT04311177 (11) [back to overview]	Disease Severity Rating Day 15
NCT04311177 (11) [back to overview]	Need for Oxygen Therapy at 15 Days
NCT04311177 (11) [back to overview]	Percentage of Participants Admitted to the Hospital
NCT04311177 (11) [back to overview]	Percentage of Patients Admitted to the Intensive Care Unit Within 15 Days
NCT04311177 (11) [back to overview]	Change in SF-12 Physical Composite Score
NCT04311177 (11) [back to overview]	Change in SF-12 Mental Composite Score
NCT04311177 (11) [back to overview]	Change in PROMIS Dyspnea Scale
NCT04312009 (14) [back to overview]	Length of Hospital Stay
NCT04312009 (14) [back to overview]	Oxygen Saturation / Fractional Inhaled Oxygen (S/F)
NCT04312009 (14) [back to overview]	Number of Ventilator-Free Days
NCT04312009 (14) [back to overview]	Number of Vasopressor-Free Days
NCT04312009 (14) [back to overview]	Number of Therapeutic Oxygen-Free Days
NCT04312009 (14) [back to overview]	ICU Admission
NCT04312009 (14) [back to overview]	Disease Severity Rating
NCT04312009 (14) [back to overview]	Difference in Estimated (PEEP Adjusted) P/F Ratio at 7 Days
NCT04312009 (14) [back to overview]	Daily Hypotensive Episodes
NCT04312009 (14) [back to overview]	Change in Viral Load by Nasopharyngeal Swab Day 15
NCT04312009 (14) [back to overview]	90-Day Mortality
NCT04312009 (14) [back to overview]	28-Day Mortality
NCT04312009 (14) [back to overview]	Proportion of Participants Requiring Vasopressors for Hypotension
NCT04312009 (14) [back to overview]	Proportion of Participants Experiencing Acute Kidney Injury
NCT04340557 (5) [back to overview]	Length of Hospital Stay
NCT04340557 (5) [back to overview]	In Hospital Mortality
NCT04340557 (5) [back to overview]	Mechanical Ventilation
NCT04340557 (5) [back to overview]	Oxygen Therapy
NCT04340557 (5) [back to overview]	ICU Transfer

Doubling of Interstitium or Any ESRD

Doubling of the interstitial or any defined ESRD (including IF/TA) (NCT00067990)
Timeframe: Baseline to 5 years

Intervention	Participants (Count of Participants)
Losartan	6
Placebo	12

Intervention	mL (Mean)
Aliskiren 300 mg	-3.89
Losartan 100 mg	0.24
Aliskiren/Losartan 300/100 mg	-2.24

Intervention	mm Hg (Least Squares Mean)
	Systolic	Diastolic
Aliskiren 300 mg	-2.67	-1.31
Aliskiren/Losartan 300/100 mg	-6.97	-4.11
Losartan 100 mg	-3.81	-1.92

Intervention	mm (Mean)
Aliskiren 300 mg	-1.07
Losartan 100 mg	-0.97
Aliskiren/Losartan 300/100 mg	-1.43

Intervention	g/m^2 (Mean)
Aliskiren 300 mg	-4.87
Losartan 100 mg	-4.79
Aliskiren/Losartan 300/100 mg	-5.81

Intervention	mm (Mean)
Aliskiren 300 mg	-0.88
Losartan 100 mg	-0.89
Aliskiren/Losartan 300/100 mg	-0.90

Intervention	mL (Mean)
Aliskiren 300 mg	-3.20
Losartan 100 mg	-4.73
Aliskiren/Losartan 300/100 mg	-5.14

Intervention	mL (Mean)
Aliskiren 300 mg	-7.05
Losartan 100 mg	-4.52
Aliskiren/Losartan 300/100 mg	-7.03

Intervention	g (Mean)
Aliskiren 300 mg	-9.81
Losartan 100 mg	-9.92
Aliskiren/Losartan 300/100 mg	-12.29

Intervention	mm (Mean)
Aliskiren 300 mg	-0.95
Losartan 100 mg	-1.20
Aliskiren/Losartan 300/100 mg	-1.17

Intervention	mm (Mean)
Aliskiren 300 mg	-0.71
Losartan 100 mg	-0.64
Aliskiren/Losartan 300/100 mg	-0.86

Intervention	mm * ms (Mean)
Aliskiren 300 mg	-104.97
Losartan 100 mg	-150.31
Aliskiren/Losartan 300/100 mg	-130.65

Intervention	g/m^2 (Least Squares Mean)
Aliskiren 300 mg	-5.51
Losartan 100 mg	-4.81
Aliskiren/Losartan 300/100 mg	-5.61

Intervention	participants (Number)
Normoalbuminuria Losartan	2
Normoalbuminuria Placebo	2
Microalbuminuria Losartan	1
Microalbuminuria Placebo	4

Intervention	Liters/minute (Mean)
	Baseline Leg Blood Flow	Insulin stimulated leg blood flow
Placebo	0.26	0.046
Treatment	0.24	0.353

Intervention	participants (Number)
	Headache, any severity	Headache, bothersome	Fatigue, any severity	Fatigue, bothersome	Mood alterations, any severity	Mood alterations, bothersome	Behavior changes, any severity	Behavior changes, bothersome	Insomnia, any severity	Insomnia, bothersome	Nightmares, any severity	Nightmares, bothersome	Dizziness with standing, any severity	Dizziness with standing, bothersome	Dizziness - other, any severity	Dizziness - other, bothersome	Fainting with loss of consciousness, any severity	Fainting with loss of consciousness, bothersome	Palpitations, any severity	Palpitations, bothersome	Chest pain, any severity	Chest pain, bothersome	Dyspnea, any severity	Dyspnea, bothersome	Wheezing, any severity	Wheezing, bothersome	Upper respiratory/Nasal congestion, any severity	Upper respiratory/Nasal congestion, bothersome	Cough, any severity	Cough, bothersome	Dysgeusia, any severity	Dysgeusia, bothersome	Stomach pain/Indigestion, any severity	Stomach pain/Indigestion, bothersome	Nausea, any severity	Nausea, bothersome	Vomiting, any severity	Vomiting, bothersome	Diarrhea, any severity	Diarrhea, bothersome	Constipation, any severity	Constipation, bothersome	Vascular (hands, feet), any severity	Vascular (hands, feet), bothersome	Muscle pain or Cramps, any severity	Muscle pain or Cramps, bothersome	Back pain, any severity	Back pain, bothersome	Periorbital edema, any severity	Periorbital edema, bothersome	Pedal edema, any severity	Pedal edema, bothersome	Other, any severity	Other, bothersome
Atenolol	112	10	84	0	54	7	21	2	60	2	52	2	60	0	25	0	5	5	60	0	54	1	43	3	15	2	106	0	47	1	10	0	47	0	30	1	23	0	35	1	44	0	35	0	59	2	60	3	13	0	2	0	21	3
Losartan	114	10	105	0	49	3	23	1	61	2	53	3	58	2	27	1	9	9	53	0	58	5	38	0	14	1	117	2	59	0	3	0	61	1	35	0	23	0	43	1	35	0	34	1	58	4	67	2	15	0	3	0	16	1

Intervention	Participants (Number)
	Achieved Target Blood Pressure	Did NOT achieve target Blood Pressure
Overall Intend to Treat	1200	514
Overall Per Protocol	1200	311
Overall Total	1200	538

Intervention	Patients (Number)
	Achieved Target Blood Pressure	Did Not Achieve Target Blood Pressure
Losartan 50 mg/HCTZ 12.5 mg	253	140
Valsartan 80 mg/HCTZ 12.5 mg	241	104

Intervention	Days (Mean)
Losartan 50 mg/HCTZ 12.5 mg	62.3
Valsartan 80 mg/HCTZ 12.5 mg	57.3

Intervention	umol/L (Mean)
Losartan 50 mg/HCTZ 12.5 mg	0.3
Valsartan 80 mg/HCTZ 12.5 mg	21.7

Intervention	mm Hg (Mean)
Losartan 50 mg/HCTZ 12.5 mg	-16.7
Valsartan 80 mg/HCTZ 12.5 mg	-18.2

losartan

Description

Cross-References

Synonyms (138)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (2)

Pathways (2)

Protein Targets (61)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (303)

Molecular Functions (119)

Ceullar Components (66)

Bioassays (587)

Research

Studies (6,943)

Market Indicators

Research Demand Index: 143.87

Study Types

Clinical Trials (360)

Trial Overview

Trial Outcomes

Doubling of Interstitium or Any ESRD

Number of Participants With Cortical Interstitial Volume Expansion or Any ESRD

Number of Participants That Were Hospitalized for Heart Failure

Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization

Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure

Number of Participants That Experienced Cardiovascular Hospitalization

Number of Participants That Died (Any Cause)

Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular Stroke Volume as Measured by MRI From Baseline to End of Study (Week 36)

Change From Baseline in Mean 24-hour Ambulatory Diastolic and Systolic Blood Pressure From Baseline to the End of the Study (Week 36)

Change in the Left Ventricular Hypertrophy (LVH) Parameter Sokolow-Lyon Voltage as Measured by Electrocardiogram From Baseline to End of Study (Week 36)

Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular Mass Index as Measured by MRI From Baseline to End of Study (Week 36)

Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular Inferolateral Wall Thickness as Measured by MRI From Baseline to End of Study (Week 36)

Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular End Systolic Volume as Measured by MRI From Baseline to End of Study (Week 36)

Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular End Diastolic Volume as Measured by MRI From Baseline to End of Study (Week 36)

Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular End Diastolic Mass as Measured by MRI From Baseline to End of Study (Week 36)

Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular Ejection Fraction as Measured by MRI From Baseline to End of Study (Week 36)

Change in the Left Ventricular Hypertrophy (LVH) Parameter Left Ventricular Anteroseptal Wall Thickness as Measured by MRI From Baseline to End of Study (Week 36)

Change in the Left Ventricular Hypertrophy (LVH) Parameter Diameter of Ascending Aorta as Measured by MRI From Baseline to End of Study (Week 36)

Change in the Left Ventricular Hypertrophy (LVH) Parameter Cornell Voltage Duration Product as Measured by Electrocardiogram From Baseline to End of Study (Week 36)

Change in Left Ventricular Mass Index (LVMI) From Baseline to End of Study (Week 36)

Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 16

Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8

Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12

Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12

Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 16

Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8

Number of Participants With Decline in GFR

Glomerular Volume

Insulin-stimulated Leg Glucose Uptake

Leg Blood Flow Response to Insulin

Adverse Drug Reactions Reported at the Baseline Visit

Number of Participants With the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.

Event Rate of the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.

Annual Rate of Change in Body Mass Index for Age Z-score

Number of Participants With Aortic-root Surgery.

Number of Participants With Aortic Dissection.

Number of Death.

Event Rate of Death

Event Rate of Aortic-Root Surgery

Event Rate of Aortic Dissection.

Annual Rate of Change in Body Mass Index

Annual Rate of Change in Ascending-aorta-diameter Z Score, Adjusted by Body-surface-area.

Annual Rate of Change in Arm Span to Height Ratio

Annual Rate of Change in Aortic-annulus-diameter Z Score, Adjusted by Body-surface Area

Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score

Annual Rate of Change in Weight-for-height Z-score

A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73mm in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73mm, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death

Intervention	mm Hg (Mean)
Losartan 50 mg/HCTZ 12.5 mg	-19.9
Valsartan 80 mg/HCTZ 12.5 mg	-20.8

Intervention	umol/L (Mean)
Losartan 50 mg/HCTZ 12.5 mg	-0.3
Valsartan 80 mg/HCTZ 12.5 mg	0.5

Intervention	IU/L (Mean)
Losartan 50 mg/HCTZ 12.5 mg	-1.8
Valsartan 80 mg/HCTZ 12.5 mg	-0.1

Intervention	IU/L (Mean)
Losartan 50 mg/HCTZ 12.5 mg	-0.7
Valsartan 80 mg/HCTZ 12.5 mg	-0.0

Intervention	mm Hg (Mean)
Losartan 50 mg/HCTZ 12.5 mg	-10.6
Valsartan 80 mg/HCTZ 12.5 mg	-10.5

Intervention	mm Hg (Mean)
Losartan 50 mg/HCTZ 12.5 mg	-8.4
Valsartan 80 mg/HCTZ 12.5 mg	-9.1

Intervention	umol/L (Mean)
Losartan 50 mg/HCTZ 12.5 mg	-0.4
Valsartan 80 mg/HCTZ 12.5 mg	29.9

Intervention	Percent Change in Pr/Cr (Geometric Mean)
Losartan Open Label Extension	-30.01
Enalapril Open Label Extension	-40.45

Intervention	mm Hg (Least Squares Mean)
Losartan-Hypertensive Participants	-5.5
Amlodipine-Hypertensive Participants	-0.1

Intervention	mm Hg (Least Squares Mean)
Losartan-Hypertensive Participants	-3.8
Amlodipine-Hypertensive Participants	0.8